

## Risk Factors Comparison 2024-11-07 to 2023-10-30 Form: 10-K

**Legend:** **New Text** ~~Removed Text~~ Unchanged Text **Moved Text Section**

Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales of any Rafael Medical Devices' device (s) that receives approval, marketing authorization, or clearance and adversely affect **their and** our business, results of operations, and financial condition. Even if Rafael Medical Devices receives regulatory approval, marketing authorization, or clearance for any device candidate, they will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Any regulatory approvals, marketing authorizations, or clearances that Rafael Medical Devices may receive for their device candidates will require the regular submission of reports to regulatory authorities and surveillance to monitor the safety and effectiveness of the medical device, may contain significant limitations related to use restrictions for specified age groups **or patient populations**, warnings, precautions or contraindications, and may include burdensome post-approval study requirements. If the FDA or a comparable foreign regulatory authority approves, issues a marketing authorization for, or clears a device candidate, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export, and recordkeeping for Rafael Medical Devices' devices, if any, will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, **maintenance of cGMP compliance at and registration-registrations for all manufacturing facilities**, as well as continued compliance with **eGMP and GCP** requirements for any clinical trials that are conducted post-approval. Manufacturers of approved devices and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Later discovery of previously unknown problems with marketed devices, including adverse events of unanticipated severity or frequency, or with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: ● restrictions on the marketing or manufacturing of any Rafael Medical Devices' device that receives approval, **marketing authorization** or clearance, **if any**, withdrawal of the device from the market or voluntary or mandatory device recalls; ● requirements to conduct post-marketing studies or clinical trials; ● fines, restitutions, disgorgement of profits or revenue, warning letters, untitled letters or holds on clinical trials; ● refusal by the FDA to approve or clear pending applications or supplements to approved **marketing authorized or cleared** applications filed by Rafael Medical Devices or suspension or revocation of approvals, if any; ● product seizure or detention, or refusal to permit the import or export of Rafael Medical Devices' devices; and ● injunctions or the imposition of civil or criminal penalties. The occurrence of any event or penalty described above may inhibit Rafael Medical Devices' ability to commercialize their device candidates and generate revenue and could require Rafael Medical Devices to expend significant time and resources in response and could generate negative publicity. In addition, the FDA's and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval, marketing authorization, or clearance of Rafael Medical Devices' device candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the results of the 2020 United States Presidential Election impacted our business and industry. Namely, the Trump Administration took several Executive Actions, including the issuance of a number of Executive Orders, that imposed significant burdens on, or otherwise materially delayed, the FDA's ability to engage in routine oversight activities, such as implementing statutes through rulemaking, issuance of guidance, and review and approval of applications seeking approval, marketing authorization, or clearance of device candidates. It is difficult to predict whether or how these orders will be rescinded and replaced under the Biden Administration **or future Administrations**. The policies and priorities of any **administration Administration and the U. S. Congress** are unknown and could materially impact the regulations governing **our Rafael Medical Devices'** device candidates. If we or Rafael Medical Devices are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or they are not able to maintain regulatory compliance as a result of a changing regulatory landscape or otherwise, we or they may be subject to enforcement action, may lose any regulatory approval (s), marketing authorization (s), or clearance (s) that **we or** they obtain, if any, or fail to obtain new regulatory approvals, marketing authorizations, or clearances, **and we** and they may not be able to achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Rafael Medical Devices is dependent upon third parties for a variety of functions. These arrangements may not provide Rafael Medical Devices with the benefits they expect. Rafael Medical Devices relies on third parties to perform a variety of functions. Rafael Medical Devices is party to numerous agreements that place substantial responsibility on clinical research organizations, contract manufacturing organizations, consultants, and other service providers for the development of Rafael Medical Devices' device candidates. Rafael Medical Devices also relies on medical and academic institutions to perform aspects of its clinical trials of device candidates. In addition, an element of Rafael Medical Devices' research and development strategy has been to in-license technology and device candidates from academic and government institutions in order to minimize or eliminate investments in early research. Rafael Medical Devices may not be able to enter new arrangements without undue delays or expenditures or on favorable terms, and these arrangements may not allow Rafael Medical Devices to compete successfully. Moreover, if third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct clinical trials in accordance with regulatory requirements or applicable protocols, Rafael Medical Devices' device candidates may not be approved, receive marketing authorization, or be cleared for marketing and commercialization or such approval, marketing authorization, or clearance may be delayed. If that occurs, Rafael Medical Devices or its collaborators will not be able, or may be delayed in their efforts, to commercialize Rafael Medical Devices' device candidates. Product liability lawsuits against Rafael Medical Devices or their collaborators or us could cause substantial liabilities and could limit commercialization of any medical devices that Rafael Medical Devices or their collaborators may develop. Rafael Medical Devices and their collaborators and we face an inherent risk of product liability exposure related to the testing and manufacturing of Rafael Medical Devices' device candidates in human clinical trials and will face an even greater risk if Rafael Medical Devices or they commercially sell any medical devices that Rafael Medical Devices or they may develop that secure regulatory approval, marketing authorization, or clearance. Rafael Medical Devices' device candidates are designed to affect, and any future devices will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with Rafael Medical Devices' device candidates or devices could result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and we cannot assure you that **and Rafael Medical Devices** will not face product liability claims. We **and Rafael Medical Devices** may be subject to product liability claims if Rafael Medical Devices' device candidates or devices cause, or merely appear to have caused, patient injury or death, even if such injury or death was as a result of supplies or components that are produced by third-party suppliers. Product liability claims may be brought against us by consumers, healthcare providers or others selling or otherwise coming into contact with **our Rafael Medical Devices'** products, among others. If Rafael Medical Devices or their collaborators, or we, cannot successfully defend themselves or ourselves against product liability claims that Rafael Medical Devices' device candidates or devices caused injuries, Rafael Medical Devices and we could incur substantial liabilities and reputational harm. Regardless of merit or eventual outcome, liability claims may result in: ● decreased demand for any device candidates or devices that Rafael Medical Devices may develop; ● injury to Rafael Medical Devices' reputation and significant negative media attention; ● withdrawal of clinical trial participants; ● significant costs to defend the related litigation; ● substantial monetary awards to trial participants or patients; ● loss of revenue; ● product recalls or withdrawals from the market; ● reduced resources of Rafael Medical Devices' management to pursue Rafael Medical Devices' business strategy, and diverted time and attention from executing on that strategy; and ● the inability to commercialize any devices that Rafael Medical Devices may successfully develop, if any. Although Rafael Medical Devices and we maintain product liability and / or clinical study liability insurance coverage that they and we believe is appropriate, this insurance is subject to deductibles and coverage limitations, and it may not be adequate to cover all liabilities that Rafael Medical Devices may incur. Rafael Medical Devices' and our current product liability insurance may not continue to be available to them or us on acceptable terms, if at all. If Rafael Medical Devices or we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, they or we could be exposed to significant liabilities. We anticipate that Rafael Medical Devices will need to increase their insurance coverage as they continue to run clinical trials and if they successfully commercialize any device that receives regulatory approval, marketing authorization, or clearance. Insurance coverage in this setting is increasingly expensive. Rafael Medical Devices or we may not be able to maintain insurance coverage at a reasonable cost, if at all, or in an amount adequate to protect them or us against any product liability claim that may arise. In addition, if one of Rafael Medical Devices' collaboration partners were to become subject to product liability claims or were unable to successfully defend themselves against such claims, any such collaboration partner could be more likely to terminate such relationships and could potentially seek indemnification from Rafael Medical Devices, and therefore substantially limit the commercial potential of Rafael Medical Devices' device candidates. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could adversely affect our **and Rafael Medical Devices'** business, results of operations, and financial condition. If Rafael Medical Devices fails to comply with environmental, health and safety laws and regulations, they could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of their businesses. Rafael Medical Devices is subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Rafael Medical Devices' operations involve the use of hazardous materials, including chemical materials. Rafael Medical Devices' operations also produce hazardous waste products. Rafael Medical Devices generally contracts with third parties for the disposal of these materials and wastes. Rafael Medical Devices cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from their use of hazardous materials, Rafael Medical Devices could be held liable for any resulting damages, and any liability could exceed their resources. Rafael Medical Devices also could incur significant costs associated with civil or criminal fines and penalties. Although Rafael Medical Devices maintains workers' compensation insurance to cover them for costs and expenses they may incur due to injuries to their employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Rafael Medical Devices may not maintain adequate insurance for environmental liability or toxic tort claims that may be asserted against them in connection with their storage or disposal of hazardous materials. In addition, Rafael Medical Devices may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Rafael Medical Devices' research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. Risks Related to Reliance on Third Parties The **Investment Portfolio** Companies currently rely on, and plan to rely on in the future, third parties to conduct and support their preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, the **Investment Portfolio** Companies

and may not be able to obtain regulatory approval of or commercialize their product candidates. The **Investment Portfolio** Companies have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs, and strategic partners to conduct and support their preclinical studies and clinical trials under written agreements. The **Investment Portfolio** Companies will generally have to negotiate budgets and contracts with CROs, trial sites, and CMOs, and they may not be able to do so on favorable terms, if at all, which may result in delays to anticipated development timelines and increased costs. We expect that the **Investment Portfolio** Companies will rely heavily on these third parties over the course of their preclinical studies and clinical trials, and they will control only certain aspects of their activities. As a result, the **Investment Portfolio** Companies will have less direct control over **resource allocations and thus** the conduct, timing, and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if they were relying entirely upon their own staff. Nevertheless, the **Investment Portfolio** Companies are responsible for ensuring that each of their studies is conducted in accordance with the applicable protocol, legal and regulatory requirements, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. The **Investment Portfolio** Companies and these third parties are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections, both announced and unannounced, of trial sponsors, principal investigators, and **trial sites, and manufacturing sites**, and the corresponding books and records of such parties. If the Pharmaceutical Companies or Rafael Medical Devices or any of these third parties fail to comply with applicable GLP or GCP regulations, the preclinical data generated in their preclinical studies and / or the clinical data generated in their clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require them to repeat clinical trials and / or to perform additional preclinical studies and / or clinical trials before approving any marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of the Pharmaceutical Companies' or Rafael Medical Devices' preclinical studies and / or clinical trials comply with the GLP or GCP regulations. In addition, such clinical trials must be conducted with pharmaceutical product or a medical device produced under **applicable cGMP and QSR** regulations and will require a large number of test patients. The Pharmaceutical Companies' or Rafael Medical Devices' failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require them to repeat clinical trials and / or to perform additional clinical studies, which would delay the regulatory approval process. Moreover, **their and** our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. Any third parties conducting the Pharmaceutical Companies' or Rafael Medical Devices' preclinical studies and clinical trials will not be their employees and, except for remedies available to them under **our their** agreements with such third parties, the **Investment Portfolio** Companies cannot control whether or not any third-party personnel will devote sufficient time and resources to the Pharmaceutical Companies' product candidates or Rafael Medical Devices' device candidates. These third parties may also have relationships with other commercial entities, including competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the preclinical and / or clinical data they obtain is compromised due to the failure to adhere to preclinical or clinical protocols or regulatory requirements or for other reasons, the Pharmaceutical Companies' and Rafael Medical Devices' preclinical studies and clinical trials may be extended, delayed or terminated, and they may not be able to complete development of, obtain regulatory approval of, or successfully commercialize their product candidates or device candidates. As a result, **their and** our financial results and commercial prospects would be adversely affected, **their and** our costs could increase, **and their** and our ability to generate revenue could be delayed. The **Investment Portfolio** Companies currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture **our the Portfolio Companies'** product candidates and device candidates, and **we they** may rely on third parties to produce and process **our their** products, if approved. **Our The Portfolio Companies'** business could be adversely affected if **we they** are unable to use third-party manufacturing suites or if the third-party manufacturers fail to provide **us them** with sufficient quantities of our product candidates or device candidates or fail to do so in a cGMP-compliant manner, at acceptable quality levels or at acceptable prices. **We The Portfolio Companies** do not currently own any facility that may be used as a clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates. The **Investment Portfolio** Companies have not yet caused their product candidates or device candidates to be manufactured on a commercial scale and may not be able to do so. We expect that the **Investment Portfolio** Companies will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of **our their** product candidates and device candidates, and they may not be able to do so on favorable terms. The facilities used by contract manufacturers to manufacture **product candidates or** approved products must also be approved by the FDA or other comparable foreign regulatory authorities following inspections for any such approved products that generally will be conducted after the Pharmaceutical Companies or Rafael Medical Devices submit an application to the FDA or other comparable foreign regulatory authorities. Such inspections also could occur, for other products being manufactured by contract manufacturers, before the Pharmaceutical Companies or Rafael Medical Devices submit an application to the FDA or other comparable foreign regulatory authorities, and any adverse regulatory findings from such inspections could adversely impact a contract manufacturer's ability to be a contract manufacturer for the **Investment Portfolio** Companies. The **Investment Portfolio** Companies may not **directly** control the manufacturing process of, and may be completely dependent on, contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of product candidates and device candidates and of any products that receive regulatory approval or clearance. Beyond periodic audits, the **Investment Portfolio** Companies have no **direct** control over the ability of their contract manufacturers to maintain adequate quality control, quality assurance, and qualified personnel. **Nevertheless, the Portfolio Companies are responsible for ensuring that all manufacturing is conducted in accordance with the applicable cGMP or QSR and other legal and regulatory requirements and scientific standards, and the Portfolio Companies' reliance on third parties does not relieve them of their regulatory responsibilities.** If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of any approved or cleared products or if they withdraw any approval in the future, the **Investment Portfolio** Companies may need to find alternative manufacturing facilities, which would require the incurrence of significant additional **time and** costs and materially adversely affect the ability to develop, obtain regulatory approval or clearance for or market any product candidates or device candidates, if approved or cleared. Similarly, if any third-party manufacturers on which the Pharmaceutical Companies or Rafael Medical Devices **will** fail to manufacture quantities of their product candidates or device candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows them to achieve profitability, **their and** our business, financial condition, and prospects could be materially and adversely affected. The anticipated reliance on a limited number of third-party manufacturers exposes **the Portfolio Companies and** us to a number of risks, including the following: ● the Pharmaceutical Companies **and Rafael Medical Devices** may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and the FDA must inspect any manufacturers for **applicable cGMP and QSR** compliance as part of **our the Pharmaceutical Companies' and Rafael Medical Devices'** marketing applications; ● a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates; ● third-party manufacturers might be unable to timely manufacture Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates or produce the quantity and quality required to meet their clinical and commercial needs, if any; ● contract manufacturers may not be able to execute the Pharmaceutical Companies' and Rafael Medical Devices' manufacturing procedures and other logistical support requirements appropriately; ● future contract manufacturers may not perform as agreed, may not devote sufficient resources to the Pharmaceutical Companies' product candidates or Rafael Medical Devices' device candidates, or may not remain in the contract manufacturing business for the time required to supply clinical trials or to successfully produce, store, and distribute approved or cleared products, if any; ● manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies and foreign regulatory authorities to ensure strict compliance with cGMP and QSR and other government regulations and corresponding foreign standards, and the **Healthcare Portfolio** Companies have no **direct** control over third-party manufacturers' compliance with these regulations and standards. **although the Portfolio Companies' reliance on third parties does not relieve them of their regulatory responsibilities**; ● the **Healthcare Portfolio** Companies may not own, or may have to share, the intellectual property rights to any improvements made by any third-party manufacturers in the manufacturing process for the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates; ● third-party manufacturers could breach or terminate their agreements with us, the Pharmaceutical Companies or Rafael Medical Devices; ● raw materials and components used in the manufacturing process, particularly those for which the **Healthcare Portfolio** Companies have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; ● contract manufacturers and critical reagent suppliers may be subject to **public health emergencies**, inclement weather, as well as natural or man-made disasters; and ● contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and the Pharmaceutical Companies **and Rafael Medical Devices** will have no direct control over contract manufacturers' ability to maintain adequate quality control, quality assurance, and qualified personnel. **although the Pharmaceutical Companies' and Rafael Medical Devices' reliance on third parties does not relieve them of their regulatory responsibilities.** **Our The Portfolio Companies'** business could be materially adversely affected by business disruptions caused by third-party providers that could materially adversely affect **their and** our potential future revenue and financial condition and increase **their and** our costs and expenses. Each of these risks could delay or prevent the completion of the Pharmaceutical Companies' or Rafael Medical Devices' clinical trials or the approval of any of the Pharmaceutical Companies' product candidates or Rafael Medical Devices' device candidates by the FDA or comparable foreign regulatory authorities. **We The Portfolio Companies** may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and **we the Portfolio Companies** may not realize the benefits of such collaborations, alliances or licensing arrangements. **We The Portfolio Companies** may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that **we they** believe will complement or augment **our their** development and commercialization efforts with respect to the Pharmaceutical Companies' product candidates, any future product candidates that we or they may develop, Rafael Medical Devices' device candidates, and any future device candidates that we or they may develop. Any of these relationships may require **the Portfolio Companies or** us to incur non-recurring and other charges, increase **our near** - and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our **or their** management and business. In addition, **we and the Portfolio Companies** face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, **we and the Portfolio Companies** may not be successful in our **or their** efforts to establish a strategic partnership or other alternative arrangements for any product candidates because they may be deemed to be at too early of a stage of development for collaborative effort, and third parties

may not view such product candidates as having the requisite potential to demonstrate safety and efficacy and obtain regulatory approval **or clearance**. Further, collaborations involving **our the Portfolio Companies'** product candidates and device candidates are subject to numerous risks, which may include the following: ● collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; ● collaborators may not pursue development and commercialization of **our the Portfolio Companies'** product candidates or device candidates or may elect not to continue or renew development or commercialization of **our their** product candidates or device candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; ● collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate or device candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate or device candidate for clinical testing; ● collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates; ● a collaborator with marketing and distribution rights to one or more product candidates or device candidates may not commit sufficient resources to their marketing and distribution in the event that they were to receive regulatory approval or clearance; ● collaborators may not properly maintain or defend **our or the Portfolio Companies'** intellectual property rights or may use **our or their** intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate **our or their** intellectual property or proprietary information or expose us **or them** to potential liability; ● disputes may arise between us **and / or the Portfolio Companies** and a collaborator that cause the delay or termination of the research, development or commercialization of a product candidate or device candidate, or that result in costly litigation or arbitration that diverts management attention and resources; ● collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or device candidates; and ● collaborators may own or co-own intellectual property covering **our or the Portfolio Companies'** products that results from **our or their** collaborating with them, and in such cases, we **and they** would not have the exclusive right to commercialize such intellectual property. As a result, if we **or the Portfolio Companies** enter into future collaboration agreements and strategic partnerships or out-license the Pharmaceutical Companies' product candidates or Rafael Medical Devices' device candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with **our or their** existing operations and company culture, which could delay **our or their** timelines or otherwise adversely affect **our or their** business. We **and the Portfolio Companies** also cannot be certain that, following a strategic transaction or license, we **or they** will achieve the revenue or specific net income that justifies such transaction. Furthermore, if conflicts arise between **our or their** future corporate or academic collaborators or strategic partners and us **or them**, the other party may act in a manner adverse to us **or them** and could limit **our or their** ability to implement **our or their** strategies. Any delays in entering into future collaborations or strategic partnership agreements related to **our or their** product candidates or device candidates could delay the development and commercialization of **our or their** product candidates and device candidates in certain geographies for certain indications, which would harm **our and their** business prospects, financial condition and results of operations. The Pharmaceutical Companies' and Rafael Medical Devices' relationships with customers, physicians and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If the Pharmaceutical Companies or Rafael Medical Devices or their respective employees, independent contractors, consultants, commercial partners, or vendors violate these laws, they could face substantial penalties. The Pharmaceutical Companies' and Rafael Medical Devices' relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. These laws may impact, among other things, **our their** clinical research program, as well as **our their** proposed and future sales, marketing, and education programs. In particular, the promotion, sales, and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive, and other business arrangements. The **Investment Portfolio** Companies may also be subject to federal, state, and foreign laws governing the privacy and security of identifiable patient information. The U. S. healthcare laws and regulations that may affect their ability to operate include, but are not limited to: ● the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully, offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term "remuneration" has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that may be alleged to be intended to induce prescribing, purchases or recommendations, include any payments of more than fair market value, and may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation; ● federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act and the civil monetary penalties statute; ● the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal civil and criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; ● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health **Act**, and their respective implementing regulations, which impose requirements on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, and their respective business associates that perform services for them that involve the use or disclosure of individually identifiable protected health information, as well as their covered subcontractors, including breach notification regulations; ● **new regulations adopted by the Securities and Exchange Commission, or SEC, effective December 18, 2023, that require greater disclosure regarding cybersecurity risk management, strategy and governance, as well as disclosure of material cybersecurity incidents, which may require reporting of a cybersecurity incident before its impact has been fully assessed or the underlying issue has been remediated, which could divert management's attention from incident response and could potentially reveal system vulnerabilities to threat actors, and for which failure to timely report such incidents under these or other similar rules could also result in monetary fines, sanctions or other forms of liability.** ● analogous state data privacy and security laws and regulations that govern the collection, use, disclosure, transfer, storage, disposal, and protection of personal information, such as social security numbers, medical and financial information, and other information, including data breach laws that require timely notification to individuals, and at times regulators, the media or credit reporting agencies, if a company has experienced the unauthorized access or acquisition of personal information, as well as the California Consumer Privacy Act or CCPA, which, among other things, contains new disclosure obligations for businesses that collect personal information about California residents and affords those individuals numerous rights relating to their personal information that may affect companies' ability to use personal information or share it with business partners, and the California Privacy Rights Act, or CPRA, which expands the scope of the CCPA, imposes new restrictions on behavioral advertising, and establishes a new California Privacy Protection Agency that will enforce the law and issue regulations, and **is scheduled to become became** "operative" on January 1, 2023, with a 12-month "lookback provision" **applicable to personal data collected on or after January 1, 2022**, and the various state laws and regulations may be more restrictive and not preempted by United States federal laws; ● analogous foreign data protection laws, including among others the EU General Data Protection Regulation, or the GDPR, **and** EU member states' implementing legislation, **and the UK GDPR**, which imposes data protection requirements that include strict obligations and restrictions on the ability to collect, analyze, and transfer **EU-EEA or UK** personal data, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances, and possible substantial fines for any violations (including possible fines for certain violations of up to the greater of 20 million Euros or 4% of total worldwide annual turnover of the preceding financial year), with legal requirements in foreign countries relating to the collection, storage, processing, and transfer of personal data continuing to evolve **and varying widely across jurisdictions**; and ● the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such reporting obligations **will** include payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives. The **Investment Portfolio** Companies may also be subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope **and vary significantly from the federal laws**. For example, **we they** may be subject to the following: state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug and device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing; state and local laws requiring the registration of pharmaceutical and device sales and medical representatives; and state and foreign laws, such as the GDPR governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Additionally, **we they** may be subject to federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of **our the Portfolio Companies'** business activities, or **our their** arrangements with physicians, could be subject to challenge under one or more of such laws. It is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we **and the**

**Portfolio Companies** take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us **or them** from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our **and their** business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our **or their** business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If the Pharmaceutical Companies or Rafael Medical Devices or their respective employees, independent contractors, consultants, commercial partners, and vendors violate these laws, **they and** we may be subject to investigations, enforcement actions and / or significant penalties, including the imposition of significant civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and / or oversight if **they or** we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of the Pharmaceutical Companies' and Rafael Medical Devices' operations, any of which could adversely affect their ability to operate their business and their **and our** results of operations. In addition, the approval or clearance **, if any,** and commercialization of any of the Pharmaceutical Companies' product candidates or Rafael Medical Devices' device candidates outside the United States will also likely subject **them and** us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Risks Related to our Commercial Real Estate Business We may be unable to renew leases or relet space as leases expire. If tenants decide not to renew their leases upon expiration, we may not be able to relet the space. Even if tenants do renew or we can relet the space, the terms of a renewal or new lease, taking into account among other things, the cost of improvements to the property and leasing commissions, may be less favorable than the terms in the expired leases. In addition, changes in space utilization by tenants may impact our ability to renew or relet space without the need to incur substantial costs in renovating or redesigning the internal configuration of the relevant property. If we are unable to promptly renew the leases or relet the space at similar rates or if we incur substantial costs in renewing or reletting the space, our cash flow and ability to service debt obligations and pay dividends and distributions to security holders could be adversely affected. We face competition for tenants. The leasing of real estate is highly competitive. The principal competitive factors are rent, location, services provided and the nature and condition of the property to be leased. We directly compete with all owners, developers and operators of similar space in the areas in which our properties are located. There are number of competitive office properties in the areas in which our property is located, which may be newer or better located than our property and could have a material adverse effect on our ability to lease office space at our property, and on the effective rents we are able to charge. Risks Related to Intellectual Property If **we or** the companies in which we hold interests are unable to adequately maintain or protect **their-our** proprietary technology and product candidates **and device candidates and services**, if the scope of the patent protection obtained is not sufficiently broad, or if the terms of patents are insufficient to protect product candidates **, device candidates, services or technologies** for an adequate amount of time, competitors could develop and commercialize technology and products similar or identical to that technology or those product candidates **, device candidates and the services, and our** ability to successfully commercialize technology or product candidates **, device candidates or services** may be materially impaired. We **and the companies in which we hold interests** rely primarily upon a combination of patents, trademarks, trade secret protection, and other intellectual property rights as well as nondisclosure, confidentiality, and other contractual agreements to protect **the-our** intellectual property related to our brands, product candidates and device candidates **, services,** and other proprietary technologies. Our success depends on our ability to develop, manufacture, market, and sell our product candidates **and device candidates**, if approved, and **our delivery of services and** use **our-of** proprietary technologies without alleged or actual infringement, misappropriation or other violation of the patents and other intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting patents and other intellectual property rights in the biopharmaceutical **industries industry**. We cannot assure you that our product candidates and device candidates **, services or technologies** will not infringe existing or future third-party patents. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing our product candidates or device candidates if they receive approval or clearance **or our services or technologies**. There may also be issued patents or pending patent applications that we are aware of, but that we think are irrelevant to our product candidates or device candidates, which may ultimately be found to be infringed by the manufacture, sale, or use of our product candidates or device candidates **, services or technologies**. Moreover, we may face claims from non-practicing entities that have no relevant product revenue and against whom our **own**-patent portfolio may thus have no deterrent effect. In addition, many of our product candidates have a complex structure that makes it difficult to conduct a thorough search and review of all potentially relevant third-party patents. Because we have not yet conducted a formal freedom to operate analysis for patents related to our product candidates or device candidates, we may not be aware of issued patents that a third party might assert are infringed by one of our current or future product candidates or device candidates, which could materially impair our ability to commercialize our product candidates or device candidates **if they receive regulatory approval or clearance**. Even if we diligently search third-party patents for potential infringement by our products or product candidates, or devices or device candidates, we may not successfully find patents that our products or product candidates **or** devices or device candidates may infringe. If we are unable to secure and maintain freedom to operate, others could preclude us from commercializing our product candidates or device candidates. The process of obtaining patent protection is expensive and time-consuming, and we may not be able to prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in certain jurisdictions, and, under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, in some jurisdictions, some of our products currently or in the future may not be protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop **competing their-own** products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. Furthermore, we cannot guarantee that any patents will be issued from any pending or future owned or licensed patent applications, or that any current or future patents will be valid or enforceable or provide us **or them** with any meaningful protection or competitive advantage. Even if issued, existing or future patents may be challenged, including with respect to ownership, narrowed, invalidated, held unenforceable or circumvented, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our product candidates or device candidates. Moreover, should we be unable to obtain meaningful patent coverage for clinically relevant infusion rates in jurisdictions with commercially significant markets, our ability to extend and reinforce patent protection for these product candidates in those jurisdictions may be adversely impacted, which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for those product candidates. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us **or them** the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our products or practicing our **own**-patented technology. The patent positions of biopharmaceutical companies can be highly uncertain and involve complex legal, scientific, and factual questions for which important legal principles remain unresolved. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights may be uncertain. The standards that the United States Patent and Trademark Office, or the USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. Changes in either the patent laws, implementing regulations or the interpretation of patent laws may diminish the value of our rights **and the rights of the companies in which we hold interests**. The legal systems of certain countries do not protect intellectual property rights to the same extent as the laws of the United States, if at all, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the human body more than United States law does. In addition, many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to "work" the invention in that country, or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. Because patent applications in the United States, Europe, and many other jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to conceive or reduce to practice the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or pending patent applications. We can give no assurance that all of the potentially relevant art relating to our patents and patent applications has been found; overlooked prior art could be used by a third party to challenge the validity, enforceability, and scope of our patents or prevent a patent from issuing from a pending patent application. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the validity, enforceability, and scope of our patents in the United States, Europe, and in other countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against our competitors. Third parties may challenge any existing patent or future patent **we-that is own-owned** or **license licensed by us** through adversarial proceedings in the issuing offices or in court proceedings, including as a response to any assertion of our patents against them. In any of these proceedings, a court or agency with jurisdiction may find our patents invalid and / or unenforceable, or **even** if valid and enforceable, insufficient to provide protection against competing products and services sufficient to achieve our business objectives. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or reexamination by the USPTO if a third party asserts a substantial question of patentability against any claim of a U. S. patent we own or license. The adoption of the Leahy-Smith America Invents Act, or the Leahy-Smith Act, in September 2011 established additional opportunities for third parties to invalidate U. S. patent claims, including inter partes review and post-grant review proceedings. Outside of the United States, patents we own or license may become subject to patent opposition or similar proceedings, which may result in loss of scope of some claims or the entire patent. In addition, such proceedings are very complex and expensive **and** may divert our management's attention from our core business. If any of our patents are challenged, invalidated, **or** circumvented by third parties or otherwise limited or expire prior to the commercialization of our products **,**

**services or technologies**, and if we do not own or have exclusive rights to other enforceable patents protecting our products, **services** or other technologies, competitors and other third parties could market products and use processes that are substantially similar, or superior, to ours **and theirs**, and our business would suffer. The entities in which we hold interests or in which we may invest may not make necessary payments or take other actions to protect intellectual property or other rights that they **own**, license or have acquired from third parties, which could result in the loss or impairment of those rights and the reduction of the value of our interests. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. For example:

- others may be able to develop products that are similar to, or better than, ours in a way that is not covered by the claims of our patents;
- **we** might not have been the first to conceive or reduce to practice the inventions covered by our patents or pending patent applications;
- we might not have been the first to file patent applications for our inventions;
- any patents that we obtain may not provide us **or them** with any competitive advantages or may ultimately be found invalid or unenforceable; and / or
- we may not develop additional proprietary technologies that are patentable. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. We currently in-license certain intellectual property from third parties to be able to use such intellectual property in our products and product candidates and to aid in our research activities. In the future, we may in-license intellectual property from additional licensors. We may rely on certain of these licensors to file and prosecute patent applications and maintain, or assist us in the maintenance of, patents and otherwise protect the intellectual property we license from **them-these licensors**. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted diligently or in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate, or support our efforts to initiate, an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us **or them**. If we or our licensors fail to adequately protect this intellectual property, our ability to **develop and commercialize product candidates and products and device candidates and devices, if any receive regulatory approval or clearance**, could suffer. We **and the companies in which we hold interests** may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful. Competitors may infringe, misappropriate or otherwise violate **our-the** patents, trademarks, copyrights, trade secrets or other intellectual property **of us or the companies in which we hold interests**, or those of our licensors. To counter infringement, misappropriation, unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. We **and the companies in which we hold interests** may not be able to prevent, alone or with our licensees or any future licensors, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us **or them** alleging that we infringe their patents. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third party or a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates **or device candidates, services or technologies**. Such a loss of patent protection could harm our business. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from exploiting the claimed subject matter at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent's claims narrowly or decide that we do not have the right to stop the other party from exploiting its technology on the grounds that our patents do not cover such technology. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making, using, importing, and selling similar or competitive products, **services, or technologies**. Any of these occurrences could adversely affect our competitive business position, business prospects, and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question or has not infringed them. In this case, we could ultimately be forced to cease use of such trademarks. In any infringement, misappropriation or other intellectual property litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us **or them** a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. Our commercial success **and that of the companies in which we hold interests** depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties. The biopharmaceutical **industries industry are is** subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our competitors **and those of the companies in which we hold interests**, in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use, and sell our product candidates, device candidates, services, and technologies. Numerous third-party patents exist in the fields relating to our products and services, and it is difficult for industry participants, including us **and them**, to identify all third-party patent rights relevant to our product candidates, device candidates, services, and technologies. As the biopharmaceutical **industries industry expand expands** and more patents are issued, the risk increases that our product candidates or device candidates, **services or technologies** may give rise to claims of infringement of the patent rights of others. Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that cover our product candidates, device candidates, services, and technologies. Therefore, it is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies for our product candidates, device candidates, **services or processes-technologies**, or to obtain licenses or cease certain activities. Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, any final product itself **if it received regulatory approval**, or our device candidates, the holders of any such patents may be able to block our ability to commercialize the product candidate or device candidate unless we obtain a license under the applicable patents, or until such patents expire or they are determined to be held invalid or unenforceable. Our failure to obtain or maintain a license to any technology that we require to develop or commercialize our current and future product candidates and device candidates, may materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our **or** product candidates, components of our product candidates, device candidates, components of our device candidates, services, and / or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include:
- **we or-and** our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our product candidates, device candidates, or processes do not infringe those third parties' patents;
- **we or-and** our collaborators may participate at substantial cost in International Trade Commission proceedings to abate importation of third-party products that would compete unfairly with our products;
- if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;
- if third parties initiate litigation claiming that our processes or product candidates **or those of the companies in which we hold interests**, infringe their patent or other intellectual property rights, we, **they** and our collaborators will need to defend against such proceedings;
- if third parties initiate litigation or other proceedings, including inter partes reviews, oppositions or other similar agency proceedings, seeking to invalidate patents owned by or licensed to us **or the companies in which we hold interests**, or to obtain a declaratory judgment that their products, services, or technologies do not infringe our patents or patents licensed to us **or them**, we will need to defend against such proceedings;
- we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our product candidate; and
- if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or product candidates **or those of the companies in which we hold interests** infringe or misappropriate its patent or other intellectual property rights and / or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business **and that of the companies in which we hold interests**. Any such claim could also force **use-us** to do one or more of the following:
- incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product candidate, service, or technology at issue infringes or violates the third party's rights, and if the court finds that the infringement was willful, we could be ordered to pay up to treble damages and the third party's attorneys' fees;
- pay substantial damages to our customers or end users **and those of the companies in which we hold interests** to discontinue use or replace infringing technology with non-infringing technology;
- stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology;
- obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all;
- redesign our product candidates, services, and technology **and those of the companies in which we hold interests** so they do not infringe or violate the third party's intellectual property rights, which may not be possible or may require substantial monetary expenditures and

time; ● enter into cross-licenses with our competitors **and those of the companies in which we hold interests**, which could weaken our overall intellectual property position; ● lose the opportunity to license our technology **that of the companies in which we hold interests** to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others; ● find alternative suppliers for non-infringing products and technologies, which could be costly and create significant delay; or ● relinquish rights associated with one or more of our patent claims **or those of the companies in which we hold interests**, if **our those** claims are held invalid or otherwise unenforceable. Some of our competitors **and those of the companies in which we hold interests** may be able to sustain the costs of complex intellectual property litigation more effectively than we can because **they those competitors** have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us **or them** from manufacturing, marketing or otherwise commercializing our products, services, and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. In addition, we may indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our product candidates or device candidates, **services or technologies**. Third parties may assert infringement claims against our customers or distributors. These claims may require us **or them** to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the product candidates, or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information **and that of the companies in which we hold interests** could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our common stock. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows. If we **and the companies in which we hold interests** are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. In addition to patent and trademark protection, we **and the companies in which we hold interests** also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Because we expect to rely on third parties to manufacture our product candidates **and device candidates**, and we expect to continue to collaborate with third parties on the development of our product candidates **and device candidates**, we must, at times, share trade secrets with them. We seek to protect our **respective** trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them prior to disclosing our proprietary information, such as our consultants and vendors, or our former or current employees. These agreements typically limit the rights of third parties to use or disclose our confidential information, including our trade secrets. We also enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, however, any of these parties may breach the agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to enforce trade secret protection. A competitor's discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, operating results, and financial condition. Additionally, we cannot be certain that competitors will not gain access to our trade secrets and other proprietary confidential information or independently develop substantially equivalent information and techniques. Changes in patent law could diminish the value of patents in general, thereby impairing **our the ability of us and the companies in which we hold interests** to protect our **respective** existing and future product **candidates, device candidates and processes**. As is the case with other biopharmaceutical companies, our success **and that of the companies in which we hold interests** is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical **industries industry** involves both technological and legal complexity, and is therefore costly, time consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith Act was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, and switched the United States patent system from a "first-to-invent" system to a "first-to-file" system. Under a "first-to-file" system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had conceived or reduced to practice the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, **only** became effective on March 16, 2013. **It Accordingly,** it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We **and the companies in which we hold interests** cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. The United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a "nonexclusive, nontransferable, irrevocable, paid-up license" for its own benefit. The Bayh-Dole Act also provides federal agencies with "march-in rights." March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a "nonexclusive, partially exclusive, or exclusive license" to a "responsible applicant or applicants." If the patent owner refuses to do so, the government may grant the license itself. We partner with a number of universities, including the University of Iowa and the University of Texas Southwestern Medical Center, with respect to certain of our research, development, and manufacturing. While it is our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. If we **and the companies in which we hold interests** do not obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates **and device candidates**, thereby potentially extending the term of marketing exclusivity for such product candidates **and device candidates**, our business may be harmed. In the United States, a patent that covers an FDA-approved drug, **biologic or biologic medical device** may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration, and conditions of FDA regulatory approval of our **and the companies in which we hold interests** product **candidates and device candidates**, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to a maximum of five years beyond the normal expiration of the patent if the patent is eligible for such an extension under the Hatch-Waxman Act as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We **and the companies in which we hold interests** may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request, and the patent term may still expire before or shortly after we receive FDA **marketing regulatory** approval. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection **and that of the companies in which we hold interests** could be reduced or eliminated for non-compliance with these requirements. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, device candidates, **processes or procedures technologies**, we may not be able to stop a competitor from marketing products that are the same as or similar to our own **or theirs**, which would have a material adverse effect on our business. If our trademarks and trade names **and those of the companies in which we hold interests** are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We **and the companies in which we hold interests** have not yet registered trademarks for a commercial trade

name for all of our product candidate (s) or device candidates, including in the United States or elsewhere. During trademark registration proceedings, our trademark application (s) may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product **candidate (s) or device** candidate (s) in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Our registered or unregistered trademarks or trade names **and those of the companies in which we hold interests** may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. In addition, third parties have used trademarks similar and identical to our trademarks in foreign jurisdictions, and have filed or may in the future file for registration of such trademarks. If **they-such third parties** succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In any case, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We **and the companies in which we hold interests** may not be able to adequately protect our intellectual property rights throughout the world. Certain of our key patent families **and those of the companies in which we hold interests** have been filed in the United States, as well as in numerous jurisdictions outside the United States. However, our intellectual property rights in certain jurisdictions outside the United States may be less robust. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. For example, the requirements for patentability may differ in certain countries, particularly developing countries, and we may be unable to obtain issued patents that contain claims that adequately cover or protect our current or future product candidates or device candidates, **services or technologies**. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market current or future product candidates or device candidates. Consequently, we may not be able to prevent third parties from practicing our technology in all countries outside the United States, or from selling or importing products made using our technology in and into those other jurisdictions where we do not have intellectual property rights. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop **their-such competitors'** own products and may also export infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our product candidates or device candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent **them-such competitors** from competing. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our **product candidates, device candidates, services, and technology-technologies**. We **and the companies in which we hold interests** may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates. We cannot guarantee that any of our or our licensors' patent searches or analyses, **or those of the companies in which we hold interests**, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates or device candidates. For example, U. S. patent applications filed before November 29, 2000 and certain U. S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or device candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates, device candidates, or the use of our products. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, and the patent's prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates or device candidates. We may incorrectly determine that our product candidates or device candidates are not covered by a third-party patent or may incorrectly predict whether a third party's pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates, device candidates, services, and technologies. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates, device candidates, services, and technologies. If we **and the companies in which we hold interests** fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates or device candidates that are held to be infringing. We might, if possible, also be forced to redesign products, product candidates, devices, device candidates, or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us **and them** to divert substantial financial and management resources that we would otherwise be able to devote to our business. Patent terms may be inadequate to protect our competitive position **and that of the companies in which we hold interests** on our product candidates or device candidates for an adequate amount of time. Patents have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U. S. non-provisional filing date. Even if patents covering our product candidates and device candidates are obtained, once the patent life has expired for patents covering a product or product candidate, a device or a device candidate, we **and the companies in which we hold interests** may be subject to competition from competitive products and services. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Intellectual property rights do not necessarily address all potential threats to our business. While we **and the companies in which we hold interests** seek broad coverage under our existing patent applications, there is always a risk that an alteration to products or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. In addition, patents, if granted, expire and we cannot provide any assurance that any potentially issued patents will adequately protect our product candidates or device candidates. Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked ~~or~~ may lose the allowed or granted claims altogether. In addition, the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business, provide a lawful barrier to entry against our competitors or potential competitors or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our **processes or technology-technologies**, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: ● others may be able to develop and / or practice **processes or technology-technologies** that ~~is are~~ similar to our **processes or technology-technologies** or aspects of our **processes or technology-technologies**, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue; ● we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; ● we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions; ● others may independently develop similar or alternative **processes or technologies** or duplicate any of our **processes or technologies** without infringing our intellectual property rights; ● it is possible that our pending patent applications will not lead to issued patents; ● issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; ● third parties performing manufacturing or testing for us using our product candidates **or device candidates**, including **our processes and technologies**, could use the intellectual property of others without obtaining a proper license; ● parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; ● we may not develop or in-license additional proprietary technologies that are patentable; ● we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and ● the patents of others may have an adverse effect on our business. Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. We **and the companies in which we hold interests** may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. We **and the companies in which we hold interests** do and may employ individuals who were previously employed at universities or other biopharmaceutical companies, including our licensors, competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be

required to obtain a license from such third party to commercialize our **processes, technology technologies, product candidates or product device** candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees and could result in customers seeking other sources for the **technology technologies or processes** or ceasing from doing business with us. Our intellectual property agreements **and those of the companies in which we hold interests** with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology. Certain provisions in our intellectual property agreements **and those of the companies in which we hold interests** may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, while we typically require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. To the extent that we fail to obtain such assignments, such assignments do not contain a self-executing assignment of intellectual property rights or such assignment agreements are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property, and this may interfere with our ability to capture the commercial value of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. We may be subject to claims that former collaborators or other third parties have an ownership interest in our patents or other intellectual property. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we are unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. We **and the companies in which we hold interests** may not be successful in obtaining necessary intellectual property rights to future products through acquisitions and in-licenses. Although we **and the companies in which we hold interests** intend to develop products and technology through our own internal research, we may also seek to acquire or in-license technologies to grow our product offerings and technology portfolio. However, we may be unable to acquire or in-license intellectual property rights relating to, or necessary for, any such products or technology from third parties on commercially reasonable terms or at all. In that event, we may be unable to develop or commercialize such products or technology. We may also be unable to identify products or technology that we believe are an appropriate strategic fit for our Company and protect intellectual property relating to, or necessary for, such products and technology. The in-licensing and acquisition of third-party intellectual property rights for product candidates and device candidates is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights for products that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional technologies or products, our business, financial condition, results of operations and prospects for growth could suffer. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for products and technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for products or technology on terms that would allow us to make an appropriate return on our investment. Risks Related to Employee Matters, Managing Our Growth, and Other Risks Related to Our Business Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. To succeed, we must recruit, retain, manage, and motivate qualified clinical, scientific, technical, and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biopharmaceutical field is intense and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other biopharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop, and commercialize our product candidates and device candidates will be limited, and the potential for successfully growing our business will be harmed. The requirements of being a public company may strain our resources, result in more litigation, and divert management's attention. As a public company, we are and will continue to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly, and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. We are required to disclose changes made in our internal controls over financial reporting on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal controls over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management's attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We have invested and intend to continue to invest in resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected. These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, during certain periods, including currently, we may utilize alternatives for such coverage, accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. By disclosing information in filings required of us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management's resources and seriously harm our business. Public health threats could have an adverse effect on the Company's operations and financial results. In 2020, a strain of novel coronavirus disease, COVID-19, was declared a pandemic and spread across the world, including throughout the United States, Europe, and Asia. The pandemic and government measures taken in response **have also** had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages **have** occurred, clinical trials **were have been** suspended, supply chains **were have been** disrupted, and facilities and production **were have been** suspended. The impacts on the operations and specifically the ongoing clinical trials of the Pharmaceutical Companies have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible, including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies. In the earlier days of the pandemic's impact, Cornerstone experienced certain delays in enrollment in certain clinical trials. We believe, however, that those trials' enrollment goals were ultimately attained in a timely manner. **Similar impacts could be experienced by Rafael Medical Devices in response to the COVID-19 pandemic, subsequent variants or comparable public health emergencies.** We have implemented a number of measures to protect the health and safety of our workforce, including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings. **We will maintain these as necessary and appropriate in response to the COVID-19 pandemic, subsequent variants or comparable public health emergencies.** As a result of the COVID-19 pandemic, **subsequent variants or comparable public health emergencies, we and the Pharmaceutical Companies and Rafael Medical Devices** may experience further disruptions that could severely impact our **or their** business, preclinical studies, and clinical trials, including: **• difficulties or delays in initiating, enrolling, conducting or completing any planned and ongoing nonclinical and preclinical studies and clinical trials;** **• delays in receiving approval from local regulatory authorities to initiate our the Pharmaceutical Companies' and Rafael Medical Devices' planned clinical trials;** **• delays or difficulties in enrolling patients in our the Pharmaceutical Companies' and Rafael Medical Devices' clinical trials;** **• limits or halts imposed on clinical trials and clinical trial sites, including hospitals and medical centers, among others;** **• delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;** **• diversion of healthcare resources away from the conduct of the Pharmaceutical Companies' and Rafael Medical Devices' clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;** **• risk that participants enrolled in our clinical trials or staff involved in or related staff to clinical trials will acquire COVID-19 or subsequent variants** while the clinical trial is ongoing, which could impact the **duration and** results of the clinical trial, including by increasing the number of observed adverse events; **• interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state**

governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints; ● **prolonged government shutdowns or global health concerns preventing the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities;** ● interruption or delays in the operations of the FDA, which may impact review and approval timelines; ● interruption of, or delays in receiving, supplies of **our the Pharmaceutical Companies' product candidates and Rafael Medical Devices' device candidates from our their** contract manufacturing organizations due to staffing or supply shortages, production slowdowns, global shipping delays or stoppages and disruptions in delivery systems; ● limitations on employee resources that would otherwise be focused on the conduct of **our the Pharmaceutical Companies' and Rafael Medical Devices' preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;** ● refusal of the FDA **or comparable foreign regulatory authorities** to accept data from clinical trials in affected geographies; ● impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our **, the Pharmaceutical Companies' and Rafael Medical Devices'** business continuity plans; and ● delays or difficulties with equity offerings due to disruptions and uncertainties in the securities market. **Any inability by the Pharmaceutical Companies or Rafael Medical Devices to successfully initiate or complete nonclinical and preclinical studies or clinical trials could result in additional costs or impair our ability to generate revenue from future product sales of any product candidates or device candidates that were thought to be on track to receive regulatory approval or clearance.** The COVID-19 pandemic, **subsequent variants or comparable public health emergencies** could also negatively impact our real estate business in a number of ways, including: ● the financial condition of our tenants and their ability or willingness to pay rent in full on a timely basis; ● the impact on rents and demand for office and retail space; ● a complete or partial closure of operations resulting from government action; ● the impact of new regulations or norms on physical space needs and expectations; ● the effectiveness of governmental measures aimed at slowing and containing the spread; ● the extent and terms associated with governmental relief programs; ● the ability of debt and equity markets to function and provide liquidity; ● the ability to avoid delays or cost increases associated with building materials or construction services necessary for development, redevelopment and tenant improvements; and ● our tenants' ability to ensure business continuity in the event a continuity of operations plan is not effective or improperly implemented. Due to both known and unknown risks, including quarantines, closures, and other restrictions resulting from **the outbreak COVID-19, subsequent variants or comparable public health emergencies**, our operations and those of **our holdings the companies in which we have interests** may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic **or, a subsequent variant or comparable public health emergencies** may have on our business, financial condition, results of operations, and cash flows. The impact will depend on future developments, such as the ultimate duration and the severity of the spread **in the U. S. and globally** of the COVID-19 pandemic **and, any subsequent variant or comparable public health emergencies in the U. S. and globally,** the effectiveness of federal, state, local, and foreign government actions on mitigation and spread of COVID-19 **and any, a subsequent variant or comparable public health emergencies**, the pandemic's impact on the U. S. and global economies, changes in our **, the Pharmaceutical Companies' and Rafael Medical Devices'** customers' behavior emanating from the pandemic **, a subsequent variant or comparable public health emergencies** and how quickly we **, the Pharmaceutical Companies and Rafael Medical Devices** can resume our **and their** normal operations, among others. For all these reasons, we **, the Pharmaceutical Companies and Rafael Medical Devices** may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business. If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. We are required to disclose changes made in our internal controls and procedures on a quarterly basis and to disclose any changes and material weaknesses in those internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. We cannot be certain that we will continue to maintain an effective system of internal controls over our financial reporting in future periods. Any failure to maintain such internal controls could adversely impact our ability to report our financial results on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis as required by the Securities and Exchange Commission and The New York Stock Exchange, we could face severe consequences from those authorities. In either case, there could result a material adverse effect on our business. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. We have identified material weaknesses in our internal controls over financial reporting. Maintaining effective internal controls over financial reporting is necessary for us to produce reliable financial statements. In the past, we have identified material weaknesses in our internal controls over financial reporting which have since been remediated. If additional material weaknesses in our internal controls over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results. Conditions in Israel, including the **recent terrorist attack by ongoing war between Israel and Hamas, and other conflicts in terrorist organizations from the Gaza Strip and Israel's war against them the region,** may adversely affect our real estate holding and operations of our **Investment Portfolio** Companies, which would lead to a decrease in revenues. **On In October 7, 2023, Hamas terrorists and members of other terrorist organizations infiltrated Israel's southern border from the Gaza Strip and conducted a series of terror attacks on civilian and military targets. Hamas also thereafter, these terrorists launched extensive rocket attacks on Israeli population and industrial centers located along the Israeli- Israel's border with the Gaza Strip and in . It is possible that other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers, as well as evacuations of tens of thousands of civilians from their homes. Following the attack, Israel's security cabinet declared war against Hamas and a military campaign against these terrorist organizations will join commenced in parallel to their continued rocket and terror attacks. Furthermore, hostilities along Israel's northern border with Hezbollah located in Lebanon and Iran have accelerated, and each of these clashes may escalate in the future into a greater regional conflict. The intensity and duration of Israel's current war against Hamas is difficult to predict, as are such war's economic implications on our business and operations and on Israel's economy in general. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel's economic standing, for instance, a downgrade in Israel's credit rating by rating agencies (such as the recent downgrade by Moody's of its credit rating of Israel from A1 to A2, as well as the downgrade of its outlook rating from "stable" to "negative" and the S & P Global lowered its long-term credit rating from AA- to A, including Hezbollah in Lebanon as well as a downgrade of its short-term credit ratings from A-1 to A-1, with and an outlook on Palestinian military organizations in the West Bank long-term ratings "negative", as well as the recent downgrade by Fitch Ratings of its credit rating of Israel from A to A, with an outlook rating of "negative"), which may have a material adverse effect on our company and our ability to effectively conduct its operations.** Our real estate holding in Jerusalem and operations of **Lipomedix LipoMedix** and Day Three in Jerusalem and Rosh Haayin, respectively, are not only within the range of rockets from the Gaza Strip, but also within the range of rockets that can be fired from Lebanon, Syria or elsewhere in the Middle East. Our lone real estate holding can be damaged as a result of hostile action or hostilities or the ongoing operations of **Lipomedix LipoMedix** and Day Three may be disrupted. Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. As a result of the Israeli security cabinet's decision to declare war against Hamas, several hundred thousand Israeli reservists were drafted to perform immediate military service. Certain of our employees and consultants in Israel, in addition to employees of our service providers located in Israel, have been called for service in the current war with Hamas as of the date of this **registration statement annual report,** and such persons are expected may be absent for an extended period of time. As a result, operations of **Lipomedix LipoMedix** and Day Three may be disrupted by such absences, which may materially and adversely affect their business and results of operations. The relationships between Howard S. Jonas and IDT Corporation, **and Genie Energy and Cornerstone Pharmaceuticals** could conflict with our stockholders' interests. Howard S. Jonas, Chairman of our Board of Directors and Executive Chairman and former Chief Executive Officer, is also the chairman of IDT Corporation and Chairman of the Board of Genie **and holds certain direct and indirect interests in Cornerstone and serves as Chairman of its Board in addition to his interests through ownership of our common stock.** These relationships may cause a conflict of interest with our stockholders. Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to uninsured liabilities. Some of the insurance policies we currently maintain, or which we have maintained in the past, include general liability, employment practices liability, property, product liability, workers' compensation, umbrella, and directors' and officers' insurance. These policies may not adequately cover all categories of risk that our business may encounter. Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain regulatory approval or clearance for any of the **Investment Portfolio** Companies' product candidates or device candidates, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates or device candidates we develop. We may not carry adequate specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals **and clearances, if any,** could be suspended **or withdrawn**. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and, during certain periods, including

currently, we may utilize alternatives for such coverage, accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any **cyber-security-cybersecurity** incidents, could harm our ability to operate our business and that of the companies in which we hold interests effectively. **Despite We and the Portfolio Companies and our and the their implementation other third- party vendors and collaborators receive, collect, process, use and store a large amount of information, including personal information, intellectual property, protected health and other sensitive and confidential information. This data is often accessed through transmissions over public and private networks, including the internet. The secure transmission of such information over the internet and other mechanisms is essential to maintain confidence in our and their information technology systems yet is vulnerable to unauthorized access and disclosure. We have implemented security measures, technical controls and contractual precautions designed to identify, detect and prevent unauthorized access, alteration, use or disclosure of data. We may face increased cybersecurity risks due to our reliance on internet technology and the Investment number of employees who are working remotely, which may create additional opportunities to exploit vulnerabilities. Beyond external activity, systems that access or control access to services and databases may be compromised as a result of human error, fraud or malice on the part of employees or third parties, or may result from accidental technological failure. Because the techniques used to circumvent security systems can be highly sophisticated and change frequently, often are not recognized until launched against a target, and may originate from less regulated and remote areas around the world, we may be unable to proactively address all possible threats or implement adequate preventive measures for all situations. Despite the implementation of security measures, our and the Portfolio Companies' internal computer systems and those of other third parties with which we and the Investment Portfolio Companies collaborate and contract are vulnerable to attempted breaches of security, unauthorized disclosure of information, attacks which reduce availability of systems such as denial of service, damage from cyber- attacks, computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures , and the perception that personal and / or other sensitive or confidential information in our possession is not secure.** System failures, accidents or security breaches could cause interruptions in our and the Investment Portfolio Companies' operations —and could result in a material disruption of our and their clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays **inf- in the Investment Portfolio Companies' regulatory approval and clearance** efforts and significantly increase their costs to recover or reproduce the data **and pursue regulatory approval or clearance**. To the extent that any disruption or security breach were to result in a loss of, or damage to, our or the Investment Portfolio Companies' data or applications, or inappropriate disclosure of confidential or proprietary information, we and the Investment Portfolio Companies could incur **substantial legal liability or significant harm to our reputation, and our** and their product research, development, and commercialization efforts could be delayed. **We face risks related to the protection of information that we maintain — or for which a third- party engaged to maintain information security on our behalf — including unauthorized access, acquisition, use, disclosure, or modification of such information. Cyberattacks are increasing in their frequency, sophistication and intensity and have become increasingly difficult to detect and respond to. Cyberattacks could include the deployment of harmful malware, ransomware, denial- of- service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. The techniques used in these attacks change frequently and may be difficult to detect for periods of time, and we may face difficulties in anticipating and implementing adequate preventative measures. A material cyberattack or security incident could cause interruptions in our or their operations and could result in a material disruption of our or their business operations, damage to our or their reputation, financial condition, results of operations, cash flows and prospects.** Furthermore, we , **the Portfolio Companies** and our third- party providers **and business partners** rely on electronic communications and information systems to conduct our operations. We and our third- party providers have been, and may continue to be, targeted by parties using fraudulent e- mails and other communications in attempts to misappropriate bank accounting information, passwords, or other personal information or to introduce viruses or other malware to our information systems. In October 2021, we experienced a cybersecurity incident where a related party's email was hacked which led to payment of two invoices. As of the date of this filing, one of the invoice payments had been recovered by the Company. We continue to explore a range of steps to enhance our security protections and prevent future unauthorized activity. Although we endeavor to mitigate these threats, such cyber- attacks against us , **the Portfolio Companies** or our third- party providers and business partners remain a serious issue. The pervasiveness of cybersecurity incidents in general and the risks of cyber- crime are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information systems and are exploring various measures to manage the risk of a security breach or disruption, there can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. **Risks Related to the Merger with Cyclo The Exchange Ratio used in the Merger will be determined in accordance with a formula and is not yet knowable. The actual Exchange Ratio could be materially different than currently anticipated. At the First Effective Time (as defined in the Notes to the consolidated financial statements), outstanding shares of Cyclo Common Stock will be automatically cancelled and retired and cease to exist, and will entitle a holder of shares of Cyclo common stock to receive shares of our Class B Common Stock in exchange for the holder's Cyclo Common Stock equal to the Exchange Ratio. The Merger Agreement contains an illustration of the calculation of the Exchange Ratio based on the assumptions described therein. Those assumptions will likely not reflect the actual metrics as of the Closing. The actual Exchange Ratio will be based upon a price for Cyclo common stock of \$ .95 per share and the sum of (i) our cash, cash equivalents and marketable securities as of the Closing Date, (ii) certain other of our assets and (iii) the amounts loaned by us to Cyclo prior to closing of the Merger, less our current liabilities, divided by the total number of shares of our capital stock outstanding as of the Closing Date, including any shares issuable upon exercise or conversion of our outstanding securities with exercise or conversion prices not exceeding 150 % of the then- current market price of our Class B Common Stock issued to Cyclo stockholders. Accordingly, the Exchange Ratio could be significantly higher or lower than in the illustration provided. This will impact the value of the deal to the Cyclo stockholders and the number of shares of our Class B Common Stock to be issued to the Cyclo stockholders. Uncertainty about the Merger may adversely affect our business and stock price whether or not the Merger is completed. We are subject to risks in connection with the announcement and pendency of the Merger, including the pendency and outcome of any legal proceedings against us, our directors and others relating to the Merger and the risks from possibly foregoing opportunities we might otherwise pursue absent the proposed Merger. In addition, in response to the announcement of the proposed Merger, our existing or prospective suppliers or collaboration partners may: • delay, defer or cease providing goods or services to us; • delay or defer other decisions concerning us, or refuse to extend credit terms to us; • cease further joint development activities; or • otherwise seek to change the terms on which they do business with us. While we are attempting to address these risks, our existing and prospective customers, suppliers or collaboration partners may be reluctant to purchase our products, supply us with goods and services or continue collaborations due to the potential uncertainty about the direction of our product offerings and the support and service of our products after the completion of the Merger. While the Merger is pending, we are subject to contractual restrictions that could harm our business, operating results, and stock price. The Merger Agreement includes restrictions on our conduct prior to the completion of the Merger, generally requiring us to conduct our businesses in the ordinary course, consistent with past practice, and restricting us from taking certain specified actions absent prior written consent from the other party. We may find that these and other obligations in the Merger Agreement may delay or prevent us from or limit our ability to respond effectively to competitive pressures, industry developments and future business opportunities that may arise during such period, even if our management or Board think they may be advisable. The Merger Agreement also contains restrictions on the conduct of our business prior to the completion of the Merger, prohibiting our ability to acquire another business or restructure, reorganize or completely or partially liquidate absent the other's prior written consent. These restrictions could adversely impact our business, operating results and stock price and the perceived acquisition value, regardless of whether the Merger is completed. The Merger will involve substantial costs. We have incurred and expect to continue to incur substantial costs and expenses relating to the Merger and the issuance of our Class B common stock in connection with the Merger, including, as applicable, fees and expenses payable to financial advisors, other professional fees and expenses, insurance premium costs, SEC filing fees, printing and mailing costs and other transaction- related costs, fees and expenses. We may also incur significant costs relating to the acquisition of Cyclo, including the payment to certain holders of Cyclo's warrants who have the right to elect to receive cash payment as a result of the Merger as well as ongoing liabilities of Cyclo that remain in the business after the Merger is completed. We continue to assess the magnitude of these costs, and additional unanticipated costs may be incurred in connection with the Merger. In addition, if the Merger is not completed, we will have incurred substantial expenses for which no ultimate benefit will have been received by either company. We will incur significant transaction and Merger- related transaction costs in connection with the Merger. We expect that we will incur significant, non- recurring and operating costs in connection with consummating the Merger and funding the operations of Cyclo during the pendency of the Merger and post- closing. We will also incur additional costs to retain key employees of Cyclo under employee agreements with the merged company. We will also incur significant fees and expenses relating to legal services (including any costs that would be incurred in defending against any potential class action lawsuits and derivative lawsuits in connection with the Merger if any such proceedings are brought), accounting and other fees and costs associated with consummating the Merger. We will also incur costs in connection with the payment to certain holders of Cyclo Warrants as a result of the Merger. Some of these costs are payable regardless of whether the Merger is completed. We continue to assess the magnitude of these costs, additional unanticipated costs may be incurred in the Merger and the operation of the business of Cyclo following the Merger. We or Cyclo may waive one or more of the closing conditions to the Merger without re- soliciting approval from our respective stockholders. To the extent permitted by law, we or Cyclo may determine to waive, in whole or part, one or more of the conditions to our or their respective obligations to consummate the Merger. We and Cyclo expect to evaluate the materiality of any waiver and its effect on Cyclo or our stockholders in light of the facts and circumstances at the time to determine whether any amendment the Registration Statement or any re- solicitation of proxies is required in light of such waiver. Any determination as to whether to waive any condition to the consummation of the Merger, and as to whether to re- solicit the stockholders' approval as a result of such waiver, will be made by us and Cyclo at the time of such waiver based on the facts and circumstances as they**

exist at that time. We may be targets of securities class action and derivative lawsuits which could result in substantial costs and may delay or prevent the Merger from being completed. Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are without merit, defending against these claims could result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Merger, then that injunction may delay or prevent the Merger from being completed, or from being completed within the expected timeframe, which may adversely affect our business, financial position and results of operations. Changes in the market prices of our Class B Common Stock may result from a variety of factors that are beyond our control. The market value of our Class B Common Stock has fluctuated since the date of the announcement of the Merger and will continue to fluctuate to the Closing Date and following the completion of the Merger. The market value of our Class B Common Stock at the time of the closing of the Merger may vary significantly from the price of our Class B Common Stock on the date of the Merger Agreement, the date of the Registration Statement or the date of our Special Meeting. Changes in the market prices of our Class B Common Stock may result from a variety of factors that are beyond our control, including changes in our business, operations and prospects, general market conditions, regulatory considerations, governmental actions, and legal proceedings and developments. We may not realize the anticipated benefits and cost savings of the Merger. While we will continue to operate independently following the completion of the merger, the success of the merger will depend, in part, on our ability to realize the anticipated benefits and cost savings from Cyclo's businesses as a wholly owned subsidiary of ours following the Merger. Our ability to realize these anticipated benefits and cost savings is subject to certain risks, including, among others: ● our ability to successfully operate the businesses following the closing of the Merger; ● the risk that our businesses will not perform as expected; ● the extent to which we will be able to realize the expected synergies, which include realizing potential savings from eliminating duplication and redundancy in overhead, adopting an optimized operating model between our company and Cyclo's company and leveraging scale, our funding the merged company following the completion of the Merger, and creating value resulting from the Merger; ● the reduction of cash available for operations and other uses by us; ● the possibility of costly litigation challenging the Merger. If we are not able to successfully integrate their businesses within the anticipated time frame, or at all, the anticipated cost savings and other benefits of the Merger may not be realized fully or may take longer to realize than expected, and we may not perform as expected. Failure to complete the merger Merger could negatively impact our stock price and our future business and financial results. Our obligations to complete the Merger are subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement. There can be no assurance that the conditions to completion of the Merger will be satisfied or waived or that the Merger will be completed. If the Merger is not completed for any reason, our ongoing business may be materially and adversely affected and, without realizing any of the benefits of having completed the Merger, we would be subject to a number of risks, including the following: ● We may experience negative reactions from the financial markets, including negative impacts on trading prices of our Class B Common Stock and from our customers, vendors, regulators and employees; ● We may be required to pay certain expenses incurred in connection with the Merger, whether or not the Merger is completed including the payment of up to \$ 250, 000 of expenses of the other party in certain circumstances involving a breach of the representations, warranties and covenants in the Merger Agreement; ● the Merger Agreement places certain restrictions on the operation of our business prior to the closing of the Merger, and such restrictions, the waiver of which is subject to the consent of Cyclo, may prevent us from making certain acquisitions, taking certain other specified actions or otherwise pursuing business opportunities during the pendency of the Merger that we would have made, taken or pursued if these restrictions were not in place; and ● matters relating to litigation the Merger will require substantial commitments of time and resources by our management and the expenditure of significant funds in the form of fees and expenses, which would otherwise have been devoted to day-to-day operations and other opportunities that may have been beneficial to us. We In addition, we could be subject to litigation related to any failure to complete the proposed merger Merger with Cornerstone or related to any proceeding to specifically enforce our obligations under the merger Merger agreement Agreement. If any of these risks materialize, they may materially and adversely affect our business, financial condition, financial results and stock prices. Third parties may terminate or alter existing contracts or relationships with us. We have contracts with customers, vendors and other business partners which may require us, as applicable to obtain consents from these other parties in connection with the Merger. If these consents cannot be obtained, the counterparties to these contracts and other third parties with which we currently have relationships may have the ability to terminate, reduce the scope of or otherwise materially adversely alter their relationships with us in anticipation of the Merger, or with us following the Merger. The pursuit of such rights may result in our suffering additional losses, a loss of potential future revenue, incurring liabilities in connection with a breach of such agreements or losing rights that are material to our business. Any such disruptions could limit our ability to achieve the anticipated benefits of the Merger. The adverse affect of such disruptions could also be exacerbated by a delay in the completion of the Merger or the termination of the Merger. The NYSE may not list our shares of Class B Common Stock, which could limit investors' ability to make transactions in the shares of our Class B Common Stock and subject our Class B Common Stock to additional trading restrictions. In connection with the Merger, in order to continue to maintain the listing of our Class B Common Stock on the NYSE, we will be required to demonstrate compliance with the NYSE's listing requirements. We will use reasonable best efforts to cause the shares of our Class B Common Stock issuable, and required to be reserved for issuance, in connection with the Merger to be approved for listing on the NYSE, subject to official notice of issuance, prior to the Closing. We cannot provide assurance that we will be able to meet all listing requirements. Even if the shares of our Class B Common Stock are listed on the NYSE, we may be unable to maintain the listing of our securities in the future. If we fail to meet the listing requirements and the NYSE does not list our securities on its exchange, Cyclo would not be required to consummate the Merger. In the event that Cyclo elected to waive this condition, and the Merger was consummated without our securities being listed on the NYSE or on another national securities exchange, we would face significant material adverse consequences, including: ● a limited availability of market quotations for our Class B Common Stock; ● reduced liquidity for our Class B Common Stock; ● a determination that the shares of our Class B Common Stock are a " penny stock " which will require brokers trading in our Class B Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Class B Common Stock; ● a limited amount of news and analyst coverage; and; ● a decreased ability to issue additional securities or obtain additional financing in the future. The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or pre- empts the states from regulating the sale of certain securities, which are referred to as " covered securities " If the shares of our Class B Common Stock are not listed on the NYSE, such securities would not qualify as covered securities and we would be subject to regulation in each state in which we offer our securities because states are not pre- empted from regulating the sale of securities that are not covered securities. Risks Related to Ownership of our Common Stock We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock. We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain. We are controlled by our principal stockholder, which limits the ability of other stockholders to affect the management of the Company. Howard S. Jonas, our Chairman of our Board of Directors and our Executive Chairman, controls a majority of the voting power of our capital stock. As of October 27-29, 2023-2024, Mr. Jonas has voting power over 787, 163 shares of our Class A common stock (which are convertible into shares of our Class B common stock on a 1- for- 1 basis) and 665-821, 247-374 shares of our Class B common stock, representing approximately 51 % of the combined voting power of our outstanding capital stock. Mr. Jonas will be able to control matters requiring approval by our stockholders, including the election of all of the directors and the approval of significant corporate matters, including any merger, consolidation or sale of all or substantially all of our assets. As a result, the ability of any of our other stockholders to influence our management is limited. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Outstanding shares of our common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act, or to the extent that such shares have already been registered under the Securities Act and are held by non- affiliates of ours. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have registered all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance, and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. We are a " smaller reporting company, " and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors. We are considered a " smaller reporting company. " We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile. General Risk Factors If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. From time to time, we may evaluate various acquisition opportunities and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: ● increased operating expenses and cash requirements; ● the assumption of additional indebtedness or contingent liabilities; ● the issuance of our equity securities; ● assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; ● the diversion of our management' s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; ● retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; ● risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates, devices or device candidates, and any regulatory approvals or clearances ; and ● assumption of the regulatory risks, costs, and responsibilities associated with the other party' s existing products or product candidates, devices or device candidates, and any regulatory approvals or clearances; ● our inability to generate revenue from

acquired technology and / or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. In addition, if we undertake acquisitions or pursue collaborations in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Investors may suffer dilution. We may engage in equity financing to fund our future operations and growth or issue equity securities in commercial or other transactions. If we raise additional funds by issuing equity securities, or issue equity securities for other purposes, stockholders may experience significant dilution of their ownership interest (both with respect to the percentage of total securities held, and with respect to the book value of their securities) and such securities may have rights senior to those of the holders of our common stock. In addition, if we do not provide our **Investment Portfolio** Companies with the capital they require, they may seek capital from other sources, which would result in dilution and possible subordination or other diminution in value of our interests in those companies. The trading price of the shares of our Class B common stock is likely to remain volatile, and purchasers of our Class B common stock could incur substantial losses. Our stock price is likely to remain volatile. The stock market in general and the market for **Investment the Portfolio** Companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their Class B common stock at or above the price paid for the shares. The market price for our Class B common stock may be influenced by many factors, including: ● actual or anticipated variations in quarterly operating results; ● changes in financial estimates by us or by any securities analysts who might cover our stock; ● conditions or trends in our industry; ● stock market price and volume fluctuations of other publicly traded companies and, in particular, those that operate in the real estate or healthcare industries; ● announcements by us or our competitors of **preliminary or interim data from or** the results of clinical trials, new product or service offerings, or significant acquisitions; ● strategic collaborations or divestitures; ● announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; ● capital commitments; ● additions or departures of key personnel; and ● sales of our common stock, including sales by our directors and officers or specific stockholders. In addition, in the past, stockholders have initiated class action lawsuits against companies following periods of volatility in the market prices of these companies' stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management's attention and resources. The realization of any of the above risks or any of a broad range of other risks, including those described in this "Risk Factors" section, could have a dramatic and adverse impact on the market price of our common stock. If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline. The trading market for our common stock will rely in part on the research and reports that equity research analysts may publish about us and our business. We do not currently have analyst coverage and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts or others downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. We may be subject to securities litigation, which is expensive and could divert management attention. The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could seriously harm our business. Item 1B. Unresolved Staff Comments –None. **Item 1C. Cybersecurity Cybersecurity risk management and strategy** Our cybersecurity risk management is based on recognized cybersecurity industry frameworks and standards, including those of the National Institute of Standards and Technology, the Center for Internet Security Controls, and the International Organization for Standardization. We use these frameworks, together with information collected from internal assessments, to develop policies for the use of our information assets (for example, IT business information and information resources such as mobile phones, computers and workstations), access to specific intellectual property or technologies, and protection of personal information. We protect these information assets through industry-standard techniques, such as multifactor authentication and malware defenses. We also work with internal stakeholders across the company to integrate foundational cybersecurity principles throughout our organization's operations, including the employment of multiple layers of cybersecurity defenses, restricted access based on business needs, and integrity of our business information. Throughout the year, we also regularly train our employees on cybersecurity awareness, confidential information protection and simulated phishing attacks. Our cybersecurity risk management extends to risks associated with our use of third-party service providers. For instance, we conduct risk and compliance assessments of third-party service providers that request access to our information assets. Our cybersecurity risk management is an important part of our comprehensive business continuity program and enterprise risk management. Our global information security team periodically engages with a cross-functional group of subject matter experts and leaders to assess and refine our cybersecurity risk posture and preparedness. For example, we regularly evaluate and update contingency strategies for our business in the event that a portion of our information resources were to be unavailable due to a cybersecurity incident. We practice our response to potential cybersecurity incidents through regular tabletop exercises, threat hunting and red team exercises. Governance of cybersecurity risk management The board of directors, as a whole, has oversight responsibility for our strategic and operational risks. The audit committee assists the board of directors with this responsibility by reviewing and discussing our risk assessment and risk management practices, including cybersecurity risks, with members of management. The audit committee, in turn, periodically reports on its review with the board of directors. Management is responsible for day-to-day assessment and management of cybersecurity risks and reports regularly to the audit committee. Item 2. Properties –Our principal executive office is located in 520 Broad Street, Newark, New Jersey. LipoMedix has a Research and Services Agreement with Shaare Zedek Scientific Ltd. by which laboratory space at Shaare Zedek Medical Center is used for R & D activities. This agreement is conditioned to grant support for the Shaare Zedek Nano- Oncology research center either directly from LipoMedix or indirectly through the Israel Innovation Authority Fund (Israel Chief Scientist Office). This arrangement has been in place since 2012, and the grant support is negotiable and renewed on an annual basis. However, there can be no guarantees that Shaare Zedek will continue this agreement in the future. **LipoMedix leased an administrative office in Giv'at Ram Hi-Tech Park from the Hebrew University. Rent was \$ 3, 600 annually, and the lease agreement ran through September 30, 2022.** See Item 1 — "Real Estate" for a discussion of properties held by the Company for investment purposes and Item 8 — "Financial Statements and Supplemental Data," for a detailed listing of such facilities. Item 3. Legal Proceedings Legal proceedings disclosure is presented in Note 19-21 to our Consolidated Financial Statements and included in Item 8 to Part II of this Annual Report. The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, other than noted above, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company's results of operations, cash flows or financial condition. Item 4. Mine Safety Disclosures –Not applicable. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities PRICE RANGE OF COMMON STOCK Our Class B common stock trades on the New York Stock Exchange under the symbol "RFL." Trading commenced on the NYSE American on March 27, 2018 and the Company uplisted and commenced trading on the New York Stock Exchange on November 21, 2019. On **October 27, November 5, 2023-2024**, there were **262-249** holders of record of our Class B common stock and one holder of record of our Class A common stock. Howard Jonas has voting and dispositive power over all shares of Class A common stock. The number of holders of record of our Class B common stock does not include the number of persons whose shares are in nominee or in "street name" accounts through brokers. On **October 27, November 5, 2023-2024**, the last sales price reported on the NYSE for the Class B common stock was \$ **1. 55-81** per share. We do not anticipate paying dividends on our common stock **unless and** until we achieve sustainable profitability (after satisfying all of our operational needs) and retain certain minimum cash reserves. Distributions will be subject to the need to retain earnings for investment in growth opportunities or the acquisition of complementary assets. The payment of dividends in any specific period will be at the sole discretion of our Board of Directors. The information required by Item 201 (d) of Regulation S- K will be contained in our Proxy Statement for our Annual Stockholders Meeting, which we will file with the Securities and Exchange Commission within 120 days after July 31, **2023-2024**, and which is incorporated by reference herein. Performance Graph of Stock We are a smaller reporting company as defined by Rule 12b- 2 of the Securities and Exchange Act of 1934 and are not required to provide the information under this item. Issuer Repurchases of Equity Securities Item 6. [Reserved] **Item 7A.** Quantitative and Qualitative Disclosures about Market Risks FOREIGN CURRENCY RISK Revenue from tenants located in Israel represented **44 % and 53 % and 7%** of our consolidated revenues, inclusive of revenue from discontinued operations, for the years ended July 31, **2024 and 2023 and 2022**, respectively. The entirety of these revenues is in currencies other than the U.S. Dollar. Our foreign currency exchange risk is somewhat mitigated by our ability to offset a portion of these non- U.S. Dollar- denominated revenues with operating expenses that are paid in the same currencies. While the impact from fluctuations in foreign exchange rates affects our revenues and expenses denominated in foreign currencies, the net amount of our exposure to foreign currency exchange rate changes at the end of each reporting period is generally not material. INVESTMENT RISK In addition to, but separate from our primary business, we will hold a portion of our assets in hedge funds and a passive investment in another entity. Investments in hedge funds carry a degree of risk and depend to a great extent on correct assessments of the future course of price movements of securities and other instruments. There can be no assurance that our investment managers will be able to accurately predict these price movements. The securities markets have in recent years been characterized by great volatility and unpredictability. Our passive interests in other entities are not currently liquid and we cannot assure that we will be able to liquidate them when we desire, or ever. Accordingly, the value of our investments may go down as well as up and we may not receive the amounts originally **invested upon redemption**. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations This Annual Report contains forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that contain the words "believes," "anticipates," "expects," "plans," "intends" and similar words and phrases. These forward- looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the results projected in any forward- looking statement. In addition to the factors specifically noted in the forward- looking statements, other important factors, risks and uncertainties that could result in those differences include, but are not limited to, those discussed under Item 1A to Part I "Risk Factors" in this Annual Report. The forward- looking statements are made as of the date of this Annual Report, and we assume no obligation to update the forward- looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Investors should consult all of the information set forth in this report and the other information set forth from time to time in our reports filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 and the Securities Exchange Act of 1934, including our reports on Forms 10- Q and 8- K. The following discussion should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in

Item 8 of this Annual Report. Overview Rafael Holdings, Inc. (NYSE:RFL), (“Rafael Holdings”, “Rafael”, “we” or the “Company”), a Delaware corporation, is a holding company with interests in clinical and early-stage pharmaceutical companies (the “Pharmaceutical Companies”), including an investment in Cornerstone Pharmaceuticals, (and planned merger with) Cyclo Therapeutics Inc. (Nasdaq: CYTH), formerly known as Rafael Pharmaceuticals Inc. (“Cyclo Therapeutics” or “Cyclo”), a clinical stage biotechnology cancer metabolism-based therapeutics company dedicated to developing Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder, a majority equity interest in LipoMedix Pharmaceuticals Ltd. (“LipoMedix”), a clinical stage pharmaceutical company, the Barer Institute Inc. (“Barer”), a wholly-owned preclinical cancer metabolism research operation, and an investment a majority interest in Cyclo Therapeutics-Cornerstone Pharmaceuticals, Inc. (Nasdaq: CYTH) (“Cornerstone Cyclo Therapeutics” or “Cyclo”), formerly known as Rafael Pharmaceuticals Inc., a clinical cancer metabolism-stage biotechnology-based therapeutics company dedicated to developing life-changing medicines for patients and families living with challenging diseases through its lead therapeutic asset, Trappsol® Cyclo™. We also hold, an investment in Day Three Labs, Inc. (“Day Three”), a company which reimagines existing cannabis offerings with pharmaceutical-grade technology and innovation like Unlokt™ to bring to market better, cleaner, more precise and predictable products in the cannabis industry, and a majority interest in Rafael Medical Devices, LLC, (“Rafael Medical Devices”), an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc. (“Day Three”), a company which empowers third-party manufacturers to reimagine their existing cannabis offerings enabling them to bring to market better, cleaner, more precise and predictable versions by utilizing Day Three’s pharmaceutical-grade technology and innovation like Unlokt™, Day Three and Rafael Medical Devices, and Day Three Labs together with the Pharmaceutical Companies, represent our “Investment Portfolio Companies”. In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. Since then, the Company has sought partners for programs at Farber and has entered into a license agreement for one of its technologies. The Company’s primary focus is to expand our investment portfolio through opportunistic and strategic investments including therapeutics, which address high unmet medical needs. The Upon closing of the planned merger with Cyclo, the Company intends to focus its efforts on making Trappsol® Cyclo™ its lead clinical program. Historically, the Company owned real estate assets. In 2020, the Company sold an office building located in Piscataway, New Jersey and, on August 22, 2022, the Company sold the building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and several tenants and an associated public garage (the “520 Property”). As of July 31, 2024, the Company holds debt a portion of a commercial building in Jerusalem, Israel as its remaining owned real estate asset. In May 2023, the Company first invested in Cyclo Therapeutics. Cyclo is a clinical-stage biotechnology company that develops cyclodextrin-based products for the potential treatment of neurodegenerative diseases. Cyclo’s lead drug candidate is Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), a treatment for Niemann-Pick Disease, type C1 (“NPC1”). NPC1 is a rare and equity-fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. In January 2017 the FDA granted Fast Track designation to Trappsol® Cyclo™ for the treatment of NPC1. Initial patient enrollment in the U. S. Phase I study commenced in September 2017, and in May 2020 Cyclo announced Top Line data demonstrating Trappsol® Cyclo™ was well tolerated in this study. Cyclo is currently conducting a Phase III Clinical Trial Evaluating Trappsol® Cyclo™ in Pediatric and Adult Patients with Niemann-Pick Disease, Type C1. See Notes 11 and 12 to the Consolidated Financial Statements for more information on the Company’s investments in Cyclo Cornerstone, that include preferred and common equity interests and a warrant to purchase additional equity. On June 17, 2021, as discussed in more detail below, on August 21, 2021, the Company entered into a merger agreement with Cyclo. In the event the merger is consummated, the Company intends to fund acquire full ownership of Cornerstone in exchange for issuing Company Class B common stock to the other—the TransportNPC stockholders of Cornerstone (“Merger Agreement” or “Merger”). On October 28, 2021, the Company announced that the AVENGER 500 Phase 3-III clinical trial, evaluating Trappsol® Cyclo™ in Niemann-Pick C, to its interim analysis in the middle of 2025 and focus its efforts on Trappsol® Cyclo™ as its lead clinical program. At that point, the Company will make a determination as to whether or not to file an NDA for Trappsol® Cyclo™ (devimistat), Cornerstone’s lead Cyclo™. LipoMedix is a clinical stage Israeli company focused on the development of a product candidate that holds, did not meet its primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the potential pancreas. In addition, following a pre-specified interim analysis, the independent data monitoring committee for the ARMADA 2000 Phase 3 study for devimistat recommended the trial to be stopped due to a determination that it was unlikely to achieve the primary endpoint (the “Data Events”). In light of the Data Events, the Company concluded that the prospects for CPI-613 were uncertain and an fully impaired in its financial statements for the year ended innovative, safe, and effective cancer therapy based on liposome delivery. As of July 31, 2022-2024, the value of its loans, receivables, and investment in Cornerstone based upon its valuation of Cornerstone. On September 24, 2021, the Company entered into a Line of Credit Loan Agreement (the “Line of Credit Agreement”) with Cornerstone under which Cornerstone borrowed \$25 million from the Company. Due to the Data Events, the Company recorded a full reserve on the \$25 million due the Company from Cornerstone. On February 2, 2022, the Company terminated the Merger Agreement with Cornerstone Pharmaceuticals, effective immediately, in accordance with its terms. Subsequently, on February 2, 2022, the Company withdrew its Registration Statement on Form S-4 related to the proposed Merger. On March 21, 2023, the Company loaned \$2.0 million to Cornerstone which debt is represented by a Promissory Note made by Cornerstone (the “Promissory Note” or “Note”). The Note, which bears interest at a rate of seven and one-half percent (7.5%) per annum, was originally due and payable on May 22, 2023. On May 22, 2023, the Promissory Note was amended to extend the maturity date to November 30, 2023 and to waive any increase in the interest rate provided for in the Note, provided that the entire principal amount and all accrued interest thereon is repaid in cash or converted into equity securities of Cornerstone no later than November 30, 2023. Cornerstone is in the process of a comprehensive restructuring transaction including, an equity investment by the Company of \$1.5 million with other stockholders having the right to invest amounts on the same terms to avoid dilution, the conversion and modification of other Cornerstone debt obligations, the extension of the Cornerstone debt held by RP Finance, a reverse stock split, the conversion of all outstanding preferred stock of Cornerstone into common stock and the adoption of certain governance measures. This transaction is subject to a number of conditions which are beyond the Company’s control ownership interest in LipoMedix was approximately 95%. LipoMedix has completed various clinical stages of Promitil® including Phase 1A (solid tumors) and 1B (as single agent and in combination with capecitabine and / or bevacizumab in colorectal cancer). Another phase 1B testing Promitil® as radiosensitizer is ongoing and near completion. A total of 149 patients have been treated with Promitil® as a single agent, or in combination with other anticancer drugs or radiotherapy, under the framework of a phase 1A and two 1B clinical studies and under named patient approval for compassionate use. In 2019, the Company established the Barer Institute Inc., a preclinical cancer metabolism an early-stage small molecule research operation, to focused focus on developing a pipeline of novel therapeutic compounds, including compounds designed to regulate cancer metabolism with potentially broader application in other indications beyond cancer. Barer has been comprised was led by a team of scientists and academic advisors that are considered to be among the leading experts in cancer metabolism, chemistry, and drug development. In addition to its own internal discovery efforts, Barer pursued collaborative research agreements and in-licensing opportunities with leading scientists from top academic institutions. Barer’s majority owned subsidiary, Farber Partners, LLC (“Farber”), was formed to support around one such agreements- agreement with Princeton University’s Office of Technology Licensing (“Princeton”) for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, including for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program. In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer Institute. Since then, the Company has sought partners for Farber programs and has entered into a license agreement for one of its technologies. The Company owns also holds a majority 37.5% equity interest in LipoMedix RP Finance LLC (“RP Finance”), which was, until March 13, 2024 (the date of the RP Finance Consolidation, as described in Note 3 to the Consolidated Financial Statements), accounted for under the equity method. RP Finance is an entity associated with members of the family of Howard Jonas (Executive Chairman, Chairman of the Board, and controlling stockholder of the Company) which holds 37.5% equity interest of RP Finance. RP Finance holds debt and equity investments in Cornerstone. In October 2021, Cornerstone received negative results of its Avenger 500 Phase 3 study for Devimistat in pancreatic cancer as well as a clinical stage oncological pharmaceutical recommendation to stop its ARMADA 2000 Phase 3 study due to a determination that the trial would unlikely achieve its primary endpoint (the “Data Events”). Due to the Data Events, RP Finance fully impaired its then debt and equity investments in Cornerstone. On March 13, 2024, Cornerstone consummated a restructuring of its outstanding debt and equity interests (the “Cornerstone Restructuring”). As a result of the Cornerstone Restructuring, Rafael became a 67% owner of the issued and outstanding common stock of Cornerstone (the “Cornerstone Acquisition”), and Cornerstone became a consolidated subsidiary of Rafael. The Cornerstone Acquisition is accounted for as an acquisition of a variable interest entity that is not a business in accordance with U. S. GAAP. The Company was determined to be the accounting acquirer for financial reporting purposes. See Note 3 to the Consolidated Financial Statements for additional information regarding the transaction. In conjunction with the Cornerstone Restructuring and Cornerstone Acquisition, the Company reassessed its relationship with RP Finance, and as a result determined that RP Finance is still a variable interest entity and that the Company became the primary beneficiary of RP Finance as the Company now holds the ability to control repayment of the RP Finance Line of Credit which directly impacts RP Finance’s economic performance. Therefore, following the Cornerstone Restructuring and Cornerstone Acquisition, the Company consolidated RP Finance (the “RP Finance Consolidation”). See Note 3 to the Consolidated Financial Statements for additional information on the Consolidation. In May 2021, the Company formed Rafael Medical Devices, an orthopedic-focused medical device company based developing instruments to advance minimally invasive surgeries. In August 2023, the Company raised \$925,000 from third parties in Israel in exchange for 31.6% ownership of Rafael Medical Devices. In April 2023 addition, the Company has invested in other early-stage pharmaceutical ventures. In 2016, the Company first invested in Day Three LipoMedix Pharmaceuticals Ltd. (“LipoMedix”), a clinical stage company which empowers third-party manufacturers to reimagine their existing cannabis offerings enabling them to bring to market better, cleaner, more precise and predictable versions by utilizing Day Three’s pharmaceutical-grade technology and innovation like Unlokt™. In January On February 9, 2023-2024, the Company entered into a Share Purchase Agreement series of transactions with Day Three and certain shareholders LipoMedix in which LipoMedix sold 70% acquiring 000,000 ordinary shares to the Company at a controlling interest price per share of Day Three \$0.03 and an aggregate sale price of approximately \$2.1 million. Subsequent subsequently consolidating Day Three’s results to this transaction, the Company owns 95% of LipoMedix. On April 7, 2023, the Company entered into a Common Stock Purchase Agreement (the “Day Three Acquisition Purchase Agreement”) with Day Three. Day Three is a cannabinoid ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions. Pursuant to the Day Three Purchase Agreement, the

Company purchased 4,302,224 shares of common stock representing 38% of the outstanding shares of common stock of Day Three (33.33% on a fully diluted basis), for a purchase price of \$3.0 million. The Company also received a warrant exercisable for 7,528,893 shares of common stock at an aggregate purchase price of \$3.0 million, which expires five years from the date of issuance or earlier based on the occurrence of certain events as defined in the Day Three Purchase Agreement As of July 31, 2023, the Company had not exercised the warrant. Refer to Note 8 to our accompanying consolidated financial statements for further detail. On May 2, 2023, the Company entered into a Securities Purchase Agreement (the "Cyclo SPA") with Cyclo. Cyclo is a clinical stage biotechnology company, whose common stock is listed on the Nasdaq Capital Market under the symbol CYTH, that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. The Company purchased from Cyclo (i) 2,514,970 common shares (the "Purchased Shares") and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of \$0.71 per share (the "Cyclo Warrant"), at a combined purchase price equal to \$0.825 per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of \$2.1 million. The Cyclo Warrant is exercisable for a period of seven years from the date of issuance. On August 1, 2023, the Company purchased an additional 4,000,000 shares of common stock (the "Cyclo II Shares"), and a warrant to purchase an additional 4,000,000 Shares (the "Cyclo II Warrant"), for an aggregate purchase price of \$5,000,000. The Cyclo II Warrant has an exercise price of \$1.25 per share and is exercisable until July 31, 2030. The August 1, 2023 investment increased the Company's percentage ownership of Cyclo common stock to 34%. On October 20, 2023, the Company exercised the Cyclo Warrant to purchase 2,514,970 common shares at an exercise price of \$0.71 per share, pursuant to a Securities Purchase Agreement dated October 20, 2023, and in consideration received a new warrant to purchase an additional 2,766,467 common shares at an exercise price of \$0.95 per share which are exercisable for a period of four years following the issuance date (the "Cyclo III Warrant"), for an aggregate purchase price of \$1,785,629. During the fourth quarter of fiscal 2023, Rafael Medical Devices received \$825 thousand as a deposit from outside third party investors for the purchase of membership units. On August 1, 2023, the Company received an additional \$100 thousand. Following these investments, the Company holds 53.4% (on a fully diluted basis) of the ownership interests in Rafael Medical Devices. As of July 31, 2023, the Company recorded the funds received within prepaid expenses and other current assets and other current liabilities within the consolidated balance sheets. Historically, the Company owned real estate assets. In 2020, the Company sold an office building located in Piscataway, New Jersey and on August 22, 2022, the Company sold the building at 520 Broad Street in Newark, New Jersey and an associated public garage. Currently, the Company holds a portion of a commercial building in Jerusalem, Israel as its remaining real estate asset. On July 1, 2022, the Company determined that the 520 Property met the held-for-sale criteria and the Company has therefore classified the 520 Property as held-for-sale in the consolidated balance sheet at July 31, 2022. The sale of the 520 Property also represents a significant strategic shift that will have a major effect on the Company's operations and financial results. Therefore, the Company has classified the results of operations related to the 520 Property as discontinued operations in the consolidated statements of operations and comprehensive loss. Depreciation on the 520 Property ceased effective July 1, 2022, as a result of the 520 Property being classified as held-for-sale. See Note 3 to our accompanying consolidated financial statements for further information regarding discontinued operations. As of July 31, 2023, the Company's commercial real estate holdings consisted of a portion of a commercial building in Israel. On August 22, 2022, the Company completed the sale of the building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company for a purchase price of approximately \$49.4 million and realized net proceeds of approximately \$33 million. Results of Operations—Our business consists of two three reportable segments: Healthcare, **Infusion Technology**, and Real Estate. We evaluate the performance of our Healthcare segment based primarily on research and development efforts and results of clinical trials, and our **Infusion Technology and Real Estate segment segments** based primarily on results of operations. Accordingly, the income and expense line items below loss from operations are only included in the discussion of consolidated results of operations. Healthcare Segment Our consolidated expenses for our Healthcare segment were as follows: Year Ended July 31, Change 2024 2023 2022-% (in thousands) General and administrative \$ (8,338) \$ (8,794) \$ 456.5 (16,818) 8,024.48-% Research and development (3,668) (6,312) (8,742)-2,430.28-644.42-% **IPR & D expense (89,861) — (89,861) 100-% Depreciation and amortization (165) (15) (3-150) (12) —% Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit — (25,000-1000) +25,000 (100) % Provision for losses on related party receivables — (10,095) 10,095 (100) % Loss from operations \$ (102,032) \$ (15,121) \$ (60-86, 658-911) (45,537-75-575) % To date, the Healthcare segment has not generated any revenues. The entirety of the expenses in the Healthcare segment relate to the activities of Barer, LipoMedix, Barer, Farber, **Cornerstone**, and Rafael Medical Devices. As of July 31, 2023-2024, we held a 100% interest in Barer, a 95% interest in LipoMedix, a 93% interest in Farber, and a **100-67% interest in Cornerstone, and a 68%** interest in Rafael Medical Devices. On August 1, 2023, the Rafael Medical Devices closed on the sale of membership units in exchange of for \$925,000, and following that sale, the Company holds a **68-53.4% (voting interest based on a fully diluted basis) of the outstanding equity interests in Rafael Medical Devices, on a fully diluted basis.** As of July 31, 2023, the Company recorded \$825,000 of the funds received **related to the sale** within prepaid expenses and other current assets and other liabilities of \$825,000 within the consolidated balance sheets. General and administrative expenses. General and administrative expenses consist mainly of payroll, stock-based compensation expense, benefits, facilities, consulting and professional fees. **The Company operations have been scaled to meet the current needs which has led to reduced overall general and administrative expenses.** The decrease in general and administrative expenses during the year ended July 31, 2023-2024 compared to the year ended July 31, 2022-2023 is comprised of primarily due to a net decrease in insurance expense of approximately \$0.9 million, a decrease in severance pay expense of approximately \$5-0.4 million, a decrease in licenses and fees of approximately \$0.3, and a decrease in payroll expense of approximately \$3.4 million, a decrease in legal expense of approximately \$1.1 million, a decrease in professional fees of approximately \$1.2 million and a decrease in other general and administrative expenses of approximately \$0.72 million, partially offset by a net increase in professional fees stock-based compensation expense of approximately \$3-1.6 million due to a material forfeiture of granted equity interests in **Research and development expenses. Research and development expenses decreased for the year ended July 31, 2022-2024 as compared to** Research and development expenses. Research and development expenses decreased for the year ended July 31, 2023 as compared to the corresponding period in fiscal 2022. Research and development expenses are derived from activity at Barer, LipoMedix, Farber, **Cornerstone, Day Three**, and Rafael Medical Devices. In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute. The decrease for decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. Loss on line of credit. Due to the Data Events, in the year ended July 31, 2024 stems from the November 2022 decision to curtail the Company recorded a full reserve on the \$25 million due to its early-stage development efforts, including pre-clinical research at Barer, net of increases attributable to the Company from acquisitions of **Cornerstone and Day Three Pharmaceuticals** related to the Line of Credit Agreement. Loss on related party receivables In-process research and development ("IPR & D") expenses IPR & D expenses during Due to the Data Events, in the year ended July 31, 2022-2024, compared to the Company recorded a loss of approximately year ended July 31, 2023 increased by \$10-89 +9 million due to the Cornerstone Acquisition. See Note 3 to our accompanying consolidated financial statements for more information on the transaction. Year Ended July 31, Change 2024 2023-% (in thousands) Infusion Technology revenue \$ 355 \$ — \$ 355 — % Cost of Infusion Technology revenue (154) — (154) — % General and administrative (374) — (374) — % Research and development (502) — (502) — % Loss from operations \$ (675) \$ — \$ (675) — % Infusion Technology revenue. Infusion Technology revenue increased by \$355 thousand during the year ended July 31, 2024 compared to the year ended July 31, 2023 due to the acquisition of Day Three in January 2024. Cost of Infusion Technology revenue. Cost of Infusion Technology revenue increased by \$154 thousand during the year ended July 31, 2024 compared to the year ended July 31, 2023 due to the acquisition of Day Three in January 2024. The specific costs are related to the full reserve recorded on the RP supplies, materials, production labor, and travel costs. General and administrative expenses. General and administrative expenses consist mainly of payroll, finance, insurance, receivable of, software, and licenses. General and administrative expenses increased by \$9-375 million-374 thousand during the year ended July 31, 2024 compared to the year ended July 31, 2023 due to the acquisition of controlling interest in Day Three, an and subsequent consolidation equity method investment (see Note 6), and a full reserve recorded on the Cornerstone Pharmaceuticals receivable, see (Note 4) of its results, in January 2024. Research and development expenses. Research and development expenses increased by \$720-502 thousand during the year ended July 31, 2024 compared to the year ended July 31, 2023 due to the acquisition of Day Three in January 2024. Real Estate Segment The revenue and expenses of the 520 Property have been excluded from the real estate segment in the figures below due to its classification of held-for-sale and discontinued operations, and the sale of the 520 Property on August 22, 2022. The Real Estate segment consists of a portion of a commercial building in Israel. Consolidated income (loss) and expenses for our Real Estate segment were as follows: Year Ended July 31, Change 2024 2023 2022-% (in thousands) Rental — Third Party \$ 174 \$ 171 \$ 3.2 +79 (8) (4) % Rental — Related Party 108 +11 (3) (3) % Other — Related Party — 120 (120) (100) % General and administrative (142) (138) (160-4) -214 (3) % Depreciation and amortization (60) (63) 3.5 (69) 6.9 % Income from operations \$ 80 \$ 78 \$ 2.3 +181 (103) 57 % Other — Related Party. Other — related party revenues decreased by approximately \$120 thousand during the year ended July 31, 2023, compared to the year ended July 31, 2022. During the year ended July 31, 2022, the Company only billed Cornerstone Pharmaceuticals \$120 thousand for the first quarter of 2022 for administrative, finance, accounting, tax, and legal services. As of July 31, 2023 and 2022, Cornerstone Pharmaceuticals owed the Company \$720 thousand which relates to administrative and back-office services, for which a full allowance for uncollectibility has been recorded. General and administrative expenses. General and administrative expenses consist mainly of payroll, benefits, facilities, consulting and professional fees. The decrease in general and administrative expenses of approximately \$22 thousand during the year ended July 31, 2023 compared to the year ended July 31, 2022 is primarily due to a decrease in professional fees. Consolidated Operations Our consolidated income and expense line items below loss from operations were as follows: Year Ended July 31, Change 2024 2023 2022-% (in thousands) Loss from continuing operations \$ (102,627) \$ (15,043) \$ (60-87, 477-584) 45,434.75-% Interest expense — (6,582) 6-100-% Interest income 2,383 3,253 201-3,052- (1518-870) (27) % Impairment of investments- Other Pharmaceuticals — (334) 334 100-% Loss on initial investment in Day Three upon acquisition (1,633) — (1,334) (100) % Impairment of cost method investment- Cornerstone Pharmaceuticals — (79,141-633) 79,141 (100) % Realized gain (loss) on available-for-sale securities 1,772 154 1,618 1051-% Realized gain (45-loss) +99 on investment in equity securities (442-46) 309 (355) (115) % Realized gain on investment in Cyclo 424 — 424 (100) % Unrealized gain on equity securities 309 — 309-33 (33) (100) % Unrealized gain on investment in equity securities 33 — 33- Cyclo 37-2,663 (2,626) 100-% Unrealized gain on investments- convertible notes receivable, due from Cyclo 1 Therapeutics Inc.-2,663-191 — 2-1 191 663 (100) % Unrealized gain (loss) on investments-investment - Hedge Funds 63 220 (504-157) 724 (144-71) % Recovery of receivables from Cornerstone 31,305 — 31,305 100-% Interest expense (248) — (248) (100) % Other income 118 — 118 100-% Loss from continuing operations before income taxes (67,261) (8,745) (139-58, 972-516) (669) +31,227-94-% Benefit from income taxes 2,680 255 2,425 951 — 255 (100) % Equity in loss of Day Three Labs Inc. (422) (203) — (203-219) 108 100-% Equity in loss of RP Finance — (575) 575 (100) % Consolidated net loss from continuing operations (65,003) (8,693) (140-56, 547-310) (648) +31,854-94-% Income (loss) from discontinued operations related to 520 Property — 6,478 (6, 830-478) 100 8,308-454-% Net loss attributable to noncontrolling interests (30,593) (339) (17,719) 17-380- 30 98-, 254) (8924) % Net loss attributable to Rafael Holdings,**

Inc. \$ (34,410) \$ (1,876) \$ (124,322, 658,534) (1734) \$ -122,782-98-% Interest income and realized gains on available-for-sale securities. Interest income was \$ 2.4 million and \$ 3.3 million and \$ 201 thousand for the years ended July 31, 2024 and 2023 and 2022, respectively. The increase decrease is primarily due to the interest income earned maturity and sales activity which resulted in and an accretion increase of the discount realized gains on the face value of our investments in available-for-sale securities of whose balance increased to \$ 57.1, 7.6 million at July 31, 2023 from \$ 36.7 million at July 31, 2022. Impairment of investments- Other Pharmaceuticals. We recorded an impairment loss of \$ 334 thousand for the year ended July 31, 2023-2024, Impairment of investments- Other Pharmaceuticals. We recorded impairment losses of \$ 0 and \$ 334 thousand related to an our investment in Nanovibronix securities in another entity using the measurement alternative for Impairment of cost method investment- Cornerstone Pharmaceuticals. In connection with the Data Events, during the year years ended July 31, 2022-2024 and 2023, respectively we recorded a full impairment charge to our cost method investment in Cornerstone Pharmaceuticals in the amount of \$ 79 million. Realized gain (loss) on available investment - Cyclo for-sale securities. We recorded a realized gain of approximately \$ 154,424 thousand related to the sale exercise of available-for-sale securities the May Warrants in connection with our October 2023 investment in Cyclo for the year ended July 31, 2023-2024. We recorded a realized loss of approximately \$ 45 thousand related to the sale of available-for-sale securities for the year ended July 31, 2022. Realized gain on investment in equity securities. We recorded a realized gain of approximately \$ 309 thousand related to the sale of equity securities for the year ended July 31, 2023. Unrealized gain on investment- Cyclo. We recorded an unrealized gain of approximately \$ 37 thousand and \$ 2.7 million related to the change in fair value in our investment in Cyclo for the years ended July 31, 2024 and 2023, respectively. Unrealized gain on convertible notes receivable, due from Cyclo. We recorded an unrealized gain of \$ 1.2 million related to the convertible note receivable due from Cyclo for the year ended July 31, 2023-2024. Unrealized gain (loss) on investments- investment. Hedge Funds. We recorded an unrealized gains- gain of approximately \$ 63 thousand and an unrealized gain of approximately \$ 220 thousand and losses of approximately \$ 504 thousand for the years ended July 31, 2024 and 2023 and 2022, respectively. Recovery of receivables from Cornerstone. We recorded an increase in recovery of receivables from Cornerstone of approximately \$ 31.3 million for the year ended July 31, 2024. See Note 3 to our accompanying consolidated financial statements for more information related to this matter. Benefit from income taxes. In accordance with Our benefit from income taxes was approximately \$ 255 thousand and \$ 0 for the State years ended July 31, 2023 and 2022, respectively. The increase is primarily attributed to approximately \$ 274 thousand in proceeds for the sale of the Company New Jersey's 2018 and 2019 New Jersey tax credits. These benefits were realized by utilizing the New Jersey Technology Business Tax Certificate Transfer Program, which whereby the State of New Jersey allows us certain high technology and biotechnology companies to sell unused a portion of our state-net operating loss carryforwards ("NOLs") to other New Jersey-based corporate taxpayers based in New Jersey, the Company received approximately \$ 2.6 million for the sale of the Company's prior period NOLs totaling \$ 31.6 million in the year ended July 31, 2024. The Company received proceeds of approximately \$ 274 thousand from the sale of the Company's prior period NOLs totaling \$ 3.3 million in the year ended July 31, 2023. Equity in loss of Day Three Labs, Inc. We recognized a loss of approximately \$ 422 and \$ 203 thousand from our ownership interest in Day Three due to operating results for the year years ended July 31, 2024 and 2023, respectively. As of July 31, January 2, 2023-2024, the equity method investment in Day Three is a majority-owned subsidiary which is consolidated. See Note 10 to our accompanying consolidated financial statements balance sheet is approximately \$ 2.8 million. Equity in loss of RP Finance. We recognized a loss of \$ 575 thousand from our ownership interest in RP Finance due to operating results for further information regarding the acquisition year ended July 31, 2022. As of July 31, 2022, the equity method investment in RP Finance on our balance sheet was \$ 0, and no additional equity loss of RP Finance was recorded subsequent to the year ended July 31, 2022. Income (loss) from discontinued operations related to 520 Property. Discontinued operations include: (i) rental and parking revenues, (ii) payroll, benefits, facilities, consulting and professional fees dedicated to 520 Property, (iii) depreciation and amortization expenses, (iv) interest (including amortization of debt issuance costs) on the note payable that was secured by a mortgage on the 520 Property, and (v) gain on the disposal of the 520 Property. The operating results of these items are presented in our consolidated statements of operations and comprehensive loss as discontinued operations for all periods presented. The increase decrease in the net income attributable to discontinued operations for the year ended July 31, 2023-2024 as compared to the year ended July 31, 2022-2023 was due to a gain on the sale of the 520 Property of \$ 6.8 million, an approximate \$ 1.4 million decrease in interest expense, partially offset by a \$ 3.3 million decrease in rental revenue, a \$ 2.2 million decrease in general and administrative expenses (which is primarily comprised of a decrease in real estate taxes, utilities other building related repairs, maintenance expenses, and other expenses totaling approximately \$ 2.4 million, slightly offset by a \$ 129 thousand increase in expense related to the write-off of deferred rental income), and a \$ 1.3 million decrease in depreciation and amortization expense due to no depreciation expense during the year ended July 31, 2023 as depreciation stopped as of July 1, 2022 when the 520 Property was classified as held-for-sale. See Note 3-14 to our accompanying consolidated financial statements for further information regarding discontinued operations. Net loss attributable to noncontrolling interests. The change in the net loss attributable to noncontrolling interests was due is primarily attributed to an approximate net loss of Cornerstone which includes \$ 89.17-3 million loss related to the Cornerstone Pharmaceuticals impairment loss (the total impairment loss was approximately \$ 79 million) which was applicable to noncontrolling interests in certain of the Company's subsidiaries and was allocated to the holders of interests in CS Pharma and Pharma Holdings in the approximate amounts of \$ 10.4 million and \$ 6.9 million in IPR & D expenses, respectively, for the year ended July 31, 2022. Liquidity and Capital Resources As of July 31, Change 2024 2023 2022-% (in thousands) Balance Sheet Data: Cash and cash equivalents \$ 2,675 \$ 21,498 \$ 26,537 ( \$ 18,039 823 ) ( 19 88 ) % Convertible note receivable, related party 1,921 — 1,921 ( 1,921 ) ( 100 ) % Convertible note receivable 1,146 — 1,146 100 % Installment note payable 1,700 — 1,700 100 % Working capital 64,988 80,796 87,321 ( 6 15 ) 525 808 ) ( 7 20 ) % Total assets 96,832 98,829 118,320 ( 19 1 ) 491 997 ) ( 2 16 ) % Note payable, net of debt issuance costs, held-for-sale — 15,000 ( 15,000 ) ( 100 ) % Total equity attributable to Rafael Holdings, Inc. 82,185 100,293 100,515 ( 222 18,108 ) — ( 18 ) % Noncontrolling interests 4,073 ( 3,664 ) 7 ( 3 737 309 ) ( 355 ) 11 211 % Total equity 86,258 96,629 97,206 ( 577 10,371 ) ( 1 11 ) % For the Years- Year Ended July 31, Change 2024 2023 2022-% (in thousands) Cash flows (used in) provided by Operating activities of continuing operations \$ ( 7,802 ) \$ ( 10,247 ) \$ 2 ( 26 445 24 038 ) 15 791 ( 61 ) % Investing activities of continuing operations ( 10,820 ) ( 26,960 ) 16 ( 63 140 60 683 ) 36 723 ( 58 ) % Financing activities of continuing operations ( 179 ) ( 218 ) 39 18 103 864 ( 104 082 ) ( 100 ) % Effect of exchange rates on cash and cash equivalents ( 22 ) ( 146 ) 124 85 ( 306 ) 160 ( 52 ) % Operating, investing, and financing activities of discontinued operations — 32,532 ( 154 ) 32 686 532 ) ( 100 21 224 ) % (Decrease) increase in cash and cash equivalents \$ ( 18,823 ) \$ ( 5,039 ) \$ ( 13 784 683 ( 18 722 ) 274 ( 137 ) % Capital Resources As of July 31, 2023-2024, we held cash and cash equivalents of approximately \$ 21-2, 5-7 million and available-for-sale securities valued at approximately \$ 57-63, 7-3 million. On August 22, 2022, the Company received net proceeds of approximately \$ 33 million in connection with the sale of the 520 Property (see Note 3-14 to our accompanying consolidated financial statements for further details). The Company expects its balance of cash and cash equivalents, and available-for-sale securities, to be sufficient to meet our obligations for at least the next 12 months from the filing of this Annual Report on Form 10-K. Operating Activities The decrease in cash used in operating activities for the year ended July 31, 2023 as compared to the year ended July 31, 2022 was primarily related to the lower loss from continuing operations of \$ 8.7 million in fiscal 2023 as compared to the corresponding period in fiscal 2022 due to an impairment of cost method investment in Cornerstone Pharmaceuticals of approximately \$ 79 million, a provision for loss on receivable from Cornerstone Pharmaceuticals of \$ 25 million, and a provision for losses on related party receivables of approximately \$ 10 million in fiscal 2022, coupled with the impact from non-cash items, primarily \$ 1.2 million in accretion of discount on available-for-sale securities, \$ 0.2 million in net unrealized (gain) loss on investments- Hedge Funds, \$ 0.2 million in realized (gain) loss on available-for-sale securities, offset by impairment of investments- other pharmaceuticals of \$ 0.3 million and stock-based compensation of \$ 2.2 million. The decrease was also impacted by a decrease in prepaid expenses and other current assets of \$ 0.4 million and a decrease in accounts payable and accrued expenses of \$ 0.8 million, as well as other changes in assets and liabilities. Cash used in operating activities decreased by \$ 2.4 million from cash used of \$ 10.2 million for the year ended July 31, 2022-2023 was primarily related to cash used of \$ 7.8 million for the year ended July 31, 2024, as the increase in the loss from continuing operations was more than of \$ 140.5 million and an increase in prepaid expenses and other current assets of \$ 3.5 million, partially offset by the impact from non-cash items included, such as \$ 89.9 million in the loss-in-process research and development expense, \$ 31.3 million from operations, principally the impairment recovery of receivables the Company's cost method investment in Cornerstone Pharmaceuticals of \$ 79 million, the reserve on the amounts due the Company from Cornerstone Pharmaceuticals related to the Line of Credit Agreement of \$ 25 million, and the reserve on receivables due from Cornerstone Pharmaceuticals totaling \$ 10.1 million, changes in other current liabilities of \$ 3.6 million, as well as other changes in assets and liabilities. Investing Activities Cash used in investing activities for the year ended July 31, 2024 was primarily due to purchases of available-for-sale securities of approximately \$ 155.7 million, purchase of \$ 4.0 million in convertible notes receivable from Cyclo, and the investment in Cyclo common stock and warrants of \$ 6.8 million, partially offset by proceeds of \$ 153.4 million from sales and maturities of available-for-sale securities and \$ 2.5 million in proceeds from hedge funds. Cash used in investing activities for the year ended July 31, 2023 was primarily due to purchases of available-for-sale securities of approximately \$ 204.8 million, the investment in Day Three of \$ 3.0 million, the purchase of investment in Cyclo common stock and warrants of \$ 2.1 million, the loan of \$ 2.0 million to Cornerstone and the purchase of equity securities of \$ 1.6 million. This is partially offset by proceeds of \$ 185.1 million from the sale and maturities of available-for-sale securities and proceeds of \$ 1.3 million from the sale of equity securities. Cash used in investing activities for the year ended July 31, 2022 was primarily related to purchases of available-for-sale securities of approximately \$ 65 million, amounts loaned to Cornerstone Pharmaceuticals of approximately \$ 25 million pursuant to the Line of Credit Agreement and the payments to fund our portion of advances under the line of credit between RP Finance and Cornerstone Pharmaceuticals in the amount of approximately \$ 1.9 million, partially offset by proceeds of \$ 28.5 million from the maturities of available-for-sale securities. Financing Activities Cash used in financing activities for the year ended July 31, 2024 was primarily related to a principal payment of \$ 0.8 million on the installment note acquired during the Day Three Acquisition, partially offset by the proceeds from sale of RMD membership units of \$ 0.9 million. Cash used in financing activities for the year ended July 31, 2023 was primarily related to repayment of the \$ 15.0 million note payable in connection with the sale of 520 Property and for payment of taxes related to shares withheld for employee taxes on vesting of shares granted to employees. Cash provided by financing activities for the year ended July 31, 2022 was primarily related to proceeds of approximately \$ 110 million related to the sale of our common stock to investors and a related party, partially offset by payment of transaction costs of \$ 6.2 million. We do not anticipate paying dividends on our common stock until we achieve sustainable profitability and retain certain minimum cash reserves. The payment of dividends in any specific period will be at the sole discretion of our Board of Directors. Operating, Investing, and Investing Activities of Discontinued Operations The cash flows from discontinued operations- 520 Property for the year ended July 31, 2023 represents represent the net income excluding non-cash depreciation and amortization, as well as the net proceeds from the sale of the 520 Property. For the year ended July 31, 2023, net cash used in operating activities of discontinued operations totaled \$ 0.6 million. Net cash provided by investing activities of discontinued operations of \$ 48.2 million related to proceeds from sale of

the 520 Property of \$ 49. 4 million, slightly offset by payment of transaction costs of \$ 1. 2 million. Net cash used in financing activities of discontinued operations of \$ 15. 0 million related to the payment of the Note Payable in connection with sale of the 520 Property. For the year ended July 31, 2022, net cash used in operating activities of discontinued operations totaled \$ 41 thousand, and net cash used in investing activities of discontinued operations totaled \$ 113 thousand. Critical Accounting Estimates We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial condition in conformity with U. S. GAAP. We apply these accounting policies in a consistent manner. Our significant accounting policies are discussed in Note 2, " Summary of Significant Accounting Policies, " in our accompanying consolidated financial statements. The application of critical accounting policies requires that we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. These estimates and assumptions are based on historical and other factors believed to be reasonable under the circumstances. We evaluate these estimates and assumptions on an ongoing basis and may retain outside consultants to assist in our evaluation. If actual results ultimately differ from previous estimates, the revisions are included in results of operations in the period in which the actual amounts become known. The critical accounting policies that involve the most significant management judgments and estimates used in preparation of our consolidated financial statements, or are the most sensitive to change from outside factors, are discussed below. **the measurement alternative is made for each eligible Investments- Investment. The Company has Measured at Fair Value We have elected the fair value option to account for our-its investment in and convertible notes due from Cyclo Therapeutics Inc. over which we have the Company has significant influence. The fair value option is irrevocable once elected. We The Company measure measured our its initial investment in Cyclo at fair value and shall record all subsequent changes in fair value in earnings in the consolidated statement of operations. We The Company believe believes the fair value option best reflects the underlying economics of the investment. We hold convertible notes receivable that are classified as available- See Note 9, " Investments, " in our accompanying consolidated financial statements for further details - sale as defined under Accounting Standards Codification (" ASC ") Corporate incorporated Bonds a discount for the overall lack of marketability for the Cyclo Warrants. Certain inputs utilized in our Black- Scholes model may fluctuate in future periods based upon factors which are outside of the Company' s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of our warrant liability which could also result in material non- cash gain or loss being reported in our consolidated statements of operations and comprehensive loss. The Company' s marketable securities are also considered to be available- for- sale as defined under ASC 320, Investments- Debt and Equity Securities, and are recorded at fair value based on the quoted price in active markets for similar assets and inputs that are observable for the asset. Unrealized gains or losses are included in accumulated other comprehensive income. Realized gains or losses are released from accumulated other comprehensive income and into earnings on the consolidated statements of operations and comprehensive loss operations of acquired businesses are included in the consolidated financial statements from the acquisition date. We account Convertible Note Receivable, Related Party The Convertible Note Receivable is classified as available- for - sale as defined under our investments in hedge funds in accordance with ASC 320-321. Investments - Debt and Equity Securities ; and is recorded at fair value. Subsequent Unrealized gains and losses resulting from the changes- change in fair value are recorded of these securities is included in accumulated unrealized (loss) gain on investments - Hedge Funds in other- the consolidated statements of operations and comprehensive loss. Hedge funds classified as Level 3 include investments and securities for which fair value may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets Convertible Note Receivable is estimated using a scenario- based analysis based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. Business Combinations Amounts paid for acquisitions are allocated probability- weighted present value of future investment returns, considering each of the possible outcomes available to the assets acquired Company, including cash repayment, equity conversion, and liabilities assumed based on collateral transfer scenarios. Estimating the their estimated fair value at the date of acquisition. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions provided by management, including expected future cash flows. We allocate any excess purchase price over the fair value of the identifiable net assets and liabilities acquired to goodwill. Identifiable intangible assets with finite lives are amortized over the their Convertible Note Receivable requires useful lives. Acquisition- related costs, including advisory, legal, accounting, valuation, and the other development costs, are expensed in the periods in which the costs are incurred. The results of significant operations of acquired businesses are included in the consolidated financial statements from the acquisition date. Goodwill The Company assesses goodwill for impairment on and- an subjective estimates annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgement. In performing the Company' s annual goodwill impairment test, and are the Company is permitted to first assess qualitative factors to determine whether it is more likely than not the fair value of the Company' s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to - change over the reporting unit duration of the instrument with related changes in internal and external the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. The Company assesses goodwill for impairment on an annual basis as of May 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge during the year ended July 31, 2024. Stock- based Compensation We record stock- based compensation for options granted and restricted stock units awarded to employees, non- employees, and to members of the board of directors for their services on the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight- line basis over the requisite service period. Forfeitures are recognized when they occur. The fair value of restricted stock units is determined by the grant date market price of our common shares. We use the Black- Scholes- Merton option pricing model to determine the fair value of stock options. The use of the Black- Scholes- Merton option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk- free interest rates and expected dividend yields of the common stock. We have concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of Company- specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the stock- based awards. We compute the historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the calculated expected term of its stock- based awards. The risk- free interest rate is determined by reference to U. S. Treasury zero- coupon issues with remaining maturities similar to the expected term of the options. We have not paid, and do not anticipate paying, cash dividends on shares of our common stock. Investments- Hedge Funds In- Process Research and Development We hold acquired in- process research and development (" IPR & D ") intangible assets pursuant to a business combination. These IPR & D assets are considered indefinite- lived intangible assets until completion or abandonment of the associated research and development efforts. These IPR & D assets are not amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. IPR & D acquired as part of the Cornerstone Acquisition represents the R & D asset of Cornerstone which was in- process, but not yet completed, and which had no alternative use. To value the IPR & D acquired as part of the Cornerstone Acquisition, the Company utilized the Multi- Period Excess Earnings Method (" MPEEM "), under the Income Approach. The method reflects the present value of the projected operating cash flows generated by Cornerstone' s assets after taking into account the cost to realize the revenue, and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR & D acquired represents Cornerstone' s research and development activities related to oncology- focused pharmaceuticals which seeks to exploit the metabolic differences between normal cells and cancer cells. The IPR & D acquired as part of the Cornerstone Acquisition, accounted for our investments as an asset acquisition, was expensed immediately as a component of in hedge funds - process research and development expense in accordance with ASC 321, Investments- Equity Securities. Unrealized gains and losses resulting from the change in fair value of these securities is included in unrealized (loss) gain on investments - Hedge Funds in the consolidated statements- statement of operations and comprehensive loss - Hedge funds classified as it had Level 3 include investments and securities which may not no be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. Investments - Cost Method We periodically evaluate our investments for impairment due to declines considered to be other than temporary. If we determine that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established. Investments - Fair Value Method The method of accounting applied to long- term investments in equity securities involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also include the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company' s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in equity securities may be accounted for using (i) the fair value option if elected, (ii) fair value through earnings if fair value is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative future to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each..... accompanying consolidated financial statements for further details. Off- Balance Sheet Arrangements We do not have any " off- balance sheet arrangements, " as defined in relevant SEC regulations, that are reasonably likely to have a current or future effect on**

our financial condition, results of operations, liquidity, capital expenditures or capital resources. **Discontinued Operations In accordance with the Financial..... the amounts originally invested upon redemption.** Item 8. Financial Statements and Supplementary Data. The Consolidated Financial Statements of the Company and the report of the independent registered public accounting firm thereon starting on page F- 1 are included herein. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. Item 9A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures **Procedures An** An evaluation was performed under the supervision and with the participation of the Company's management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rule 13a- 15 (e) promulgated under the Securities and Exchange Act of 1934, as amended) as of July 31, **2023-2024**. Based on that evaluation, the Company's management, including the President and Chief Executive Officer and Chief Financial Officer, concluded that the Company's disclosure controls and procedures were effective. Management's Annual Report on Internal Control over Financial Reporting The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. The internal control process has been designed under management's supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external reporting purposes in accordance with U. S. GAAP. Management conducted an assessment of the effectiveness of the Company's internal control over financial reporting as of July 31, **2023-2024**, utilizing the framework established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has determined that the Company's internal control over financial reporting as of July 31, **2023-2024**, is effective. The Company's internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that accurately and fairly reflect, in reasonable detail, transactions and dispositions of assets; and provide reasonable assurances that: (1) transactions are recorded as necessary to permit preparation of financial statements in accordance with U. S. GAAP; (2) receipts and expenditures are being made only in accordance with authorizations of management and the directors of the Company; and (3) unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the Company's financial statements are prevented or timely detected. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Changes in Internal Control over Financial Reporting There were no significant changes made in the Company's internal control over financial reporting during the fourth quarter of the year ended July 31, **2023-2024** that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. **Attestation Report of the Independent Registered Public Accounting Firm** **This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for "emerging growth companies."** Item 9B. Other Information. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. Part III Item 10. Directors, Executive Officers and Corporate Governance. The following is a list of our directors and executive officers as of **October 27-November 6, 2023-2024**, along with the specific information required by Rule 14a- 3 of the Securities Exchange Act of 1934: **Executive Officers**—Howard S. Jonas — Executive Chairman William Conkling — Chief Executive Officer David Polinsky — Chief Financial Officer **John Goldberg — Chief Medical Officer** Howard S. Jonas — Chairman of the Board **Susan Bernstein** Stephen Greenberg **Dr. Mark McCamish Stein** Dr. Michael J. Weiss The remaining information required by this Item will be contained in our Proxy Statement for our Annual Stockholders Meeting, which will be filed with the Securities and Exchange Commission within 120 days after July 31, **2023-2024**, and which is incorporated by reference herein. **Corporate Governance** We have included as exhibits to this Annual Report on Form 10-K certificates of our Chief Executive Officer and Chief Financial Officer certifying the quality of our public disclosure. We make available free of charge through the investor relations page of our web site (<http://rafaelholdings.irpass.com/>) our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, and all beneficial ownership reports on Forms 3, 4 and 5 filed by directors, officers and beneficial owners of more than 10% of our equity, as soon as reasonably practicable after such reports are electronically filed with the Securities and Exchange Commission. We have adopted codes of business conduct and ethics for all of our employees, including our principal executive officer, principal financial officer and principal accounting officer. Copies of the codes of business conduct and ethics are available on our web site. Our web site and the information contained therein or incorporated therein are not intended to be incorporated into this Annual Report on Form 10-K or our other filings with the Securities and Exchange Commission. Item 11. Executive Compensation. The information required by this Item will be contained in our Proxy Statement for our Annual Stockholders Meeting, which will be filed with the Securities and Exchange Commission within 120 days after July 31, **2023-2024**, and which is incorporated by reference herein. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. Item 13. Certain Relationships and Related Transactions, and Director Independence. Item 14. Principal Accounting Fees and Services. Part IV Item 15. Exhibits, Financial Statement Schedules. (a) The following documents are filed as part of this Report: Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements. Consolidated Financial Statements covered by Report of Independent Registered Public Accounting Firm. Financial Statement Schedules. All schedules have been omitted since they are either included in the Notes to Consolidated Financial Statements or not required or not applicable. Exhibits. The exhibits listed in paragraph (b) of this item are filed, furnished, or incorporated by reference as part of this Form 10-K. Certain of the agreements filed as exhibits to this Form 10-K contain representations and warranties by the parties to the agreements that have been made solely for the benefit of the parties to the agreement. These representations and warranties: • may have been qualified by disclosures that were made to the other parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements; • may apply standards of materiality that differ from those of a reasonable investor; and • were made only as of specified dates contained in the agreements and are subject to subsequent developments and changed circumstances. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date that these representations and warranties were made or at any other time. Investors should not rely on them as statements of fact. (b) Exhibits. Exhibit Number Description **2. 1 (1) Agreement and Plan of Merger, dated as of August 21, 2024, by and among Rafael, Cyclo, First Merger Sub and Second Merger Sub.** 3. 1 (+ **2**) Amended and Restated Certificate of Incorporation of Rafael Holdings, Inc. 3. 2 (**2-3**) Third Amended and Restated By-Laws of Rafael Holdings, Inc. 4. 2 \* Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 10. 1 (**3-4**) **2021** Equity Incentive Plan, as amended and restated 10. 2 (**2-3**) Employment Agreement dated as of June 13, 2022, between the Company and Howard S. Jonas. 10. 3 (**4-5**) Letter Agreement dated January 20, 2022, between the Company and William Conkling. 10. **4 \* Letter Agreement dated November 16, 2023, between the Company and John Goldberg** 10. 5 (**6-5**) Securities Purchase Agreement, dated August 19, 2021, by and among Rafael Holdings, Inc. and the Investors named therein. 10. **7-6** (**5-6**) Securities Purchase Agreement, dated August 19, 2021, by and among Rafael Holdings, Inc. and 19 Plus, LLC. 10. **8-7** (**5-6**) Registration Rights Agreement, dated August 19, 2021, by and among Rafael Holdings, Inc. and the Investors named therein. **10. 9 (6) Contract of Sale between Broad Atlantic Associates LLC and 520 Broad Street Propeo LLC, dated February 18, 2022. (schedules, exhibits and similar attachments to the Contract of Sale that are not material have been omitted pursuant to Item 601 (b) (2) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule, exhibit or similar attachment to the Securities and Exchange Commission upon request).** 21. 01 \* Subsidiaries of the Registrant 23. 1 \* Consent of CohnReznick LLP, Independent Registered Public Accounting Firm 31. 01 \* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31. 02 \* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32. 01 \* Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32. 02 \* Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **97 \* Compensation Clawback Policy** 101. INS \* Inline XBRL Instance Document 101. SCH \* Inline XBRL Taxonomy Extension Schema Document 101. CAL \* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF \* Inline XBRL Taxonomy Extension Definition Linkbase Document 101. LAB \* Inline XBRL Taxonomy Extension Label Linkbase Document 101. PRE \* Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 \* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). \* Filed or furnished herewith. (1) Incorporated by reference to Form **8-K, filed August 22, 2024.** (2) Incorporated by reference to Form 10- 12G / A, filed March 26, 2018. (**2-3**) Incorporated by reference to Form 8-K, filed June 14, 2022. (**3-4**) Incorporated by reference to Exhibit A of the Company's s Definitive Proxy Statement, filed with the Commission on November 28, 2022. (**4-5**) Incorporated by reference to Form 8-K, filed January 21, 2022. (**5-6**) Incorporated by reference to Form 8-K, filed August 24, 2021. (**6-7**) Incorporated by reference to Form 8-K, filed May 9, 2022. Item 16. Form 10-K Summary Signatures Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized. Rafael Holdings, Inc. By: / s / William Conkling William Conkling Chief Executive Officer Date: **October 30-November 6, 2023-2024** Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. Signature Titles Date / s / William Conkling President and Chief Executive Officer **October 30, 2023-William Conkling** (Principal Executive Officer) **November 5, 2024 William Conkling** / s / David Polinsky Chief Financial Officer **October 30, 2023-David Polinsky** (Principal Financial Officer and Principal Accounting Officer) **November 5, 2024 David Polinsky** / s / Howard S. Jonas Director, Chairman of the Board and Executive Chairman **October 30-November 5, 2023-2024** Howard S. Jonas / s / Susan Y. Bernstein **Rafael Director November 5, 2024 Susan Y. Bernstein** / s / Stephen Greenberg Director **October 30-November 5, 2023-2024** Stephen Greenberg / s / **Dr. Mark McCamish Stein** Director **October 30-November 5, 2023-2024** **Dr. Mark McCamish Stein** / s / **Dr. Michael J. Weiss** Director **October 30-November 5, 2023-2024** **Dr. Michael J. Weiss** **Rafael Holdings, Inc.** Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID 596) F- 2 Consolidated Balance Sheets as of July 31, **2024 and 2023** and 2022-F- 3 Consolidated Statements of Operations and Comprehensive Loss for the years ended July 31, **2024 and 2023** and 2022-F- 4 Consolidated Statements of Equity for the years ended July 31, **2024 and 2023** and 2022-F- 5 Consolidated Statements of Cash Flows for the years ended July 31, **2024 and 2023** and 2022-F- 7 Notes to Consolidated Financial Statements F- 8 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors and Stockholders **Rafael Holdings, Inc.** Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Rafael Holdings, Inc. as of July 31, **2024 and 2023** and 2022, and the related consolidated statements of operations and comprehensive loss, equity and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Rafael Holdings, Inc. as of July 31, **2024 and 2023** and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to Rafael Holdings, Inc. in accordance with the U. S. federal securities

laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Rafael Holdings, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matter** The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (i) related to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communications of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. Valuation of Intangible Assets and Purchase Price Consideration in the Cornerstone Pharmaceuticals, Inc. Restructuring and Acquisition Description of the matter As described in Note 3 to the consolidated financial statements, the Company, Cornerstone Pharmaceuticals, Inc. ("Cornerstone"), and other holders of debt and equity securities of Cornerstone agreed to various transactions which effected a recapitalization and restructuring of the outstanding debt and equity interests in Cornerstone. The recapitalization resulted in the Company becoming the primary beneficiary of Cornerstone, a variable interest entity, and consolidating Cornerstone. The Company was determined to be the accounting acquirer and treated the restructuring as an asset acquisition resulting in the recording of an in-process research and development asset of approximately \$ 89,861,000. The purchase consideration resulting from the restructuring included the forgiveness of a line of credit and a promissory note in exchange for Cornerstone common stock valued at \$ 37,845,000 and \$ 2,663,000, respectively. The fair value of this consideration and the in-process research and development asset were calculated by management using a blend of a discounted cash flow and comparable companies valuations. The methods used to estimate the fair value of acquired intangible assets and purchase consideration utilizing a discounted cash flow involve significant assumptions. The significant assumptions applied by management in estimating the fair value of acquired intangible assets and purchase consideration included income projections and discount rates. Significant judgment is exercised by the Company in determining the valuation of the intangible assets and purchase price consideration. Given these factors, the related audit effort in evaluating management's judgments in determining the valuation of the intangible assets and purchase price consideration was challenging, subjective, and complex and required a high degree of auditor judgment. How our Audit Addressed the Critical Audit Matter Our principal audit procedures related to this critical audit matter included the following: • We gained an understanding of and evaluated the design and implementation of the Company's controls that address the risk of material misstatement related to developing fair value estimates and management projections. • We evaluated management's significant accounting policies related to estimating the fair value of intangible assets and purchase consideration. • We tested the reasonableness of the underlying data used to determine the forecasted discounted future cash flows. • We evaluated the reasonableness of the discounted future cash flows utilized in the discounted cash flow model by comparing forecasted discounted cash flows to market information. • We evaluated the reasonableness of the probability weighting of the discounted cash flows based upon the likelihood of approval of the acquired research and development projects by comparing the probabilities to historical market information and industry data. • Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of the discount rates utilized.

/s/ CohnReznick LLP We have served as Company's auditor since 2019. New York, New York  
**October 30 November 6, 2023-2024** PART I. FINANCIAL INFORMATION RAFAEL HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) Year Ended July 31, 2024 2023 ASSETS CURRENT ASSETS Cash and cash equivalents \$ 2,675 \$ 21,498 \$ 26,537 Available-for-sale securities 63,265 57,714 36,698 Interest receivable 515 387 440 Convertible note receivables, due from Cyclo 5,191 — Accounts receivable, net of allowance for credit losses of \$ 245 at July 31, 2024 and July 31, 2023 426 213 Prepaid expenses and other current assets 430 914 Convertible note receivable, related party 1,921 — Accounts receivable, net of allowance for doubtful accounts of \$ 245 and \$ 197 at July 31, 2023 and July 31, 2022, respectively 213 157 Prepaid expenses and other current assets 914 4,621 Assets held-for-sale — 40,194 Investment in equity securities — 294 — Total current assets 72,502 82,941 408,347 Property and equipment, net 2,120 1,695 + Investments - Cyclo 12,770 10 4,763 Investments - Hedge Funds 2,547 4,984 Investment - Day Three - 2,797 Investments - Other Pharmaceuticals — 65 Convertible note receivable 1,477 Investments - Hedge Funds 4,146 984 4,764 Investment - Day Three Labs Inc. 2,797 — Goodwill 3 Investments - Cyclo Therapeutics Inc. 4,763 050 — Intangible assets, net 1,847 — In-process research and development and patents 1,575 1,575 Other assets 35 9 4,387 TOTAL ASSETS \$ 96,832 \$ 98,829 \$ 418,320 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable \$ 2,556 \$ 333 \$ 564 Accrued expenses 1,798 763 4,875 Convertible notes payable 614 — Other current liabilities 113 1,023 3,518 Due to related parties 733 26 69 Installment note payable 1,700 net of debt issuance costs, held-for-sale — 15,000 Total current liabilities 7,514 2,145 21 Accrued expenses, 926 noncurrent 2,982 — Convertible notes payable, noncurrent 73 — Other liabilities 5 55 88 TOTAL LIABILITIES 10,574 2,200 21,144 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, \$ 0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2023-2024 and July 31, 2022-2023, respectively 8 8 Class B common stock, \$ 0.01 par value; 200,000,000 shares authorized, 24,142,535 issued and 23,635,819 948 709 issued and 23,490,527 outstanding (excluding treasury shares of 101,487) as of July 31, 2023-2024, and 23,712,635 449 709 shares issued and 23,687,490 964 527 shares outstanding as of July 31, 2022-2023 238 236 237 Additional paid-in capital 280,048 264,010 262,023 Accumulated deficit (201,743) (167,333) (165 Treasury stock, 457 at cost; 101,487 and 0 Class B shares as of July 31, 2024 and July 31, 2023, respectively (168) — Accumulated other comprehensive income (loss) related to unrealized loss income on available-for-sale securities 111 (353) (663) Accumulated other comprehensive income related to foreign currency translation adjustment 3,691 3,725 3,767 Total equity attributable to Rafael Holdings, Inc. 82,185 100,293 400,515 Noncontrolling interests 4,073 (3,664) (3,309) TOTAL EQUITY 86,258 96,629 97,206 TOTAL LIABILITIES AND EQUITY \$ 96,832 \$ 98,829 \$ 418,320 See accompanying notes to the consolidated financial statements. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended July 31, 2024 2023 2022 REVENUE Infusion Technology \$ 355 \$ — Rental - Third Party \$ 174 171 \$ 179 Rental - Related Party 108 108 111 Other - Related Party — 120 Total revenue 637 279 410 COSTS AND EXPENSES Cost of Infusion Technology revenue 154 — General and administrative 8,854 8,932 46,978 Research and development 4,170 6,312 8 In-process research and development expense 89 742 861 Depreciation and amortization 225 78 72 Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit — 25,000 Provision for losses on related party receivables — 10,095 Loss from operations (102,627) (15,043) (60,477) Interest expense (6) Interest income 2,383 3,253 201 Impairment of investments- Other Pharmaceuticals — (334) Loss on initial investment in Day Three upon acquisition (1,633) — Impairment of cost method investment- Cornerstone Pharmaceuticals — (79,141) Realized gain (loss) on available-for-sale securities 1,772 154 (45) Realized gain (loss) on investment in equity securities (46) 309 — Unrealized gain on investment in equity securities — 33 Realized gain on investment- Cyclo 424 — Unrealized gain on investments- investment - Cyclo 37 Therapeutics Inc. 2,663 Unrealized gain on convertible notes receivable, due from Cyclo 1,191 — Unrealized gain (loss) on investments- investment - Hedge Funds 63 220 Recovery of receivables from Cornerstone 31,305 — Interest expense (504 248) — Other income 118 — Loss from continuing operations before income taxes (67,261) (8,745) (139,972) Benefit from income taxes 2,680 255 — Equity in loss of Day Three Labs Inc. (422) (203) — Equity in loss of RP Finance — (575) Consolidated net loss from continuing operations (65,003) (8,693) (140,547) Discontinued Operations (Note 3-14) Loss from discontinued operations related to 520 Property — (306) (1,830) Gain on disposal of 520 Property — 6,784 — Income (loss) from discontinued operations — 6,478 (1,830) Consolidated net loss (65,003) (2,215) (142,377) Net loss attributable to noncontrolling interests (30,593) (339) (17,719) Net loss attributable to Rafael Holdings, Inc. \$ (34,410) \$ (1,876) \$ (124,658) OTHER COMPREHENSIVE LOSS Consolidated net loss \$ (65,003) \$ (2,215) \$ (142,377) Unrealized (loss) gain on available-for-sale securities 464 (290) (62) Foreign currency translation adjustment (53) (42) (5) Total comprehensive Comprehensive loss (64,592) (2,547) (142,445) Comprehensive loss attributable to noncontrolling interests (30,595) (336) (17,746) Total comprehensive Comprehensive loss attributable to Rafael Holdings, Inc. \$ (33,997) \$ (2,211) \$ Income (124,699) Loss (loss) per share attributable to common stockholders Basic and diluted: Continuing operations \$ (1.45) \$ (0.36) \$ (6.22) Discontinued operations — 0.28 (0.09) Total basic and diluted loss per share \$ (1.45) \$ (0.08) \$ (6.31) Weighted average number of shares used in calculation of income (loss) per share Basic and diluted 23,745,516 23,263,111 49,767,342 CONSOLIDATED STATEMENTS OF EQUITY (in thousands, except share data) Year Ended July 31, 2023-2024 Common Stock, Series A Common Stock, Series B Additional Accumulated other Treasury Stock Shares Amount Shares Amount paid-in capital Accumulated deficit comprehensive income Noncontrolling interests Class B Shares Amount Total Equity Balance at August 1, 2023 787,163 \$ 8 23,490,527 \$ 236 \$ 264,010 \$ (167,333) \$ 3,725 (3,309) — \$ 96,629 Net loss — — — (34,410) — (30,593) — (65,003) Stock-based compensation — — — 506,826 3 2,293 — — 2,296 Shares withheld for payroll taxes — — — (75,918) (1) (135) — — (136) Unrealized gain on available-for-sale securities — — — 464 — — 464 Sale of Rafael Medical Devices membership units — — — 869 — 56 — 925 Noncontrolling interest in Day Three acquisition — — — 1,151 — 1,151 Purchases of treasury stock — — — (101,487) — — — 101,487 (168) Gain on RP Finance consolidation — — — 7,600 — — — 7,600 Paid-in capital arising from Cornerstone Acquisition — — — 7,260 — — — 7,260 Noncontrolling interest arising from Cornerstone Acquisition — — — 27,501 — 27,501 Noncontrolling interest arising from RP Finance Consolidation — — — 12,667 — 12,667 Elimination of RP Finance investment in Cornerstone — — — (1,849) — (3,082) — (4,931) Dissolution of Levco — — — 19 37 — 56 Foreign currency translation adjustment — — — (53) — — (53) Balance at July 31, 2024 787,163 \$ 8 23,819,948 \$ 238 \$ 280,048 \$ (201,743) \$ 3,802 \$ 4,073 101,487 \$ (168) \$ 86,258 Year Ended July 31, 2023 Common Stock, Series A Common Stock, Series B Additional paid-in Accumulated other comprehensive Noncontrolling Total Shares Amount Shares Amount capital deficit comprehensive income Noncontrolling Total Shares Amount Equity Balance at August 1, 2022 787,163 \$ 8 23,687,964 \$ 237 \$ 262,023 \$ (165,457) \$ 3,704 \$ (3,309) \$ 97,206 Net loss for the year ended July 31, 2023 — — — (1,876) — (339) (2,215) Stock-based compensation — — — 220,019 2 3,089 — — 3,091 Forfeiture of restricted stock — — — (296,759) (2) (901) — — — (903) Shares withheld for payroll taxes — — — (120,697) (1) (217) — — — (121) Unrealized loss on available-for-sale securities — — — (290) — — — (290) Acquisition of additional ownership interest in LipoMedix — — — 16 — — — (16) — — — Foreign currency translation adjustment — — — (42) — — — (42) — — —

Balance at July 31, 2023 787, 163 \$ 8 23, 490, 527 \$ 236 \$ 264, 010 \$ (167, 333) \$ 3, 372 \$ (3, 664) \$ 96, 629 Year Ended July 31, 2022 Common Stock, Series A Common Stock, Series B Additional paid-in Accumulated Accumulated other comprehensive Noncontrolling Total Shares Amount Shares Amount capital deficit income interests Equity Balance at August 1, 2021 787, 163 \$ 8 16, 936, 864 \$ 169, 136 \$ (40, 799) \$ 3, 772 \$ 14, 418 \$ 136, 704 Net loss for the year ended July 31, 2022 (124, 658) (17, 719) (142, 377) Stock-based compensation 1, 533, 311 16 18, 045 18, 061 Forfeiture of restricted stock (943, 305) (9) (18, 969) (18, 978) Common stock sold to investors 2, 833, 425 28 99, 142 99, 170 Transaction costs incurred in connection with sale of common stock (6, 228) (6, 228) Common stock sold to related party 3, 338, 307 33 10, 964 10, 997 Acquisition of additional ownership interest in LipoMedix 8 (8) Shares withheld for payroll taxes (10, 638) (75) Unrealized loss on available-for-sale securities (63) (63) Foreign currency translation adjustment (5) (5) Balance at July 31, 2022 787, 163 \$ 8 23, 490, 527 \$ 236 \$ 264, 010 \$ (167, 333) \$ 3, 372 \$ (3, 664) \$ 96, 629

CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended July 31, 2024 2023 2022 Operating activities Consolidated net loss \$ (65, 003) \$ (2, 215) \$ (142, 377) Less: Income (loss) from discontinued operations 6, 478 (4, 830) Loss from continuing operations (65, 003) (8, 693) (140, 547) Adjustments to reconcile consolidated net loss to net cash used in operating activities Depreciation and amortization 225 78 72 Gain on sale of property and equipment (27) Net unrealized (gain) loss on investments - investment Hedge Funds (63) (220) 504 Unrealized gain on equity securities (33) Realized loss on investment in equity securities 46 Realized gain on available-for-sale securities (1, 772) (154) Amortization of discount on available-for-sale securities (1, 891) (1, 195) Impairment of investments - Other Pharmaceuticals 334 Loss on initial investment in Day Three upon acquisition 1, 633 Realized gain in equity investments - Cyclo (424) Unrealized gain in equity investments - Cyclo Therapeutics Inc. (37) (2, 663) Unrealized gain on convertible notes receivable, due from Cyclo (1, 191) Recovery Realized (gain) loss on available-for-sale securities (154) 45 Amortization of discount on available-for-sale securities (1, 195) Impairment of investments - Other Pharmaceuticals 334 Impairment of cost method investment - Cornerstone Pharmaceuticals 79, 141 Provision for loss on receivable receivables from Cornerstone (31, 305) Pharmaceuticals pursuant to line of credit 25 In-process research and development expense 89, 000 861 Gain on dissolution of a business 18 Equity in loss of RP Finance 575 Equity in loss of Day Three 422 Labs Inc. 203 Bad debt expense 20 Provision for losses on related party receivables 10, 095 Provision for doubtful accounts 4 Stock-based compensation, net 2, 296 2, 188 (917) Change in assets and liabilities, net of effects from acquisitions and discontinued operations: Trade accounts receivable (150) (117) 74 Interest receivable (139) (247) (140) Prepaid expenses and other current assets 673 373 (3, 545) Other assets 22 (27) 130 Accounts payable and accrued expenses (146) (827) 52 Other current liabilities (938) 781 3, 566 Due to related parties 138 (43) (67) Due from Cornerstone Pharmaceuticals (120) Other liabilities (70) 15 40 Net cash used in continuing operations (7, 802) (10, 247) (26, 038) Net cash used in discontinued operations (639) (41) Net cash used in operating activities (7, 802) (10, 886) (26, 079) Investing activities Purchase Payment to Cornerstone Pharmaceuticals pursuant to Line of Credit Property and equipment (143) (25, 000) Purchases of property and equipment (2) Payment to fund RP Finance Line of Credit (1, 875) Purchases of available-for-sale securities (155, 657) (204, 798) (65, 306) Proceeds from the sale and maturities of available-for-sale securities 153, 352 185, 121 28 Proceeds from Day Three patent sale 270 Purchase of intangible assets (35) Proceeds from sales of equity securities 271 1, 500 325 Issuance of Convertible Notes, Due from Cyclo (4, 000) Issuance of convertible note receivable, related party (2, 000) Purchase of Investment in Day Three (3, 000) Purchase of Investment in Cyclo (6, 786) (2, 100) Issuance of convertible note receivable (1, 000) Issuance of Day Three Promissory Notes (1, 989) Proceeds from investments - Other Pharmaceuticals 42 78 Purchases of equity securities (1, 586) Cash acquired in acquisition of Day Three, net of cash payments 1, 099 Cash acquired in the Cornerstone Acquisition, net of cash payments 1, 256 Proceeds from hedge funds sales of equity securities 1, 325 Purchase of Investment in Day Three Labs Inc. (3, 000) Purchase of Investment in Cyclo Therapeutics Inc. (2, 500) 100 Net cash used in investing activities of continuing operations (10, 820) (26, 960) (63) Proceeds from sale of 520 Property - discontinued operations 49, 683 400 Payment of transaction costs for sale of 520 Property - discontinued operations (1, 229) Net cash provided by investing activities of discontinued operations 48, 171 Net cash (used in) provided by investing activities of discontinued operations 48, 171 (113, 100) 820 Net cash provided by (used in) investing activities 21, 211 (63, 796) Financing activities Proceeds from issuance of common stock - Principal payments on installment note payable (800) 99, 170 Proceeds from issuance of common stock from related party 10, 997 Payment of transaction costs incurred in connection with sale of common stock (6, 228) Payments for taxes related to shares withheld for employee taxes (136) (218) Purchases of treasury stock (75 168) Proceeds from sale of Rafael Medical Devices membership units 925 Net cash (used in) provided by continuing operations (218) 103, 864 Net cash used in financing activities of continuing operations (179) (218) Payment of Note Payable in connection with sale of 520 Property - discontinued operations (15, 000) Net cash (used in) provided by financing activities of discontinued operations (15, 000) Net cash used in financing activities (179) (15, 218) 403, 864 Effect of exchange rate changes on cash and cash equivalents (22) (146) (306) Net (decrease) increase in cash and cash equivalents (18, 823) (5, 039) 13, 683 Cash and cash equivalents, beginning of year 21, 498 26, 537 21, 498 26, 537 Non-cash supplemental disclosure Acquisition of additional ownership interest in LipoMedix \$ 16 Conversion of RFL Line of Credit into Cornerstone Common Stock \$ 837, 845 \$ Conversion of 2023 Promissory Note into Cornerstone Common Stock \$ 2, 663 \$ Recognition of noncontrolling interest in the Cornerstone Acquisition \$ 27, 501 \$ Recognition of noncontrolling interest in the RP Finance Consolidation, net of elimination \$ 9, 585 \$ Gain on RP Finance Consolidation recorded as an adjustment to additional paid-in capital due to related party nature of transaction, net of elimination \$ 5, 751 \$ Noncash consideration received in exchange for equipment \$ 34 \$ Elimination of principal and accrued interest on the Day Three Promissory Notes included in consideration for acquisition of Day Three \$ 2, 000 \$ See accompanying notes to the consolidated financial statements.

RAFAEL HOLDINGS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - DESCRIPTION OF BUSINESS Description of Business Rafael Holdings, Inc. (NYSE: RFL), ("Rafael Holdings", "we" or the "Company"), a Delaware corporation, is a holding company with interests in clinical and early-stage pharmaceutical companies (the "Pharmaceutical Companies"), including an investment in Cornerstone Pharmaceuticals, Inc. ("Cornerstone"), formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, a majority equity interest in LipoMedix Pharmaceuticals Ltd. ("LipoMedix"), a clinical stage pharmaceutical company, the Barer Institute Inc. ("Barer"), a wholly-owned preclinical cancer metabolism research operation, an investment in Cyclo Therapeutics Inc. (Nasdaq: CYTH), ("Cyclo Therapeutics" or "Cyclo"), a clinical-stage biotechnology company dedicated to developing life-changing medicines for patients and families living with challenging diseases through its lead therapeutic asset, Trappsol® Cyclo™, an investment in Day Three Labs, Inc. ("Day Three"), a company which reimagines existing cannabis offerings with pharmaceutical-grade technology and innovation like Unlokt™ to bring to market better, cleaner, more precise and predictable products in the cannabis industry, and a majority interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally-invasive surgeries ("Rafael Medical Devices" and Day Three Labs together with the Pharmaceutical Companies, represent our "Investment Companies"). In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. The Company's primary focus is to expand our investment portfolio through opportunistic and strategic investments including therapeutics which address high unmet medical needs. Historically, the Company owned multiple real-estate assets. In 2020, the Company sold an office building located in Piscataway, New Jersey and, on August 22, 2022, the Company sold the building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and several tenants and an associated public garage (the "520 Property"). See Note 3 for further details on the sale transaction. Currently, the Company holds a portion of a commercial building in Jerusalem, Israel as its remaining real-estate asset. The Company holds debt and equity investments in Cornerstone Pharmaceuticals that includes preferred and common equity interests and a warrant to purchase additional equity. On June 17, 2021, the Company entered into a merger agreement to acquire full ownership of Cornerstone Pharmaceuticals in exchange for issuing Company Class B common stock to the other stockholders of Cornerstone Pharmaceuticals ("Merger Agreement" or "Merger"). On October 28, 2021, the Company announced that the AVENGER 500 Phase 3 clinical trial for CPI-613® (devimistat), Cornerstone Pharmaceuticals' lead product candidate, did not meet its primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas. In addition, following a pre-specified interim analysis, the independent data monitoring committee for the ARMADA 2000 Phase 3 study for devimistat recommended the trial to be stopped due to a determination that it was unlikely to achieve the primary endpoint (the "Data Events"). In connection with the preparation of the Company's financial statements for the first quarter ended October 31, 2021, accounting principles generally accepted in the United States of America ("U.S. GAAP") required that the Company assess the impact of the Data Events and determine whether the carrying values of the Company's assets were impaired based upon the Company's expectations to realize future value. In light of the Data Events, the Company concluded that the likelihood of further development of and prospects for CPI-613 is uncertain and fully impaired in the first quarter ended October 31, 2021 the value of its loans, receivables, and investment in Cornerstone Pharmaceuticals based upon its valuation of Cornerstone Pharmaceuticals. On February 2, 2022, the Company terminated the Merger Agreement with Cornerstone Pharmaceuticals, effective immediately, in accordance with its terms. Subsequently, on February 2, 2022, the Company withdrew its Registration Statement on Form S-4 related to the proposed Merger. On March 21, 2023, the Company loaned \$ 2.0 million to Cornerstone which debt is represented by a Promissory Note made by Cornerstone (the "Promissory Note" or "Note"). Cornerstone is in the process of a comprehensive restructuring transaction including, the conversion of the debt under the Line of Credit Agreement and the Promissory Note held by the Company, the conversion and modification of other Cornerstone debt obligations, the extension of the Cornerstone debt held by RP Finance, a reverse stock split, the conversion of all outstanding preferred stock of Cornerstone into common stock and the adoption of certain governance measures. This transaction is subject to a number of conditions which are beyond the Company's control. In May 2023, the Company first invested in Cyclo Therapeutics. Cyclo is a clinical stage biotechnology company that develops cyclodextrin-based products for the potential treatment of neurodegenerative diseases. Cyclo's lead drug candidate is Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), a treatment for Niemann-Pick Type C disease Disease ("type C1, NPC NPC1"). NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver/liver, spleen, and other organs. In January 2017, the FDA granted Fast Track designation to Trappsol® Cyclo™ for the treatment of NPC NPC1. Initial patient enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 Cyclo announced Top Line data demonstrating showing a favorable safety and tolerability profile for Trappsol® Cyclo™ was well tolerated in this study. Cyclo is currently conducting a Phase 3 III Clinical Trial Evaluating Trappsol® Cyclo™ in Pediatric and Adult Patients with Niemann-Pick Disease Type C1. In 2019, See Notes 11 and 12 for more information on the Company established Barer, a preclinical cancer metabolism research operation, to focus on developing a pipeline of novel therapeutic compounds, including compounds to regulate cancer metabolism with potentially broader application in other indications beyond cancer. Barer has been comprised of scientists and academic advisors that are experts in cancer metabolism, chemistry, and drug development. In addition to its own internal discovery efforts, Barer pursued

collaborative research agreements and in-licensing opportunities with leading scientists from top academic institutions. Barer's investments in Cyclo, RAFAEL HOLDINGS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The Company owns a 37.5% equity interest in RP Finance LLC ("RP Finance"), which was, until March 13, 2024 (the date of the RP Finance Consolidation, as described in Note 3), accounted for under the equity method. RP Finance is an entity associated with members of the family of Howard Jonas (Executive Chairman, Chairman of the Board, and controlling stockholder of the Company) which holds 37.5% equity interest of RP Finance. RP Finance holds debt and equity investments in Cornerstone. In October 2021, Cornerstone received negative results of its Avenger 500 Phase 3 study for Devimistat in pancreatic cancer as well as a recommendation to stop its ARMADA 2000 Phase 3 study due to a determination that the trial would unlikely achieve its primary endpoint (the "Data Events"). Due to the Data Events, RP Finance fully impaired its then debt and equity investments in Cornerstone. On March 13, 2024, Cornerstone consummated a restructuring of its outstanding debt and equity interests (the "Cornerstone Restructuring"). As a result of the Cornerstone Restructuring, Rafael became a 67% owner of the issued and outstanding common stock of Cornerstone (the "Cornerstone Acquisition"), and Cornerstone became a consolidated subsidiary of Farber Partners, LLC ("Farber"), of Rafael. The Cornerstone Acquisition is accounted for as an acquisition of a variable interest entity that is not a business in accordance with U. S. GAAP. The Company was formed around one such agreement determined to be the accounting acquirer for financial reporting purposes. See Note 3 to the Consolidated Financial Statements for additional information regarding the transaction. In conjunction with Princeton University the Cornerstone Restructuring and Cornerstone Acquisition, the Company reassessed its relationship with RP Finance, and as a result determined that RP Finance is still a variable interest entity and that the Company became the primary beneficiary of RP Finance as the Company now holds the ability to control repayment of the RP Finance Line of Credit which directly impacts RP Finance's Office of Technology Licensing economic performance. Therefore, following the Cornerstone Restructuring and Cornerstone Acquisition, the Company consolidated RP Finance (the "RP Finance Consolidation"). See Note 3 for additional technology from the laboratory of Professor Joshua... with pharmaceutical-grade technology and innovation information like Unlokt™ to bring to market better, cleaner, more precise and predictable products in the cannabis industry. In May 2021, the Company formed Rafael Medical Devices, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. In August 2023, the Company raised \$ 925,000 from third parties in exchange for 31-62% ownership of Rafael Medical Devices. The Company also holds a 95% investment in LipoMedix, a development-stage, privately held Israeli company focused on the Consolidation development of an innovative, safe and effective cancer therapy based on liposome delivery. The "Company" in these consolidated financial statements refers to Rafael Holdings and its subsidiaries on a consolidated basis. F-9 All majority-owned subsidiaries and RP Finance, LLC are consolidated with all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the subsidiaries entities included in these consolidated financial statements are as follows: Company Country of Incorporation Percentage Owned Broad Atlantic Associates, LLC United States - Delaware 100% IDT R. E. Holdings Ltd. Israel 100% Rafael Holdings Realty, Inc. United States - Delaware 100% Barer Institute, Inc. United States - Delaware 100% \* The Barer Institute, LLC United States - Delaware 100% \* Hillview Avenue Realty, JV United States - Delaware 100% Hillview Avenue Realty, LLC United States - Delaware 100% Rafael Medical Devices, LLC Inc. United States - Delaware 400.68% Leveo Pharmaceuticals Ltd. Israel 95% \* \* Farber Partners, LLC United States - Delaware 93% Pharma Holdings, LLC United States - Delaware 90% \* \* \* LipoMedix Pharmaceuticals Ltd. (Note 9) Israel 95% \* \* \* \* Altira Capital & Consulting, LLC United States - Delaware 67% CS Pharma Holdings, LLC (Note 3) United States - Delaware 45% \* \* \* Day Three Labs, Inc. (Note 10) United States - Delaware 84% \* \* \* \* Cornerstone Pharmaceuticals, Inc. (Note 4) United States - Delaware 67% RP Finance, LLC (Note 5) United States - Delaware 38% \* In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. F-9 \* \* During Fiscal 2022, the Company discontinued further material investment in Leveo. In August 2023, Leveo was dissolved. \* \* \* 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma Holdings, LLC and Pharma Holdings LLC, collectively own securities representing 51-67% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). Refer to Note 4 for further details. \* \* \* During Fiscal 2022, the Company discontinued further material investment in Leveo. \* \* \* In May, On February 9, 2023-2024, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd Day Three Labs, Inc. from 79 an additional 11% from to 84% to 95%. On March 15, 2022, the Company dissolved IDT 225 Old NB Road, LLC. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e. g., fiscal year 2023-2024 refers to the fiscal year ended July 31, 2023-2024). The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U. S. GAAP. The accompanying consolidated financial statements reflect the activity related to the 520 Property as discontinued operations. Use of Estimates The preparation of consolidated financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. As of July 31, 2023-2024, the Company had cash and cash equivalents of approximately \$ 21.2- 5.7 million, and available-for-sale securities valued at approximately \$ 57.63- 7.3 million. On August 22, 2022, the Company received net proceeds of approximately \$ 33 million in connection with the sale of the 520 Property (see Note 3 for further details). The Company expects the balance of cash and cash equivalents, and available-for-sale securities to be sufficient to meet its obligations for at least the next 12 months from the issuance of these consolidated financial statements. F-10 Concentration of Credit Risk and Significant Customers The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. As of For the year ended July 31, 2023-2024, there was one including revenue from discontinued operations, related party parties represented 42% of the Company's revenue. As of July 31, 2023, there were two customers which represented 50.27% and 47% of the Company's accounts receivable balance. As of For the year ended July 31, 2022-2023, there was one customer which including revenue from discontinued operations, related parties represented 27.58% of the Company's revenue, and as of July 31, 2022, two customers, one of which is a related party, represented 24% and 47% of the Company's accounts receivable balance and one related party which represented 47% of the Company's accounts receivable balance. For the year ended July 31, 2024, one customer represented 51% of total revenue, and one tenant and one related party tenant represented 27% and 17% of the Company's revenue, respectively. For the year ended July 31, 2023, including revenue from discontinued operations, a related party tenant represented 42% of the Company's revenue. Cash and Cash Equivalents The Company considers all liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Reserve for Receivables The Company evaluates accounts receivable, loans, interest and fees receivable for impairment under Accounting Standards Codification ("ASC") 310, Receivables. The Company also evaluates the reserve for losses and estimates collectability of accounts receivable, loans, interest and fees receivable based on historical bad debt experience, management's assessment of the financial condition of individual companies with which the Company conducts business, current market conditions, and reasonable and supportable forecasts of future economic conditions. F-10 The allowance for doubtful accounts credit losses reflects the Company's best estimate of probable lifetime credit losses inherent in the accounts receivable balance. The allowance is determined based on known troubled accounts, historical experience and other currently available evidence. Doubtful accounts are written off upon final determination that the trade accounts will not be collected. The computation of this allowance is based on the tenants' or parking customers' payment histories, as well as certain industry or geographic specific credit considerations. If the Company's estimates of collectability differ from the cash received, then the timing and amount of the Company's reported revenue could be impacted. The credit risk Company recorded bad debt expense from continuing operations, which is included in general mitigated by the high quality of the Company's existing tenant base, inclusive of related parties, which represented 42% and 58% of administrative expenses on the Company's total revenue. Consolidated Statements of Operations and Comprehensive Loss, of approximately \$ 20 thousand and \$ 0 for the years ended July 31, 2024 and 2023 and 2022, respectively. The Company recorded bad debt expense from discontinued operations of approximately \$ 0 and \$ 110 thousand and \$ 4 thousand for the years ended July 31, 2024 and 2023 and 2022, respectively. Convertible Note Receivable - Related Party The Company holds Convertible convertible Note notes Receivable receivable is that are classified as available-for-sale as defined under Accounting Standards Codification ("ASC") 320, Investments- Debt and Equity Securities, and is recorded at fair value. Subsequent changes in fair value are recorded in accumulated other comprehensive income (loss). The fair value of the these Convertible convertible Note note Receivable receivables is are estimated using a scenario-based analysis based on the probability-weighted present value of future investment returns, considering each of the possible outcomes available to the Company, including cash repayment, equity conversion, and collateral transfer scenarios. Estimating the fair value of the convertible note requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Variable Interest Entities In accordance with ASC 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities ("VIEs"). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company - that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE's economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. F-11 The method of accounting applied to long-term investments in equity securities involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also include the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company's controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in equity securities may be accounted for using (i) the fair value option, if elected, (ii) fair value through earnings if fair value is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. The Company has elected the fair value option to account for its investment in Cyclo Therapeutics, Inc. over which, as the Company has significant influence over Cyclo's management. The fair value option is irrevocable once elected. The Company measured its initial investment in Cyclo at fair value and shall record all subsequent changes in fair value in earnings in the consolidated statement statements of operations and comprehensive loss. The Company believes the fair value option best reflects the underlying economics of the investment. The Company has determined that Cyclo is a VIE;

however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Cyclo that most significantly impact Cyclo's economic performance. See Note 9-11. "Investments- Investment in Cyclo Therapeutics, Inc." F-11 Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for in accordance with ASC 321, Investments - Equity Securities. Investments without readily determinable fair values are accounted for using the measurement alternative which is at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established. Investments- Hedge Funds The Company accounts for its investments in hedge funds in accordance with ASC 321, Investments - Equity Securities. Unrealized gains and losses resulting from the change in fair value of these securities is included in unrealized (loss)-gain on investments - investment - Hedge Funds in the consolidated statements of operations and comprehensive loss. Corporate Bonds and US Treasury Bills The Company's marketable securities are considered to be available- for- sale as defined under ASC 320, Investments- Debt and Equity Securities, and are recorded at fair value. Unrealized gains or losses are included in accumulated other comprehensive loss. Realized gains or losses are determined using the specific identification method and are released from accumulated other comprehensive loss and into earnings on the consolidated statements of operations and comprehensive loss. Effective August 1, 2023, the Company uses a current expected credit losses ("CECL") model to estimate the allowance for credit losses on available- for- sale debt securities. For available- for- sale debt securities in an unrealized loss position, management first assesses whether it intends to sell, or it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value through income. For available- for- sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized cost basis. Any decline in fair value that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. No allowance for credit losses was recognized by the Company at July 31, 2024. F- 12 Cost Method Investment Prior to the Cornerstone Acquisition, the Company had determined that Cornerstone was a VIE; however, the Company had determined that it was not the primary beneficiary as the Company did not have the power to direct the activities of Cornerstone that most significantly impact Cornerstone's economic performance. See Note 3 for additional information. Equity Method Investments Investments classified as equity method consist of investments in companies in which the Company is able to exercise significant influence but not control. Under the equity method of accounting, the investment is initially recorded at cost, then the Company's proportional share of investee's underlying net income or loss is recorded as a component of income from continuing operations, with a corresponding increase or decrease to the carrying value of the investment. These investments are evaluated for impairment if events or circumstances arise that indicate that the carrying amount of such assets may not be recoverable. The Company has determined that RP Finance and Day Three are VIEs. Prior to the RP Finance Consolidation, which occurred as a result of the Cornerstone Pharmaceuticals (see Note 4) Acquisition, and the Day Three Acquisition, the Company accounted for RP Finance and Day Three under the equity method of accounting. As of January 2, 2024, Day Three is consolidated as a VIE; however majority- owned subsidiary. In conjunction with the Cornerstone Acquisition on March 13, 2024, the Company reassessed its relationship with RP Finance and, as a result, the Company has consolidated determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals' economic performance. Equity Method Investments The Company has determined that each of RP Finance - LLC ("RP Finance") and Day Three Labs, Inc. ("Day Three"), RP Finance and Day Three, collectively, the "Equity Method Investees" and the Company's investments in RP Finance and Day Three, collectively, the "Equity Method Investments"), (see Note 6 and Note 8), are each a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of the Equity Method Investees that most significantly impact the Equity Method Investees' economic performance and, therefore, is not required to consolidate the Equity Method Investees. The Company accounts for the Equity Method Investments using the equity method of accounting. Long- Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost less accumulated depreciation and amortization. The related depreciation and amortization are depreciated on a computed using the straight- line basis method over their-- the estimated useful lives, which range as follows: Classification Years Building and improvements Tenant improvements 7- 15 Machinery and equipment 3- 5 Other (primarily office equipment and), (furniture and fixtures) On August 22, 2022, Broad Atlantic Associates LLC, a wholly- owned subsidiary of the Company ("Broad Atlantic"), completed the sale of the 520 Property for a purchase price of \$ 49. 4 million. The 520 Property served serves as the Company's headquarters and had has several other tenants, and includes a related 800- car public parking garage. The Company determined that the 520 Property met the held- for- sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. The Company owns a portion of the 6th floor of a building located at 5 Shlomo Halevi Street, in Jerusalem, Israel. The purchase price for acquisitions are allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions provided by management, including expected future cash flows. We allocate any excess purchase price over the fair value of the identifiable net assets and liabilities acquired to goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition- related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date. F- 42- 13 Impairment of Long- Lived Assets The Company assesses the recoverability of long- lived assets, which include property and equipment and, intangible assets, in- process research and development and patents, whenever significant events or changes in circumstances indicate that its carrying amount may not be recoverable. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset's carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a change charge to operating results. For the years ended July 31, 2024 and 2023 and 2022, the Company determined that there was no impairment of its long- lived assets. Assets Held- for- Sale and Discontinued Operations The Company classifies assets as held- for- sale if all held- for- sale criteria are met pursuant to ASC 360- 10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held- for- sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held- for- sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. Strategic changes in the Company's operations can be considered a discontinued operation if both the operations and cash flows of the discontinued component have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued component after the disposal transaction. The results of the discontinued operations shall be reflected as a discontinued operation on the consolidated statements of operations and comprehensive loss and prior periods shall be recast to reflect the earnings from discontinued operations. As a result of the agreement to sell the 520 Property, the accompanying consolidated financial statements reflect the activity related to the sale of the 520 Property as discontinued operations. The Company determined that the 520 Property met the held- for- sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. See Note 3- 14 for additional information regarding the results, major classes of assets and liabilities, significant non- cash operating items, and capital expenditures of discontinued operations. Debt Issuance Costs Debt issuance costs are The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded net against goodwill may be impaired. The Company regularly monitors current business conditions and the other related debt and amortized factors including, but not limited to interest expense over, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company's annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of the Company's reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company would the then life of proceed to the related debt quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. The Company assesses goodwill for impairment on an annual basis as of May 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge During during the years- year ended July 31, 2023- 2024 . The Company has acquired in- process research and 2022- development ("IPR & D") intangible assets pursuant to a business combination. These IPR & D assets are considered indefinite- lived intangible assets until completion or abandonment of the associated research and development efforts. These IPR & D assets are not amortized debt-issuance costs of \$ 0 but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. F- 14 Acquired IPR & D pursuant to and- an \$ 472 thousand, respectively, were recorded asset acquisition that has no alternative future use is expensed immediately as a component of interest in- process research and development expense which is included in Discontinued the consolidated statements of Operations operations and comprehensive loss. Revenue Recognition The Company applies the five- step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in

the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. **The Company's infusion technology revenue is derived from Day Three's Unlokt technology which is recognized in accordance with ASC 606. Day Three provides manufacturing services where they use proprietary technology, equipment, and processes to manufacture water-soluble product for their customers at their customer facilities. Day Three is acting as a principal in the transaction, as it is primarily responsible for fulfillment and acceptability of the services. Infusion technology revenue is recognized over time as the Company's performance obligation is satisfied, which is generally within a 30-day period. The criterion in ASC 606-10-25-27, that the entity's performance creates or enhances an asset that the customer controls as the asset is created or enhanced, is met given that the customer is controlling the product as Day Three is performing the service on the customer's premises. Revenue is recognized over the period of performance using an output method where the number of grams produced is the output, as such method best depicts the Company's efforts to satisfy the performance obligation. Customer billings in advance of revenue recognition result in contract liabilities. As of July 31, 2024, there were no contract liabilities recognized on the consolidated balance sheets related to infusion technology revenue.** As an owner and operator of real estate, the Company derives rental the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases. The revenue derived from the 520 Property **for the period prior to its sale**, which included leasing office and parking space to the tenants, is presented within discontinued operations in the consolidated statements of operations and comprehensive loss. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earned revenue from parking which was derived primarily from monthly and transient daily parking **which is a component of income from discontinued operations**. The monthly and transient daily parking revenue falls within the scope of ASC 606 and was accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting. **Cost of Infusion Technology Revenue** The **cost** Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants **Infusion Technology revenue includes costs related to supplies, materials, production labor, and travel costs make required rent payments or parking customers to pay amounts due.** **F-13** Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. **F-15** Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property. **Repairs and Maintenance** **The There were Company charges the cost of repairs and maintenance, including the cost of replacing minor items not no such payment constituting substantial betterment, to selling, general and administrative expenses as during these the costs are incurred years ended July 31, 2024 and 2023.** Stock-Based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures of grants as they occur. Compensation cost for awards is recognized using the straight-line method over the vesting period. Stock-based compensation is included in general and administrative expense and research and development expense in the consolidated statements of operations and comprehensive loss. Income Taxes The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change. The Company uses a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in a tax return. The Company determines whether it is more likely than not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more likely than not recognition threshold, the Company presumes that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information. Tax positions that meet the more-likely-than-not recognition threshold are measured to determine the amount of tax benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Differences between tax positions taken in a tax return and amounts recognized in the financial statements will generally result in one or more of the following: an increase in a liability for income taxes payable, a reduction of an income tax refund receivable, a reduction in a deferred tax asset, or an increase in a deferred tax liability. The Company classifies interest and penalties on income taxes as a component of income tax expense, if any. Contingencies The Company accrues for loss contingencies when both (a) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (b) the amount of loss can reasonably be estimated. When the Company accrues for loss contingencies and the reasonable estimate of the loss is within a range, the Company records its best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company discloses an estimated possible loss or a range of loss when it is at least reasonably possible that a loss may have been incurred. **F-14** The Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments. As of July 31, 2023 and 2022, the Company was not a lessee under any leasing arrangements. Fair Value Measurements Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows: ● Level 1- quoted prices in active markets for identical assets or liabilities; ● Level 2- quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or ● Level 3- unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. **F-16** A financial asset's or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. Functional Currency The U. S. Dollar is the functional currency of our entities operating in the United States. The functional currency for our subsidiaries operating outside of the United States is the New Israeli Shekel, the currency of the primary economic environment in which such subsidiaries primarily expend cash. The Company translates those subsidiaries' financial statements into U. S. Dollars. The Company translates assets and liabilities at the exchange rate in effect as of the consolidated financial statement date, and translates accounts from the consolidated statements of operations and comprehensive loss using the weighted average exchange rate for the period. The Company reports gains and losses from currency exchange rate changes related to intercompany receivables and payables, **currently in non which are not of a long operating expenses term investment nature, as part of other comprehensive loss**. Loss Per Share Basic loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share is determined in the same manner as basic loss per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase would be anti-dilutive. The Company uses **income loss** from continuing operations as the "control number" or benchmark to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting earnings (loss) per share for discontinued operations. **Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments- Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which was codified in ASC 326, Financial Instruments- Credit Losses ("ASC 326"). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because the Company is a smaller reporting company, ASC 326 became effective for the Company for fiscal years beginning after December 15, 2022. As such, the Company adopted ASC 326 effective August 1, 2023, utilizing the modified retrospective transition method. Upon adoption, the Company updated its impairment model to utilize a forward-looking CECL model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including its accounts receivable. In relation to available-for-sale ("AFS") debt securities, the guidance eliminates the concept of "other-than-temporary" impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.** **Recently Issued Accounting Standards Not Yet Adopted** From time to time, new accounting pronouncements are issued by the **Financial Accounting Standards Board ("FASB")** or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. **F-15** In June 2016, the FASB issued Accounting Standards Update ("ASU") 2016-13, **Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments**, which changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including

interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company intends to adopt the standard on August 1, 2023 and does not believe the adoption will have a material impact on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies an issuer's accounting for convertible instruments by reducing the number of accounting models that require separate accounting for embedded conversion features. ASU 2020-06 also simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification and makes targeted improvements to the disclosures for convertible instruments and earnings-per-share ("EPS") guidance. This update will be effective for the Company's fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Entities can elect to adopt the new guidance through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard as of August 1, 2024. **F-17 In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which clarifies the guidance in ASC Topic 820, Fair Value Measurement ("Topic 820"), when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and intends to adopt the standard as of August 1, 2024. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The new guidance is effective for the Company in the annual period beginning August 1, 2024 and interim periods beginning February 1, 2025. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.**

**NOTE 3 – CORNERSTONE RESTRUCTURING, ACQUISITION, AND RP FINANCE CONSOLIDATION** Prior to the Cornerstone Restructuring, Rafael (directly via certain of its subsidiaries, and through an equity method investment in RP Finance) held certain debt and equity investments in Cornerstone, which are described in Note 4. Restructuring of Cornerstone On March 13, 2024, Rafael, Cornerstone, and other holders of debt and equity securities of Cornerstone agreed to various transactions which effected a recapitalization and restructuring of the outstanding debt and equity interests in Cornerstone. In the Cornerstone Restructuring, Rafael obtained shares of common stock of Cornerstone ("Cornerstone Common Stock") that gave the Company control over approximately 67% of the outstanding voting interests of Cornerstone (the "Cornerstone Acquisition"). For accounting purposes, Rafael was determined to be the acquirer, as the Company has been determined to be the primary beneficiary of Cornerstone, a VIE, in accordance with ASC 810. For Rafael, the Cornerstone Acquisition is the result of the Cornerstone Restructuring. As part of the Cornerstone Restructuring: (i) all issued and outstanding shares of Cornerstone's preferred stock and non-voting common stock converted into shares of Cornerstone Common Stock (the "Mandatory Common Conversion") on a one-for-one basis, which shares of Cornerstone Common Stock were then subjected to the Reverse Stock Split (as defined below), including the conversion of Rafael's 60,673,087 shares of Cornerstone's Series D Preferred Stock into 6,067,306 shares of post-Reverse Stock Split Cornerstone Common Stock; (ii) Cornerstone offered shares of Cornerstone's Common Stock to all holders of Cornerstone's promissory notes convertible into Cornerstone Series C preferred stock (the "Series C Convertible Notes") who were Accredited Investors with the purchase price to be paid through conversion of the outstanding principal amount and accrued interest on their Series C Convertible Notes held by each holder into Common Stock at the Cornerstone Restructuring Common Stock Price as described below (the "Series C Convertible Notes Exchange"). Approximately 94% of the outstanding Series C Convertible Notes participated in the Series C Convertible Notes Exchange, and \$15.5 million of principal and accrued interest outstanding on the Series C Convertible Notes was converted into 15,739,661 shares of post-Reverse Stock Split Cornerstone Common Stock. Series C Convertible Notes with an aggregate principal and accrued interest amount of \$0.9 million remaining outstanding, of which Series C Convertible Notes with an aggregate principal and accrued interest amount of \$93 thousand were amended in the Cornerstone Restructuring to (A) extend the maturity date thereof to May 31, 2028 and (B) provide that, on conversion thereof, the converting holder will receive shares of Cornerstone Common Stock. The holders of these amended Series C Convertible Notes that remain outstanding waived such holders' rights in connection with the Cornerstone Restructuring. Series C Convertible Notes with an aggregate principal and accrued interest amount of \$0.8 million remained outstanding and were not amended in connection with the Cornerstone Restructuring. The principal and accrued interest are included in Convertible notes on the consolidated balance sheets; F-18 (iii) Rafael converted the approximately \$30.6 million of the outstanding principal and accrued interest under the RFL Line of Credit (as defined in Note 4) into 30,080,747 shares of post-Reverse Stock Split Cornerstone Common Stock. The conversion of the RFL Line of Credit, inclusive of accrued interest, into equity in Cornerstone represents a recovery of a previously written-off asset, and the Company recorded the recovery in accordance with ASC 326, by recognizing a gain of \$30.6 million in the year ended July 31, 2024, in conjunction with and immediately prior to the Cornerstone Restructuring equal to the fair value of the Cornerstone Common Stock, up to the amount of principal and accrued interest on the instrument, that was received in settlement of the RFL Line of Credit in connection with the Cornerstone Restructuring. Upon the consummation of the Cornerstone Acquisition, the investment was eliminated as Cornerstone became a majority-owned subsidiary of Rafael and the difference between the investment's carrying value and its fair value included in purchase consideration, which is based on the value of Cornerstone's Common Stock, resulted in a gain of \$7.3 million that was recorded to the Company's additional paid-in capital given the related party nature of the transaction; (iv) Rafael converted the approximately \$2.1 million of the outstanding principal and accrued interest pursuant to the 2023 Promissory Note (as defined in Note 4) into 2,116,932 shares of post-Reverse Stock Split Cornerstone Common Stock. Prior to the Cornerstone Restructuring, the Company recorded the 2023 Promissory Note at its fair value as the security was classified as available-for-sale. The 2023 Promissory Note is included in the consideration paid at its fair value (which was deemed to be the fair value of the Cornerstone Common Stock received) in the Cornerstone Acquisition in accordance with ASC 810-10-30-4. The Company recognized a gain of \$0.6 million in the year ended July 31, 2024 for the realization of previously unrealized gains on the fair value of the 2023 Promissory Note in other comprehensive loss; (v) Cornerstone and RP Finance amended the RPF Line of Credit (as defined in Note 5) to (i) extend the maturity date of the approximately \$21.9 million in borrowings thereunder to May 31, 2028, (ii) limit the number of shares to be issued thereunder in respect of anti-dilution protection provided for therein in connection with the Cornerstone Restructuring and to provide RP Finance 3,658,368 shares of post-Reverse Stock Split Cornerstone Common Stock so that following the Cornerstone Restructuring, RP Finance holds six percent (6%) of the outstanding Common Stock of Cornerstone (the "RPF 6% Top Up Shares"), (iii) terminate any anti-dilution protection in respect of such ownership interest following consummation of the Cornerstone Restructuring, and (iv) terminate all future lending obligations of RP Finance under the RPF Line of Credit (as so amended, the "Amended RPF Line of Credit"); (vi) Rafael invested an additional \$1.5 million in cash in exchange for 1,546,391 shares of post-Reverse Stock Split Cornerstone Common Stock; (vii) Cornerstone amended and restated its certificate of incorporation, to, among other things, effect a reverse split of all of Cornerstone's capital stock on a one-for-ten basis (the "Reverse Stock Split"), set the number of authorized shares of Cornerstone Common Stock to be sufficient for issuance of the Common Stock in the Cornerstone Restructuring and eliminate the authorized preferred stock not required to be authorized as a result of the Mandatory Common Conversion; (viii) Cornerstone amended prior agreements in place giving certain parties rights to designate members of the Board and those rights have been eliminated. All directors are elected by the Cornerstone stockholders and as the majority stockholder, Rafael can control that vote. The Company has entered into a voting agreement (the "Voting Agreement") whereby Rafael has agreed to maintain three directors of Cornerstone that are independent of Rafael; and (ix) Cornerstone increased the available reserve of Cornerstone Common Stock for grant to employees, consultants and other service providers to approximately 10% of Cornerstone's fully diluted capital stock (the "Reserve Increase"). Acquisition of Cornerstone As a result of the Cornerstone Restructuring, Rafael became a 67% owner of the issued and outstanding Common Stock of Cornerstone, which became a consolidated subsidiary of Rafael. The Cornerstone Acquisition is accounted for as an acquisition of a VIE that is not a business in accordance with U.S. GAAP. The Company was determined to be the accounting acquirer for financial reporting purposes. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen test is met, the acquired entity is not a business for financial reporting purposes. Accordingly, the Cornerstone Acquisition will be accounted for as an asset acquisition as substantially all of the fair value of Cornerstone's gross assets is concentrated within in-process research and development, an intangible asset. Under ASC 810, the initial consolidation of a VIE shall not result in goodwill being recognized, and the acquirer shall recognize a gain or loss for the difference of (a) the sum of (i) the fair value of any consideration paid, (ii) the fair value of any noncontrolling interests, and (iii) the reported amount of any previously held interests, and (b) the net amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805, Business Combinations ("ASC 805"). In accordance with the calculation within ASC 810, no gain or loss was recognized on the Cornerstone Acquisition. F-19 The net amount of the VIE's identifiable assets and liabilities recognized with respect to the Cornerstone Acquisition is based upon management's preliminary estimates of and assumptions related to the fair values of assets acquired and liabilities assumed, using currently available information. For this purpose, fair value shall be determined in accordance with the fair value concepts defined in ASC 820, Fair Value Measurements and Disclosures. The following table presents, in accordance with ASC 810, the sum of (i) the fair value of consideration paid, (ii) the fair value of noncontrolling interests, and (iii) the reported amount of previously held interests (amounts in thousands): Fair value of consideration paid Fair value of RFL Line of Credit \$ 37,845 Fair value of 2023 Promissory Note 2,663 Cash consideration 1,500 (i) Total fair value of consideration paid 42,008 (ii) Fair value of noncontrolling interests 27,501 (iii) Reported value of previously held interests (1) — Sum of (i), (ii), and (iii) \$ 69,509 (1) Rafael's interest in the Series D Preferred Stock of Cornerstone, that was converted into Cornerstone Common Stock in the Cornerstone Restructuring, represents a previously held interest in Cornerstone that is included at its reported amount, or \$0. The following table presents, in accordance with ASC 810, the net preliminary amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805 (amounts in thousands): Assets acquired and liabilities assumed Cash and cash equivalents \$ 2,756

Prepaid expenses and other current assets 121 Property and equipment 19 Other assets 48 Acquired IPR & D 89, 861 Accounts payable (2, 006) Accrued expenses (1, 188) Series C Convertible Notes, short-term portion (614) Due to related parties (1, 289) Other current liabilities (28) Series C Convertible Notes, long-term portion (70) Creditor payable, noncurrent (2, 745) Amended RPF Line of Credit (15, 336) Other liabilities (20) Total \$ 69, 509 In accordance with the calculation within ASC 810, no gain or loss was recognized on the initial consolidation of Cornerstone. The Company incurred transaction costs of \$ 716 thousand for the year ended July 31, 2024 for consulting, legal, accounting, and other professional fees that have been expensed as general and administrative expenses as part of the Cornerstone Restructuring, Cornerstone Acquisition, and RP Finance Consolidation. The Company recognized a gain in the amount of \$ 720 thousand on the reversal of a reserve on a receivable due from Cornerstone, which was fully reserved for by the Company due to the Data Events. This receivable balance is then eliminated in consolidation against the corresponding payable balance acquired from Cornerstone recorded in Cornerstone's Due to related parties balance in the assets acquired and liabilities assumed in the Cornerstone Acquisition. F- 20 To value the IPR & D, the Company utilized the Multi- Period Excess Earnings Method (" MPEEM "), under the Income Approach. The method reflects the present value of the projected operating cash flows generated by Cornerstone's assets after taking into account the cost to realize the revenue, and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR & D acquired represents Cornerstone's research and development activities related to oncology- focused pharmaceuticals which seeks to exploit the metabolic differences between normal cells and cancer cells. IPR & D represents the R & D asset of Cornerstone which is in- process, but not yet completed, and which has no alternative use. As the Cornerstone Acquisition has been accounted for as an acquisition of a VIE that is not a business, it was determined that the fair value of IPR & D asset acquired with no alternative future use should be charged to IPR & D expense at the acquisition date. The Company assumed Cornerstone's liability to RP Finance under the Amended RPF Line of Credit at its fair value in the Cornerstone Acquisition and acquired RP Finance's receivable from Cornerstone under the Amended RPF Line of Credit at its fair value in the RP Finance Consolidation. These intercompany amounts are eliminated in consolidation. The Company will accrete the fair value of Cornerstone's liability and RP Finance's receivable under the Amended RPF Line of Credit to the amount due on May 31, 2028 as interest expense and interest income, respectively, in the consolidated statements of operations and comprehensive loss over the estimated term of the Amended RPF Line of Credit. The creditors of Cornerstone do not have legal recourse to the Company's general credit. The consolidated financial statements include the results of the Cornerstone Acquisition subsequent to the closing date. Cornerstone did not produce any revenue for the period from the closing date through July 31, 2024. Cornerstone incurred a net loss of \$ 93. 0 million, of which \$ 30. 7 million is attributable to non- controlling interests, for the period from the closing date through July 31, 2024, which is included in the Company's consolidated statements of operations and comprehensive loss for the year ended July 31, 2024. Cornerstone's results of operations included IPR & D expense of \$ 89. 9 million, related to the IPR & D asset acquired with no alternative future use, that was pushed down to the entity. Consolidation of RP Finance RP Finance, an entity in which the Company owns a 37. 5 % equity interest (previously accounted for as an equity method investment of Rafael), and in which an entity associated with members of the family of Howard Jonas holds an additional 37. 5 % equity interest, holds debt and equity investments in Cornerstone (which is included in the Company's 67 % equity ownership interest in Cornerstone). In conjunction with the Cornerstone Acquisition, the Company reassessed its relationship with RP Finance and, as a result of the Cornerstone Restructuring and resulting Cornerstone Acquisition, determined that RP Finance is still a VIE and that the Company is now considered the primary beneficiary of RP Finance as the Company now holds the ability to control repayment of the RPF Line of Credit, which directly impacts RP Finance's economic performance. Therefore, the Company has consolidated RP Finance as a result of the Cornerstone Acquisition (the " RP Finance Consolidation "). The RP Finance Consolidation is accounted for as an acquisition of a VIE that is not a business in accordance with U. S. GAAP as RP Finance does not meet the definition of a business under U. S. GAAP. Under ASC 810, the initial consolidation of a VIE shall not result in goodwill being recognized, and the acquirer shall recognize a gain or loss for the difference of (a) the sum of (i) the fair value of any consideration paid, (ii) the fair value of any noncontrolling interests, and (iii) the reported amount of any previously held interests, and (b) the net amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805. (i) Fair value of consideration paid \$ — (ii) Fair value of noncontrolling interests 12, 667 (iii) Reported value of previously held interests (1) — Sum of (i), (ii), and (iii) \$ 12, 667 (1) Rafael ownership of 37. 5 % of the equity interests in RP Finance, accounted for as an equity method investment prior to the RP Finance Consolidation, represents a previously held interest in Cornerstone that is included at its reported amount, or \$ 0. F- 21 The following table presents, in accordance with ASC 810, the net amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805 (amounts in thousands): Assets acquired and liabilities assumed Investments- Cornerstone common stock \$ 4, 931 Due from Cornerstone- Amended RPF Line of Credit 15, 336 Total \$ 20, 267 In accordance with the calculation within ASC 810, a gain of \$ 7. 6 million was recognized as an adjustment to Rafael's additional paid- in capital, due to the related parties involved, upon the RP Finance Consolidation. The acquired RP Finance investment in Cornerstone of \$ 4. 9 million, consisting of the fair value of RP Finance's 3, 919, 598 shares of post- Reverse Stock Split Cornerstone Common Stock, is eliminated in consolidation, as Cornerstone is a consolidated subsidiary of Rafael with a corresponding decrease of \$ 1. 8 million to Rafael's additional paid- in capital and corresponding decrease of \$ 3. 1 million to noncontrolling interests, equivalent to their respective proportionate ownership interest in RP Finance's shares of Cornerstone Common Stock. The consolidated financial statements include the results of RP Finance subsequent to the closing date. The results of operations of RP Finance were insignificant. Pro Forma Financial Information The following table sets forth the pro forma consolidated results of operations of Rafael, Cornerstone, and RP Finance after giving effect to the Cornerstone Restructuring, the Cornerstone Acquisition, and the RP Finance Consolidation for the year ended July 31, 2024 and 2023, as if the Cornerstone Restructuring, the Cornerstone Acquisition, and the RP Finance Consolidation had collectively occurred on August 1, 2022. The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the Cornerstone Restructuring, the Cornerstone Acquisition, and RP Finance Consolidation had taken place on the date noted above, or of results that may occur in the future. (in thousands, except for share and per share amounts) Twelve Months ended July 31, 2024 2023 Revenue \$ 637 \$ 279 Loss from operations (15, 803) (117, 234) Net loss from continuing operations attributable to common stockholders (6, 745) (42, 483) Net loss per share from continuing operations attributable to common stockholders (0. 28) (1. 83) Weighted average common shares outstanding 23, 745, 516 23, 263, 211 The pro forma loss from operations for the year ended July 31, 2023 includes the IPR & D expense of \$ 89. 9 million, related to the IPR & D asset acquired in the Cornerstone Acquisition with no alternative future use, which is reported in Rafael's historical financial statements for the year ended July 31, 2024. The pro forma net loss from continuing operations attributable to common stockholders for the year ended July 31, 2023 includes a gain of \$ 31. 3 million on the recovery of receivables from Cornerstone and the recognition of a net loss attributable to noncontrolling interests of Cornerstone of \$ 31. 5 million, which are reported in Rafael's historical financial statements for the year ended July 31, 2024. NOTE 4 – INVESTMENT IN CORNERSTONE Cornerstone is a clinical stage, cancer metabolism- based therapeutics company focused on the development and commercialization of therapies that seeks to exploit the metabolic differences between normal cells and cancer cells. F- 22 Prior to the Cornerstone Restructuring described in Note 3, Rafael (directly via certain of its subsidiaries, and through an equity method investment in RP Finance) held certain debt and equity investments in Cornerstone which included: (a) 44. 0 million shares of Series D Preferred Stock of Cornerstone held by Pharma Holdings LLC (" Pharma Holdings "), a 90 % owned non- operating subsidiary of the Company, and 16. 7 million shares of Series D Preferred Stock of Cornerstone held by CS Pharma Holdings LLC (" CS Pharma "), a non- operating subsidiary of the Company (the " Series D Preferred Stock "). Pharma Holdings owns 50 % of CS Pharma. Accordingly, the Company holds an effective 45 % indirect interest in the assets held by CS Pharma. The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Cornerstone that are in turn distributed by CS Pharma will need to be made pro rata to all members, which would entitle Pharma Holdings to 50 % (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90 % (based on current ownership) of such distributions. Due to the Data Events, the Company previously recorded a full impairment of the value of the Series D Preferred Stock included in the Company's cost method investment in Cornerstone; (b) a loan of \$ 25 million by the Company to Cornerstone under a Line of Credit Agreement (the " RFL Line of Credit "). Due to the Data Events, the Company previously recorded a full reserve on the \$ 25 million in principal due to the Company, and on the accrued interest, from Cornerstone; (c) a \$ 2 million promissory note (the " 2023 Promissory Note ") from Cornerstone, bearing interest at a rate of seven and one- half percent (7. 5 %) per annum, held by the Company. The 2023 Promissory Note was secured by a first priority security interest in all of Cornerstone's right, title and interest in and to all of the tangible and intangible assets purchased by Cornerstone pursuant to the purchase agreement between Cornerstone and Calithera Biosciences, Inc. (" Calithera "), which was a clinical- stage, precision oncology biopharmaceutical company that was developing targeted therapies to redefine treatment for biomarker- specific patient populations, and all proceeds therefrom and all rights to the data related to CB- 839 (the " Collateral "). The Company recorded the 2023 Promissory Note at fair value and the security was classified as available- for- sale prior to the Cornerstone Restructuring; (d) a \$ 720 thousand receivable balance due from Cornerstone, which was fully reserved for by the Company due to the Data Events; and (e) loans in the aggregate amount of \$ 21. 9 million by RP Finance to Cornerstone under a Line of Credit Agreement which provided for a revolving commitment of up to \$ 50 million to fund clinical trials and other capital needs (the " RPF Line of Credit ", see Note 5). The Company owns 37. 5 % of the equity interests in RP Finance and was required to fund 37. 5 % of funding requests from Cornerstone under the RPF Line of Credit. RP Finance also holds 261, 230 post- Reverse Stock Split shares of Cornerstone Common Stock (" RPF Historical Cornerstone Shares "), issued to RP Finance in connection with entering into the RPF Line of Credit representing 12 % of the issued and outstanding shares of Cornerstone Common Stock prior to the Cornerstone Restructuring, with such ownership interest subject to anti- dilution protection as set forth in the RPF Line of Credit agreement. The Company accounted for its investment in RP Finance under the equity method. Due to the Data Events on October 28, 2021, the Company recorded a full impairment for the assets recorded related to Rafael's cost method investment in Cornerstone, the amounts due to Rafael under the RFL Line of Credit, and its investment in RP Finance. A trust for the benefit of the children of Howard Jonas (Chairman of the Board and Executive Chairman and former Chief Executive Officer of the Company and Member of the Board of Cornerstone) holds a financial instrument (the " Instrument ") that owns 10 % of Pharma Holdings. The Instrument holds a contractual right to receive additional shares of Cornerstone capital stock equal to 10 % of the fully diluted capital stock of Cornerstone (the " Bonus Shares ") upon the achievement of certain milestones, each of which the Company has determined not to be probable. The additional

10 % is based on the fully diluted capital stock of Cornerstone, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Prior to the Cornerstone Restructuring described in Note 3, the Company indirectly owned 51 % of the issued and outstanding equity in Cornerstone and had certain governance rights, with approximately 8 % of the issued and outstanding equity owned by the Company's subsidiary CS Pharma and 43 % owned by the Company's subsidiary Pharma Holdings. Prior to the Cornerstone Restructuring, the Company had determined that Cornerstone was a VIE; however, the Company had determined that it was not the primary beneficiary as it did not have the power to direct the activities of Cornerstone that most significantly impact Cornerstone's economic performance. In addition, the interests held in Cornerstone were Series D Convertible Preferred Stock and did not represent in-substance common stock. F- 23 On March 13, 2024, Cornerstone consummated a restructuring of its outstanding debt and equity interests. See Note 3 for additional information regarding the Cornerstone Restructuring transaction. NOTE 5 – INVESTMENT IN RP FINANCE, LLC On February 3, 2020, Cornerstone entered into a Line of Credit with RP Finance ("RPF Line of Credit") which provided a revolving commitment of up to \$ 50,000,000 to fund clinical trials and other capital needs. In connection with entering into the RPF Line of Credit, Cornerstone issued to RP Finance 261,230 shares (post-Reverse Stock Split) of Cornerstone Common Stock representing 12 % of the issued and outstanding shares of Cornerstone Common Stock, with such interest subject to anti-dilution protection as set forth in the RPF Line of Credit. The Company owns 37.5 % of the equity interests in RP Finance, an entity associated with members of the family of Howard Jonas owns 37.5 % of the equity interests in RP Finance, and the remaining 25 % equity interests in RP Finance are owned by other stockholders of Cornerstone. RP Finance had funded a cumulative total of \$ 21.9 million to Cornerstone under the RPF Line of Credit, of which the Company had funded a cumulative total of \$ 9.375 million in accordance with its 37.5 % ownership interests in RP Finance. Due to the Data Events, the amounts funded had been fully reserved. Prior to the Cornerstone Restructuring and resulting RP Finance Consolidation described in Note 3, the Company had determined that RP Finance was a VIE; however, the Company had determined that it was not the primary beneficiary as the Company did not have the power to direct the activities of RP Finance that most significantly impacted RP Finance's economic performance and, therefore, was not required to consolidate RP Finance. Therefore, the Company used the equity method of accounting to record its investment in RP Finance. On March 13, 2024, Cornerstone consummated the Cornerstone Restructuring of its outstanding debt and equity interests. As part of the Cornerstone Restructuring, Cornerstone and RP Finance amended the RPF Line of Credit agreement. See Note 3 for additional information regarding the Cornerstone Restructuring transaction. NOTE 6 – CONVERTIBLE NOTES PAYABLE As of July 31, 2024, Cornerstone has \$ 686 thousand in principal, and \$ 236 thousand of accrued interest thereon, of Series C Convertible Notes outstanding (the "Series C Convertible Notes"). The Series C Convertible Notes accrue interest at a rate of 3.5 % per annum and are due, together with accrued interest, one year (unless amended) from date of issuance and automatically accelerate upon the sale of Cornerstone in its entirety or the sale or license of substantially all of Cornerstone's assets or intellectual property. The Series C Convertible Notes (including all accrued and unpaid interest thereon) automatically convert into the same class of securities (including stock warrants) sold in Cornerstone's next equity financing (i) where Cornerstone receives gross proceeds of at least \$ 10,000,000 from Institutional Investors (a "Qualified Financing"), or (ii) from an underwritten initial public offering ("IPO"). The conversion price of the Series C Convertible Notes upon a Qualified Financing shall be the lesser of (i) 90 % of the price per share (or unit) at which the securities in the Qualified Financing are sold, or (ii) \$ 1.25 price per share (or unit) (whichever is less) at the holder's selection of (i) or (ii), and 90 % of the share price per share (or unit) at which securities in an IPO are first sold. The outstanding Series C Convertible Notes are convertible, at the option of the holders, in certain equity financings consummated by Cornerstone or into equity securities and warrants to purchase equity securities of Cornerstone. In the event of a liquidation event of Cornerstone prior to the repayment or conversion of the Series C Convertible Notes, the holders are entitled to receive either (a) an amount equal to the outstanding principal and interest due, or (b) the pro rata per share amount of the proceeds of such liquidation the holders would be entitled to had they exercised their conversion right. Of the Series C Convertible Notes outstanding as of July 31, 2024: (a) Series C Convertible Notes with an aggregate principal amount of \$ 614 thousand remain outstanding and were not amended in connection with the Cornerstone Restructuring. The interest accrued on these Series C Convertible Notes is \$ 213 thousand and is recorded in accrued expenses on the consolidated balance sheet as of July 31, 2024. In the Cornerstone Acquisition, Rafael recorded these Series C Convertible Notes as current liabilities at the value of their aggregate principal amount of \$ 614 thousand, and \$ 205 thousand of accrued interest thereon recorded in accrued expenses on the consolidated balance sheet as of the date of the Cornerstone Acquisition, as these values approximate their fair values. As of July 31, 2024, these Series C Convertible Notes are currently in default as they are beyond the maturity date; and F- 24 (b) Series C Convertible Notes with an aggregate principal amount of \$ 72 thousand were amended in the Cornerstone Restructuring to (i) extend the maturity date thereof to May 31, 2028 and (ii) provide that, on conversion thereof, the converting holder will receive shares of Cornerstone Common Stock. The holders of these amended Series C Convertible Notes that remain outstanding waived such holders' rights in connection with the Cornerstone Restructuring. The interest accrued on these Series C Convertible Notes is \$ 23 thousand as of July 31, 2024. In the Cornerstone Acquisition, Rafael recorded these Series C Convertible Notes as noncurrent liabilities at their fair value of \$ 70 thousand, which considers the aggregate principal plus accrued interest. The Company will accrete the fair value of these Series C Convertible Notes to the value of the principal plus accrued interest thereon as of the date of the Cornerstone Acquisition as interest expense in the consolidated statements of operations and comprehensive loss over the estimated term of these amended Series C Convertible Notes. During the year ended July 31, 2024, the Company recorded \$ 9 thousand of interest expense in relation to the Cornerstone Series C Convertible Notes to interest expense on the consolidated statements of operations and comprehensive loss. NOTE 7 – ACCRUED EXPENSES Accrued expenses consist of the following: July 31, 2024 July 31, 2023 (in thousands) Accrued expenses, current Accrued bonuses \$ 654 \$ 403 Accrued professional fees 437 276 Accrued payroll expenses 441 7 Accrued interest 213 — Other accrued expenses 53 77 Total accrued expenses, current 1,798 763 Creditor payable, noncurrent 2,982 — Total accrued expenses \$ 4,780 \$ 763 In the Cornerstone Acquisition, Rafael assumed a forbearance agreement, signed by Cornerstone on June 2, 2023, with a major creditor (the "Creditor") of Cornerstone to which Cornerstone owed approximately \$ 10.5 million arising from unpaid amounts in connection with work performed and costs incurred by the Creditor under previous work orders. The outstanding balance does not bear interest. As part of Cornerstone's plan to seek new capitalization, it paid \$ 2.0 million following the execution of a change order on July 21, 2023. Cornerstone also agreed to an additional payment of \$ 2,000,000 upon the issuance of a FDA authorization to market any product of Cornerstone (the "FDA Approval Payment"). In the event Cornerstone completes a capital transaction which results in an aggregate of \$ 100 million in additional capital received after January 1, 2023, Cornerstone agrees to pay an additional \$ 4.0 million to the Creditor within 15 days of such capital transaction (the "Capital Raise Payment"). In exchange for Cornerstone's agreement to make timely payments of the above-mentioned sums due in the Agreement, and after the payment of the FDA Approval Payment and the Capital Raise Payment, the Creditor will waive approximately \$ 2.5 million of outstanding debt representing all remaining amounts due to the Creditor. Following the payment of the initial \$ 2.0 million, and pursuant to the terms of the agreement, the Creditor agreed to forbear from exercising any of its rights, remedies or claims in respect to the outstanding balance. The forbearance shall not be deemed to have otherwise waived, released, or adversely affected any of the Creditor's rights, remedies or claims in respect to the outstanding balance. F- 25 As part of the Cornerstone Acquisition, the creditor payable was recognized by the Company as an assumed liability and measured at its fair value of \$ 2.7 million as of the date of the Cornerstone Acquisition. The Company will accrete the fair value of the creditor payable to the amount payable of \$ 8.5 million owed to the Creditor as interest expense in the consolidated statements of operations and comprehensive loss over the estimated term of the forbearance agreement. The Company recorded \$ 237 thousand of accretion in relation to the creditor payable recorded to interest expense in the consolidated statements of operations and comprehensive loss for year ended July 31, 2024. The carrying value of the creditor payable was \$ 3.0 million as of July 31, 2024 and is included in accrued expenses, noncurrent on the consolidated balance sheets. NOTE 8 – CONVERTIBLE NOTE RECEIVABLE On March 8, 2024, Day Three entered into a convertible note subscription agreement with a third-party company, Steady State LLC. Steady State LLC promises to pay to Day Three \$ 1,000,000, together with interest, on October 16, 2026. The convertible note will accumulate simple interest at the annual rate being the lesser of: (i) the Bank of England base rate (updated on the first business day of each quarter) plus eight (8) percentage points, or (ii) 15 % (computed on the basis of 365 days per year). Upon the closing and funding of a bona fide offering of equity securities by Steady State, LLC in an aggregate amount of at least \$ 5,000,000, the convertible note will automatically convert into the number of membership interests equal to the outstanding principal plus accrued and unpaid interest divided by eighty percent (80 %) of the price per membership unit in the offering. If a qualifying bona fide offering has not occurred on or before the maturity date, the principal and unpaid accrued interest of the convertible note may be converted, at the option of Day Three, into membership units. The convertible note receivable is classified as available-for-sale and recorded at fair value- see Note 15. NOTE 9 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD. LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. In March 2021, the Company provided bridge financing in the principal amount of up to \$ 400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8 % per annum. As of September 1, 2021, LipoMedix was in default on the terms of the loan and as such, the interest rate has increased to 15 % per annum. On November 15, 2021, the Company entered into a share purchase agreement with LipoMedix to purchase up to 15,975,000 ordinary shares at \$ 0.1878 per share for an aggregate purchase price of \$ 3.0 million (the "LipoMedix SPA"). Additionally, LipoMedix issued the Company a warrant to purchase up to 15,975,000 ordinary shares at an exercise price of \$ 0.1878 per share which expired on November 11, 2022. As of the date of the LipoMedix SPA, there was an outstanding loan balance including principal of \$ 400 thousand and accrued interest of \$ 21.8 thousand owed by LipoMedix to the Company on a note made by LipoMedix in favor of the Company issued in March 2021. The amount due on the loan was netted against the approximately \$ 3.0 million aggregate purchase price due to LipoMedix, resulting in a cash payment by the Company of approximately \$ 2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company's ownership of LipoMedix increased to approximately 84 % with a noncontrolling interest of approximately 16 %. The Company recorded approximately \$ 8 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company's increased ownership interest in LipoMedix's net assets. On February 9, 2023, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 70,000,000 ordinary shares at \$ 0.03 per share for an aggregate purchase price of \$ 2.1 million (the "2023 LipoMedix SPA"). As a result of the share purchase, the Company's ownership of LipoMedix increased to approximately 95 % with a noncontrolling interest of approximately 5 %. The Company recorded approximately \$ 16 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company's increased ownership interest in LipoMedix's net assets. As of July 31, 2024, the Company held

95 % of the issued and outstanding ordinary shares of LipoMedix and has consolidated LipoMedix from the second quarter of fiscal 2018. F- 26 NOTE 10 – INVESTMENT IN DAY THREE LABS INC. Initial investment in Day Three On April 7, 2023, the Company entered into a Common Stock Purchase Agreement (the “ Day Three Purchase Agreement ”) with Day Three. Day Three is a company which reimagines existing cannabis offerings with pharmaceutical- grade technology and innovation like Unlokt™ to bring to market better, cleaner, more precise and predictable products. Pursuant to the Day Three Purchase Agreement, the Company purchased 4, 302 shares of common stock, post DTL Reverse Stock Split (as defined below), representing 38 % of the outstanding shares of common stock of Day Three (33 % on a fully diluted basis), for a purchase price of \$ 3. 0 million. The Company also received a warrant exercisable for 7, 529 shares of common stock, post DTL Reverse Stock Split, which expires five years from the date of issuance or earlier based on the occurrence of certain events as defined in the Day Three Purchase Agreement (the “ Day Three Warrant ”). Prior to January 2024, the Company accounted for this investment as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 38 % ownership interest in Day Three and its right to designate two members of the Board of Directors of Day Three (out of a current total of seven members) indicates that the Company is able to exercise significant influence. The Company determined that Day Three is a VIE; however, the Company determined that, prior to January 2024, it was not the primary beneficiary as it did not have the power to direct the activities that most significantly impacted Day Three’s economic performance. The Company has therefore concluded it was not required to consolidate Day Three. The Company used the equity method of accounting to record its investment in Day Three. Day Three’s fiscal year ends on December 31 and, as a result, the Company recognizes its share of Day Three’s earnings / loss on a one- month lag. For the years ended July 31, 2024 and 2023, the Company recognized approximately \$ 422 thousand and \$ 203 thousand of equity in loss of Day Three, based on its proportionate share of Day Three’s results through January 2, 2024, the effective date of the Day Three Acquisition, as discussed below. The assets and operations of Day Three are not significant to the Company’s assets or operations. Acquisition of Day Three In January 2024, the Company entered into a series of transactions with Day Three and certain shareholders to purchase an aggregate of 13, 771 shares of common stock, post DTL Reverse Stock Split, of Day Three, acquiring a controlling interest of Day Three (the “ Day Three Acquisition ”). As a result of the Day Three Acquisition, the Company holds an aggregate 79 % of the issued and outstanding shares of common stock of Day Three. Day Three has options and warrants outstanding that, if and when exercised, could dilute the Company’s ownership interest in Day Three. In connection with the Day Three Acquisition, the Day Three Warrant was terminated. The acquisition date was determined to be January 2, 2024, which is the date that Rafael obtained a controlling interest of the common stock of Day Three. The Day Three Acquisition is being accounted for as a business combination in accordance with ASC 805. During the period of October 2023 through January 2024, the Company advanced \$ 250, 000 to Day Three pursuant to a promissory note (the “ Day Three Note I ”), \$ 150, 000 to Day Three pursuant to a promissory note (the “ Day Three Note II ”), \$ 1, 000, 000 to Day Three pursuant to a third promissory note (the “ Day Three Note III ”), and \$ 589, 024 to Day Three pursuant to a fourth promissory note (the “ Day Three Note IV ”) (collectively, the “ Day Three Promissory Notes ”). The Day Three Promissory Notes accrue interest at rate of between 5. 01 % and 5. 19 % per annum. The aggregate consideration of the Day Three Acquisition was \$ 3. 1 million, which consisted of 1) cash consideration of \$ 0. 2 million, 2) accrued consideration of \$ 0. 2 million, 3) the exchange of principal and accrued interest amounts totaling to \$ 2. 0 million owed by Day Three to the Company pursuant to the Day Three Promissory Notes for common stock, and 4) the fair value of previously held interests in Day Three of \$ 0. 7 million. F- 27 The following table summarizes the purchase consideration transferred in the Day Three Acquisition as defined in ASC 805: (in thousands) Purchase Consideration Cash consideration \$ 200 Accrued consideration 200 Exchange of Day Three Promissory Notes for Common Stock 2, 000 Fair value of previously held interests (1) 742 Total purchase consideration \$ 3, 142 (1) The Company remeasured its previously held equity interest in Day Three immediately before the Day Three Acquisition, previously accounted for under the equity method of accounting, to its fair value (determined using the implied enterprise value based on the purchase price multiplied by the ratio of the number of shares previously held to total shares, as of the acquisition date) and recognized a loss of \$ 1. 6 million recorded on the statements of operations and comprehensive loss as a Loss on initial investment in Day Three upon acquisition. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed in the Day Three Acquisition as of the acquisition date: (in thousands) January 2, 2024 Cash and cash equivalents \$ 1, 499 Accounts receivable 63 Prepaid expenses and other current assets 77 Property and equipment 408 Goodwill 3, 050 Identifiable intangible assets 2, 180 Accounts payable (386) Accrued expenses (98) Installment note payable (2, 500) Total fair value of net assets acquired 4, 293 Less: noncontrolling interest (1, 151) Net assets acquired attributable to Rafael \$ 3, 142 The preliminary fair values of the assets acquired and liabilities assumed in the Day Three Acquisition are subject to change as we perform additional reviews of our assumptions utilized. During the year ended July 31, 2024, the Company recognized an adjustment which changed the fair value of certain acquired liabilities and goodwill as a result of obtaining additional information about the estimated liabilities. Further adjustments may be necessary as additional information related to the fair values of assets acquired, liabilities assumed, and tax implications thereon is assessed during the measurement period (up to one year from the acquisition date). The noncontrolling interest was recognized at fair value, which was determined using the implied enterprise value based on the purchase price multiplied by the ratio of the number of shares owned by minority holders to total shares, as of the acquisition date. Included in the acquired liabilities assumed in the Day Three Acquisition is a non- interest bearing installment note payable of \$ 2. 5 million. The installment note was recognized by Day Three in relation to a 2021 asset purchase agreement for certain patents. The assumed installment note payable had a balance of \$ 800 thousand due January 2024 (which was paid in January 2024) and the remaining \$ 1. 7 million due in November 2024. At July 31, 2024, the installment note payable has a remaining balance due of \$ 1. 7 million which is included in Installment note payable on the consolidated balance sheets. Goodwill of \$ 3. 1 million arising from the Day Three Acquisition was included in the Infusion Technology segment as of July 31, 2024 and was attributable to potential synergies and an assembled workforce. The calculated goodwill is not deductible for tax purposes. F- 28 Intangible assets acquired primarily include patents, technology licenses and non- compete agreements. The weighted average amortization period for the acquired intangible assets is approximately 14. 7 years. The consolidated financial statements include the results of the Day Three Acquisition subsequent to the closing date. Pro forma information is not presented as the acquisition was not considered significant. On January 23, 2024, Day Three entered into an asset purchase agreement for the sale of certain patents for \$ 280 thousand. On March 20, 2024, Day Three amended and restated its certificate of incorporation to, among other things, effect a reverse split of all of Day Three’s common stock on a one- for- one- thousand basis (the “ DTL Reverse Stock Split ”). On May 1, 2024, Rafael entered into a stock purchase agreement with Day Three to purchase 7, 194 shares of common stock at a purchase price of \$ 173. 75 per share for an aggregate purchase price of \$ 1. 25 million, \$ 1 million of which was funded through the relief of an existing intercompany receivable. As a result of the transaction, Rafael has an 84 % ownership interest in Day Three. NOTE 11 – INVESTMENT IN CYCLO THERAPEUTICS, INC. On May 2, 2023, the Company entered into a Securities Purchase Agreement (the “ Cyclo SPA ”) with Cyclo. Cyclo is a clinical- stage biotechnology company dedicated to developing life- changing medicines for patients and families living with challenging diseases through its lead therapeutic asset, Trappsol®. The Company purchased from Cyclo (i) 2, 514, 970 common shares (the “ Purchased Shares ”) and (ii) a warrant to purchase 2, 514, 970 common shares with an exercise price of \$ 0. 71 per share (the “ May Warrant ”), at a combined purchase price equal to \$ 0. 835 per Purchased Share and May Warrant to purchase one share, for an aggregate purchase price of \$ 2. 1 million. The May Warrant is exercisable until August 1, 2030. Cyclo and the Company are party to a Registration Rights Agreement requiring Cyclo to file a registration statement with the Securities and Exchange Commission to register the resale of the shares and shares of common stock underlying the May Warrant, upon the request of Rafael. On August 1, 2023, pursuant to a Securities Purchase Agreement (the “ Cyclo II SPA ”) dated June 1, 2023, the Company purchased an additional 4, 000, 000 shares of common stock (the “ Cyclo II Shares ”), and received a warrant to purchase an additional 4, 000, 000 Shares (the “ Cyclo II Warrant ”), for an aggregate purchase price of \$ 5, 000, 000. The Cyclo II Warrant has an exercise price of \$ 1. 25 per share and is exercisable until August 1, 2030. The August 1, 2023 investment increased the Company’s percentage ownership of Cyclo common stock to approximately 34 % at the time of investment. As of the date of this filing, the Company has not exercised the Cyclo II Warrant. On October 20, 2023, the Company exercised the May Warrant to purchase 2, 514, 970 common shares at an exercise price of \$ 0. 71 per share, pursuant to a Securities Purchase Agreement dated October 20, 2023, and received a new warrant (the “ Replacement Warrant ”) to purchase 2, 766, 467 common shares at an exercise price of \$ 0. 95 per share. The Replacement Warrant is exercisable until October 20, 2027. As of the date of this report, the Company had not exercised the Replacement Warrant. Both the Cyclo II Warrant and Replacement Warrant (collectively, the “ Cyclo Warrants ”) are subject to the restriction that exercise (s) do not convey more than 49 % ownership to the Company (the “ Cyclo Blocker ”). Upon exercise of the May Warrant, the Company recognized a realized gain of \$ 424 thousand. The October 20, 2023 investment increased the Company’s percentage ownership of Cyclo common stock to approximately 40 % at the time of investment. William Conkling, Rafael’s CEO, serves on Cyclo’s Board of Directors. The Company has determined that Cyclo is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Cyclo that most significantly impact Cyclo’s economic performance and, therefore, is not required to consolidate Cyclo. The Company has elected to account for its investment in Cyclo under the fair value option, with subsequent changes in fair value recognized as unrealized (gain) loss on investment- Cyclo in the consolidated statements of operations and comprehensive loss. During the years ended July 31, 2024 and 2023, the Company recognized an unrealized gain of \$ 37 thousand and \$ 2. 7 million related to its investment in Cyclo common stock and warrants, respectively. Summarized Fair Value Method Investment Details The 31. 5 % ownership percentage as of July 31, 2024 is comprised of the shares of common stock owned by the Company and does not include the Cyclo Warrants. The total aggregate fair value of the Cyclo investment of \$ 12, 009, 630 as of July 31, 2024 is comprised of common shares with an aggregate fair value of \$ 10, 745, 629 and Cyclo Warrants with an aggregate fair value of \$ 1, 264, 001. The total aggregate fair value of the Cyclo investment of \$ 4, 763, 102 as of July 31, 2023 is comprised of common shares with an aggregate fair value of \$ 3, 898, 204 and the May Warrants with an aggregate fair value of \$ 864, 898, see Note 15. Subsequent to year end, the Company entered into an Agreement and Plan of Merger with Cyclo. See Note 27 for further details. F- 29 NOTE 12 – CONVERTIBLE NOTE RECEIVABLES, DUE FROM CYCLO THERAPEUTICS, INC. On June 11, 2024, the Company entered into a Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of \$ 2 million (the “ Cyclo Convertible Note I ”) to the Company for \$ 2 million in cash. The Cyclo Convertible Note I was issued with a maturity date of November 11, 2024 and bears interest at a rate of 5 % per annum, payable upon maturity. The principal amount of the Cyclo Convertible Note I is convertible into shares of Cyclo’s common stock at the option of the Company unless converted automatically upon certain events, as defined in the Cyclo Convertible Note I Note Purchase Agreement. On October 8, 2024, the maturity date of Convertible

Note I was amended to be December 21, 2024, refer to Note 27. On July 16, 2024, the Company entered into a First Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of \$ 2 million (the “ Cyclo Convertible Note II ”) to the Company for \$ 2 million in cash. The Cyclo Convertible Note II was issued with a maturity date of November 11, 2024 and bears interest at a rate of 5 % per annum, payable upon maturity. The principal amount of the Cyclo Convertible Note II is convertible into shares of Cyclo’s common stock at the option of the Company unless converted automatically upon certain events, as defined in the Cyclo Convertible Note II Note Purchase Agreement. On October 8, 2024, the maturity date of Convertible Note II was amended to be December 21, 2024, refer to Note 27. The Cyclo Convertible Note I and Cyclo Convertible Note II are together referred to as the “ Cyclo Convertible Notes. ” In the event that Cyclo consummates any public or private offering of its Equity Securities resulting in gross proceeds of at least \$ 8, 000, 000 (excluding this Note) (a “ Qualified Financing ”) at any time prior to the earlier of the Maturity Date and the repayment in full of this Note, then the outstanding principal balance of the Cyclo Convertible Notes, together with any accrued and unpaid interest thereon, will automatically convert into shares of Cyclo’s common stock, par value \$ .0001 per share (the “ Common Stock ”), at a conversion price equal to the lesser of (i) \$ .95 (the “ Base Price ”), and (ii) eighty percent (80 %) of the purchase price paid by the investors purchasing the Equity Securities in the Qualified Financing. For purposes of the Cyclo Convertible Notes, the term “ Equity Securities ” shall mean (1) any shares of Common Stock or preferred stock of Cyclo, (2) any security convertible or exchangeable for Common Stock or preferred stock of Cyclo, and (3) any other rights to purchase or otherwise acquire Common Stock or preferred stock of Cyclo, in each case issued in a Qualified Financing following the date hereof. In the event Cyclo consummates a Sale Transaction (“ Sale Transaction ” as defined in the Cyclo Convertible Notes’ Agreements as a) the sale of all or substantially all of Cyclo’s assets, b) the consolidation or merger of Cyclo or any of its subsidiaries with or into any other corporation or other entity or person or other similar transaction, or c) any other transaction or series of related transactions to which Cyclo is a party in which in excess of fifty percent (50 %) of Cyclo’s voting securities are transferred) with (i) Rafael or its affiliates, the Cyclo Convertible Notes shall be treated for as provided for in the terms of the definitive agreements relating to such Sale Transaction, or (ii) a third party other than Rafael or its affiliates, at the election of the Rafael, either (x) the outstanding principal balance of the Cyclo Convertible Notes, together with any accrued and unpaid interest thereon, shall convert into that number of shares of Common Stock at a conversion price equal to the lesser of (1) the base price of \$ 0.95 and (ii) eighty percent (80 %) of the implied value of Cyclo in the Sale Transaction, or (y) Cyclo will pay to Rafael an amount equal to the outstanding principal balance of the Cyclo Convertible Notes, together with any accrued and unpaid interest thereon, in full satisfaction of Cyclo’s obligations under Cyclo Convertible Notes. Additionally, the Cyclo Convertible Notes shall be convertible, in whole or in part, and from time to time, at the discretion of Rafael, into validly issued, fully paid and non-assessable shares of Common Stock at a conversion price equal to the lowest of (i) the base price (Cyclo Convertible Note I and Cyclo Convertible Note II), (ii) the closing price of the Common Stock on NASDAQ on the trading date immediately preceding the date of conversion (Cyclo Convertible Note II, only) and (iii) 80 % of the purchase price paid by the investors purchasing equity securities in any financing consummated within sixty (60) days preceding the date of conversion (Cyclo Convertible Note II only). The Cyclo Convertible Notes are required to be accounted for at fair value pursuant to ASC 825, Financial Instruments (“ ASC 825 ”), at their respective dates of issuance and in subsequent reporting periods, as the Company elected to account for its prior investment in Cyclo common stock under the fair value option. The Company has elected to present interest income from the Cyclo Convertible Notes, together with the changes in fair value of the notes, along with the changes in fair value related to the investments in Cyclo, in unrealized gain on investments— Cyclo on the consolidated statements of operations and comprehensive loss. During the year ended July 31, 2024, the Company recognized an unrealized gain of \$ 1.2 million, related to its investment in Cyclo Convertible Notes receivable. See Note 15 for further details. F-30 Subsequent to year end, the Company entered into an Agreement and Plan of Merger with Cyclo and entered into the Second and Third Amended and Restated Note Purchase Agreements with Cyclo, whereby the Company was issued \$ 6.0 million in convertible notes receivable for \$ 6 million in cash. See Note 27 for further details. NOTE 13 – INVESTMENTS IN MARKETABLE SECURITIES The Company has classified its investments in corporate bonds, U. S. agency bonds, and U. S. treasury bills as available- for- sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity until realized. Investment transactions are recorded on their trade date. Gains and losses on marketable security transactions are reported on the specific- identification method. Interest income is accrued daily and adjusted for amortization of premiums and accretion of discounts on the corporate bonds, U. S. agency bonds, and U. S. treasury bills. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available- for- sale securities as of July 31, 2024 and July 31, 2023 are as follows: July 31, 2024 Amortized cost Gross unrealized gains Gross unrealized (losses) Fair value (in thousands) Available- for- sale securities: U. S. Treasury Bills \$ 3, 969 \$ — (2) \$ 3, 967 U. S. Agency bonds 4, 079 — (3) 4, 076 Corporate bonds 55, 252 (32) 55, 222 Total available- for- sale securities \$ 63, 300 \$ 2 \$ (37) \$ 63, 265 July 31, 2023 Amortized cost Gross unrealized gains Gross unrealized (losses) Fair value (in thousands) Available- for- sale securities: U. S. Treasury Bills \$ 11, 222 \$ 53 \$ — \$ 11, 275 Corporate bonds 46, 766 4, 333 (4, 660) 46, 439 Total available- for- sale securities \$ 57, 988 \$ 4, 386 \$ (4, 660) \$ 57, 714 During the year ended July 31, 2024, the Company reclassified approximately \$ 1.8 million of unrealized gains out of accumulated other comprehensive income (loss) related to the sale of available- for- sale securities into realized gain on available- for- sale securities. During the year ended July 31, 2023, the Company reclassified approximately \$ 154 thousand of unrealized gains out of accumulated other comprehensive income (loss) related to the sale of available- for- sale securities into realized gain on available- for- sale securities. Corporate bonds, U. S. agency bonds, and U. S. Treasury Bills held as of July 31, 2024 were all due within one year. Marketable securities in an unrealized loss position as of July 31, 2024 and 2023 were not deemed impaired at acquisition. Effective August 1, 2023, the Company evaluates subsequent unrealized losses to determine whether the decline in fair value has resulted from credit losses or other factors. No such credit losses have been identified during the year ended July 31, 2024. NOTE 14 – DISCONTINUED OPERATIONS On July 1, 2022, the Company determined that the 520 Property met the held- for- sale criteria and the Company therefore classified the 520 Property as held- for- sale in the consolidated balance sheets at July 31, 2022. The sale of the 520 Property also represented a significant strategic shift that will have a major effect on the Company’s operations and financial results. Therefore, the Company has classified the results of operations related to the 520 Property as discontinued operations in the consolidated statements of operations and comprehensive loss. Depreciation on the 520 Property ceased on July 1, 2022, as a result of the 520 Property being classified as held- for- sale. F-31 On August 22, 2022, Broad Atlantic completed the sale of the 520 Property for an aggregate gross purchase price of \$ 49.4 million. The 520 Property was encumbered by a mortgage securing a \$ 15 million note payable which was paid off in this transaction. See Refer to Note 15-20 for further information on the note payable. After repaying the note payable, commissions, taxes, and other related costs, the Company received a net cash amount of approximately \$ 33 million at closing. The carrying value of major classes of assets and liabilities related to discontinued operations at July 31, 2022 was as follows: As of July 31, 2022 (in thousands) Current assets held- for- sale Building and Improvements \$ 45, 437 Land 10, 412 Furniture and Fixtures 1, 145 Other 205 Property and equipment 57, 199 Less Accumulated Depreciation (17, 005) Property and equipment, net 40, 194 Total current assets held- for- sale 40, 194 Current liabilities held- for- sale Total current liabilities \$ 15, 000 F-16 The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was \$ 0 and approximately \$ 150 thousand as of July 31, 2023 and 2022, respectively. The non-current portion of deferred rental income included in Other Assets was \$ 0 and approximately \$ 1.3 million as of July 31, 2023 and 2022, respectively. The deferred rental income pertains to the 520 Property and was settled at the date of the sale of the 520 Property with the other working capital accounts of the 520 Property. Discontinued operations include (i) rental and parking revenues, (ii) payroll, benefits, facility costs, real estate taxes, consulting and professional fees dedicated to the 520 Property, (iii) depreciation and amortization expenses and (iv) interest (including amortization of debt issuance costs) on the note payable on the 520 Property. The operating results of these items are presented in our consolidated statements of operations and comprehensive loss as discontinued operations for all periods presented. The following table details the components comprising net loss from our discontinued operations: Year Ended July 31, 2023 2022 (in thousands) Revenue from discontinued operations: Rental – Third third Party party \$ 68 \$ 644 Rental – Related related Party party 115 2, 161 Parking 66 694 Total revenue from discontinued operations 249 3, 499 Costs and expenses from discontinued operations: General and administrative 468 2, 683 Depreciation and amortization — 1, 317 Loss from discontinued operations (219) (501) Other income — 157 Interest expense (87) (1, 486) Loss from discontinued operations (306) (1, 830) Gain on disposal of discontinued operations 6, 784 Income — Gain (loss) from discontinued operations \$ 6, 478 \$ (1, 830) The gain on disposal of discontinued operations of approximately \$ 6.8 million was derived from the gross proceeds of approximately \$ 49.4 million from the sale of the 520 Property, less the carrying value of the 520 Property of approximately \$ 40.2 million, net of approximately \$ 1.2 million in transaction costs and the write off of approximately \$ 1.2 million of deferred rental income. NOTE 4 – INVESTMENT IN CORNERSTONE PHARMACEUTICALS Equity Investment in Cornerstone Pharmaceuticals and Impairment of Cost Method Investment Cornerstone Pharmaceuticals is a clinical stage, cancer-metabolism-based therapeutics company focused on the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The Company owns debt and equity interests and rights in Cornerstone Pharmaceuticals through a 90 % owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings. Pharma Holdings owns 50 % of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Cornerstone Pharmaceuticals. Accordingly, the Company holds an effective 45 % indirect interest in the assets held by CS Pharma. A trust for the benefit of the children of Howard Jonas (Chairman of the Board and Executive Chairman and former Chief Executive Officer of the Company and Member of the Board of Cornerstone Pharmaceuticals) holds a financial instrument (the “ Instrument ”) that owns 10 % of Pharma Holdings. F-17 Pharma Holdings holds 44.0 million shares of Cornerstone Pharmaceuticals’ Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56 % of the fully diluted equity interests in Cornerstone Pharmaceuticals (the “ Warrant ”). The exercise price of the Warrant is the lower of 70 % of the price sold in an equity financing, or \$ 1.25 per share, subject to certain adjustments. On March 25, 2020, the Board of Directors of Cornerstone Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021, and on August 31, 2020 the Board of Directors of Cornerstone Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021. In connection with the Merger Agreement, the Warrant expiration was extended to April 1, 2022. The Company has asserted that it may be entitled to a further extension of the Warrant. At this time, the Company does not intend to exercise the Warrant. Pharma Holdings also holds certain governance rights in Cornerstone Pharmaceuticals including appointment of directors. Pharma Holdings is not the primary beneficiary of Cornerstone Pharmaceuticals as it does not control or direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals’ economic performance. CS Pharma holds 16.7 million shares of Cornerstone Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a \$ 10 million Series D Convertible Note, with 3.5 % interest, in Cornerstone

Pharmaceuticals which was converted to shares of Series D Preferred Stock in January 2019. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). The Series D Convertible Preferred Stock has a stated value of \$ 1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the Board of Cornerstone Pharmaceuticals, prior to any dividends to any other class of capital stock of Cornerstone Pharmaceuticals. In the event of any liquidation, dissolution or winding up of Cornerstone Pharmaceuticals, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Cornerstone Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions. The Company evaluated its investments in Cornerstone Pharmaceuticals in accordance with ASC 323, Investments—Equity Method and Joint Ventures, to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting or consolidation and is carried at cost. The Company has determined that Cornerstone Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals' economic performance. In addition, the interests held in Cornerstone Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in substance common stock. The Instrument holds a contractual right to receive additional shares of Cornerstone Pharmaceuticals capital stock equal to 10% of the fully diluted capital stock of Cornerstone Pharmaceuticals (the "Bonus Shares") upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Cornerstone Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. F-18 Pharma Holdings holds the Warrant as well as other equity and governance rights in Cornerstone Pharmaceuticals. The Company currently owns 51% of the issued and outstanding equity in Cornerstone Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company's subsidiary CS Pharma and 43% is held by the Company's subsidiary Pharma Holdings. The Company's subsidiary Pharma Holdings holds the Warrant. The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant. Following any exercise, a portion of the Company's interest in Cornerstone Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Cornerstone Pharmaceuticals may also issue additional equity interests, such as employee stock options, which will require the Company to pay additional cash to maintain the Company's ownership percentage or exercise the Warrant in full. The terms of the Warrant provide that it expired on April 1, 2022; however, the Company has asserted that it may be entitled to a further extension of the Warrant. At this time, the Company does not intend to exercise the Warrant. Due to the Data Events, on October 28, 2021, the Company recorded an impairment charge of approximately \$ 79.1 million related to the cost method investment in Cornerstone Pharmaceuticals representing the total amount of the Company's cost method investment. The impairment loss was included in "Impairment of cost method investment—Cornerstone Pharmaceuticals" in the consolidated statements of operations and comprehensive loss for the year ended July 31, 2022. Approximately \$ 17.3 million of the total impairment loss of \$ 79.1 million was applicable to noncontrolling interests in certain of the Company's subsidiaries and was allocated to the holders of interests in CS Pharma and Pharma Holdings in the approximate amounts of \$ 10.4 million and \$ 6.9 million, respectively. Line of Credit to Cornerstone Pharmaceuticals and Impairment of Related Receivable On September 24, 2021, the Company entered into a Line of Credit Loan Agreement (the "Line of Credit Agreement") with Cornerstone Pharmaceuticals under which Cornerstone Pharmaceuticals borrowed \$ 25 million from the Company. The first advance was in the amount of \$ 1.9 million on September 24, 2021. On October 1, 2021, a second advance was made in the amount of \$ 23.1 million. The Line of Credit Agreement accrues interest at 9% per annum. The maturity date of the Line of Credit Agreement was June 17, 2022, and the amounts due on that date were not paid. The Company is in discussions with Cornerstone Pharmaceuticals and is evaluating its rights and plan of action with respect to the Line of Credit Agreement (in the contexts of all of its interests in Cornerstone Pharmaceuticals). Due to the Data Events, the Company recorded a full reserve on the amounts due the Company from Cornerstone Pharmaceuticals related to the Line of Credit Agreement for \$ 25 million during the year ended July 31, 2022. The Company also recorded a loss on related party receivables of approximately \$ 2.6 million related to other amounts owed by Cornerstone Pharmaceuticals during the year ended July 31, 2022. The Company recorded a reserve on related party interest receivable of \$ 1.9 million in Interest income, net, on the consolidated statements of operations and comprehensive loss during the year ended July 31, 2022. There were no amounts recorded during the year ended July 31, 2023. Planned Restructuring NOTE 5— CONVERTIBLE NOTE RECEIVABLE, RELATED PARTY On March 21, 2023, the Company loaned \$ 2.0 million to Cornerstone which is represented by a Promissory Note (the "Promissory Note" or "Note") made by Cornerstone. The Note, which bears interest at a rate of seven and one-half percent (7.5%) per annum, was originally due and payable on May 22, 2023. On May 22, 2023, the Promissory Note was amended to extend the maturity date to November 30, 2023 and to waive any increase in the interest rate provided for in the Note, provided that the entire principal amount and all accrued interest thereon is repaid in cash or converted into equity securities of Cornerstone no later than November 30, 2023. The Promissory Note is secured by a first priority security interest in all of Cornerstone's right, title and interest in and to all of the tangible and intangible assets purchased by Cornerstone pursuant to the Purchase Agreement between Cornerstone and Calithera Biosciences, Inc. ("Calithera"), a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations, and all proceeds therefrom and all rights to the data related to CB-839 (the "Collateral"). F-19 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The interest on the Promissory Note accrues from the issuance date until the Note is paid in full or converted, which shall accrue on a quarterly basis. Subject to the amendment described above, in the event the total outstanding amount under the Promissory Note is not repaid by the amended maturity date, the rate of interest shall be eleven percent (11%), retroactive from and after the maturity date. Subject to the amendment described above, following the occurrence of and during the continuation of an uncured Event of Default (as defined below), the outstanding principal amount shall bear interest at the rate of fourteen percent (14%) per annum (the "Default Interest Rate") until the earliest of (i) cure of such Event of Default, (ii) repayment of all outstanding amounts due under the Note, (iii) conversion of all then outstanding obligations under the Note, or (iv) transfer of all its rights related to the Collateral. The entire (and not less than the entire) outstanding principal amount due under the Promissory Note together with all accrued unpaid interest thereon and other amounts owing thereunder (together, the "Owed Amount"), may, at Cornerstone's election at any time prior to the maturity date, be converted into a number of shares (the "Conversion Shares") calculated by dividing the entire Owed Amount by the conversion price used by Cornerstone in a Qualified Offering / Conversion (as defined in the Note), and if no such Qualified Offering / Conversion has been consummated, the fair market value for the Conversion as determined by an independent third party valuation firm (the "Conversion Price"). The Promissory Note contains certain trigger events (as defined in the Note) that generally, if uncured within five (5) trading days, may result in an event of default in accordance with the terms of the Notes (such event, an "Event of Default"). Upon an Event of a Default, the Company may consider the Promissory Note immediately due and payable. Upon an Event of Default, the interest rate may also be increased to the lesser of 18% per annum or the maximum rate permitted under applicable law. The Company recorded the Promissory Note at fair value as the security is classified as available-for-sale. Subsequent changes in fair value are recorded in unrealized gain or loss on available-for-sale securities as a component of other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. For the year ended July 31, 2023, the Company recorded a change in fair value of approximately \$ 79 thousand related to the decrease in fair value of the Promissory Note which was recognized in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Interest income on the Promissory Note totaled approximately \$ 54 thousand for the year ended July 31, 2023 and is recorded in interest receivable on the consolidated balance sheets. NOTE 6— INVESTMENT IN RP FINANCE, LLC On February 3, 2020, Cornerstone Pharmaceuticals entered into a Line of Credit with RP Finance ("RPF Line of Credit") which provides a revolving commitment of up to \$ 50,000,000 to fund clinical trials and other capital needs. The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The remaining 25% equity interests in RP Finance are owned by other stockholders of Cornerstone Pharmaceuticals. Under the RPF Line of Credit, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U. S. Internal Revenue Service. The maturity date is the earliest of February 3, 2025, upon a change of control of Cornerstone Pharmaceuticals or a sale of Cornerstone Pharmaceuticals or its assets. Cornerstone Pharmaceuticals can draw on the facility on 60 days' notice. The funds borrowed under the RPF Line of Credit must be repaid out of certain proceeds from equity sales by Cornerstone Pharmaceuticals. In connection with entering into the RPF Line of Credit, Cornerstone Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Cornerstone Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the RPF Line of Credit. The Company has determined that RP Finance is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance's economic performance and, therefore, is not required to consolidate RP Finance. Therefore, the Company will use the equity method of accounting to record its investment in RP Finance. The Company has recognized \$ 0 in earnings from its ownership interests of 37.5% in RP Finance for the years ended July 31, 2023 and 2022, respectively, and a loss of \$ 0 and \$ 575 thousand from its ownership interests of 37.5% in RP Finance for the years ended July 31, 2023 and 2022, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 16). F-20 In August 2020, Cornerstone Pharmaceuticals called for a \$ 5 million draw on the RPF Line of Credit and the facility was funded by RP Finance in the amount of \$ 5 million. In November 2020, Cornerstone Pharmaceuticals called for a second \$ 5 million draw on the RPF Line of Credit and the facility was funded by RP Finance in the amount of \$ 5 million. In June 2021 and July 2021, Cornerstone Pharmaceuticals called for a total aggregate of \$ 10 million in draws on the line of RPF Line of Credit and the facility was funded by RP Finance in the amount of \$ 10 million. In September 2021, Cornerstone Pharmaceuticals called for a \$ 5 million draw on the RPF Line of Credit and the facility was funded by RP Finance LLC in the amount of \$ 5 million. As of July 31, 2023 and 2022, the Company has funded a cumulative total of \$ 9.375 million in accordance with its 37.5% ownership interests in RP Finance. The Company recorded a reserve on related party interest receivable of \$ 1.9 million in Interest income, net, on the consolidated statements of operations and comprehensive loss during the year ended July 31, 2022. Impairment of Equity Method Investment Due to the Data Events, during the three months ended October 31, 2021, the Company recorded

equity in the loss of RP Finance of \$ 575 thousand. As of July 31, 2023 and 2022, the equity method investment on the Company's balance sheet was \$ 0, and no additional equity loss of RP Finance was recorded during the year ended July 31, 2023. The Company was not obligated to guarantee obligations of RP Finance and is not committed to provide further financial support for RP Finance. Additionally, during the year ended July 31, 2022, the Company recorded a loss on related party receivables of \$ 9.375 million related to amounts owed by RP Finance. NOTE 7 — INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD. LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. As of July 31, 2023, the Company held 95% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018. In March 2021, the Company provided bridge financing in the principal amount of up to \$ 400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8% per annum. As of September 1, 2021, LipoMedix was in default on the terms of the loan and as such, the interest rate has increased to 15% per annum. On November 15, 2021, the Company entered into a share purchase agreement with LipoMedix to purchase up to 15,975,000 ordinary shares at \$ 0.1878 per share for an aggregate purchase price of \$ 3.0 million (the "LipoMedix SPA"). Additionally, LipoMedix issued the Company a warrant to purchase up to 15,975,000 ordinary shares at an exercise price of \$ 0.1878 per share which expired on November 11, 2022. As of the date of the LipoMedix SPA, there was an outstanding loan balance including principal of \$ 400 thousand and accrued interest of \$ 21.8 thousand owed by LipoMedix to the Company on a note made by LipoMedix in favor of the Company issued in March 2021. The amount due on the loan was netted against the approximately \$ 3.0 million aggregate purchase price due to LipoMedix, resulting in a cash payment by the Company of approximately \$ 2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company's ownership of LipoMedix increased to approximately 84% with a noncontrolling interest of approximately 16%. The Company recorded approximately \$ 8 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company's increased ownership interest in LipoMedix's net assets. On February 9, 2023, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 70,000,000 ordinary shares at \$ 0.03 per share for an aggregate purchase price of \$ 2.1 million (the "2023 LipoMedix SPA"). As a result of the share purchase, the Company's ownership of LipoMedix increased to approximately 95% with a noncontrolling interest of approximately 5%. The Company recorded approximately \$ 16 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company's increased ownership interest in LipoMedix's net assets. F-21 NOTE 8 — INVESTMENT IN DAY THREE LABS INC. On April 7, 2023, the Company entered into a Common Stock Purchase Agreement (the "Day Three Purchase Agreement") with Day Three. Day Three is a cannabinoid ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions. Pursuant to the Day Three Purchase Agreement, the Company purchased 4,302,224 shares of common stock representing 38% of the outstanding shares of common stock of Day Three (33.333% on a fully diluted basis), for a purchase price of \$ 3.0 million. The Company also received a warrant exercisable for 7,528,893 shares of common stock at an aggregate purchase price of \$ 3.0 million, which expires five years from the date of issuance or earlier based on the occurrence of certain events as defined in the Day Three Purchase Agreement. As of the date of this report, the Company had not exercised the warrant. The Company has accounted for this investment as an equity method investment in accordance with the guidance in ASC 323, Investments—Equity Method and Joint Ventures. The Company determined that a 38% ownership interest in Day Three and its right to designate two members of the Board of Directors of Day Three (out of a current total of seven members) indicates that the Company is able to exercise significant influence. Upon exercise of the warrant, the Company will have the right to appoint a third member of the Day Three Board of Directors. The Company has determined that Day Three is a VIE; however, the Company is not the primary beneficiary as it does not have the power to direct the activities that most significantly impact Day Three's economic performance. The Company has therefore concluded it is not required to consolidate Day Three. The Company uses the equity method of accounting to record its investment in Day Three. Day Three's fiscal year ends on December 31, and as a result, the Company will recognize its share of Day Three's earnings / loss on a one-month lag. For the year ended July 31, 2023, the Company recognized approximately \$ 203 thousand of equity in loss of Day Three, based on its proportionate share of Day Three's results through June 30, 2023. The assets and operations of Day Three are not significant. NOTE 9 — INVESTMENT IN CYCLO THERAPEUTICS, INC. On May 2, 2023, the Company entered into a Securities Purchase Agreement (the "Cyclo SPA") with Cyclo. Cyclo is a clinical stage biotechnology company, whose common stock is listed on the Nasdaq Capital Market under the symbol CYTH, that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. The Company purchased from Cyclo (i) 2,514,970 common shares (the "Purchased Shares") and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of \$ 0.71 per share (the "Cyclo Warrant"), at a combined purchase price equal to \$ 0.835 per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of \$ 2.1 million. The Cyclo Warrant may be exercised for the seven-year period following the date Cyclo obtains the approval of the stockholders of Cyclo to the exercise of the Cyclo Warrant. On July 31, 2023, the Cyclo stockholders approved the exercise in full of the warrant. On June 1, 2023, the Company entered into another Securities Purchase Agreement (the "Cyclo II SPA") with Cyclo. Pursuant to the Cyclo II SPA, the Company agreed to purchase an additional 4,000,000 shares of common stock (the "Cyclo II Shares"), and a warrant to purchase an additional 4,000,000 Shares (the "Cyclo II Warrant"), for an aggregate purchase price of \$ 5,000,000. The Cyclo II Warrant has an exercise price of \$ 1.25 per share and is exercisable for a period of seven years following the date of issuance. On July 31, 2023, Cyclo obtained the approval of its stockholders for the transactions contemplated by the Cyclo II SPA. Subsequent to year end, on August 1, 2023, the Company completed the Cyclo II SPA with Cyclo, whereby the Company purchased 4,000,000 shares of common stock (the "Cyclo II Shares"), and a warrant to purchase an additional 4,000,000 Shares (the "Cyclo II Warrant"), for an aggregate purchase price of \$ 5,000,000. The August 1, 2023 investment increased the Company's percentage ownership of Cyclo common stock to 34%. As of the date of this report, the Company had not exercised the Cyclo II Warrant. Pursuant to the Cyclo II SPA, the Registration Rights Agreement between the Company and Cyclo, dated May 2, 2023, has been amended to require Cyclo to file a registration statement with the Securities and Exchange Commission to register the resale of the Cyclo II Shares and shares of common stock underlying the Cyclo II Warrants, upon the request of the Company, and (ii) Cyclo agreed to appoint a designee of the Company (in addition to William Conkling, the Company's Chief Executive Officer) to Cyclo's Board of Directors, and to nominate such designee to serve as a director of Cyclo in connection with Cyclo's solicitation of proxies for Cyclo's next Annual Meeting of Stockholders. The Cyclo II SPA purchase price was paid on August 1, 2023, which is the effective date of the second Cyclo investment. Subsequent to year end, on October 20, 2023, the Company exercised the Cyclo Warrant to purchase 2,514,970 common shares at an exercise price of \$ 0.71 per share, pursuant to a Securities Purchase Agreement dated October 20, 2023, and in consideration received a new warrant to purchase an additional 2,766,467 common shares at an exercise price of \$ 0.95 per share which are exercisable for a period of four years following the issuance date (the "Cyclo III Warrant"), for an aggregate purchase price of \$ 1,785,629. F-22 The Company has elected to account for its investment in Cyclo under the fair value option. The investment was measured at fair value and the Company has recorded the subsequent changes in fair value as unrealized gain (loss) in the consolidated statements of operations and comprehensive loss. The investment in the Cyclo SPA resulted in an unrealized gain of approximately \$ 2.1 million as the purchase price was lower than the fair value of the investment. The Company recognized total unrealized gains on its investment of \$ 2.7 million in the accompanying consolidated statements of operations and comprehensive loss for the year ended July 31, 2023. Summarized Fair Value (Level 1) Method Investment Details Ownership % Aggregate Fair Value July 31, 2023 July 31, 2022 Cyclo 16% \$ 4,763,102 The 16% ownership percentage as of July 31, 2023 is comprised of the shares of common stock owned by the Company and does not include the Cyclo Warrant. The total aggregate fair value of the Cyclo investment of \$ 4,763,102 as of July 31, 2023 is comprised of common shares with an aggregate fair value of \$ 3,898,204 and warrants with an aggregate fair value of \$ 864,898. Summarized consolidated financial information of Cyclo, reported on a one-month lag, is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue \$ 117,118 \$ 541,886 \$ 269,529 \$ 736,790 Loss from operations \$ (4,632,942) \$ (3,456,024) \$ (9,640,074) \$ (6,390,481) Net loss \$ (4,636,455) \$ (3,451,990) \$ (9,643,540) \$ (6,223,581) NOTE 10 — INVESTMENTS The Company has classified its investments in corporate bonds, U. S. treasury bills, and convertible note receivable as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders' equity until realized. Investment transactions are recorded on their trade date. Gains and losses on marketable security transactions are reported on the specific identification method. Interest income is accrued daily and adjusted for amortization of premiums and accretion of discounts on the corporate bonds and U. S. treasury bills. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities as of July 31, 2023 and 2022 are as follows: July 31, 2023 Amortized cost Gross unrealized gains Gross unrealized (losses) Fair value (in thousands) Available-for-sale securities: U. S. Treasury Bills \$ 11,222 \$ 53 — \$ 11,275 Corporate bonds 46,766 4,333 (4,660) 46,439 Convertible note receivable, related party 2,000 — (79) 1,921 Total available-for-sale securities \$ 59,988 \$ 4,386 \$ (4,739) \$ 59,635 F-23 July 31, 2022 Amortized cost Gross unrealized gains Gross unrealized (losses) Fair value (in thousands) Available-for-sale securities: Corporate bonds \$ 36,761 \$ 81 \$ (144) \$ 36,698 Total available-for-sale securities \$ 36,761 \$ 81 \$ (144) \$ 36,698 During the year ended July 31, 2023, the Company reclassified approximately \$ 154 thousand of unrealized gains out of accumulated other comprehensive loss related to the sale of available-for-sale securities into consolidated net loss in the consolidated statements of operations and comprehensive loss in realized gain on available-for-sale securities. Maturities of corporate bonds and U. S. Treasury Bills held as of July 31, 2023 were all due within one year. Marketable securities in an unrealized loss position as of July 31, 2023 were not deemed impaired at acquisition and subsequent declines in fair value are not deemed attributed to declines in credit quality. The Company believes that it is more likely than not that it will receive a full recovery of par value on the securities, although there can be no assurance that such recovery will occur. NOTE 11 — FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: ● Level 1—quoted prices in active markets for identical assets or liabilities; ● Level 2—quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or ● Level 3—unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. F-32 The following is a listing of the Company's assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of July 31, 2024 and July 31, 2023 and are as follows: July 31, 2022 2024 Level 1 Level 2 Level 3 Total (in thousands) Assets Available-for-sale securities—Corporate and U. S. Agency Bonds \$ — \$ 59,298 \$ — \$ 59,298 Available-for-sale securities—U. S. Treasury Bills 3,967 — 3,967 Investment in Cyclo—Common Stock 10,746 — 10,746 Convertible note receivables, due from Cyclo — 5,191 5,191 Investment in Cyclo—Warrants — 1,264 1,264 Hedge funds — 2,547 2,547 Convertible note receivable — 1,146 1,146 Total \$ 14,743 \$ 59,298 \$ 10,148 \$ 84,159 July 31, 2023 Level 1 Level 2 Level 3 Total (in thousands) Assets Available-for-sale securities—Corporate Bonds \$ — \$ 46,439 \$ — \$ 46,439 Available-for-sale securities—U. S. Treasury Bills 11,275 — 11,275 Investment in equity securities 294 — 294 Investment in Cyclo Therapeutics Inc.—Common stock 3,898 — 3,898 Investment in Cyclo Therapeutics Inc.—Warrants 865 — 865 Hedge funds — 4,984 4,984 Convertible note receivable, related party — 1,921 1,921 Total \$ 16,

332 \$ 46,439 \$ 6,905 \$ 69,676 As of F-24 July 31, 2022-2024 and Level 1 Level 2 Level 3 Total (in thousands) Assets: Available-for-sale securities Corporate Bonds \$ — \$ 36,698 \$ — \$ 36,698 Hedge funds 4,764 4,764 Total \$ — \$ 36,698 \$ 4,764 \$ 41,462 As of July 31, 2023 and 2022, the Company did not have any liabilities measured at fair value on a recurring basis. F-33 The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Year Ended July 31, 2024 2023 2022 (in thousands) Balance, beginning of period \$ 6,905 \$ 4,764 \$ 5- Withdrawal from Hedge Fund Investments (2,268) Total 500 — Unrealized gain (on Hedge Fund 63 220 Investment in Cyclo Warrants 1,338 — Unrealized loss on Cyclo Warrants) included in earnings 220 (504 74) — Funding of Convertible note receivable, related party — 2,000 Unrealized gain on Convertible note receivable, related party 742 — Realized loss on Convertible note receivable, related party released from AOCI (663) — Conversion of convertible note receivable, related party (2,000) — Funding of Convertible note receivable 1,000 — Change in fair value of Convertible note receivable 146 — Funding of Cyclo Convertible Note I 2,000 — Funding of Cyclo Convertible Note II 2,000 — Unrealized gain on issuance of Cyclo Convertible Note I 665 — Unrealized gain on issuance of Cyclo Convertible Note II 648 — Change in fair value of Cyclo Convertible Notes (122) — Total loss included in other comprehensive loss — (79) — Balance, end of period \$ 10,148 \$ 6,905 \$ 4,764 Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. During the year ended July 31, 2024, the Company requested a withdrawal from Hedge Fund Investments of \$ 2.5 million. The withdrawal was funded during the three months ended January 31, 2024. Available-for-sale securities classified as Level 3 include a convertible note receivable, related party (see Note 5-8) which may not be based on readily observable data inputs. The availability of observable inputs can vary and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of this asset is estimated using a scenario-based analysis based on the probability-weighted present value of future investments-investment returns, considering each of the possible outcomes available to us, including cash repayment, equity conversion, and collateral transfer scenarios. Estimating the fair value of the convertible note requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Therefore, this asset is classified as Level 3. The Company recognizes the fair value of the Cyclo Warrants utilizing a Black-Scholes option pricing valuation model (“Black-Scholes model”) at acquisition and each reporting date. The application of the Black-Scholes model utilizes significant assumptions, including expected volatility, expected life, marketability discount and risk-free interest rate. In order to determine the volatility, we measured expected volatility based on several inputs, including considering a peer group of publicly traded companies and the implied volatility of Cyclo’s publicly-traded warrants. As a result of the unobservable inputs that were used to determine the expected volatility of the Cyclo Warrants, the fair value measurement of these warrants reflected a Level 3 measurement within the fair value measurement hierarchy. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The expected volatility is a key assumption or input to the valuation of the Cyclo Warrants; however, changes in the expected volatility assumption will have less of an effect on the Black-Scholes model valuation as the Cyclo Warrants approach their expiration. The Cyclo Warrants are subject to limits on exercise and any sales of the underlying shares of common stock would be subject to volume restrictions for which a discount to the stock price of Cyclo was applied. The Black-Scholes model further incorporated a discount for the overall lack of marketability for the Cyclo Warrants. F-34 Below are the unobservable inputs to the Cyclo Warrants which reflect a Level 3 measurement within the fair value measurement hierarchy as of July 31, 2024: Unobservable Input Range Weighted Average Price Per Share [ 1 ] \$ 0.7 - \$ 0.74 \$ 0.72 Exercise Price \$ 0.95 - \$ 1.25 \$ 1.13 Expected Volatility 85% - 104 % 96.2 % Risk-Free Rate [ 2 ] 4.0 % - 4.1 % 4.04 % Marketability Discount 38 % - 41 % 55.0 % Remaining Term (Years) 3.2 - 6.0 4.9 Fair Value per Warrant [ 3 ] \$ 0.19 \$ 0.19 [ 1 ] Closing price of Cyclo’s common shares adjusted to reflect regulatory resale restrictions which ranged from 40.0 % to 50.0 % [ 2 ] US Treasury rate for a period commensurate with the Remaining Term. [ 3 ] Concluded fair value per warrant as of July 31, 2024. The Company used a scenario-based analysis to estimate the fair value of the Cyclo Convertible Notes based on the probability-weighted present value of future investment returns, considering each of the possible outcomes available to the Company, including cash repayment and equity conversion. Estimating the fair values of the Cyclo Convertible Notes requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. The four scenarios included maturity, a subsequent financing, a change in control, and an event of default, whereby total probability of one-hundred percent (100 %) is allocated across the four scenarios, at issuance and each subsequent reporting period. With respect to the scenario reflecting maturity of the Cyclo Convertible Notes, the associated volatility assumption reflects voluntary conversion of the Cyclo Convertible Notes prior to their respective maturities. The Company used scenario-based analyses at June 11, 2024, July 16, 2024, and July 31, 2024 to determine the issuance date and period-end fair values of the Cyclo Convertible Note I and Cyclo Convertible Note II, respectively, with the following inputs: Convertible Note I Convertible Note II Input Issuance at June 11, 2024 Remeasured at July 31, 2024 Issuance at July 16, 2024 Remeasured at July 31, 2024 Discount factor 0.927 - 0.932 0.95 - 0.955 0.942 0.955 Conversion price \$ 0.95 \$ 0.95 \$ 0.95 \$ 0.95 Dividend 0 % 0 % 0 % 0 % Risk free rate 5.29 % - 5.30 % 5.24 % - 5.26 % 5.25 % 5.26 % Stock price \$ 1.24 \$ 1.19 \$ 1.22 \$ 1.19 Term 0.39 - 0.42 years 0.28 - 0.25 years 0.30 years 0.25 years Equity volatility 61.0 % - 73.0 % 59.0 % - 67.0 % 65.0 % 59.0 % Black-Scholes Merton Call Value \$ 0.22 - \$ 0.39 \$ 0.15 - \$ 0.31 \$ 0.19 - \$ 0.33 \$ 0.15 - \$ 0.29 The Company holds \$ 0 — and \$ 65 thousand 9-5 million as of July 31, 2024 and July 31, 2023 and 2022, respectively, in investments in securities in another entity that are not liquid, which were included in Investments- Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is was liquidated during the year ended July 31, 2024. The investment was accounted for under ASC 321, Investments- Equity Securities, using the measurement alternative as defined within the guidance, and the Company recorded an impairment loss of \$ 334 thousand and \$ 0 for the years ended July 31, 2023 and 2022, respectively. Fair Value of Other Financial Instruments The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. F-35 The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amounts of accounts receivable, accounts payable and due to related parties approximate their fair value due to their short-term nature. F-25 NOTE 12-16 – ACCOUNTS RECEIVABLE Accounts receivable consisted of the following: July 31, 2023-2024 July 31, 2022-2023 (in thousands) Accounts Receivable receivable - Third third Party party \$ 338 \$ 247 \$ 196 Accounts Receivable Receivable - Related related Party party 333 211 458 Less Allowance allowance for Doubtful credit losses (245) (245) Accounts (245) (197) Accounts Receivable receivable, net \$ 426 \$ 213 \$ 157 NOTE 13-17 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: July 31, 2024 July 31, 2023 2022 (in thousands) Building and Improvements improvements \$ 2,505 \$ 2,505 Machinery and equipment 552 — Other 81 68 3,682, 573 138 2,573 Less Accumulated accumulated Depreciation depreciation and amortization (1,018) (878) (803) Total \$ 12,695 120 \$ 1,770 695 Other property and equipment consist of other equipment and miscellaneous computer hardware. Depreciation expense and amortization pertaining to property and equipment was approximately \$ 137 thousand and \$ 78 thousand and \$ 72 thousand for the years ended July 31, 2024 and 2023 and 2022, respectively. F-36 NOTE 18- GOODWILL AND INTANGIBLE ASSETS The following is a summary of goodwill Company’s headquarters are located at 520 Broad Street in Newark, New Jersey, where it occupies office space and which was previously owned by reportable segment the Company. The table above excludes the assets of the 520 Property which were classified as held-for the year ended - sale as of July 31, 2022-2024 and subsequently sold; Healthcare Real Estate Infusion Technology Consolidated (in thousands) Balance as of July 31, 2023 \$ — \$ — \$ — Day Three Acquisition — 3,050 3,050 Balance as of July 31, 2024 \$ — \$ — \$ 3,050 3,050 The following is a summary of intangible assets at July 31, 2024: Weighted average remaining useful life (years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount (in thousands) Intellectual Property 15 \$ 1,885 (73) \$ 1,812 on Non August 22- compete Agreements 2.50 (15) 35 Total Intangible Assets \$ 1, 2022-Refer 935 (88) \$ 1,847 Amortization expense for the next five years and thereafter for intangible assets is estimated to Note 3 be as follows for further information on years ending: Year Ending July 31, (in thousands) 2025 \$ 148 2026 132 2027 123 2028 123 2029 123 Thereafter 1,198 Total \$ 1,847 Amortization of intangible assets totaled \$ 88 thousand for the 520 Property year ended July 31, 2024, and is included in depreciation and amortization expense within the consolidated statements of operations and comprehensive loss. NOTE 14-19 – LOSS PER SHARE Basic loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share includes potentially dilutive securities such as stock options, unvested restricted stock, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. The securities set forth in the table below have been excluded from the calculation of diluted net loss per share for the years ended July 31, 2023 and 2022 because inclusion of all such securities would have been anti-dilutive for all periods presented. The following table summarizes the Company’s potentially dilutive securities which have been excluded from the calculation of diluted loss per share as their effect would be anti-dilutive: F-37 Year Ended July 31, 2024 2023 2022 Shares issuable upon exercise of stock options 638,409 388,409 1,021,277 Shares issuable upon vesting of restricted stock 608,540 684,766 1,507 246, 373 949 1,073,175 2,528,650 F-26 The diluted loss per share computation equals basic loss per share for the years ended July 31, 2024 and 2023 and 2022 because the Company had a net loss from continuing operations in all such periods and the impact of the assumed vesting of restricted shares and exercise of stock options and warrants would have been anti-dilutive. The following table summarizes the basic and diluted loss per share calculations (in thousands, except for share and per share amounts): Year Ended July 31, 2024 2023 2022 Numerator: Net loss from continuing operations \$ (65,003) \$ (8,693) \$ (140,547) Net loss attributable to noncontrolling interests (30,593) (339) (17,719) Numerator for net loss from continuing operations (34,410) (8,354) (122,828) Numerator for discontinued operations — 6,478 (1,830) Net loss attributable to Rafael Holdings, Inc. \$ (34,410) \$ (1,876) \$ (124,658) Denominator: Weighted average basic and diluted shares outstanding 23,745,516 23,263,211 19,767,342 Loss per share attributable to common stockholders Basic and diluted: Continuing operations \$ (1.45) \$ (0.36) \$ (6.22) Discontinued operations — 0.28 (0.09) Total basic and diluted loss per share \$ (1.45) \$ (0.08) \$ (6.31) NOTE 15-20 – NOTE PAYABLE, HELD-FOR-SALE On July 9, 2021, the Company, as guarantor, Rafael Holdings Realty, Inc., a wholly-owned subsidiary of the Company (“Realty”), as pledgor, and Broad-Atlantic, a wholly-owned subsidiary of Realty (“Borrower,” and together with the Company and Realty, the “Borrower Parties”), as borrower, entered into a loan agreement (the “Loan Agreement”) with 520 Broad Street LLC, a third-party lender (the “

Lender"). The Loan Agreement provided for a loan in the amount of \$ 15 million (the " Note Payable ") from Lender to Borrower secured by (i) a first mortgage on 520 Broad Street, Newark, New Jersey 07102 - 5, and (ii) a first priority security interest in the equity of the Borrower as set forth in the Pledge and Security Agreement between Realty and Lender. The Note Payable bore interest at a rate per annum equal to seven and one- quarter percent (7. 25 %) from July 9, 2021 through July 31, 2021 and thereafter at an interest rate per annum equal to the 30- day LIBOR Rate, as published in The Wall Street Journal, plus 6. 90 % per annum, but in no event less than seven and one- quarter percent (7. 25 %) per annum. The Note Payable was due on August 1, 2022, subject to the Company' s option to extend the maturity date until August 1, 2023 for a fee equal to three- quarters of one percent (0. 75 %) of the Note Payable. The Loan Agreement contained customary affirmative covenants, negative covenants and events of default, as defined in the Loan Agreement, including covenants and restrictions that, among other things, restricted the Borrower' s ability to incur liens, or transfer, lease or sell the collateral as defined in the Loan Agreement. A failure to comply with these covenants would have permitted the Lender to declare the Borrower' s obligations under the Loan Agreement, together with accrued interest and fees, to be immediately due and payable. The Company was in compliance with the covenants in the Loan Agreement as of July 31, 2022. The Company extended the maturity date to November 1, 2022 and paid an extension fee of \$ 37, 500 on July 29, 2022. F- 27- 38 In connection with the sale of the 520 Property, on August 22, 2022, the Company paid off the outstanding principal balance of \$ 15 million and accrued interest of approximately \$ 87, 000 on the Note Payable. See Refer to Note 3- 14 for further details on the subsequent sale of the 520 Property. Interest expense under the Note Payable, which is recognized in loss on discontinued operations, amounted to \$ 0 and \$ 87 thousand for the year ended July 31, 2023, and \$ 1. 2 million for the year ended July 31, 2022. Unamortized debt issuance costs on the Note Payable totaled approximately \$ 0 as of July 31, 2023 and 2022. Amortization of the debt discount on the Note Payable totaled approximately \$ 0 and \$ 472 thousand for the years ended July 31, 2024 and 2023 and 2022, respectively. NOTE 46- 21 - RELATED PARTY TRANSACTIONS The Company IDT Corporation (" IDT "), a related party through common ownership and some common members of management, has historically maintained a an intercompany balance due to / from balance related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company' s personnel that were paid by IDT as the relevant persons were also providing services to IDT. IDT billed the Company approximately \$ 296 thousand and \$ 313 thousand and \$ 343 thousand for services during the years ended July 31, 2024 and 2023 and 2022, respectively, of which \$ 70 thousand and \$ 69 thousand is included in due to related parties at July 31, 2024 and 2023 and 2022, respectively. IDT leased, prior to the Company' s sale of the 520 Property, approximately 80, 000 square feet of office space plus parking at the 520 Property and currently leases approximately 3, 600 square feet of office space in Jerusalem, Israel. The Company invoiced IDT approximately \$ 108 thousand and \$ 211 thousand for of which approximately \$ 102 thousand is included in discontinued operations during the year years ended July 31, 2024 and 2023, respectively. The As of July 31, 2024 and 2023, IDT owed the Company invoiced IDT approximately \$ 332 thousand and 2. 1 million, of which approximately \$ 210 thousand, respectively, 2. 0 million is included in discontinued operations for office rent and parking plus Israeli value added during the year ended July 31, 2022. As of July 31, 2023 and 2022, IDT owed the Company approximately \$ 210 thousand and \$ 157 thousand, respectively, for office rent and parking. Until October 31, 2021, the Company had provided Cornerstone Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S Genie Energy Ltd, Genie Energy Ltd Jonas and William Conking currently serve on the Board of Directors of Cornerstone Pharmaceuticals. (" Genie ") The Company billed Cornerstone Pharmaceuticals \$ 120 thousand for the year ended July 31, 2022. As of July 31, 2023 and July 31, 2022, Cornerstone Pharmaceuticals owed the Company \$ 720 thousand, for which a full allowance for uncollectibility has been recorded. Due to the Data Events, in the year ended July 31, 2022, the balance owed to the Company by Cornerstone Pharmaceuticals was fully reserved, resulting in a loss on related party through common ownership receivable of \$ 720 thousand (see Note 4). On March 21, 2023, the Company entered into a Promissory Note with Cornerstone Pharmaceuticals, wherein, Cornerstone Pharmaceuticals promises to pay the Company \$ 2 million together with all interest accrued on May 22, 2023, or such earlier date as the Promissory Note is required or permitted to be repaid (see Note 5). On May 22, 2023, the Promissory Note was amended to extend the maturity date to November 30, 2023 and some common members of management to waive the interest increase (see Note 5). Genie Energy, Ltd. The Company leased office space at 520 Broad Street prior to Genie the Company' s sale of the 520 Property. The Company invoiced Genie approximately \$ 19 thousand which is included in discontinued operations during the year ended July 31, 2023. Genie pays the Company for payroll costs for certain personnel which totaled approximately \$ 10 thousand during the year ended July 31, 2023. Related Party Rental Income The Company leased space to related parties (including IDT Corporation - see above) which represented approximately 17 % and 42 % and 58 % of the Company' s total revenue for the years ended July 31, 2024 and 2023 and 2022, respectively. The portion of related party rental income pertaining to the 520 Property has been classified in discontinued operations on the consolidated statements of operations and comprehensive loss for the years ended July 31, 2023 and 2022. F- 28 For the year ended July 31, 2023, the Company recognized \$ 0 from its ownership interests of 37. 5 % in RP Finance. For the year ended July 31, 2022, the Company recognized a loss of \$ 575 thousand in income from its ownership interests of 37. 5 % in RP Finance. Howard Jonas, Chairman of the Board and, Former Chief Executive Officer In December 2020, IDT Corporation and Genie Energy Ltd, on whose Boards of Directors Howard Jonas, the Company' s Chairman of the Board and Executive Chairman and former Chief Executive Officer serves, each purchased 218, 245 shares of Class B common stock for consideration of \$ 5 million each. In connection with the purchases, each purchaser was granted warrants (the " Issued Warrants ") to purchase twenty percent (20 %) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of \$ 22. 91 per share and expired on June 6, 2022. The Issued Warrants were not exercised. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4 (a) (2) of the Securities Act of 1933, as amended. On June 22, 2022, the Company entered into a Stock Purchase Agreement (the " 19 SPA ") with 19 Plus, LLC, an entity affiliated with members of the family of Howard Jonas. On July 6, 2022, pursuant to the 19 SPA, the Company sold 3, 225, 806 shares of the Company' s Class B common stock to 19 Plus, LLC at a price per share of \$ 1. 86 and an aggregate sale price of \$ 6 million. On July 31, 2023, eight trusts, each for the benefit of a child of Howard S. Jonas, the Company' s Executive Chairman and Chairman of the Board, with independent trustees, transferred an aggregate of 787, 163 shares of Class A common stock of the Company (representing all of the issued and outstanding shares of the Class A common stock of the Company, and 51. 3 % of the aggregate voting power of all issued and outstanding shares of capital stock of the Company) to a limited partnership. Howard Jonas is the sole manager of the sole general partner of the limited partnership and, therefore, has sole voting and dispositive power over the shares of Class A common stock held by the limited partnership. Following the transfer, Mr. Jonas is will be the controlling stockholder of the Company and the Company is a controlled company as defined in Section 303A of the New York Stock Exchange Listed Company Manual. During LipoMedix Pharmaceuticals, Ltd. As of the date of the LipoMedix SPA, on November 15, 2021, there - the year ended July 31, 2024, was an outstanding loan balance including principal of \$ 400 thousand and accrued interest of \$ 21. 8 thousand owed by LipoMedix to the Company paid Sam Beyda, who serves on the note from March 2021. The amount due on the loan was - as Chief Executive Officer and netted against the \$ 3. 0 million aggregate purchase price due LipoMedix, resulting in a Director cash payment by the Company of Day Three approximately \$ 2. 6 million in exchange for the 15, 975, 000 shares purchased. As a result of the share purchase, the Company' s ownership of LipoMedix increased to approximately 84 % with a noncontrolling interest of approximately 16 %. On February 9, 2023, the Company entered into a share purchase agreement with LipoMedix to purchase 70, 000, 000 ordinary shares at \$ 0. 03 per share for an and is aggregate purchase price of \$ 2. 1 million. As a result of the share purchase, the Company' s ownership of LipoMedix increased to approximately 95 % with a noncontrolling interest of approximately 5 %. The Company recorded approximately \$ 16 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company' s increased ownership interest in LipoMedix' s net assets. Investment in Equity Securities The Company entered into a Cooperation Agreement with Genie, IDT and trusts for the benefit of certain family members of Howard Jonas ' son - related to an investment in - law, a salary in third- party publicly traded company. Subsequently, the amount of Company and Genie agreed to share the expenses related to the investment equally and each would retain any return from its own investments. The Company invested \$ 160 1. 6 million in the third- party company and after selling a portion of its interest made a profit of \$ 309 thousand. F- 29- 39 NOTE 47- 22 - INCOME TAXES At July 31, 2023, the Company had federal net operating loss (" NOL ") carryforwards from domestic operations of approximately \$ 63. 2 million, to offset future taxable income, state NOLs of \$ 40. 4 million, and NOLs from foreign operations of \$ 7. 6 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80 % of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire. The components of loss from continuing operations before income taxes, including equity in loss of Day Three, are as follows: For the Years Ended July 31, 2024 2023 2022 (in thousands) Domestic \$ ( 67, 653 ) \$ ( 6, 259 ) \$ ( 137, 978 ) Foreign ( 30 ) ( 2, 689 ) ( 1, 994 ) Loss before income taxes \$ ( 67, 683 ) \$ ( 8, 948 ) \$ ( 139, 972 ) Benefit from income taxes as presented in the consolidated statements of operations and comprehensive loss consisted of the following: For the Year Years Ended July 31, 2024 2023 2022 (in thousands) Current: Foreign \$ 19 \$ - \$ 19 Federal - State ( 2, 602 ) ( 274 ) - Total current expense (benefit) (2, 583 ) (255) - Deferred: Foreign - (73) - Federal - (17) - State - (7) - Total deferred expense - benefit (97) - Benefit from income taxes \$ ( 2, 680 ) \$ ( 255 ) - The differences reconciliation between income taxes expected at the Company' s effective U. S. federal statutory income tax rate on attributable to pretax loss from continuing operations and income the statutory taxes - tax attributable to pretax loss from continuing operations are reported rate for the years ended July 31, 2024 and July 31, 2023 is as follows: At For the Years Ended July 31, 2024 2023 2022 (in thousands) U. S. federal income tax at statutory rate \$ ( 14, 213 ) \$ ( 1, 877 ) \$ ( 29 ) Permanent items- Cornerstone Acquisition 18, 514 871 - Nondeductible items 672 - State income tax 1, 807 (479) (8, 752) Valuation allowance 2, 958 35, 001 Foreign operations (1) (583) Other 627 - Cornerstone Acquisition impact to deferred tax assets rate differential ( 583- 51, 546 ) (459) Tax law change - Derecognition of Cornerstone investment due to Cornerstone Acquisition 23, 312 - Permanent differences - 3, 632 Rate change - Sale Sales of state NOLs ( 2, 613 ) ( 274 ) - Other - 92 Change in valuation allowance 20, 404 2, 958 Benefit from income taxes \$ ( 2, 680 ) \$ ( 255 ) - During the year ended July 31, 2023- 2024, the Company received proceeds of approximately \$ 274 thousand and 2. 6 million from the sale of the Company' s 2018 and 2019- 2020- 2022 New Jersey tax credits NOLs totaling \$ 31. 6 million through the New Jersey Technology Business Tax Certificate Transfer Program. The During the year ended July 31, 2023, the Company has not recorded U received proceeds of approximately \$ 274 thousand from the sale of the Company' s 2019 New Jersey NOLs totaling \$ 3. 3 million through the New Jersey Technology Business Tax Certificate Transfer Program. Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax expense for foreign purposes. Realization of net deferred tax assets is dependent upon future earnings, if because it has not generated any foreign earnings, the timing and amount of which are uncertain. F- 30- 40 Significant components of the Company' s deferred tax assets and deferred tax liabilities are as follows: At July 31, 2024 2023 2022 (in thousands) Deferred tax assets: Net operating loss carryforwards \$ 61, 204 \$ 17, 852 \$ 15, 170 Unrealized gain / loss - 30, 236 31, 850 Depreciation (1) I- R & D amortization credits, net of uncertain tax position 6, 145 - Capitalized Sec. 174 research and experimental expenditures 3, 121 689 - Reserves and accruals 237- 236 Stock- based compensation 2, 486 1, 858 Depreciation 286 ( 1, 839 ) Reserves and accruals 249 237

Charitable contributions 141 — Gross deferred tax assets 71,362 (50,871) (49,096) Less valuation allowance ( 71,275 ) ( 50,871 ) ( 49,096 ) Total deferred tax assets, net of valuation allowance 2,357 — Deferred tax liabilities: Unrealized gain (2,327) — Amortization (30) — Total deferred tax liabilities — (2,357) — Deferred tax assets liability, net \$ — \$ — The Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors. Deferred tax assets established for the excess outside tax basis of an investee are derecognized upon the event that the investee becomes a domestic subsidiary as a result of a business combination or consolidation, as it is likely that the deferred tax asset will no longer qualify for recognition. During the year ended July 31, 2024, the Company derecognized unrealized loss deferred tax assets related to prior investments in Cornerstone and Day Three as a result of the Cornerstone Acquisition and Day Three Acquisition, respectively. As of July 31, 2024, based on the Company's history of losses and its assessment of future losses, management believes that it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation allowance has been applied to deferred tax assets. Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation ("R & E") activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R & E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R & E activities in the US must be amortized over a 5-year period and R & E expenses incurred outside the US must be amortized over a 15-year period. R & E activities are broader in scope than qualified research activities that are considered under IRC Section 41 (relating to the research tax credit). As of July 31, 2024, the Company has federal, state, and foreign net operating loss carryforwards of approximately \$ 270.0 million, \$ 17.5 million and \$ 11.6 million, respectively. Federal net operating loss carryforwards in the amount of \$ 83.1 million begin expiring in 2025 and approximately \$ 186.9 million have an indefinite life. Federal NOL carryforwards generated after tax year 2021 are subject to an 80% limitation on taxable income, do not expire and will carryforward indefinitely. State net operating loss carryforwards in the amount of \$ 17.5 million begin expiring in 2042. Foreign net operating loss carryforwards in the amount of \$ 11.6 million have an indefinite life. F-41 The utilization of the Company's net operating losses may be subject to a U. S. federal limitation due to the "change in ownership provisions" under Section 382 and 383 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations may result in a reduction of the amount of net operating loss carryforwards and research and development tax credits in future years and possibly the expiration of certain net operating loss and research and development tax credits carryforwards before their utilization. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examinations by federal, foreign, and state and local jurisdictions, where applicable. There are currently no pending tax examinations. The Company's tax years are still open under statute from 2021 to the present in the U. S. and from 2020 to present in the Company's foreign operations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state and local tax authorities to the extent utilized in a future period. The Company is also subject to certain non-income taxes such as value added taxes, sales taxes, and property taxes. The Company has taken certain positions that management feels, although not free from doubt, should not result in a successful challenge by certain tax authorities. As required by the uncertain tax position guidance in ASC No. 740, Income Taxes, ("ASC 740") the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied the uncertain tax position guidance in ASC 740 to all tax positions for which the statute of limitations remained open. Any estimates of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. Any interest and penalties related to uncertain tax positions would be included as part of the income tax provision. The Company's conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors. A reconciliation of the beginning and ending amount of unrecognized tax benefits associated with uncertain tax positions is as follows: At July 31, 2024 2023 (in thousands) Balance, beginning of the year \$ — \$ — Additions of tax positions related to the prior year 6,218 — Balance, end of year \$ 6,218 \$ — NOTE 48-23 – BUSINESS SEGMENT INFORMATION The Company conducts business as two-three operating segments, Healthcare, Infusion Technology and Real Estate. The Company's reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company's Chief Executive Officer who is the chief operating decision-maker. Following the Day Three Acquisition, the chief operating decision-maker began reviewing the operating results of Day Three and in accordance with the Company's accounting policy, the Company concluded this resulted in a new operating segment, which the Company refers to as Infusion Technology. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Healthcare segment based primarily on research and development efforts and results of clinical trials and the Infusion Technology and Real Estate segment segments based primarily on results of operations. The Healthcare segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Cornerstone Pharmaceuticals, a majority equity interest in LipoMedix, Barer, Cornerstone Farber, and Rafael Medical Devices. To date, the Healthcare segment has not generated any revenues. F-42 The Real Estate segment consists of the Company's real estate holdings, which is currently comprised of a portion of a commercial building in Israel. The revenue-revenues, and (loss) income from operations, and (loss) income before taxes of the 520 Property have been excluded from the Real Estate segment in the figures below due to its classification of held-for-sale and discontinued operations, and the sale. The Infusion Technology segment is comprised of a majority equity interest in Day Three. Revenues associated with the 520 Property on August 22, 2022 Infusion Technology segment include infusion technology revenue derived from Day Three's Unlokt technology. Operating results for the business segments of the Company are as follows: (in thousands) Healthcare Infusion Technology Real Estate Total Year Ended July 31, 2024 Revenues \$ — \$ 355 \$ 282 \$ 637 (Loss) income from operations (102,032) (675) 80 (102,627) (in thousands) Healthcare Infusion Technology Real Estate Total Year Ended July 31, 2023 Revenues \$ — \$ 279 \$ 279 (Loss) income from operations (15,121) — 78 (15,043) Total assets by segment are not provided to or reviewed by the CODM. Year Ended July 31, 2022 Revenues \$ — \$ 410 \$ 410 (Loss) income from operations (60,658) 181 (60,477) F-31 Geographic Information Infusion Technology Segment Revenue from the Infusion Technology segment is entirely from customers located in the United States. Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-U. S. customers as a percentage of total revenues, which are inclusive of revenue from discontinued operations, were as follows (revenues by country are determined based on the location of the related facility): Year Ended July 31, 2024 2023 2022 Revenue from tenants located in Israel 100% 53% 7% Net property, plant, and equipment and total assets summarized by geographic area held outside of the United States, which are located in Israel, were as follows: (in thousands) United States Israel Total July 31, 2024 Property, plant, and equipment, net \$ 783 \$ 1,337 \$ 2,120 Total assets 93,434 \$ 3,398 96,832 July 31, 2023 Property, plant, and equipment, net \$ 293 \$ 1,402 \$ 1,695 Total assets 95,244 \$ 3,585 98,829 F-43 July 31, 2022 Property, plant, and equipment, net \$ 305 \$ 1,465 \$ 1,770 Total assets 114,053 \$ 4,267 118,320 NOTE 49-24 – COMMITMENTS AND CONTINGENCIES The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company's results of operations, cash flows or financial condition. License Agreements Cornerstone is a party to two license agreements in connection with certain technology being used for products under development and is required to make certain annual maintenance payments. In addition December 2022, Broad Atlantic entered into royalty payments, calculated on a low single digit percentage of net sales, as defined in the respective agreements, will be required upon the commercialization of licensed technology. Sublicensing fees are calculated and due based upon a percentage of gross sublicense fees. Cornerstone expenses license obligation payments to research and development on the consolidated settlement-- statements of operations and comprehensive loss. One worldwide license agreement requires Cornerstone to reimburse the other party for costs associated with filing and defending various patents worldwide. Payment obligations under this license agreement remain in effect until the last underlying patents granted under the license agreement expire in their respective countries. The last patent expired in 2019. License maintenance fees are currently \$ 20,000 per year and continue for the term of the agreement, which expires in 2026. The license maintenance fees are replaced by minimum royalties of \$ 10,000 during the first year following governmental approval to market products and escalates to \$ 1,000,000 during the term of the agreement. Cornerstone is also responsible to pay fees on any sub-licensing of the licensed patents. Cornerstone may credit each annual license maintenance fee in full against all royalties and sublicensing fees due during the same calendar year. Cornerstone may terminate the license agreement upon 90 days' notice. Either party may terminate the license agreement if the other party commits any material breach of any covenant or promise and does not cure such breach within 30 days of the receipt of written notice of such material breach. In May 2017, Cornerstone renegotiated the agreement referred to as the "second license." In exchange for a waiver of certain product development milestones, Cornerstone modified the agreement to pay a low single digit percentage royalty for a duration of five years on Net Sales of product sold after the expiration of the licensed patent and potentially up to eight years. As of July 31, 2024, there are no products being marketed which are covered by the patents under the license agreement. The remaining minimum payments required under the license agreement, assuming the agreement is not terminated by Cornerstone, excluding any escalation for receiving government marketing approval subsequent to July 31, 2018, are \$ 20,000 per year. The agreement may continue until January 1, 2029 (if not earlier terminated). Cornerstone's second license continues until the termination of the later of the last to expire patent or royalty obligation under the agreement on a country-by-country basis (currently, or as otherwise provided in the license agreement). Fifty percent of the maintenance fee payments, up to \$ 1.1 million, may be credited against the potential future royalty payments, calculated on a single digit percentage of net sales, as defined, that Cornerstone would have to make to the license holder should royalties be paid. The agreement may be terminated on 15 days' written notice after default by the other party if said default is not cured within 30 days of receipt of notice by the defaulting party. In addition, Cornerstone may terminate the agreement on 15 days' written notice to the license holder. Royalties are due based on Gross Sales, as defined, for products sold relating to patented and unpatented technology, and shall terminate on the 15th anniversary of the first commercial sale of the product in the corresponding country or territory. Sublicense payments are due in connection with any sublicense fees received relating to patented and non-patented

products related to the patented technology and proprietary know-how, as provided in the agreement. As of July 31, 2024, there were no products being marketed which are covered by the patents under the license agreement. There were no additional annual license maintenance fees required beyond 2010. As part of a royalty agreement, Cornerstone is obligated to pay royalties, based upon percentage (low single digit) of net sales, to Altira Capital and Consulting LLC ("Altira"), a consolidated subsidiary of the Company. The royalty obligations remain in effect, on a country-by-country basis, until the last to expire patent claims associated with such products and services expire or are no longer in force. No payments have been made in connection with a vendor providing for royalty pool. As of July 31, 2024, the last to expire patent claim is to remain by the Company of \$113 thousand representing payment in full for force until fiscal 2034 repair work done on the premises prior to our sale of the 520 Property. This amount is included in discontinued operations on the consolidated statements of operations and comprehensive loss. NOTE 20-25 - EQUITY Share Repurchase Program In Effective April 14, 2023, the Company's Board of Directors approved a share repurchase program (the "2023 Share Repurchase Program") authorizing the repurchase of up to \$5 million of the Company's Class B common stock. Under the 2023 Share Repurchase Program, which took effect on April 14, 2023, the Company may be authorized to purchase, at purchase prices up to \$1.75 per share, shares of its shares Class B common stock from time to time until the earlier of June 16, 2023 (the "Plan Termination Date") or when \$5 million worth of shares at \$1.75 per share or below have been purchased. In July 2023, the 2023 Share Repurchase Program was amended to extend the Plan Termination Date to the earlier of July 1, 2024, or when \$5 million worth of shares at \$1.75 per share. On December 22, 2023, the Company suspended the share or below have been purchased - repurchase program through the Plan Termination Date. F-44 The timing and amount of any share repurchases under the 2023 Share Repurchase Program will be determined at the Company's discretion and based on market conditions and other considerations. Share repurchases under the authorizations may be made through open market purchases or pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934. The program does not obligate the Company to acquire any particular amount of its Class B common stock, and the repurchase program may be suspended or discontinued at any time at the Company's discretion. During the year ended July 31, 2023-2024, the Company did not repurchase repurchased any 101,487 of its Class B common stock for a total cost of \$168 thousand under the 2023 Share Repurchase Program. Class A Common Stock and Class B Common Stock The rights of holders of Class A common stock and Class B common stock are identical except for certain voting and conversion rights and restrictions on transferability. The holders of Class A common stock and Class B common stock receive identical dividends per share when and if declared by the Company's Board of Directors. In addition, the holders of Class A common stock and Class B common stock have identical and equal priority rights per share in liquidation. The Class A common stock and Class B common stock do not have any other contractual participation rights. The holders of Class A common stock are entitled to three votes per share and the holders of Class B common stock are entitled to one-tenth of a vote per share. Each share of Class A common stock may be converted into one share of Class B common stock, at any time, at the option of the holder. Shares of Class A common stock are subject to certain limitations on transferability that do not apply to shares of Class B common stock. F-32 On May 27, 2021, the Company filed a Registration Statement on Form S-3, whereby the Company may sell up to \$250 million of Class B common stock. This Registration Statement was declared effective on June 7, 2021. On June 1, 2021, the Company filed a Registration Statement on Form S-3 to issue 48,859 shares of Class B common stock for payment due on the purchase of Altira, an investment which has been subsequently fully impaired. On August 19, 2021, the Company entered into a Securities Purchase Agreement (the "Institutional Purchase Agreement") with certain third-party institutional investors (the "Institutional Investors") and a Securities Purchase Agreement with I9Plus, LLC, (the "Jonas Purchase Agreement"), an entity affiliated with Howard S. Jonas, the Chairman of the Board of Directors of the Company. On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the "Institutional Shares"), par value \$0.01 per share, to the Institutional Investors, at a purchase price equal to \$35.00 per share, for aggregate gross proceeds of approximately \$99.2 million, before deducting placement agent fees and other offering expenses. Additionally, pursuant to the Jonas Purchase Agreement, the Company issued 112,501 shares of Class B common stock to I9Plus, LLC, at a purchase price equal to \$44.42 per share, which was equal to the closing price of a share of the Class B common stock on the New York Stock Exchange on August 19, 2021 (the "Jonas Offering"). The Jonas Offering resulted in additional aggregate gross proceeds of approximately \$5.0 million. The total net proceeds from the issuance of shares were \$98.0 million after deducting transaction costs of \$6.2 million. On August 19, 2021, in connection with the Institutional Purchase Agreement, the Company entered into a Registration Rights Agreement with the Institutional Investors whereby the Company agreed to prepare and file a registration statement with the SEC within 30 days after the earlier of (i) the date of the closing of the Merger Agreement, and (ii) the date the Merger Agreement is terminated in accordance with its terms, for purposes of registering the resale of the Institutional Shares and any shares of Class B common stock issued as a dividend or other distribution with respect to the Institutional Shares. On February 15, 2022, the Company filed a Registration Statement on Form S-3 (as amended on March 2, 2022) registering the resale by the Institutional Investors of the shares purchased by them. The Registration Statement was declared effective on March 7, 2022. In March 2018, the Company established its 2018 Equity Incentive Plan was created and adopted by the Company in March 2018. On January 19, 2022, the Company's stockholders approved the 2021 Equity Incentive Plan (the "2021 Plan"). The 2018 Equity Incentive Plan was suspended and replaced by the 2021 Plan and, following January 19, 2022, no new grants are to be awarded under the 2018 Equity Incentive Plan. Existing grants under the 2018 Equity Incentive Plan will not be impacted by the adoption of the 2021 Plan. Any of the Company's employees, directors, consultants, and other service providers, and those of the Company's affiliates, are eligible to participate in the 2021 Plan. In accordance with applicable tax rules, only employees (and the employees of parent or subsidiary corporations) are eligible to be granted incentive stock options. The 2021 Plan authorizes stock options (both incentive stock options or non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. On January 19, 2022, the Company filed a Registration Statement on Form S-8 registering 1,919,025 shares of Class B Common common Stock stock reserved for issuance under the 2021 Plan. On November 28, 2022, the Company's Board of Directors approved an amendment to the 2021 Plan that, among other things, increases the number of shares of the Company's Class B Common common Stock stock available for the grant of awards thereunder by an additional 696,770, which the stockholders approved on January 23, 2023. The maximum number of shares of Class B common stock that may be issued under the 2021 Plan is 2,615,795 shares. As of July 31, 2023-2024, there were 953-171, 516-986 shares still available for issuance under the 2021 Plan. F-45 On February 15 July 6, 2022, pursuant to the Company filed a Registration Statement on Form S-3 (as amended on March 2, 2022) registering the resale by institutional investors (the "Institutional Investors") of the shares purchased by them - the 19 SPA dated. The Registration Statement was declared effective on March 7, 2022. On June 22, 2022, the Company entered into a Stock Purchase Agreement (the "19 SPA") with I9 Plus - On July 6, 2022 LLC, pursuant to an entity affiliated with members of the 19 SPA family of Howard Jonas, the Company sold 3,225,806 shares of the Company's Class B common stock to I9 Plus, LLC at a price per share of \$1.86 and an aggregate sale price of \$6 million presented in common stock sold to related party within the statement of stockholders' equity. The price per share was calculated to be the greater of (1) the volume weighted average price for the Class B common stock on the New York Stock Exchange for the five trading days ending on June 21, 2022 (which were the five trading days beginning with the first full trading day following the date that the transaction was approved by the Board of Directors of the Company, and its Corporate Governance Committee which consists solely of independent members of the Board) and (2) the closing price of the Class B common stock on June 21, 2022 (the trading day immediately preceding the date of the 19 SPA to ensure that the sale price was not below the Minimum Price under NYSE Rule 312-03(b)). The shares were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. F-33 Employment Agreement On June 13, 2022, the Company entered into an employment agreement with Howard S. Jonas (who serves as the Chairman of the Board and Executive Chairman of the Company) (the "Employment Agreement"), which provides, among other things: (i) a term of five years (subject to extension unless either party elects not to renew); (ii) an annual base salary of \$260,000, of which \$250,000 is payable through the issuance of restricted shares of the Company's Class B common stock ("Class B Stock") with the value of the shares based upon the volume weighted closing price of the Class B Stock on the NYSE on the thirty days ending with the NYSE trading day immediately preceding the issuance to be issued within thirty days of the date of the Employment Agreement (the "Start Date") and each annual anniversary, and such shares vesting, contingent on Mr. Jonas' remaining in continuous service to the Company, in substantially equal amounts on the three, six, nine and twelve month anniversaries of the Start Date or annual anniversary; and (iii) a grant of restricted shares of Class B common stock with a value of \$600,000, issuable within 30 days with the value of the shares based upon the volume weighted closing price of the Class B common Stock on the NYSE on the thirty-30 days ending with the NYSE trading day immediately preceding the issuance and such shares, and vesting, contingent on Mr. Jonas' remaining in continuous service to the Company, in substantially equal amounts on the first and second annual anniversaries of the Start Date. On June 19, 2024, the Employment Agreement was amended to provide an annual base salary of \$294,000, of which \$250,000 is payable through the issuance of Class B common stock in accordance with the terms defined above. Stock Options A summary of stock option activity for the Company is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2022 1, 2021- 021 683- 414 277 \$ 12.11 4. 47 13-3-05 \$ 26,982-Granted 518-175 304-20-000 2. 54-08 9. 51 - Expired (589, 25-205) - - - - Cancelled / Forfeited (480-218 441-663) - - - - Outstanding at July 31, 2022 2023 1-388, 409 \$ 14 021, 277 12. 11 4 51 8. 47-71 \$ - Granted 175-250, 000 2-1 08-84 9. 50 51 - Expired (589-205) - - - - Cancelled / Forfeited (218, 663) - - - - Outstanding at July 31, 2023 2024 388-638, 409 \$ 14 9. 51-55 8. 74-39 \$ - Exercisable at July 31, 2023 2024 65-114, 456-602 \$ 20, 98 8-13, 13 7. 61 \$ - The weighted average grant date fair value per unit for the options granted during the years ended July 31, 2024 and 2023, was \$1.34 and \$1.58, respectively. At July 31, 2023-2024, there is were unrecognized compensation costs related to non-vested stock options of \$1.3 million, which are expected to be recognized over the next 3-2, 2 years from July 31, 2024. F-46 The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the years ended July 31, 2024 and 2023, respectively: For the Year Ended July 31, 2024 2023 2022 Risk-free interest rate 3.60 98 % -3.66 0-0.67 % -1.7 % Expected term (in years) 6. 25 11-6-04 -6. 11 Expected volatility 88 % 95 -00 % 75 % -93 % Expected dividend yield - % - % The options granted had a \$1.58 and \$3.29 weighted average grant date fair value during the years ended July 31, 2023 and 2022, respectively. F-34 Rafael Medical Devices - Ine-Stock Options The Rafael Medical Devices - Ine-2022 Equity Incentive Plan (the "RMD 2022 Plan") was created and adopted by the Company in May 2022. The RMD 2022 Plan allows for the issuance of up to 10,000 shares of Class B common stock which may be awarded in the form of incentive stock options or restricted shares. In connection with the conversion of Rafael Medical Devices from a Delaware corporation to a Delaware limited liability company, Rafael Medical Devices adopted the Rafael Medical Devices, LLC 2023 Equity Incentive Plan (the "RMD 2023 Plan") in August 2023. The RMD 2023 Plan allows for issuance of up to 46,125 Class A Units (the "Units"). There are 4 were 2, 734 shares 247 Units available for issuance under the RMD 2022-2023 Plan as of July 31, 2023-2024. The fair value of Rafael Medical Devices, LLC common records compensation expense for stock-based awards based upon an assessment of the grant date fair value for options using the Black-Scholes model. The expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the

lack of company specific historical and implied volatility data, the estimated estimate for financial reporting purposes of expected volatility is primarily based on the historical volatility of a valuation group of \$4 similar companies that are publicly traded. For these analyses, characteristics from comparable companies are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The risk-free interest rate is determined by reference to the U.S. Treasury Constant Maturity Treasury rates with remaining maturities similar to the expected term of the options. Expected dividend yield is zero as of January 31, Rafael Medical Devices, 2022 LLC has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. To determine the fair value of Units granted under the common stock, the Company first determined an enterprise value using accepted valuation approaches; adjusted these valuation approaches with relevant discounts and then allocated RMD 2023 Plan during the year ended July 31, 2024. Risk-free interest equity value to the common stock and common stock equivalents on a fully diluted basis. The enterprise value was estimated using the generally accepted income approach. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment. 4.24-4.54 % Expected term (in years) 5 a similar company in a similar industry or having a similar history of revenue growth. The Company then subtracted the net non-6 operating assets and applied a discount for lack of marketability to determine equity fair value. 25 Expected volatility 113 % Expected dividend yield — % A summary of stock option activity for Rafael Medical Devices, LLC Inc. is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2021 — \$ — Granted 5,266 \$ 3.82 9.76 Outstanding at July 31, 2022 5,266 \$ 3.82 9.76 \$ — Granted — — Outstanding at July 31, 2023 5,266 \$ 3.82 8.76 \$ — Granted 43,878 10.00 9.01 — Cancelled / Forfeited (5,266) 3.82 — — Outstanding at July 31, 2024 43,878 \$ 10.00 9.01 \$ — Exercisable at July 31, 2023-2024 2-11, 633-886 \$ 3-10, 82-800 9.76-01 \$ — F-47 The weighted average grant date fair value per unit for the RMD option grants during the year ended July 31, 2024 was \$ 8.50. At July 31, 2023-2024 there are total unrecognized compensation costs related to non-vested stock option awards granted was \$ 193 thousand, which the Company expects to recognize over a weighted average period of approximately 3.0 years. Cornerstone Stock Options Cornerstone has outstanding stock options and non-qualified options to purchase Cornerstone's common stock which were granted under Cornerstone's 2009 and 2018 Stock Incentive Plans (the "Plans"), as well as additional options issued during a prior capital raise. At July 31, 2024, there were 1,004,341 options outstanding granted under the Plans that are vested with a weighted average exercise price of \$ 5 thousand, which 24.17 per are share expected and a weighted average remaining contractual term of 4.4 years. The fair value of outstanding options granted under the Plans assumed during the Cornerstone Acquisition were determined to be recognized over de minimis. In connection with Cornerstone's 2003 common stock offerings, Cornerstone entered into an option agreement with an individual in connection with identifying investors. The option agreement grants the right to purchase an option (a "Purchase Option") to purchase 472,000 Class A Options ("Class A Options"), which allows the purchase of 0.25 shares of common stock for each Class A Option at \$ 11.00 per share. In order to secure this Class A Option, a Purchase Option must initially be purchased for \$ .005 per potential share of Class A options. Upon exercise of each Class A Option, a right is granted to one Class B Option ("Class B Options"), which allow the purchase of 0.25 shares of common stock for each Class B Option at \$ 12.50 per share. The expiration date of the Class A Options is the later of October 29, 2005 or six months from the date the Company's shares become publicly traded. The Class B Options expire 180 days from the exercise of the Class A Options. In 2003, 625,000 options (the "Cornerstone Common Options") were granted with an exercise price of \$ 11.00 per share to a 2003 investor. These Cornerstone Common Options are set to expire 180 days following the closing of an IPO, or from the date Cornerstone's shares become publicly traded. The fair value of the Class A Options, Class B Options, and Cornerstone Common Options assumed during the Cornerstone Acquisition were determined to be de minimis. As part of the Cornerstone Restructuring, as detailed in Note 3, Cornerstone increased the available reserve of Cornerstone Common Stock for grant to employees, consultants and the other next 1.44 years service providers to approximately 10 % of Cornerstone's capital stock following the Cornerstone Restructuring, the Mandatory Common Conversion and the Reverse Stock Split (the "Reserve Increase") but prior to the issuance of the RPF 6 % Top Up Shares or any shares to the holders of the Remaining Series C Convertible Notes after the Closing. Restricted Stock The fair value of restricted shares of the Company's Class B common stock is determined based on the closing price of the Company's Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service. In January 2022, the Company granted 33,360 restricted shares of Class B common stock to non-employee directors, 18,336 of which were granted under the 2018 Equity Incentive Plan, and 15,024 of which were granted under the 2021 Plan. The restricted shares vested immediately on the grant date. The share-based compensation cost was approximately \$ 151 thousand, which was included in general and administrative expense in the consolidated statement of operations and comprehensive loss. On February 1, 2022, the Company issued 986,835 shares of Class B restricted stock to two members of the executive team officers. Approximately 24 % of the restricted shares vest in December 2022, with the remaining shares vesting ratably each quarter through December 2025. On June 14, 2022, the Company issued 452,130 shares of Class B restricted stock to Howard S. Jonas. In January 2023, the Company issued 120,019 shares of Class B restricted stock to certain members of its Board of Directors, and 100,000 shares of Class B restricted stock to its new Chief Financial Officer. During January 2023, 296,759 shares of Class B restricted stock were cancelled or forfeited due to (i) the cancellation of 285,036 shares of restricted stock in connection with the departure of the Company's former Chief Financial Officer and (ii) the remaining shares forfeited upon the termination of certain employees of the Company. F-35-48 In connection with Patrick Fabbio's January 27, 2023 departure as the Company's Chief Financial Officer, the Company and Mr. Fabbio entered into a Separation and General Release Agreement (the "Separation Agreement"), which provides, among other things, that the Company shall pay Mr. Fabbio severance in the amount of \$ 307,913, which is included in selling, general and administrative expense on the consolidated statement of operations and comprehensive loss for the year ended July 31, 2023. In connection with the termination of Mr. Fabbio's position as Chief Financial Officer of the Company, there was a material forfeiture of his Class B restricted shares and stock options resulting in a reversal of approximately \$ 915 thousand in stock-based compensation expense for the year ended July 31, 2023 that was previously recorded to selling, general and administrative expense. On August 28, 2023, the Company issued 111,408 shares of Class B restricted stock to Howard S. Jonas. On October 25, 2023, the Company issued 135,000 shares of Class B restricted stock to employees of the Company. On January 5, 2024, the Company issued 101,402 shares of Class B restricted stock to certain members of its Board of Directors. On June 13, 2024, the Company issued 159,016 shares of Class B restricted stock to Howard S. Jonas. A summary of the status of the Company's grants of restricted shares of Class B common stock is presented below: Number of Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at July 31, 2021-2022 1,007-507, 975-373 \$ 46-4, 77-22 Granted 220,019 \$ 5.33-3.11 4-24 99 Vested (90 745, 608)-(16,86-867) 3.37 Cancelled / Forfeited (943-296, 305-759) (48 5, 50-10) Outstanding at July 31, 2022-2023 1-684, 766-507-373 \$ 4-22-04 Granted 220-506, 019 826 1.99-75 Vested (745-583, 867-052) 3.15-37 Cancelled / Forfeited (296,759)-(5-10) Non-vested shares at July 31, 2023-2024 684-608, 766-540 \$ 4-2, 04-99 At July 31, 2023-2024, there was \$ 4-0, 8 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next four years. On November 21, 2021, Ameet Malik resigned as Chief Executive Officer of the Company, effective January 31, 2022. In connection with his resignation, there was a material forfeiture of the former CEO's Class B restricted shares, resulting in a reversal of approximately \$ 19.0 million in stock-based compensation expense that was previously recorded to selling, general and administrative expense. Additionally, pursuant to the terms of his employment agreement, the Company paid \$ 5.0 million relating to his severance payout, which is included in selling, general and administrative expense on the consolidated statement of operations and comprehensive loss for the year ended July 31, 2022. A summary of the stock-based compensation expense for the Company's equity incentive plans is presented below (in thousands): For the Year Ended July 31, 2024 2023 2022 General and administrative \$ 2,000 \$ 3,044 \$ 17,270 Research and development 296 194 791 Forfeiture of RSUs within general and administrative (931) (18,978) Forfeiture of RSUs within research and development (119) — Net stock-based compensation expense \$ 2,296 \$ 2,188 \$ (917) On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the "SPA") for the sale of 567,437 shares of the Company's Class B common stock at a price per share of \$ 22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020, the trading day immediately preceding the date of the SPA) for an aggregate purchase price of \$ 13 million. F-36-49 Approximately \$ 8.2 million of the proceeds received pursuant to the SPA were used by the Company to exercise an additional portion of the a warrant warrant in order to maintain the Company's relative position in Cornerstone Pharmaceuticals in light of issuances of Cornerstone Pharmaceuticals equity securities to third-party shareholders of Cornerstone Pharmaceuticals, due to warrant exercises by these shareholders. The Company is using the remaining proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas (the Registrant's Chairman of the Board and former Chief Executive Officer), serves, each purchased 218,245 shares of Class B common stock for consideration of \$ 5 million each. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. Equity-classified Warrants In connection with the SPA entered into on December 7, 2020, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Company issued warrants to purchase 113,487 shares of Class B common stock to the purchasers. The warrants are exercisable at a per share exercise price of \$ 22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022. The Company determined that these warrants are equity-classified. During fiscal 2021, IDT and Genie each exercised 43,649 warrants, resulting in a total of 87,298 shares of Class B common stock issued for proceeds of approximately \$ 2 million. On June 6, 2022, the Company's outstanding warrants to purchase 26,189 shares of common stock at an exercise price of \$ 22.91 per share expired. As There were no exercises of warrants during the year ended July 31, 2022-2024. At July 31, 2022, the Company had no outstanding warrants. NOTE 21-26 LEASES The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025. Lease income included on the consolidated statements of operations and comprehensive loss was \$ 282 thousand 0.3 million and \$ 279 thousand 0.3 million for the years ended July 31, 2024 and 2023 and 2022, respectively. During the years ended July 31, 2024 and 2023 and 2022, no real estate property taxes were included in rental income. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of July 31, 2023-2024, under a non-cancellable operating leases lease which expire on various dates through 2025 are as follows: Year ending July 31, Related Parties Other Total (in thousands) 2024-2025 \$ 77-78 \$ 77-78 Total Minimum Future Rental Income \$ 155-78 \$ — \$ 155-78 A related party has the right to terminate the Israeli lease upon four months' notice. NOTE 22-27 SUBSEQUENT EVENTS On August 21, 2024, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company; Tandem Therapeutics, Inc., a Nevada corporation and a wholly-owned subsidiary of the Company ("First Merger Sub"); Tandem Therapeutics, LLC, a Nevada limited liability company and a wholly-owned subsidiary of the Company ("Second Merger Sub" and together with First Merger Sub, the "Merger Subs");

and Cyclo. The Merger Agreement and the transactions contemplated thereby were unanimously approved by the Company and Cyclo's boards of directors (the "Boards"). The Merger Agreement also requires approval of Cyclo's stockholders (the "Cyclo Shareholder Vote") and the issuance of the Company's Class B Common Stock. On August 28, 2023, \$ 0.01 par value per share ("Rafael Class B Common Stock") in the Business Combination (as defined below) requires approval by the Company granted 111,408 restricted's stockholders (the "Rafael Shareholder Vote"). Upon such approvals and satisfaction or waiver of all other conditions set forth in the Merger Agreement and the effectiveness of a registration statement on Form S-4 to register the shares of Rafael Class B Common Stock of Rafael to be issued in the Business Combination, as defined below, the Business Combination will be consummated (the date upon which is referred to as the "Closing Date"). F-50

The Business Combination The Merger Agreement provides for, among other things, that at the First Effective Time (the "First Effective Time"), First Merger Sub will merge with and into Cyclo (the "First Merger"). First Merger Sub will cease to exist, and Cyclo will become a wholly-owned subsidiary of the Company. Immediately following the First Merger, Cyclo will merge with and into Second Merger Sub, with Second Merger Sub being the Surviving Entity of the subsequent merger (the "Second Merger") and together with the First Merger, the "Business Combination"). If the Business Combination is consummated, Rafael would become the primary beneficiary of Cyclo, a VIE that constitutes a business. In accordance with ASC 810, the initial consolidation of a VIE that is a business shall be accounted for as a business combination in accordance with the provisions in Topic 805. Consideration to Cyclo Equity Holders in the Business Combination At the First Effective Time: (i) any shares of Cyclo Capital Stock then held by Cyclo or in Cyclo's treasury immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; (ii) any shares of Cyclo Capital Stock then held by Rafael immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; (iii) except as provided in (i) and (ii) above, each share of Cyclo Common Stock issued and outstanding immediately prior to the First Effective Time shall cease to be an existing and issued share of Cyclo Common Stock, and shall be converted, by virtue of the First Merger and without any action on the part of the holders thereof, into the right to receive a number of validly issued, fully paid and nonassessable shares of Rafael Common Stock equal to the Exchange Ratio (as defined below). The shares of Rafael Common Stock to be issued upon conversion of the Cyclo Common Stock are referred to as the "Merger Consideration". The "Exchange Ratio" means the quotient (rounded down to four decimal places) obtained by dividing (x) \$ 0.95 by (y) the sum of the (A) Total Net Cash Amount, plus (B) Total Loan Amount, divided by the total number of shares of Rafael Capital Stock outstanding at the First Effective Time, including any shares of Rafael Capital Stock issuable upon exercise or conversion of outstanding securities of Rafael with exercise or conversion prices that are no greater than 150 % of the then market price for the Rafael Class B common stock. The "Total Net Cash Amount" is defined in the Merger Agreement as (a) the sum of the total of (i) cash, cash equivalents and marketable securities of Rafael as of the Closing Date; and (ii) Included Assets (as defined below), minus (b) the amount of Rafael's current liabilities (on an unconsolidated basis), including, without limitation, accounts payable and accrued expenses, as of the end of the last month immediately prior to the Closing Date, updated for material changes to such amounts following such date until the Closing Date, and determined in a manner consistent with the manner such liabilities were historically reflected in Rafael's financial statements. The "Included Assets" is defined in the Merger Agreement as the appraised value of the real estate located at 5 Shlomo Levy Street, Har Hotzvim Jerusalem and the value of the Globis Capital Partners, L.P. holdings as of the latest calendar quarter ending prior to the First Effective Time. Total Loan Amount shall mean the outstanding principal amount of all amounts loaned by Rafael to Cyclo between June 11, 2024 and the Closing, including, without limitation, the Cyclo Convertible Notes, Cyclo Convertible Note III (as defined below) and Cyclo Convertible Note IV (as defined below), plus the accrued and unpaid interest thereon as of the date of the Closing. The "Parent Capital Stock" (also referred to as "Rafael Capital Stock") is defined in the Merger Agreement as the Rafael Class B common stock, \$ 0.01 par value per share, the Rafael Class A common stock, par value \$ 0.01 per share, of Rafael and the Rafael preferred stock, \$ 0.01 par value per share. All compensatory options to purchase Cyclo common stock shall automatically convert into options to acquire, on substantially similar terms and conditions, an adjusted number of shares of Rafael Class B Common Stock, based upon the Exchange Ratio (rounded down to the nearest whole share), at an adjusted exercise price per share, based upon the Exchange Ratio (rounded up to the nearest whole cent). Unless otherwise provided for in outstanding warrant agreements, all outstanding warrants to purchase Cyclo common stock (other than those held by Rafael which will be cancelled) will automatically be converted into warrants to purchase an adjusted number of shares of Rafael Class B Common Stock, based upon the Exchange Ratio, at an adjusted exercise price per share, based upon the Exchange Ratio. Certain Cyclo warrants have the right to elect to receive cash payment in lieu of receiving warrants to purchase Rafael Class B Common Stock. F-51 For U.S. federal income tax purposes, the Business Combination is intended to qualify as a "reorganization" within the meaning of Section 368 (a) (1) of the Internal Revenue Code of 1986, as amended. No fractional shares of Rafael Class B Common Stock will be issued in connection with the Business Combination, and holders of Cyclo common stock who would otherwise be entitled to receive a fraction of a share of Rafael Class B Common Stock, shall, in lieu of any such fractional shares to which they would otherwise be entitled, receive the number of shares of Rafael Class B Common Stock to which such holder of Cyclo common stock would be entitled to receive aggregated and rounded up to the nearest whole share. Cyclo Securities held by the Company Cyclo's common stock and warrants held by the Company will be cancelled and retired and shall cease to exist upon consummation of the Business Combination. The Cyclo Convertible Notes, Cyclo Convertible Note III (as defined below), Cyclo Convertible Note IV (as defined below) and Cyclo Convertible Note V (as defined below) will be forgiven at the closing of the Business Combination. Representations and Warranties: Covenants The Merger Agreement contains representations, warranties and covenants of each of the parties thereto that are customary for transactions of this type. Under the Merger Agreement, (a) Cyclo has agreed, among other things, (i) to conduct its business in the ordinary course, and not to take certain actions without the consent of the Company, (ii) not to solicit or engage in discussions regarding any alternative acquisition proposal or other transaction similar to the Business Combination, (iii) seek approval of its stockholders to the Business Combination, and (iv) use reasonable best efforts to cause all conditions to the Business Combination to be satisfied and to consummate the Business Combination, and (b) the Company has agreed (i) not to take certain actions without the consent of Cyclo, (ii) use reasonable efforts to cause the shares of Rafael Class B Common Stock to be issued in the Business Combination to be listed on the New York Stock Exchange, (iii) create, register with the Securities and Exchange Commission ("SEC") and list on the New York Stock Exchange a class of warrants to be issued to certain holders of publicly-traded warrants to purchase Cyclo common stock, (iv) increase the number of shares available for grant under its equity plan to cover options to be issued to holders of Cyclo Options, (v) seek approval of its stockholders to the issuance of the shares of the Rafael Class B Common Stock in the Business Combination, and (vi) use reasonable best efforts to cause all conditions to the Business Combination to be satisfied and to consummate the Business Combination. The Company has also agreed, so long as Cyclo is not in active discussions regarding an acquisition proposal, to fund Cyclo through the earlier of the consummation of the Business Combination or termination of the Merger Agreement in such amounts as may be necessary for Cyclo to operate its business and pay its debts and obligations as they become due, provided that Cyclo is being operated in a manner consistent with the terms of the Merger Agreement and the financial forecast previously shared with the Company (the "Pre-Closing Funding"). Following the closing, the Company will fund Cyclo's TransportNPC™ clinical trial to its 48-week interim analysis up to a maximum amount, when added to the Pre-Closing Funding, of \$ 25 million. The Merger Agreement places certain restrictions on the operation of Rafael's business prior to the closing of the Business Combination, and such restrictions, the waiver of which is subject to the consent of Cyclo, may prevent Rafael from making certain acquisitions, taking certain other specified actions or otherwise pursuing business opportunities during the pendency of the Business Combination that Rafael would have made, taken or pursued if these restrictions were not in place. In addition, in connection with the closing of the Business Combination, the Company has agreed to appoint Markus W. Sieger, a current independent member of Cyclo's board of directors, to the Company's Board. Lock-Up Agreements The Merger Agreement provides that Cyclo's directors and their affiliates that will receive shares of Rafael Class B Common Stock pursuant to the Merger Agreement or upon exercise of Rafael options received upon conversion of Cyclo options in the Business Combination have each agreed to enter into a lock-up agreement which contains certain restrictions on transfer of such shares of Rafael Class B Common Stock for a period of the earlier of (a) six (6) months following closing of the Business Combination or (b) the date on which Rafael completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of Rafael's stockholders having the right to exchange their Rafael Class B Common Stock for cash, securities or other property. F-52 In connection with the entry into the Merger Agreement, Rafael and certain other holders of Cyclo common stock entered into voting agreements pursuant to which those holders have agreed to vote in favor of the Merger Agreement and the consummation of the Business Combination at any meeting of Cyclo's stockholders and take other actions in furtherance of the consummation of the Business Combination until the earlier of (i) the First Effective Time and (ii) the termination of the Merger Agreement (the "Voting Agreement"). Support Agreement In connection with the entry into the Merger Agreement, Howard Jonas entered into a support agreement (the "Support Agreement") with Rafael and Cyclo, under which Mr. Jonas has agreed to vote all shares of Rafael capital stock over which he the Chairman of exercises voting control to approve the Board issuance of the Rafael Class B Common Stock to the stockholders of Cyclo as contemplated by the Merger Agreement. The Merger Agreement may be terminated under certain customary and Executive Chairman and former Chief Executive Officer limited circumstances prior to closing of the Business Combination, including, but not limited to, (i) by the mutual written consent of the Company and Cyclo Member of the Board of Cornerstone Pharmaceuticals, (ii) by the Company, subject to certain exceptions, if any of the representations or warranties of Cyclo are not true and correct or if Cyclo fails to perform any of its covenants or agreements under the Merger Agreement (iii) by Cyclo, subject to certain exceptions, if any of the representations or warranties made by the Company are not true and correct or if the Company fails to perform any of its covenants or agreements under the Merger Agreement; (iv) by either the Company or Cyclo, if the Business Combination has not been consummated on or prior to November 30, 2024; provided, however, that, in the event that the SEC has not declared effective under the Securities Act of 1933, as amended (the "Securities Act") the Form S-4 by the date which is 45 calendar days prior to the End Date of November 30, 2024 pursuant to his employment the Merger agreement Agreement, then the End Date shall automatically be extended to December 31, 2024 (the "End Date"), unless the breach of any covenants or obligations under the Merger Agreement by the party seeking to terminate was the principal cause of the failure to consummate the transactions contemplated by the Merger Agreement; (v) by either the Company or Cyclo, if any governmental entity has issued an order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by the Merger Agreement and such order or other action has become final and non-appealable; (vi) by either the Company or Cyclo, if the required approvals by the stockholders of the Company and Cyclo have not been obtained; and (vii) by the Company, if Cyclo's Board (or a committee thereof) makes a Cyclo

Adverse Change Recommendation, as defined in the Merger Agreement. A "Cyclo Adverse Change Recommendation" means during the pre-closing Period, neither Cyclo's board nor any committee thereof shall (i) (A) withdraw, withhold, amend or qualify or modify, in each case, in a manner adverse to Rafael Medical Devices, LLC outside or publicly propose to withdraw, withhold, amend or qualify or modify, in each case, in a manner adverse to Rafael, Cyclo's board recommendation, (B) fail to include Cyclo's board recommendation in the joint proxy statement / prospectus, (C) fail to publicly reaffirm Cyclo's board recommendation within ten (10) business days after Rafael so requests in writing (it being understood that the Rafael shall only be entitled to make up to two (2) such reaffirmation requests), (D) approve, recommend or declare advisable, or publicly propose to approve, recommend or declare advisable, any acquisition proposal other than from Rafael and Rafael's affiliates or (E) if any tender offer or exchange offer is commenced for equity securities of Cyclo, fail to recommend against such tender offer or exchange offer by the earlier of (1) the tenth (10th) business day after the commencement of such tender offer or exchange offer and (2) the third (3rd) business day prior to Cyclo's stockholders meeting other than a "stop, look and listen" communication pursuant to Rule 14d-9 (f) under the Exchange Act. If the Business Combination is validly terminated in accordance with the Merger Agreement, then either of Rafael or Cyclo shall reimburse the terminating party investment. During their reasonable documented out-of-pocket expenses, including all fees and expenses of counsel, financial advisors and accountants, actually incurred in connection with the Merger Agreement, in an amount not to exceed \$ 250,000 in cash, or if Rafael terminates the Business Combination in the event of a Cyclo Adverse Change Recommendation, Cyclo will promptly pay to Rafael an amount equal to \$ 400,000 in cash (the "Company Termination Fee"). The Business Combination is expected to close in the fourth calendar quarter of the year ended July 31, 2023-2024, following the receipt Company received \$ 825 thousand as a deposit from outside third party investors for the purchase of membership units of the required approvals by Rafael Medical Devices, LLC and Cyclo stockholders and the fulfillment of other customary closing conditions. F- 53 Second Amended and Restated Note Purchase Agreement On August 1-21, 2023-2024, the Company received Rafael entered into a Second Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of \$ 100 thousand and closed 3 million to Rafael for \$ 3 million (the "Cyclo Convertible Note III") in cash. The Cyclo Convertible Note III matures on the sale December 21, 2024 and bears interest at a rate of units 5 % per annum, payable upon maturity. The principal amount of the Cyclo Convertible Note III is convertible into shares of Cyclo's common stock at the option of Rafael (provided, however, that Rafael may not elect to convert the convertible note (or prior convertible notes) issued by Cyclo to Rafael in exchange connection with previous loans if, following such conversion, Rafael will beneficially own more than 49.9 % of Cyclo's common stock); and automatically on certain other events. On September 9, 2024, Rafael entered into a Third Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of \$ 3 million (925 thousand, whereby the Company "Cyclo Convertible Note IV") to Rafael for \$ 3 million in cash. The Cyclo Convertible Note IV matures on December 21, 2024 and bears interest at a rate of 5 % per annum, payable upon maturity. The principal amount of the Cyclo Convertible Note IV is convertible into shares of Cyclo's common stock at the option of Rafael (provided, however, that Rafael may not elect to convert the convertible note (or prior convertible notes) issued by Cyclo to Rafael in connection with previous loans if, following such conversion, Rafael will now hold 53 beneficially own more than 49.9 % (of Cyclo's common stock); and automatically on certain other events. Fourth Amended and Restated Note Purchase Agreement On October 8, 2024, Rafael entered into a fully diluted basis ownership interests Fourth Amended and Restated Note Purchase Agreement with Cyclo, pursuant to which Cyclo issued and sold a convertible promissory note in the principal amount of \$ 3 million (the "Cyclo Convertible Note V") to Rafael Medical Devices, LLC for \$ 3 million in cash. As of July 31 The Cyclo Convertible Note V matures on December 21, 2023-2024 and bears interest at a rate of 5 % per annum, payable upon maturity. The principal amount of the Company recorded Cyclo Convertible Note V is convertible into shares of Cyclo Common Stock at the funds received option of Rafael (provided, however, that Rafael may not elect to convert the convertible note (or prior convertible notes issued by Cyclo to Rafael in connection with - with prepaid expenses - previous loans if, following such conversion, Rafael will beneficially own more than 49.9 % of Cyclo Common Stock); and automatically on certain other current assets and events. Also on October 8, 2024, other - the current liabilities within maturity dates of the consolidated balance sheets Cyclo Convertible Note I and the Cyclo Convertible Note II were amended to be December 21, 2024. F- 542021false FY2023- 370-36-6-22-0-09-0-28-0-08 - 01 6-3123263211In November 2022 2024, the Company resolved to curtail its early - 07 stage development efforts, including pre- 312024- 01- 31us- gaap: CommonClassAMember2024- clinical research at Barer The decision..... in LipoMedix Pharmaceuticals Ltd. an additional 11 % from 84 % to 95 %- 23263211 0- 36-6-22-0-09-0-28-0- FairValueInputsLevel3Member us- 05us- gaap: WarrantMember2023- CommonClassBMember2024- 11- 052024- 07- 312023 - 07- 31us- gaap: WarrantMember2023- RelatedPartyMember2024 - 07- 31us- gaap: RelatedPartyMember2023 FairValueInputsLevelHMember us- gaap- 07- 31rf: HedgeFundsMember2023- CycloMember2024- 07- 31rf: CycloMember2023 - 07- 31us- gaap: FairValueInputsLevel2Member us- gaap: HedgeFundsMember2023- HedgeFundsMember2024 - 07- 31us- gaap: FairValueInputsLevel3Member us- gaap: HedgeFundsMember2023- 07- 31us- gaap: HedgeFundsMember2023- 07- 31us- 31rf: DayThreeLabsIncMember2024 - gaap- 07- 31rf: DayThreeLabsIncMember2023 FairValueInputsLevelHMember us- gaap- 07- 31rf: ConvertibleDebtSecuritiesMember2023- OtherPharmaceuticalsMember2024- 07- 31rf: OtherPharmaceuticalsMember2023 - 07- 31us- gaap: CommonClassAMember2024 FairValueInputsLevel2Member us- gaap: ConvertibleDebtSecuritiesMember2023- 07- 31us- gaap: CommonClassAMember2023 FairValueInputsLevel3Member us- gaap: ConvertibleDebtSecuritiesMember2023- 07- 31us- gaap: ConvertibleDebtSecuritiesMember2023- CommonClassBMember2024 - 07- 31us- gaap: FairValueInputsLevel1Member2023- CommonClassBMember2023 - 07- 31us 31rf: InfusionTechnologyMember2023 - 08 6- 31false FY2022 - 01 2024- 07- 31rf: InfusionTechnologyMember2022 - 08- 01 2023- 07- 312023- 31rf: RentalThirdPartyMember2023- 08- 01 2024 - 31us- gaap: CommonClassAMember2023- ..... 07- 31us- gaap: CommonClassBMember2022 - 07- 31rf: RentalThirdPartyMember2022- 08- 01 2023- 07- 31rf: RentalThirdPartyMember2021 RentalRelatedPartyMember2023 - 08 07- 31us- gaap: MachineryAndEquipmentMember2023- CommonClassAMember2023- 10- 27us- gaap: CommonClassBMember2023- 10- 272023 - 07- 312022 31srt: OtherPropertyMember2024 - 07- 31srt 31rf: OtherPropertyMember2023- OtherPharmaceuticalsMember2023- 07- 31rf: OtherPharmaceuticalsMember2022 - 07- 31us- gaap: HealthCareMember2023- HedgeFundsMember2023 - 07- 31us- gaap: RealEstateMember2023- HedgeFundsMember2022 - 07- 31rf: InfusionTechnologyMember2023- INVESTMENTINDAYTHREELABSINCMember2023- 07- 31rf: INVESTMENTINDAYTHREELABSINCMember2022- 07- 31rf: InvestmentInCycloTherapeuticsIncMember2023- 07- 31rf: InvestmentInCycloTherapeuticsIncMember2022 - 07- 31us- gaap: RelatedPartyMember2023 HealthCareMember2023- 08- 01 2024 - 07- 31us- gaap: RelatedPartyMember2022 RealEstateMember2023- 08- 01 2024- 07- 31rf: InfusionTechnologyMember2023- 08- 01 2024 - 07- 31us- gaap: HealthCareMember2024- CommonClassAMember2023 - 07- 31us- gaap: CommonClassAMember2022 RealEstateMember2024- 07- 31rf: InfusionTechnologyMember2024 - 07- 31us- gaap: IntellectualPropertyMember2024 CommonClassBMember2023 - 07- 31us- gaap: CommonClassBMember2022 NoncompeteAgreementsMember2024- 07- 31rf: SharesIssuableUponExerciseOfStockOptionsMember2023 - 01 2022- 02- 012022- 06- 14 2022- 06- 14srt: BoardOfDirectorsChairmanMember2023- 01- 31 2023- 01- 31srt: ChiefFinancialOfficerMember2023- 01- 31 2023- 01- 31srt: ChiefFinancialOfficerMember rfi: EquityIncentivePlanMember2023- 01- 31 2023- 01- 31us 312023- 01- 27 2023- 01- 27rf: JonasOfferingMember2023- 08- 28 2023- 08- 282023- 10- 25 2023- 10- 25us - gaap: CommonStockMember2024 RestrictedStockMember2023- 07- 31us- gaap: RestrictedStockMember2022- 08- 01 2023 - 05 07- 31srt: ChiefExecutiveOfficerMember2021- 11- 21 2021- 2024 - 11- 21srt: ChiefExecutiveOfficerMember2021- 08- 01 2022 - 05rf 07- 31rf: SecuritiesPurchaseAgreementMember StockOptionsMember us- gaap: CommonClassBMember2020- CommonClassBMember2024 - 12- 06 - 07- 13 2020- 2024 - 12- 06 - 07rf- 13rf: SecuritiesPurchaseAgreementMember StockOptionsMember us- gaap: CommonClassBMember2020- CommonClassBMember2024 - 07- 31rf: RentalRelatedPartyMember2022- 08- 01 2022- 07- 31rf: SecuritiesPurchaseAgreementMember us- gaap: CommonClassBMember2020- 12- 07 2020- 12- 07rf: SecuritiesPurchaseAgreementMember us- gaap: CommonClassBMember2020- 12- 07rf: SecuritiesPurchaseAgreementMember us- gaap: CommonClassBMember2020- 12- 04 2020- 12- 04rf: SecuritiesPurchaseAgreementMember2022 SecuritiesPurchaseAgreementMember2023 - 08- 01 2023- 2024 - 07- 31rf: SecuritiesPurchaseAgreementMember us- gaap: CommonClassBMember2022 CommonClassBMember2023 - 08- 01 2023- 2024 - 07- 31us- gaap: WarrantMember2020- 12- 07 2020- 12- 07us- gaap: WarrantMember us- gaap: CommonClassBMember2020- 12- 07us- gaap: WarrantMember WarrantMember2022 rfi- 06- 06us- gaap - IDFCorporationMember2020 WarrantMember2022 - 08- 06 - 01- 06 2021- 2022 - 06- 06rf: RafaelMedicalDevicesLLCMember2022 - 07- 31rf 31us- gaap: WarrantMember RafaelMedicalDevicesLLCMember2022 - 08- 01 2023- 07- 31rf: RentalRelatedPartyMember2021 RafaelMedicalDevicesLLCMember2023- 07- 31rf: RafaelMedicalDevicesLLCMember2023 - 08- 01 2022- 2024 - 07- 31rf: OtherRelatedPartyMember2022 RafaelMedicalDevicesLLCMember2024- 07- 31rf: BlackScholesOptionMember2023- 08- 01 2024- 07- 31rf: BlackScholesOptionMember2022 - 08- 01 2023- 07- 31srt: MinimumMember rfi: RafaelMedicalDevicesStockOptionsMember2023- 08- 01 2024- 07- 31srt: MaximumMember rfi: RafaelMedicalDevicesStockOptionsMember2023- 08- 01 2024- 07- 31rf: OtherRelatedPartyMember2021 RafaelMedicalDevicesStockOptionsMember2023 - 08- 01 2022- 2024 - 07- 312021- 08- 01 2022- 07- 31rf: OtherMember2024 InvestmentInCycloTherapeuticsIncMember2022- 08- 01 2023- 07- 31rf: InvestmentInCycloTherapeuticsIncMember2021- 08- 01 2022- 07- 31us- gaap: HedgeFundsMember2022- 08- 01 2023- 07- 31us- gaap: HedgeFundsMember2021- 08- 01 2022- 07- 31rf: DayThreeLabsIncMember2022- 08- 01 2023- 07- 31rf: DayThreeLabsIncMember2021- 08- 01 2022- 07- 31rf: RPFinancelLCMember2022- 08- 01 2023- 07- 31rf: RPFinancelLCMember2021- 08- 01 2022- 07- 31us- gaap: CommonClassAMember us- gaap: CommonStockMember2022 - 07- 31us- gaap: CommonClassBMember us- gaap: CommonStockMember2022 SubsequentEventMember2024- 08- 21us- gaap: CommonClassBMember rfi: RefaelMember2024 - 07- 31us- gaap: AdditionalPaidInCapitalMember2022 CommonClassAMember rfi: RefaelMember2024 - 07- 31us- gaap: RetainedEarningsUnappropriatedMember2022 PreferredStockMember rfi: RefaelMember2024 - 07- 31us 31rf: CycloConvertibleNoteIIIMember us - gaap: ConvertibleNotesPayableMember us AccumulatedOtherComprehensiveIncomeMember2022 - 07- 31us- gaap: NonecontrollingInterestMember2022- SubsequentEventMember2024 - 07- 08 - 31us 21 2024- 08- 21rf: RefaelMember rfi: CycloConvertibleNoteIIIMember us - gaap: CommonClassAMember- ConvertibleNotesPayableMember us- gaap: CommonStockMember2022 SubsequentEventMember2024 - 08- 01 21 2023- 2024 - 07- 08 - 31us 21rf: CycloConvertibleNoteIIIMember us - gaap: CommonClassBMember SubsequentEventMember2024- 08- 21rf: RefaelMember rfi: CycloConvertibleNoteIIIMember us- gaap: CommonStockMember2022- SubsequentEventMember2024 - 08- 21rf: CycloConvertibleNoteIVMember us 01- 2023- 07- 31us- gaap: AdditionalPaidInCapitalMember2022 ConvertibleNotesPayableMember us- gaap: SubsequentEventMember2024- 09- 09 2024- 09- 09rf: RefaelMember rfi: CycloConvertibleNoteIVMember us- gaap: ConvertibleNotesPayableMember us- gaap: SubsequentEventMember2024- 09- 09 2024- 09- 09rf:

CycloConvertibleNoteIVMember us- gaap: SubsequentEventMember2024- 09- 09rfli: RefaelMember rfli: CycloConvertibleNoteIVMember us- gaap: SubsequentEventMember2024- 09- 09rfli: CycloConvertibleNoteVMember us- gaap: ConvertibleNotesPayableMember us- gaap: SubsequentEventMember2024- 10- 08- 01- 2023- 2024 - 07- 10- 31us08rfli: RefaelMember rfli: CycloConvertibleNoteVMember us : gaap: RetainedEarningsUnappropriatedMember2022

ConvertibleNotesPayableMember us- gaap: SubsequentEventMember2024- 10 - 08 -01-2023-2024 - 07- 10 - 31us08rfli: CycloConvertibleNoteVMember us - gaap: AccumulatedOtherComprehensiveIncomeMember2022 SubsequentEventMember2024 - 08- 10- 01-2023-07- 31us08rfli: RefaelMember rfli: CycloConvertibleNoteVMember us - gaap: SubsequentEventMember2024 NoncontrollingInterestsMember2022- 08- 01-2023-..... PharmsHoldingsMember2023- 07- 31rfli: RafaelPharmaceuticalsMember2021 - 10- 01 2021- 10- 28rfli:..... gaap: SubsequentEventMember2023- 08- 01iso4217 08iso4217 : USD xbrli: sharesiso4217: USDxbrli: sharesxbrli: pure utr: sqfExhibit 4. 2 DESCRIPTION OF THE REGISTRANT' S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital stock consists of (i) 35 million shares of Class A common stock, (ii) 200 million shares of Class B common stock, and (iii) 10 million shares of Preferred Stock. The following description of our classes of authorized stock does not purport to be complete and is subject to and qualified in its entirety by reference to our charter and bylaws, copies of which are filed as exhibits to the Annual Report on Form 10- K to which this Exhibit 4. 2 is a part. Holders of shares of our Class A common stock are entitled to three votes for each share on all matters to be voted on by the stockholders. Holders of our Class A common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors in its discretion from funds legally available therefor. Each share of our Class A common stock may be converted, at any time and at the option of the holder, and automatically converts upon transfers to unaffiliated parties, into one fully paid and non- assessable share of our Class B common stock. As of October 27 November 5, 2023- 2024, there were 787, 163 of our shares of Class A common stock outstanding. Holders of shares of our Class B common stock are entitled to one tenth of one vote for each share on all matters to be voted on by the stockholders. Holders of our Class B common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors in its discretion from funds legally available therefor. As of October 27 November 5, 2023- 2024, there were 23, 749- 886, 472- 987 shares of Class B common stock outstanding. The Board of Directors has the authority to fix the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the stockholders. As of October 27 November 5, 2023- 2024, there were no shares of our preferred stock were outstanding. Anti- Takeover Effects of Our Charter and By- Laws Some provisions of Delaware law and our Certificate of Incorporation and By- Laws could make the following more difficult: • acquisition of us by means of a tender offer; • acquisition of us by means of a proxy contest or otherwise; or • removal of our incumbent officers and directors. These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions also are designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits of increased protection give us the potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us and outweigh the disadvantages of discouraging those proposals because negotiation of them could result in an improvement of their terms. Certificate of Incorporation; By- Laws Our Certificate of Incorporation and By- Laws contain provisions that could make more difficult the acquisition of us by means of a tender offer, a proxy contest or otherwise. These provisions are summarized below. Undesignated Preferred Stock. The authorization of our undesignated preferred stock makes it possible for our Board of Directors to issue our preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes of control of our management. Size of Board and Vacancies. Our Certificate of Incorporation provides that the number of directors on our Board of Directors will be between three and seventeen. Newly created directorships resulting from any increase in our authorized number of directors or any vacancies in our Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause will be filled solely by the vote of our remaining directors in office. Stockholder Meetings. Under our By- Laws, only our (i) Chairman of the Board, (ii) Executive Chairman, (iii) Chief Executive Officer, (iv) President, (v) Corporate Secretary, or (vi) any Assistant Secretary may call special meetings of our stockholders and shall be called by any such officer at the request in writing of a majority of our Board of Directors or at the request in writing of stockholders owning our issued and outstanding capital stock representing not less than a majority of the voting power of all our issued and outstanding capital stock. Exhibit 10. 4 November 16, 2023 Dear Dr. Goldberg; It is our pleasure to offer you a position at Rafael Holdings, Inc. and or its subsidiaries ( " Rafael " or the " Company "). This letter agreement (the " Letter Agreement ") outlines the terms of your employment at the Company as follows: 1. Position and Duties: You will serve as Chief Medical Officer (the " Position "), reporting to the CEO or to such other person as designated by the Company from time to time (in either case, as relevant, your " Supervisor "). In this Position you will oversee all aspects of the medical facets of the Company' s operations and its subsidiaries, affiliates and entities in which the Company holds a significant stake. This is a full- time position for which you agree to devote one hundred percent of your working hours. You may work at the Company' s Newark, NJ headquarters or work from home on a regular basis but in no event less than three days in the office every other week. You will travel for purposes of Company business, in accordance with the Company' s needs, as such needs are determined by Supervisor. 2. Term: Your employment at the Company will commence on November 20, 2023 (the " Start Date "). Please note that your employment shall be at- will and shall not be for any set or fixed period of time, and shall continue until terminated by either you or the Company. 3. Compensation: During the Term, you will be compensated at an annual base salary rate of \$ 425, 000 (the " Base Salary "), which will be paid to you on a prorated basis less payroll deductions and required withholdings, in accordance with the Company' s standard payroll procedures. Your position is classified as exempt for purposes of relevant wage- hour law and therefore you will not be entitled to overtime pay. In addition to the Base Salary, you will also be eligible for an annual discretionary bonus in an amount up to 40 % of your Base Salary (prorated for your initial year of employment), your entitlement to which and any amount thereof to be determined in the sole and absolute discretion of the Company paid out based upon the achievement of personal and corporate objectives attainment. 4. Equity: Subject to the approval of the Compensation Committee of the Board of Directors of the Company you will be entitled to an initial grant of employee stock options to purchase 250, 000 shares of Class B common stock (the " Options "). The Options shall be submitted for approval at the Company' s next regularly scheduled quarterly Compensation Committee Meeting of the Board of Directors of the Company held post your Start Date, and if approved, granted within thirty (30) days thereafter. The vesting schedule shall be as follows: Options with respect to twenty- five percent (25 %) of the underlying shares shall vest on the first anniversary of the grant date and additional Options with respect to twenty- five (25 %) (in each case, rounded to a whole number of shares) of the underlying shares shall vest on each twelve- month anniversary of the first anniversary, so that all Options shall vest by the fourth anniversary of the grant date. The terms and conditions of the grant of the Options shall be as set forth in the Company' s 2018 Stock Option and Incentive Plan, as amended from time to time (the " Plan ") and the related grant agreement and related terms as required by the Company. All unvested Options shall terminate if your full- time employment with the Company shall cease for any reason. You will be eligible to receive additional equity grants at the sole discretion of the Compensation Committee of the Board. 5. Paid Time Off and Benefits: In addition to Company- designated paid holidays, each calendar year you shall be entitled to take paid time off in accordance with the Company' s applicable policies, as may be updated from time to time, and applicable law. As a full- time employee of the Company, you will be eligible for health insurance coverage and other employee benefits, in each case as available to similarly situated employees, in accordance with the relevant plans, as such plans are adopted by the Company. You shall also be entitled to reimbursement for pre- approved business expenses incurred by you in the course of your performance of your duties, as per Company policy, provided that you submit to the Company applicable invoices and other documentation, in form and in substance in accordance with Company policy. 6. Company Property: During the Term, the Company may provide you with the benefit of using Company property, such as, but not limited to, a Company- provided laptop. You are obligated to use such Company property in accordance with Company guidelines, and to return any such property to the Company upon the Company' s request, but in any case, upon the termination of your employment, regardless of the reason for such termination. 7. Restrictive Covenants: As a condition of your employment at the Company, you are obligated to sign and comply with the terms set forth in the Non- Disclosure and Non- Competition Agreement attached to this Letter Agreement as Schedule A (the " NDNC "). 8. Governing Law and Agreements: During the period of your employment at the Company, you will be expected to abide by all policies of the Company, as established from time to time. The terms of your employment, as well as your post- employment obligations, will be governed by the terms of this Letter Agreement, the NDNC, and applicable law. It is agreed that the terms of this Letter Agreement (including any attachments hereto) constitute the entire understanding between you and the Company regarding the subject matter hereof and supersede any previous understanding or agreement (whether oral or written) between you and the Company, and / or the Company' s management. The Company shall have the right to assign its rights and obligations under this Letter Agreement to any individual, entity, corporation, or partnership that succeeds to all or a portion of the relevant business or assets of the Company. This Letter Agreement is personal to you, and you may not assign your rights and obligations under this Letter Agreement to any third party. By your signature below, you represent that you are not bound by any agreement, whether oral or written, with a third party, where such agreement would in any way limit your ability to perform your obligations under this Letter Agreement, and you agree that at no time during your employment with the Company will you undertake responsibilities or obligations that will present a conflict of interest with, or limit your ability to fulfill the duties of, your position at the Company. 9. Notices: All notices and other communications under this Letter Agreement shall be in writing and shall be given by hand, by email, or by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three (3) days after mailing, twenty- four (24) hours after transmission of an email, or immediately upon hand delivery or explicit acknowledgement of receipt. 10. Section 409A of the Internal Revenue Code of 1986 as amended: You and the Company hereby affirm that with respect to any and all payments and benefits under this Letter Agreement, the intent is that such payments and benefits either: (i) do not constitute " nonqualified deferred compensation " within the meaning of Section 409A of the Internal Revenue Code ( " Section 409A "), and therefore are exempt from Section 409A, (ii) are subject to a " substantial risk of forfeiture " and are exempt from Section 409A under the " short - term deferral rule " set forth in Treasury Regulation § 1. 409A - 1 (b) (4), or (iii) are in compliance with the terms of 409A. In any event, you and the Company further confirm that they intend to have all provisions of this Letter Agreement construed, interpreted and administered in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. By way of example, and not limitation, solely for purposes of determining the time and form of payments, which are subject to Section 409A, due you under this Letter Agreement in connection with your termination of employment with the Company, you shall not be deemed to have incurred a termination of employment unless and until you shall incur a " separation from service " within the meaning of Section 409A. Each amount or installment to be paid or benefit to be provided under this Letter Agreement shall be construed as a separate and distinct payment for purposes of Section 409A. Without limiting the foregoing and notwithstanding anything contained herein to

the contrary, to the extent required to avoid accelerated taxation and / or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Letter Agreement or any other arrangement between you and the Company during the six (6) month period immediately following your separation from service shall instead be paid on the first business day after the date that is six (6) months following your separation from service (or, if earlier, your date of death). To the extent required to avoid accelerated taxation and / or tax penalties under Section 409A, amounts reimbursable to you under this Letter Agreement shall be paid to you on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to you) during one year may not affect amounts reimbursable or provided in any subsequent year. The Company makes no representation that any or all of the payments described in this Letter Agreement will be exempt from or comply with Section 409A and makes no undertaking to preclude Section 409A from applying to any such payment. You understand and agree that you shall be solely responsible for the payment of any taxes, penalties, interest or other expenses incurred by you on account of non-compliance with Section 409A.

**11. Dispute Resolution:** In the event of a dispute between you and the Company arising out of or related to your employment with the Company (with the exception of disputes arising under the NDNC set forth in Schedule A and claims that pursuant to applicable law a party is prohibited from requiring another party to agree to submit to arbitration), you and the Company agree to exclusively settle such dispute by means of arbitration pursuant to the Federal Arbitration Act, administered by the American Arbitration Association ("AAA"), with such arbitration to take place in New Jersey or another mutually agreed upon location and to be conducted in accordance with the AAA's Employment Arbitration Rules. In such arbitration, a single arbitrator, appointed by the mutual agreement of you and the Company: (i) shall not amend or modify the terms of this Letter Agreement or of any Company policy, and (ii) shall render a decision within ten (10) business days from the later of closing statements or submission of post-hearing briefs by the parties. The arbitration award shall be final and binding, and any state or federal court shall have jurisdiction to enter a judgment on such award. It is understood that this requirement to arbitrate disputes means that by signing below, you and the Company specifically waive any right either party may have to a trial by jury in a court of law with respect to all claims and demands arising out of or related to your employment with the Company, including, without limitation, any rights you may assert under any federal, state, or local laws or regulations applicable to your employment with the Company (with the exception of disputes arising under the NDNC set forth in Schedule A and claims that pursuant to applicable law a party is prohibited from requiring another party to agree to submit to arbitration). For the avoidance of doubt, the parties acknowledge and agree that the existence of a claim by a party that is not subject to arbitration pursuant to this paragraph shall not impair the enforceability of this paragraph with respect to any other claim brought by that party. Notwithstanding the foregoing, nothing in this paragraph shall be interpreted to mean that you cannot file a charge with the Equal Employment Opportunity Commission and / or the National Labor Relations Board or any comparable federal, state, or local governmental agency. The terms of this Letter Agreement are conditional upon your providing to the Company, within your first three (3) days of employment, a completed I-9 form accompanied by documentation that you are authorized to work in the United States, in accordance with applicable law. In addition, the Company reserves the right to conduct a background check, and your employment at the Company shall be conditional upon the results of such background check, in each case accordance with applicable law. If the Company determines not to have you commence employment based on the results of a background check (in accordance with all requirements of applicable law), your employment relationship with the Company shall be null and void, and the Company shall have no further obligations to you whatsoever. We are excited to have you join us as a member of the Rafael team. To accept this offer of employment and the terms and conditions hereof, please sign this Letter Agreement below and the attached Schedule A (and Exhibit A thereto) in the spaces provided and return all signed documents to David Polinsky at david.polinsky@rafaelholdings.com. Very truly yours, /s/ David Polinsky, David Polinsky, Chief Financial Officer AGREED TO AND ACCEPTED BY: /s/ John Goldberg, MD John Goldberg, MDDATE: 11/17/2023 Exhibit 21. 01 DOMESTIC SUBSIDIARIES Altira Capital & Consulting, LLC (DE) Barer Institute, Inc. (DE) Broad-Atlantic Associates, LLC (DE) CS Pharma Holdings, LLC (f/k/a Mor2Chai Partners, LLC) (DE) Day Three Labs, Inc. (DE) Farber Partners, LLC (DE) Pharma Holdings, LLC (f/k/a IDT-Rafael Holdings, LLC (DE) Rafael Holdings Realty, Inc. (f/k/a IDT Capital, Inc.) (DE) Rafael Medical Devices, LLC (DE) RP Finance LLC (DE) Tandem Therapeutics, Inc. (NV) Tandem Therapeutics, LLC (NV) The Barer Institute, LLC (f/k/a Rafael Realty, LLC) (NJ) FOREIGN SUBSIDIARIES IDT R. E. Holdings Ltd. (Israel) LipoMedix Pharmaceuticals Ltd. (Israel) Exhibit 23. 1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in registration statement No. 333- 282558 on Form S- 4, registration statement No. 333-274254 on Form S- 8, registration statement No. 333- 262754 on Form S- 3 / A, registration statement No. 333- 256865 on Form S- 3, registration statement No. 333- 256565 on Form S- 3 and registration statement No. 333- 253455 on Form S- 3 of Rafael Holdings, Inc. of our report dated October 30, November 6, 2023-2024 related to our audits of the consolidated financial statements of Rafael Holdings, Inc. as of July 31, 2024 and 2023 and 2022 and for the years then ended, included in the Annual Report on Form 10- K of Rafael Holdings, Inc. for the year ended July 31, 2023-2024. /s/ CohnReznick LLP New York, New York Exhibit 31. 01 Certification of Chief Executive Officer pursuant to Section 302 OF THE SARBANES-OXLEY ACT OF 2002 I, William Conkling, certify that: 1. I have reviewed this Annual Report on Form 10- K of Rafael Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer (s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15 (f) and 15d- 15 (f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: October 30, 2023 /s/ William Conkling Exhibit 31. 02 CERTIFICATION OF CHIEF FINANCIAL OFFICER Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David Polinsky, certify that: 1. The registrant's other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): /s/ David Polinsky Exhibit Polinsky David Polinsky Chief Financial Officer Exhibit 32. 01 CERTIFICATION PURSUANT TO Certification Pursuant to 18 U. S. C. SECTION Section 1350 (AS ADOPTED PURSUANT TO SECTION as Adopted Pursuant to Section 906 OF THE SARBANES OF THE SARBANES - OXLEY ACT OF Oxley Act Of 2002) In connection with the Annual Report of Rafael Holdings, Inc. (the " Company ") on Form 10- K for the annual period ended July 31, 2023-2024 as filed with the Securities and Exchange Commission (the " Report "). I, William Conkling, Chief Executive Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that to my knowledge: 1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/ William Conkling William Conkling Chief Executive Officer A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Exhibit 32. 02 Certification Pursuant to 18 U. S. C. Section 1350 (as Adopted Pursuant to Section 906 of the Sarbanes- Oxley Act Of 2002) In connection with the Annual Report of Rafael Holdings, Inc. (the " Company ") on Form 10- K for the annual period ended July 31, 2023-2024 as filed with the Securities and Exchange Commission (the " Report "), I, David Polinsky, Chief Financial Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that to my knowledge: /s/ Davd Polinsky Davd Polinsky Chief Financial Officer A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. v3. 23-24. 3Cover 3Document And Entity Information- USD (\$) \$ in Millions 12 Months Ended Jul. 31, 2023-2024 Oct Nov. 27-05, 2023-2024 Jan. 31, 2023 Document 2024 Document Information [ Line Items ] Entity Registrant Name RAFAEL HOLDINGS, INC. Trading Symbol RFL Document Type 10- K Document Annual Report true Document Transition Report false Document Financial Statement Error Correction [ Flag ] false Entity Interactive Data Current Yes ICFR Auditor Attestation Fiscal Year End Date-- 07-31 Entity Public Float \$ 70. 2 Amendment Flag false Amendment Flag false Entity Central Index Key Entity Current Reporting Status Yes Entity Voluntary Filers No Entity Filer Category Non- accelerated Filer Entity Well- known Seasoned Issuer No Document Period End Date Jul. 31, 2023 2024 Document Fiscal Year Focus Document Fiscal Period Focus FY Entity Information [ Line Items ] Entity Registrant Name RAFAEL HOLDINGS, INC. Entity Central Index Key Entity File Number 000- 55863 Entity Tax Identification Number 82- 2296593 Entity Incorporation, State or Country Code DE Current Fiscal Year End Date-- 07- 31 Entity Well- known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Shell Company false Entity Filer Category Non- accelerated Filer Entity Small Business true Entity Emerging Growth Company true Entity Shell Company false Entity Public Float \$ 34. Ex Transition Period

false ICFR Auditor Attestation Flag false Document Annual Report true Document Transition Report false Entity 4 Entity Contact Personnel [ Line Items ] File Number 000-55863 Entity Incorporation, State or Country Code DE Entity Tax Identification Number 82-2296593 Entity Address, Address Line One 520 Broad Street Entity Address, City or Town Newark Entity Address, State or Province NJ Entity Address, Postal Zip Code Entity Phone Fax Numbers [ Line Items ] City Area Code (212) Local Phone Number 658-1450 Entity Listings [ Line Items ] Title of 12 (b) Security Class B common stock, par value \$ 0.01 per share Trading Symbol RFL Security Exchange Name NYSE Entity Interactive Data Current Yes Document Financial Statement Error Correction [ Flag ] false Auditor Firm ID Auditor Name CohnReznick LLP Auditor Location New York, New York Class A Common Stock Document Information Entity Listings [ Line Items ] Entity Common Stock, Shares Outstanding 787, 163 Class B Common Stock Document Information Entity Listings [ Line Items ] Entity Common Stock, Shares Outstanding 23, 719, 886, 472, 987 X- Definition Boolean flag that is true when the XBRL content amends previously- filed or accepted submission. References No definition available. Details Name: dei\_AmendmentFlag Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: ..... dei\_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- Definition Area code of city References No definition available. Details Name: dei\_CityAreaCode Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition End date of current fiscal year in the format-- MM- DD. References No definition available. Details Name: dei\_CurrentFiscalYearEndDate Namespace Prefix: dei\_ Data Type: xbrli: gMonthDayItemType Balance Type: na Period Type: durationX- Definition Boolean flag that is true only for a form used as an annual report. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_DocumentAnnualReport Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Indicates whether any of the financial statement period in the filing include a restatement due to error correction. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection w Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 4: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\_DocumentFinStmntErrorCorrectionFlag Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY. References No definition available. Details Name: dei\_DocumentFiscalPeriodFocus Namespace Prefix: dei\_ Data Type: dei: fiscalPeriodItemType Balance Type: na Period Type: durationX- Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. References No definition available. Details Name: dei\_DocumentFiscalYearFocus Namespace Prefix: dei\_ Data Type: xbrli: gYearItemType Balance Type: na Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: dei\_DocumentInformationLineItems Namespace Prefix: dei\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition For the EDGAR submission types of Form 8- K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY- MM- DD. References No definition available. Details Name: dei\_DocumentPeriodEndDate Namespace Prefix: dei\_ Data Type: xbrli: dateTimeItemType Balance Type: na Period Type: durationX- Definition Boolean flag that is true only for a form used as a transition report. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Forms 10- K, 10- Q, 20- F- Number 240- Section 13- Subsection a- 1 Details Name: dei\_DocumentTransitionReport Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition The type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. References No definition available. Details Name: dei\_DocumentType Namespace Prefix: dei\_ Data Type: dei: submissionTypeItemType Balance Type: na Period Type: durationX- Definition Address Line 1 such as Attn, Building Name, Street Name References No definition available. Details Name: dei\_EntityAddressAddressLine1 Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition Name of the City or Town References No definition available. Details Name: dei\_EntityAddressCityOrTown Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition Code for the postal or zip code References No definition available. Details Name: dei\_EntityAddressPostalZipCode Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition Name of the state or province. References No definition available. Details Name: dei\_EntityAddressStateOrProvince Namespace Prefix: dei\_ Data Type: dei: stateOrProvinceItemType Balance Type: na Period Type: durationX- Definition A unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntityCentralIndexKey Namespace Prefix: dei\_ Data Type: dei: centralIndexKeyItemType Balance Type: na Period Type: durationX- Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [ Member ], Common Class B [ Member ] or Partnership Interest [ Member ] onto the Instrument [ Domain ] of the Entity Listings, Instrument. References No definition available. Details Name: dei\_EntityCommonStockSharesOutstanding Namespace Prefix: dei\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: dei\_EntityContactPersonnelLineItems Namespace Prefix: dei\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. References No definition available. Details Name: dei\_EntityCurrentReportingStatus Namespace Prefix: dei\_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- Definition Indicate if registrant meets the emerging growth company criteria. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntityEmergingGrowthCompany Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Securities Act- Number 7A- Section B- Subsection 2 Details Name: dei\_EntityExTransitionPeriod Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence number may contain 1- 8 digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen. References No definition available. Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_ Data Type: dei: fileNumberItemType Balance Type: na Period Type: durationX- Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non- accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntityFilerCategory Namespace Prefix: dei\_ Data Type: dei: filerCategoryItemType Balance Type: na Period Type: durationX- Definition Two- character EDGAR code representing the state or country of incorporation. References No definition available. Details Name: dei\_EntityIncorporationStateCountryCode Namespace Prefix: dei\_ Data Type: dei: edgarStateCountryItemType Balance Type: na Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: dei\_EntityInformationLineItems Namespace Prefix: dei\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- T- Number 232- Section 405 Details Name: dei\_EntityInteractiveDataCurrent Namespace Prefix: dei\_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: dei\_EntityListingsLineItems Namespace Prefix: dei\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: dei\_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition The aggregate market value of the voting and non- voting common equity held by non- affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. References No definition available. Details Name: dei\_EntityPublicFloat Namespace Prefix: dei\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntityRegistrantName Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntityShellCompany Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition Indicates that the company is a Smaller Reporting Company (SRC). References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\_EntitySmallBusiness Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9- digit value assigned by the IRS. References Reference 1:

http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2DetailsName:  
dei\_EntityTaxIdentificationNumber Namespace Prefix: dei\_Data Type: dei: employerIdItem Type Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the  
registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei\_EntityVoluntaryFilers  
Namespace Prefix: dei\_Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned  
issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.  
ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameSecuritiesAct-Number230-Section405DetailsName:  
dei\_EntityWellKnownSeasonedIssuer Namespace Prefix: dei\_Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- ReferencesReference 1: http://www.  
xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310Reference 2: http://www.xbrl.org/2003/role/presentationRef-  
PublisherSEC-NameForm20-F-Number249-Section220-SubsectionfReference 3: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm40-F-  
Number249-Section240-SubsectionfDetailsName: dei\_IcfrAuditorAttestationFlag Namespace Prefix: dei\_Data Type: xbrli: booleanItem Type Balance Type: na Period Type:  
durationX- DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei\_LocalPhoneNumber Namespace Prefix: dei\_Data Type: xbrli:  
normalizedStringItem Type Balance Type: na Period Type: durationX- DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: http://www.xbrl.org/2003/role/  
presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb2DetailsName: dei\_Security12bTitle Namespace Prefix: dei\_Data Type: dei:  
securityTitleItem Type Balance Type: na Period Type: durationX- DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: http://www.xbrl.  
org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectiond1-1DetailsName: dei\_SecurityExchangeName Namespace  
Prefix: dei\_Data Type: dei: edgarExchangeCodeItem Type Balance Type: na Period Type: durationX- DefinitionTrading symbol of an instrument as listed on an exchange.  
ReferencesNo definition available. Details Name: dei\_TradingSymbol Namespace Prefix: dei\_Data Type: dei: tradingSymbolItem Type Balance Type: na Period Type:  
durationX- Details Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details  
Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: Location New York, New York X  
**Balance Type: na Period Type: durationX** - Definition PCAOB issued Audit Firm Identifier ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-  
PublisherSEC-NameForm10-K-Number249-Section310Reference 2: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Number249-  
Section220-SubsectionfReference 3: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm40-F-Number249-Section240-SubsectionfDetails  
Name: dei\_AuditorFirmId Namespace Prefix: dei\_Data Type: dei: nonemptySequenceNumberItem Type Balance Type: na Period Type: durationX- ReferencesReference 1: http://  
www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310Reference 2: http://www.xbrl.org/2003/role/presentationRef-  
PublisherSEC-NameForm20-F-Number249-Section220-SubsectionfReference 3: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm40-F-  
Number249-Section240-SubsectionfDetailsName: dei\_AuditorLocation Namespace Prefix: dei\_Data Type: dei: internationalNameItem Type Balance Type: na Period  
Type: durationX- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310Reference 2: http://  
www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Number249-Section220-SubsectionfReference 3: http://www.xbrl.org/2003/role/  
presentationRef-PublisherSEC-NameForm40-F-Number249-Section240-SubsectionfDetailsName: dei\_AuditorName Namespace Prefix: dei\_Data  
Type: dei: internationalNameItem Type **Balance Type Consolidated duration Consolidated** Balance Sheets- USD (\$) \$ in Thousands Jul. 31, 2023 2024 Jul. 31, 2022 CURRENT  
2023 CURRENT ASSETS Cash and cash equivalents \$ 2,675 \$ 21,498 \$ 26,537 Available 498 Available, for-sale securities 63,265 57,714 Interest 714 26,698 Interest  
receivable Convertible note receivable receivables, related party due from Cyclo 5, 921-191 Accounts receivable, net of allowance for doubtful accounts credit losses of \$ 245  
and \$ 197 at July 31, 2023 2024 and July 31, 2023 Prepaid 2022, respectively Prepaid expenses and other current assets Investment assets 4,621 Assets held for sale 40,  
194 Investment in equity securities Total current assets 72,502 82,941 108,347 Property 941 Property and equipment, net 2,120 1,695 Convertible note receivable 1,146  
Goodwill 3,050 Intangible assets, net 1,847 In 695-1,770 In-process research and development and patents-1,575 1,575 Other assets TOTAL assets 1,387 TOTAL ASSETS  
96,832 98,829 118,320 CURRENT 829 CURRENT LIABILITIES Accounts payable Accrued payable 2,556 Accrued expenses 1,798 Convertible notes payable 875 Other  
Other current liabilities 1,023 Installment note 233-3,518 Note payable 1,700 Net of debt-issuance costs, held-for-sale 15,000 Total current liabilities 7,514 2,145 21  
145 Accrued expenses, noncurrent 2,982 Deferred income tax liabilities, net 026 Other liabilities TOTAL LIABILITIES 10,574 2,200 21,114 COMMITMENTS  
200 COMMITMENTS AND CONTINGENCIES EQUITY Treasury stock Additional paid-in capital 264,010 262 at cost; 101,023 Accumulated deficit (167,487 and 0  
Class B shares as of July 31, 333) (165 2024 and July 31, 457 2023, respectively (168)) Accumulated other comprehensive income (loss) related to unrealized loss income  
on available-for-sale securities (353 ) (63 ) Accumulated other comprehensive income related to foreign currency translation adjustment 3,725 691 3,767 Total 725 Total equity  
attributable to Rafael Holdings, Inc. 82,185 100,293 100,515 Noncontrolling 293 Noncontrolling interests 4,073 (3,664 ) (3,309 ) TOTAL EQUITY 86,258 96,629 97,  
206 TOTAL 629 TOTAL LIABILITIES AND EQUITY 96,832 98,829 118,320 Related Party CURRENT ASSETS Convertible note receivable, related party 1,  
921 CURRENT LIABILITIES Due to related parties Cyclo CURRENT ASSETS Investments 12,010 4,763 Hedge Funds CURRENT ASSETS Investments 2,547 4,  
984 Day Three CURRENT ASSETS Investments 2,797 Other Pharmaceuticals CURRENT ASSETS Investments 320 Class A Common Stock EQUITY Common  
stock value Class B Common Stock EQUITY Common stock value Additional paid-in capital 280 value Other Pharmaceuticals CURRENT ASSETS Investments Hedge Funds  
CURRENT ASSETS Investments 4,984 4,048 264,010 Accumulated deficit 764 Day Three Labs Inc CURRENT ASSETS Investments 2,797 Cyclo Therapeutics Inc  
CURRENT ASSETS Investments 4,763 Related Party CURRENT LIABILITIES Other current liabilities \$ 26 (201,743) \$ 69X (167,333) X Definition Convertible  
Definition Amount of convertible note receivable, related party. ReferencesNo definition available. Details Name: rf\_ConvertibleNoteReceivableRelatedParty-----  
rf\_ConvertibleNoteReceivableNoncurrent Namespace Prefix: rf\_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX- Definition In process  
research and development Definition Convertible note receivable, related party. ReferencesNo definition available. Details Name: rf\_InProcessResearchAndDevelopment  
rf\_ConvertibleNoteReceivableRelatedParty Namespace Prefix: rf\_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX- Definition Convertible  
note Definition Amount, after allowance, receivable receivables, due from customers, clients, or other third parties, and receivables classified as other due within one year or the  
normal operating cycle, if longer. ReferencesNo definition available. Details Name: rf\_ConvertibleNoteReceivablesDueFromCyclo us-  
gaap\_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-rf\_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX- gaap-  
Definition Due to related parties. ReferencesNo definition available. Details Name: rf\_DueToRelatedParties Namespace Prefix: rf\_Data Type: xbrli:  
monetaryItem Type Balance Type: credit Period Type: instantX- Definition Represents the amount of in-process research and development. ReferencesNo definition  
available. Details Name: rf\_InProcessResearchAndDevelopmentNoncurrent Namespace Prefix: rf\_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type:  
instantX- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and  
services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).  
ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/exampleRefRef/legacyRef-Topic 852-210-SubTopic 10-Name Accounting Standards  
Codification-Section 55-S99-Paragraph 1-Subparagraph (SX 10-210-5-02-19 (a)) - Publisher FASB-URI https://asc.fasb.org/1943274/2147481372-2147480566/  
210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-  
Name Accounting Standards Codification-Topic 210-Section 55-SubTopic Paragraph 10-Section S99-Paragraph 1-Subparagraph (SX 210-5-02-19 (a)) - Publisher FASB-  
URI https://asc.fasb.org/1943274/2147480566-2147481372/210-852-10-S99-55-1-10 Details Name: us-gaap\_AccountsPayableCurrent us-  
gaap\_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItem Type Balance Type: credit  
Period Type: durationX- instantX- Definition Amount, after allowance for credit loss, of unrealized gain (loss) on investment right to consideration from customer for  
product sold and service rendered in marketable security normal course of business, classified as current. ReferencesReference 1: http://fasb.org/2009-us-gaap/  
role/commonPracticeRefRef/legacyRef-Topic 220-310-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 2-Subparagraph (SX 210-5-03  
(7)(e)) - Publisher FASB-URI https://asc.fasb.org/1943274/2147483621-2147481990/220-310-10-S99-45-2 Details Name: us-  
gaap\_MarketableSecuritiesUnrealizedGainLoss gaap\_AccountsReceivableNetCurrent Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItem Type Balance Type: credit  
debit Period Type: durationX- instantX- Definition Amount Definition The portion of profit expenses incurred but not yet paid or nor invoiced loss for the period, and  
liabilities classified as net of income taxes, which is attributable to the other parent. ReferencesReference-ReferencesNo definition available. Details Name: us-  
gaap\_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX-  
Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or  
accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current  
portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-  
SubTopic 10-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210-5-02-19 (a)) - Publisher FASB-URI https://  
asc.fasb.org/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItem Type  
Balance Type: credit Period Type: instantX- Definition Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change  
in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-  
SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 14- Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14  
Details Name: us-gaap\_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap\_Data Type: xbrli:  
monetaryItem Type Balance Type: credit Period Type: instantX- Definition Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial  
statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency  
translation gains or losses. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-  
Section 45-Paragraph 11- Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/

disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 14A- Publisher FASB- URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 5A- Publisher FASB- URI https://asc.fasb.org/1943274/2147482736/825-10-45-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 10A- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 14- Publisher FASB- URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 Details Name: us-gaap\_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-02 (30) (a) (1))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionSum-DefinitionAmount of the carrying amounts as of the balance sheet date of all assets- asset that are recognized for present right to- Assets are probable future economic benefits- benefit obtained or controlled by an entity as a result of past transactions or events- ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef- Topic 810-280- SubTopic 10- Name Accounting Standards Codification- Section 50-55- Paragraph 48-3- Subparagraph (bb)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203/2147482785/810-280-10-50-55-3Reference 48Reference 2: http://www.xbrl.org/2003/role/disclosureRef-exampleRef- Topic 810-280- SubTopic 10- Name Accounting Standards Codification- Section 45-55- Paragraph 49-25- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481231/2147482785/810-280-10-45-55-25Reference 49Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 235-270- SubTopic 10- Name Accounting Standards Codification- Section S99-50- Paragraph 1- Subparagraph (i) (SX 210. 4-08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480678/2147482964/235-270-10-S99-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Topic 323-280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3-32- Subparagraph (e-ee)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481687/2147482810/323-280-10-50-3Reference 32Reference 5: http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/otherTransitionRef- Topic 825-280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28-32- Subparagraph (fd)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482907/2147482810/825-280-10-50-28Reference 32Reference 6: http://www.xbrl.org/2003/role/exampleRef-disclosureRef- Topic 852-280- SubTopic 10- Name Accounting Standards Codification- Section 55-50- Paragraph 40-22- Publisher FASB- URI https://asc.fasb.org/1943274/2147481372/2147482810/852-280-10-55-50-40Reference 22Reference 7: http://www.xbrl.org/2003/role/exampleRef-disclosureRef- Topic 946-810- SubTopic 830-10- Name Accounting Standards Codification- Section 55-50- Paragraph 42-3- Subparagraph (bb)- Publisher FASB- URI https://asc.fasb.org/1943274/2147480167/2147481203/946-810-830-10-55-50-42Reference 3Reference 8: http://www.xbrl.org/2003/role/disclosureRef- Topic 944-810- SubTopic 210-10- Name Accounting Standards Codification- Section S99-45- Paragraph 1-25- Subparagraph (SX 210. 7-03 (a) (12))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479440/2147481231/944-810-210-10-S99-45-1Reference 25Reference 9: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-235- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 22-1- Subparagraph (SX 210. 4-08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810/2147480678/280-235-10-50-S99-22Reference 1Reference 10: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-323- SubTopic 210-10- Name Accounting Standards Codification- Section S99-50- Paragraph 1-3- Subparagraph (c SX 210. 6-04 (8))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479617/2147481687/946-323-210-10-S99-50-1Reference 3Reference 11: http://www.xbrl.org/2003/role/disclosureRef- Topic 210-825- SubTopic 10- Name Accounting Standards Codification- Section S99-50- Paragraph 1-28- Subparagraph (f SX 210. 5-02 (18))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/2147482907/210-825-10-S99-50-1Reference 28Reference 12: http://www.xbrl.org/2003/role/disclosureRef-exampleRef- Topic 470-852- SubTopic 10- Name Accounting Standards Codification- Section S99-55- Paragraph 1A- Subparagraph (SX 210. 13-01 (a) (4) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/2147481372/470-852-10-S99-55-1AReference 10Reference 13: http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef- Topic 470-946- SubTopic 10-830- Name Accounting Standards Codification- Section S99-55- Paragraph 12-1A- Subparagraph (SX 210. 13-01 (a) (4) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/2147479168/470-946-10-830-S99-55-1AReference 12Reference 14: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 470-944- SubTopic 40-210- Name Accounting Standards Codification- Section S99- Paragraph 1A-1- Subparagraph (SX 210. 13-7-01-03 (a) (12.4) (iii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/2147478777/470-944-40-210-S99-1AReference 1Reference 15: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-946- SubTopic 40-210- Name Accounting Standards Codification- Section S99- Paragraph 1A-1- Subparagraph (SX 210. 13-6-01-04 (8) (a) (4) (iii) (A))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/2147479170/470-946-40-210-S99-1AReference 1Reference 16: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A-1- Subparagraph (SX 210. 13-5-01-02 (18) (a) (4) (iv))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/2147480566/470-210-10-S99-1AReference 1Reference 17: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13-01 (a) (5-4) (i))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210. 13-02-01 (a) (4) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 1AReference 19: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210. 13-02-01 (a) (4) (iii) (A))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 1AReference 20: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210. 13-02-01 (a) (5))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 1AReference 21: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210. 13-02-01 (a) (4) (iv))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 1AReference 22: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210. 13-02-01 (a) (5))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 1AReference 23: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 852-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 7-1B- Subparagraph (SX 210. 13-02 (a) (4) (i))- Publisher FASB- URI https://asc.fasb.org/1943274/2147481404/2147480097/852-470-10-50-S99-7Reference 1BReference 24: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 30-1B- Subparagraph (e SX 210. 13-02 (a) (4) (iii) (A))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810/2147480097/280-470-10-50-S99-30Reference 1BReference 25: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 32-1B- Subparagraph (d SX 210. 13-02 (a) (4) (iii) (B))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810/2147480097/280-470-10-50-S99-32Reference 1BReference 26: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef- Topic 942-470- SubTopic 210-10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 9-13-03-02 (11) (a) (4) (iv))- Publisher FASB- URI https://asc.fasb.org/1943274/Paragraph 3-7- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481404/2147481004/852-946-40-505-50-7Reference 3Reference 29-32: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-946- SubTopic 40-210- Name Accounting Standards Codification- Section 50-S99- Paragraph 30-1- Subparagraph (e SX 210. 6-04 (19))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810/2147479617/280-946-40-210-50-S99-30Reference 1Reference 30-33: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef/legacyRef- Topic 942-946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph 2147479853-2147478546/942-210-S99-1 Details Name: us-gaap\_Assets Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum-DefinitionAmount of the carrying amounts-asset recognized for present right to economic benefit, classified as current of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer)- Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events- ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (bb)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 25- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 235- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 4-08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef- Topic 323- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef- Topic 825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef- Topic 852- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 10- Publisher FASB- URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Publisher FASB- URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-02 (9))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13-01 (a) (4) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13-01 (a) (4) (ii))- Publisher

FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481404/852-10-50-7-Details Name: us-gaap\_AssetsCurrent Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap\_AssetsCurrentAbstract Namespace Prefix: us-gaap\_Data Type: xbrl:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of assets held-for-sale. Type: debit Period Type: instantX-DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479130/326-30-45-1-Details Name: us-gaap\_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483467/210-10-45-1Reference 3: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482740/230-10-45-4-Details Name: us-gaap\_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. ReferencesReference 1: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 944-942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-9-03(17)(19))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479440/2147478546-944-942-210-S99-1Reference 2: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-5-04-02(15-25))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479617/2147480566-946-210-10-S99-1Reference 3: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(19))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-946-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210.9-03.17)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-6-02.25-04(15))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566/2147479170-946-210-10-S99-1-Details Name: us-gaap\_CommitmentsAndContingencies Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionValue DefinitionAggregate par or stated value of issued nonredeemable all classes of common stock held (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by shareholders the entity. May be all Note: elements or for portion of the number of nonredeemable common shares, par value and authorized. These shares exclude common shares repurchased by the other entity and held as treasury shares disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-5-04-02(29-46)(a))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479617/2147480566-946-210-10-S99-1Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic 210-852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-7-02-03(29-a)(22))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566/214748777/944-210-10-S99-1-Details Name: us-gaap\_CommonStockValueOutstanding-gaap\_CommonStockValue Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: instantX-ReferencesNo definition available. DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. 210-Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. ReferencesReference 1 3-04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480008/505-10-S99-1Reference 38: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic 235-210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-5-08-02(20)(i)(ii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480678/2147480566-235-210-10-S99-1-Details Name: us-gaap\_EquityAbstract-gaap\_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap\_Data Type: xbrl:stringItemType monetaryItemType Balance Type: na-credit Period Type: durationX-34-InstantX-DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. ReferencesReference 1: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Topic 946-944-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210.6-7-09-03(4-a)(15)(b)(2))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575/2147478777/946-944-220-210-S99-3Reference 1Reference 35-2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-740-SubTopic 220-10-Name Accounting Standards Codification-Section S99-45-Paragraph 4-3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482525/946-740-220-10-S99-45-3Reference 4Reference 36-3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-740-SubTopic 220-10-Name Accounting Standards Codification-Section S99-45-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575/2147482525/946-740-220-10-S99-45-3Reference 37-6-Details Name: http-us-gaap\_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap\_Data Type: xbrl:xbrl:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of investment in net income (FV-NI), classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(2))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482736/825-10-45-1A-Details Name: us-gaap\_EquitySecuritiesFvNi Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of investments, and noncurrent after accumulated impairment loss, of assets-asset representing classified as other. ReferencesNo definition available. Details Name: us-gaap\_InvestmentsAndOtherNoncurrentAssets Namespace Prefix: us-gaap\_Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits-benefit arising from other present obligations of an entity to transfer assets-asset acquired in business combination or provide services to other entities in the future from joint venture formation or both, that is not individually identified and separately recognized. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef/exampleRef-Topic 810-280-SubTopic 10-Name Accounting Standards Codification-Section 50-55-Paragraph 49-3-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481203/2147482785-810-280-10-50-55-3Reference 49Reference 2: http://www.xbrl.org/2003/role/disclosureRef/exampleRef-Topic 810-350-SubTopic 10-20-Name Accounting Standards Codification-Section 45-55-Paragraph 24-25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481231/2147482548-810-350-10-20-45-55-25Reference 24Reference 3: http://www.xbrl.org/2003/role/disclosureRef/exampleRef-Topic 810-820-SubTopic 10-Name

Accounting Standards Codification- Section 50-55- Paragraph 3-100- Subparagraph (bb-d)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203-2147482078/810-820-10-50-55-3Reference-100Reference-4: http://www.xbrl.org/2003/role/disclosureRef/exampleRef- Topic 235-852- SubTopic 10- Name Accounting Standards Codification- Section 50-55- Paragraph 1- Subparagraph (SX 210- 10- 4- 08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480678-2147481372/235-852-10-50-55-1Reference-10Reference-5: http://www.xbrl.org/2003/role/disclosureRef- Topic 323-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 3-1- Subparagraph (e-SX 210- 5- 02 (15))- Publisher FASB- URI https://asc.fasb.org/1943274/2147481687-2147480566/323-210-10-50-599-3Reference-1Reference-6: http://www.xbrl.org/2003/role/disclosureRef- Topic 825-350- SubTopic 40-20- Name Accounting Standards Codification- Section 50-45- Paragraph 1- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482907-2147482598/825-10-50-350-20-45-28Reference-1Reference-7: http://www.xbrl.org/2003-2009/role/exampleRef/commonPracticeRef- Topic 946-350- SubTopic 830-20- Name Accounting Standards Codification- Section 55-50- Paragraph 12-1- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/1943274/2147480167-2147482573/946-350-830-20-55-50-12Reference-1Reference-8: http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef- Topic 946-350- SubTopic 210- 20- Name Accounting Standards Codification- Section 50-599- Paragraph 1- Subparagraph (h SX 210- 6- 04 (14))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479617-2147482573/946-350-210-20-599-50-1Reference-9: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-942- SubTopic 40-210- Name Accounting Standards Codification- Section 50-599- Paragraph 1A-1- Subparagraph (SX 210- 13- 9- 01- 03 (a) 10) (1) 4(i))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147478546/470-942-40-210-599-1AReference-10-1 Details Name: us- gaap\_ Goodwill Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 470-350- SubTopic 40-30- Name Accounting Standards Codification- Section 50-599- Paragraph 1A-2- Subparagraph (SX 210- 13- 01 (a) (1) 4(ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147482665/470-350-40-30-599-50-1AReference-2Reference-11-2: http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef- Topic 470-350- SubTopic 40-30- Name Accounting Standards Codification- Section 50-599- Paragraph 1A-2- Subparagraph (b SX 210- 13- 01 (a) 4(iii) (A))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147482665/470-350-40-30-599-50-1AReference-2Reference-12-3: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-350- SubTopic 40-30- Name Accounting Standards Codification- Section 50-599- Paragraph 1A-2- Subparagraph (c SX 210- 13- 01 (a) 4(iv))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147482666/470-350-40-30-599-50-1AReference-13-1 Details Name: us- gaap\_ IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionCarrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef- Topic 470-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1A-1- Subparagraph (SX 210- 13- 5- 01- 02 (3) (a) (5) 4))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147480566/470-210-10-599-1AReference-14-1 Details Name: us- gaap\_ InterestReceivableCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1B-1- Subparagraph (SX 210- 13- 5- 02 (a) 22) (4) (ii))- SubTopic 10- Topic 210- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147480566/470-210-10-599-1BReference-1Reference-15-2: http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- Topic 470-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1B-1- Subparagraph (SX 210- 13- 5- 02 (20) a) 4(iii) (A))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147480566/470-210-10-599-1BReference-1Reference-16-3: http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- Topic 470-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1B-1- Subparagraph (SX 210- 13- 5- 02 (19) a) 4(iv))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147480566/470-210-10-599-1BReference-1Reference-17-4: http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- Topic 470-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1B-1- Subparagraph (SX 210- 13- 5- 02 (25) a) (5))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147480566/470-210-10-599-1BReference-1Reference-19-6: http://www.fasb.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef- Topic 852-210- Name Accounting Standards Codification- Section 50-599- Paragraph 7-1- Subparagraph (a-SX 210- 5- 02 (26))- Publisher FASB- URI https://asc.fasb.org/1943274/2147481404-2147480566/852-210-10-50-599-7Reference-1Reference-20-7: http://www.fasb.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef- Topic 852-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 7-1- Subparagraph (b-SX 210- 5- 02 (23))- Publisher FASB- URI https://asc.fasb.org/1943274/2147481404-2147480566/852-210-10-50-599-7Reference-1Reference-21-8: http://www.fasb.org/2003-us-gaap/role/exampleRef/ref/legacyRef- Topic 280-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 30-1- Subparagraph (d-SX 210- 5- 02 (21))- Publisher FASB- URI https://asc.fasb.org/1943274/2147482810-2147480566/280-210-10-50-599-30Reference-1Reference-22-9: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference-10: http://www.xbrl.org/2003/role/disclosureRef- Topic 210-810- SubTopic 10- 4- Name Accounting Standards Codification- 08- Section 45- Paragraph 25- Subparagraph (b) 4(i) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480678-2147481231/235-810-10-599-45-1Reference-25Reference-39-11: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef- Topic 323-810- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Subparagraph (e-bb)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481687-2147481203/323-810-10-50-3Reference-40-12: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef- Topic 825-235- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 1- Subparagraph (SX 210- 5- 4- 02- 19- 26- 08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/1943274/2147480566-2147480678/235-2147483575-946-220-10-599-3Reference-1Reference-35-13: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-323- SubTopic 220-10- Name Accounting Standards Codification- Section 50-599- Paragraph 3- Subparagraph (c SX 210- 6- 09 (6))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483575-2147481687/946-323-220-10-599-50-3Reference-36-14: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-825- SubTopic 220-10- Name Accounting Standards Codification- Section 50-599- Paragraph 3-28- Subparagraph (f SX 210- 6- 09 (7))- Publisher FASB- URI https://asc.fasb.org/1943274/2147483575-2147482907/825-10-50-28Reference-15: http://www.xbrl.org/2003/role/exampleRef- Topic 946-220-599-3Reference-37: http://www.xbrl.org/2003/role/disclosureRef- Topic SubTopic 830-505- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 12-1- Subparagraph (SX 210- 3- 04)- Publisher FASB- URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference-16: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (SX 210- 6- 04 (14))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference-17: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 3- Publisher FASB- URI https://asc.fasb.org/1943274/2147480097-2147481004/470-946-40-505-599-50-1AReference-3Reference-21-32: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-946- SubTopic 40-210- Name Accounting Standards Codification- Section 50- Paragraph 1A-1- Subparagraph (SX 210- 13- 6- 01- 04 (19) a) (5))- Publisher FASB- URI https://asc.fasb.org/1943274/2147479617/470-946-40-210-599-1AReference-1Reference-22-33: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-946- SubTopic 40-210- Name Accounting Standards Codification- Section 50- Paragraph 1B- Details Name: us- gaap\_ Liabilities Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef/ref/legacyRef- Topic 810-210- SubTopic 10- Name Accounting Standards Codification- Section 50-599- Paragraph 3-1- Subparagraph (e-SX 210- 5- 02 (21))- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203-2147480566/810-210-10-50-599-3Reference-1Reference-2: http://www.xbrl.org/2003/role/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 45-50- Paragraph 25-3- Subparagraph (b-e)- Publisher FASB- URI https://asc.fasb.org/1943274/2147481203-2147481203/810-10-45-50-25Reference-3Reference-3: http://www.xbrl.org/2003/role/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 50-45- Paragraph 3-25- Subparagraph (bb-b)- Publisher FASB- URI

https://asc.fasb.org/1943274/2147481203-2147481231/810-10-50-45-3Reference-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-810-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-3-Subparagraph (bb) SX 210.4-08(g)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678-2147481203-810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph (e) SX 210.4-08(g)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687-2147480678-235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-3-Subparagraph (fc)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907-2147481687-323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-50-Paragraph 10-28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372-2147482907-825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-55-Paragraph 5-10-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467-2147481372-852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 5-1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-45-1AReference 10: http://www.xbrl.org/2009-2003/role/economyPracticeRef-disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv)-(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph (SX 210.13-02-01(a)(5)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)-(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009-2003/role/economyPracticeRef-disclosureRef-Topic 852-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 7-1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480666-2147481404-210-852-10-S99-50-7-Details Name: us-gaap-StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-gaap-LiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: durationX instantX Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-21(12))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-LiabilitiesCurrent-gaap-LongTermInvestments Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit debit Period Type: instantX References No definition available. Details Name: us-gaap-LiabilitiesCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: durationX Definition Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. References Reference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 235-210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-5-08-02(31)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678-2147480566-235-210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-235-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph (e) SX 210.4-08(g)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687-2147480678-235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-3-Subparagraph (fc)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907-2147481687-323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-50-Paragraph 28-Subparagraph (f) SX 210.7-03(a)(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440-2147482907-825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-7-04-03(49-a)(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/2147478777-946-944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-946-SubTopic 10-210-Name Accounting Standards Codification-Section S99-Paragraph 1A-1-Subparagraph (SX 210.13-6-04-04(19-a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph (SX 210.13-02-01(a)(5)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv)-(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 942-470-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-13-03-02(22-a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853-2147480097/470-10-S99-1BReference 13: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-S99-1Reference 13: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-9-02-31-03(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147478546-942-210-10-S99-1-Details Name: us-gaap-MinorityInterest Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: instantX Definition Sum Definition Amount of the carrying values noncurrent assets classified as the other. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-OtherAssetsNoncurrent Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX Definition Amount of liabilities classified as the other, portions of long-term notes payable due within one year or the normal operating cycle, if longer. References Reference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19-20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2-Details Name: us-gaap-NotesPayableCurrent Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: instantX Definition Amount of noncurrent assets classified as other. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 210-852-SubTopic 10-Name Accounting Standards Codification-Section S99-55-Paragraph 1-Subparagraph (SX 210.10-5-02(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147481372-210-852-10-S99-55-1-Details Name: us-gaap-OtherAssetsNoneurrent Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instantX Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. References Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 210-10-S99-1-Details Name: us-gaap-OtherLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: instantX Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. References Reference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1 Details Name: us-gaap\_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-  
Publisher FASB-DefinitionAmount of long-term notes classified as other payable within one year or the normal operating cycle, if longer.  
ReferencesReference 1: <https://asc.fasb.org/1943274/2147480008/505-10-509-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29-20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29-20)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-509-1> Details Name: us-gaap\_OtherNotesPayableCurrent gaap\_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap Data  
Type: xbrli:monetaryItemType Balance Type: NameSpace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(9\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(9)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-509-1> Details Name: us-gaap\_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic852-842-SubTopic40-20>-NameAccountingStandardsCodification-Section55-50-Paragraph40-7A-Subparagraph(a)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147481372/2147480566/852-20-50-7AReference3>: <http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-55-10Reference3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-7-03\(a\)\(8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210-10-7-03(a)(8)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147479440/2147481372/852-10-55-10Reference4>: <http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-599-1Reference4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(SX210.7-03(a)(8)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480842/2147478777/944-210-599-1Reference5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(SX210.7-03(a)(8)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> Details Name: us-gaap\_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount DefinitionThe total amount due to the entity within one year of accumulated undistributed earnings, the balance sheet date (deficit or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. ReferencesReference 1: [http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-599-Paragraph1-Subparagraph\(SX40-210.5-02\(30\)\(a\)\(3\)\)](http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-599-Paragraph1-Subparagraph(SX40-210.5-02(30)(a)(3)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147481372/2147480566/852-210-10-55-599-1Reference2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph\(g\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference3](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph(g)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph\(h\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph(h)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference4): <http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph11-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480990/946-20-50-11Reference5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(23\)\(a\)\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/2147478777/944-210-599-1Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-03(a)(23)(a)(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/2147478777/944-210-599-1Reference6): <http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph11-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480990/946-20-50-11Reference7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-509-1Reference8](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-509-1Reference8): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(30\)\(a\)\(3\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(30)(a)(3)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147481372/2147480566/852-210-10-55-599-1Reference9>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-05\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/2147481372/946-210-10-599-55-2Reference10](http://www.xbrl.org/2003/role/disclosureRef-Topic946-210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-05(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617/2147481372/946-210-10-599-55-2Reference10): [http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph\(SX210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph(SX210.6-09(4)(b)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483575/2147479168/946-220-830-599-55-3Reference12>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-09\(4\)\(6-19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph(SX210.6-09(4)(6-19)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483575/2147479170/946-220-210-599-3Reference13>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph\(SX210.6-09\(5\)\(7-4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph(SX210.6-09(5)(7-4)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483575/2147479170/946-220-210-599-3Reference14>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.6-09\(4\)\(-08\)\(g\)\(b\)\(+\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.6-09(4)(-08)(g)(b)(+)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480678/2147479134/235-946-40-220-50-599-1Reference3Reference9>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic825-946-SubTopic40-220-NameAccountingStandardsCodification-Section50-599-Paragraph3-Subparagraph\(e-SX210.6-09\(7\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic825-946-SubTopic40-220-NameAccountingStandardsCodification-Section50-599-Paragraph3-Subparagraph(e-SX210.6-09(7)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482907/2147479134/825-946-40-220-50-599-28Reference3Reference11>: [http://fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-4-02-08\(29-g\)\(1\)\(ii\)\)](http://fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-4-02-08(29-g)(1)(ii)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/2147480678/210-235-10-599-1Reference12>: [http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-323-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph\(c-SX210.5-02\(31\)\)](http://www.xbrl.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-323-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph(c-SX210.5-02(31)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/2147481687/210-323-10-599-50-1Reference3Reference13>: [http://fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-825-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-28-Subparagraph\(f-SX210.5-02\(30\)\)](http://fasb.org/2009-us-gaap/role/commonPracticeRef-ref/legacyRef-Topic210-825-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-28-Subparagraph(f-SX210.5-02(30)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/2147482907/210-825-10-599-50-1Reference28Reference14>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic310-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SABTopic4.E\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480418/310-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic310-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SABTopic4.E)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480418/310-10-599-2) Details Name: us-gaap\_StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph24-6>-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483421/2147483443/250-10-45-50-24Reference6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-805-SubTopic40-60-NameAccountingStandardsCodification-Section45-65-Paragraph23-1-Subparagraph\(b-g\)](http://www.xbrl.org/2003/role/disclosureRef-Topic250-805-SubTopic40-60-NameAccountingStandardsCodification-Section45-65-Paragraph23-1-Subparagraph(b-g))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483421/2147476176/250-805-40-60-45-65-23Reference1Reference3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-805-SubTopic40-60-NameAccountingStandardsCodification-Section45-65-Paragraph5-1-Subparagraph\(b-d\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483421/2147476176/250-805-40-60-45-65-5Reference1Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic250-805-SubTopic40-60-NameAccountingStandardsCodification-Section45-65-Paragraph5-1-Subparagraph(b-d)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483421/2147476176/250-805-40-60-45-65-5Reference1Reference4): [http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph\(e-g\)\(4\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480528/2147478666/815-740-20-323-65-6Reference2Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph(e-g)(4)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480528/2147478666/815-740-20-323-65-6Reference2Reference6): [http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph\(h-d\)\(+2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480528/2147478666/815-740-20-323-65-6Reference2Reference7](http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph(h-d)(+2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480528/2147478666/815-740-20-323-65-6Reference2Reference7): [http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph\(h-d\)\(1\)\(+\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/](http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic20-323-NameAccountingStandardsCodification-Section65-Paragraph6-2-Subparagraph(h-d)(1)(+)-PublisherFASB-URIhttps://asc.fasb.org/1943274/)



gaap\_StatementClassOfStockAxis gaap\_TreasuryStockCommonValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap\_CommonClassAMember gaap\_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementClassOfStockAxis gaap\_InvestmentTypeAxis = rfl\_CycleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_InvestmentTypeAxis = us-gaap\_CommonClassBMember gaap\_HedgeFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_InvestmentTypeAxis = rfl\_DayThreeLabsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_InvestmentTypeAxis = rfl\_OtherPharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_InvestmentTypeAxis gaap\_StatementClassOfStockAxis = us-gaap\_HedgeFundsMember gaap\_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementClassOfStockAxis gaap\_InvestmentTypeAxis = rfl\_INVESTMENTINDAYTHREELABSINCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_InvestmentTypeAxis = rfl\_InvestmentInCycloTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap\_RelatedPartyMember gaap\_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: Consolidated Balance Sheets (Parentheticals)- USD (\$) \$ in Thousands Jul. 31, 2023-2024 Jul. 31, 2022 Allowance 2023 Allowance for doubtful accounts credit losses (in Dollars) \$ 245 \$ 197 Class 245 Class A Common Stock Common stock, par value (in Dollars per share) \$ 0.01 \$ 0.01 Common stock, shares authorized 35,000,000 35,000,000 Common stock, shares issued 787,163 787,163 Common stock, shares outstanding 787,163 787,163 Class B Common Stock Common stock, par value (in Dollars per share) \$ 0.01 \$ 0.01 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 24,142,535 23,635,709 23,712,449 Common stock, shares outstanding 23,819,948 23,490,527-23-527 Treasury stock, 687 shares 101,964X-487X- Definition Amount of allowance for credit loss on accounts receivable, classified as current. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 Details Name: us-gaap\_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Definition Face amount or stated value per share of common stock. ReferencesReference 1: http://www.fasb.org/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instantX- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-5-04-02(29-16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/2147480566/946-210-10-S99-1Reference 2: http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic 946-SubTopic 210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-6-02-04(29-16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/2147479170/946-210-10-S99-1 Details Name: us-gaap\_CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: http://www.fasb.org/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Details Name: us-gaap\_CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: http://www.fasb.org/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.fasb.org/2003-us-gaap/role/disclosureRef/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 2-1-Subparagraph (SX 210.6-5-05-02(4-29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/2147480566/946-210-10-S99-2Reference 1Reference 3: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-2-Subparagraph (SX 210.6-09-05(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575-2147479170/946-220-210-S99-3Reference 2Reference 4: http://www.xbrl.org/2003-2009/role/disclosureRef/commonPracticeRef-Topic 946-SubTopic 240-220-Name Accounting Standards Codification-Section S99-Paragraph 3-3-Subparagraph (SX 210.6-04-09(16-4)(a-b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617-2147479134/946-240-220-S99-1Reference 3Reference 5: http://www.xbrl.org/2009-2003/role/commonPracticeRef/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210.6-09-04(7-16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575-2147479170/946-210-S99-1Reference 6: http://www.fasb.org/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-3-Subparagraph (SX 210.5-6-02-09(29-7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147479134/210-946-10-220-S99-3 Details Name: us Accounting Standards Codification-Section 50 gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566-2147479134/210-946-10-220-S99-3 Details Name: us Accounting Standards Codification-Section 50 gaap CommonStockSharesOutstanding gaap\_TreasuryStockCommonShares Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Details Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: Consolidated Statements of Operations and Comprehensive Loss- USD (\$) \$ in Thousands 12 Months Ended Jul. 31, 2023-2024 Jul. 31, 2022 REVENUE 2023 REVENUE Total revenue \$ 279,637 \$ 410,637 COSTS AND EXPENSES Cost of Infusion Technology revenue General and administrative 8,932-16,854 8,978 Research 932 Research and development 4,170 6,312-312 In 8-process research and development expense 89,861-742 Depreciation-Depreciation and amortization Provision-amortization Loss for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit 25,000 Provision for losses on related party receivables 10,095 Loss from operations (102,627) (15,043) (60,477) Interest expense (6) Interest income 2,383 3,253 Impairment of investments-Other Pharmaceuticals (334) Loss on initial impairment of cost method investment-Cornerstone Pharmaceuticals in Day Three upon acquisition (79-1,441-633) Realized gain (loss) on available-for-sale securities 1,455 Realized gain (loss) on investment in equity securities (46) Unrealized gain on investment in equity securities Realized gain on investment-Cyclo Unrealized gain (loss) on investments-investment-Cyclo 2,663 Unrealized gain on convertible notes receivable, due from Cyclo 1,191 Unrealized gain on investment-Hedge Funds Recovery of receivables from Cornerstone 31,305 Interest expense (248) Other income Loss from continuing operations before income taxes (67,261) (8,745) (139,972) Benefit from income taxes 2,680 Equity in loss of Day Three (422) (203) Consolidated net loss from continuing operations (65,003) (8,693) (140,547) Discontinued Operations (Note 3-14) Loss from discontinued operations related to 520 Property (306) (1,830) Gain on disposal of 520 Property 6,784 Income 784 Income (loss) from discontinued operations 6,478 (1,830) Consolidated 478 Consolidated net loss (65,003) (2,215) (142,377) Net loss attributable to noncontrolling interests (30,593) (339) (17,719) Net loss attributable to Rafael Holdings, Inc. (34,410) (1,876) (124,658) OTHER COMPREHENSIVE LOSS Consolidated net loss (65,003) (2,215) (142,377) Unrealized (loss) gain on available-for-sale securities (290) (63) Foreign currency translation adjustment (53) (42) (5) Total comprehensive Comprehensive loss (64,592) (2,547) (142,445) Comprehensive loss attributable to noncontrolling interests (30,595) (336) (17,746) Total comprehensive Comprehensive loss attributable to Rafael Holdings, Inc. \$ (33,997) \$ (2,211) \$ Income (loss) 124,699- Basic and diluted-per share attributable to common stockholders Continuing operations basic (in Dollars per share) \$ (1.45) \$ (0.36) Continuing \$ (6.22) Discontinued operations diluted (in Dollars per share) (1.45) (0.28-36) Discontinued operations basic (in Dollars per share) 0.09 28 Discontinued operations diluted (in Dollars per share) 0.28 Total basic loss per share (in Dollars per share) (1.45) (0.08) Total basic and diluted loss per share (in Dollars per share) \$ (1.45) \$ (0.08) \$ (6.31) Weighted average number of shares used in calculation of income (loss) per share Weighted average number of shares used in calculation of income (loss) per share Basic and diluted (in Shares) 23,745,516 23,263,211-19-211 Weighted average number of shares used in calculation of income (loss) per share diluted (in Shares) 23,767,745,516 23,263,211 Infusion Technology REVENUE Total revenue \$ 355 342 Rental-Rental-Third Party REVENUE Total revenue Rental revenue \$ 171 \$ 179 Rental-Related Party REVENUE Total revenue Other-Related Party REVENUE Total revenue \$ 108 \$ 108X- Definition Equity in Cyclo Therapeutics Inc COSTS AND EXPENSES Unrealized gain (loss) on investments 2,663 Hedge Funds COSTS AND EXPENSES Unrealized gain (loss) on investments (504) Day Three Labs Inc COSTS AND EXPENSES Equity in loss (203) RP Finance COSTS AND EXPENSES Equity in loss \$ (575) X-ReferencesNo definition available. Details Name: rfl-BasicAndDilutedAbstract rfl\_EquityInLossOfDayThreeLabsInc Namespace Prefix: rfl Data Type: xbrli:stringItemType monetaryItemType Balance Type: debit na-Period Type: durationX-ReferencesNo definition available. Details Name: rfl-DiscontinuedOperationsNote3Abstract Namespace Prefix: rfl Data Type: xbrli:stringItemType Balance Type: na-Period Type: durationX- Definition Amount impairment of cost method investment rafael pharmaceuticals. ReferencesNo definition available. Details Name: rfl\_ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals Namespace Prefix: rfl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition In-process research and development expense Definition Provision for loss on receivable pursuant to line of credit. ReferencesNo definition available. Details Name: rfl-ProvisionForLossOnReceivablePursuantToLineOfCredit rfl\_InProcessResearchAndDevelopmentExpense Namespace Prefix: rfl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Loss

DefinitionProvision for losses on related party receivables Initial investment in Day Three upon acquisition. ReferencesNo definition available. Details Name: rfl\_Provisionforlossesonrelatedpartyreceivables rfl\_LossOnInitialInvestmentInDayThreeUponAcquisition Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of realized gain in equity investments. ReferencesNo definition available. Details Name: rfl\_RealizedGainInEquityInvestmentsCycloTherapeuticsInc Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionRecovery of receivables from cornerstone. ReferencesNo definition available. Details Name: rfl\_RecoveryOfReceivablesFromCornerstone Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionRepresent the amount of unrealized gain on convertible notes receivable, due from cyclo. ReferencesNo definition available. Details Name: rfl\_UnrealizedGainOnConvertibleNotesReceivableDueFromCyclo Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionRepresent the amount of unrealized gain on investment- hedge funds. ReferencesNo definition available. Details Name: rfl\_UnrealizedGainOnInvestmentHedgeFunds Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe amount of unrealized loss gain on investment cyclo therapeutics inc. ReferencesNo definition available. Details Name: rfl\_UnrealizedlossGainOnInvestmentCycloTherapeuticsInc Namespace Prefix: rfl Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03 (24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-04 (26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589-942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-04 (22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586-2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-04 (20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 Details Name: us-gaap\_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-20-SubTopic 10-Topic 810-SubTopic 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 19Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03 (23-22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-04 (25-24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589-942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-220-SubTopic 220-10-Name Accounting Standards Codification-Section S99-45-Paragraph 1A-Subparagraph (c) SX 210. 7-04 (21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586-2147482790/944-220-S99-10-45-1AReference 5: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 45-Paragraph 21-1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231-2147482790/810-220-10-45-21Reference 1BReference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 1A-1-Subparagraph (e) SX 210. 7-04 (20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790-2147477250/944-220-10-S99-45-1AReference 1Reference 7: http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 45-55-Paragraph 4K 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790-2147481175/220-810-10-45-55-1BReference 8 4K Details Name: us-gaap\_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 55-Paragraph 4K-48-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175-2147482785/810-280-10-55-48Reference 2 4K-Details Name: http://fasb.org/us-gaap/ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-220-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 19-2-Subparagraph (SX 210. 5-03 (21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231-2147483621/810-220-10-45-S99-19Reference 2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-1-Subparagraph (SX 210. 5-4-03-08 (22-g) (i) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621-2147480678/220-235-10-S99-2Reference 1Reference 3-4: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-323-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-3-Subparagraph (c) SX 210. 9-04 (24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589-2147481687/942-323-220-10-S99-50-1Reference 3Reference 4 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-825-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-28-Subparagraph (f) SX 210. 7-04 (20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586-2147482907/944-825-220-10-S99-50-1Reference 28Reference 5-6: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-470-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 1A-Subparagraph (e) SX 210. 13-01 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790-2147480097/220-470-10-45-S99-1AReference 6 7: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 220-470-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 1B-1A-Subparagraph (b) SX 210. 13-01 (a) (4) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790-2147480097/220-470-10-45-S99-1BReference 1AReference 7 8: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-470-SubTopic 10-Section 55-Paragraph 4K-..... gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-S99-Paragraph 28-1A-Subparagraph (b) SX 210. 13-01 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 360-470-SubTopic 10-Section 50-Paragraph 1-..... legacyRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-S99-Paragraph 5C-1B-Subparagraph (b) SX 210. 13-02 (2-a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499-2147480097/205-470-20-10-50-S99-5CReference 1BReference 2 12: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 205-470-SubTopic 20-10-Name Accounting Standards Codification-Section 45-S99-Paragraph 3B-1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483475-2147480097/205-470-20-10-45-S99-3BReference 1BReference 3 13: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 205-470-SubTopic 20-10-Name Accounting Standards Codification-Section 50-S99-Paragraph 1B-Subparagraph (b) SX 210. 13-02 (a) (4) (iii) (B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499-2147480097/205-470-20-10-50-S99-1BReference 4 14: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 205-470-SubTopic 20-10-Name Accounting Standards Codification-Section 45-S99-Paragraph 3-1B-Subparagraph (SX 210. 13-02 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483475-2147480097/205-470-20-10-45-S99-1BReference 15 3-Details Name: us-gaap\_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal. ReferencesReference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 205-470-SubTopic 20-10-Name Accounting Standards Codification-Section 45-S99-Paragraph 3A-1B-Subparagraph (SX 210. 13-02 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483475-2147480097/205-470-20-45-3AReference 2:..... /disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-..... Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX..... 2147482790/220-10-45-1B Details Name: us-gaap\_NetIncomeLossAttributableToNoncontrollingInterest-gaap\_CostOfRevenue Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role..... 280-10-50-32 Details Name: us-gaap\_OperatingIncomeLoss-gaap\_CostsAndExpensesAbstract Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type:..... gaap

Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionAmount , after tax and before adjustment, of unrealized -- realized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available- for- sale) Paragraph 3 (18) - Publisher FASB- URI https://asc.fasb.org/ /1943274/214747250-2147481004/944-946-220-505-599-50-1Reference-3Reference-20-32: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220-210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.6-07-04 (9-19)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147479134-2147479617/946-220-210-599-1Reference-21-33: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220-210- Name Accounting Standards Codification- Section S99- Paragraph 1- Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to- maturity) from transfer to available- for- sale. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 320- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9- Subparagraph (d)- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147481800/320-10-50-9Reference-2: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 10A- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482790/220-10-45-10AReference-3: http://www.xbrl.org/2003/role/disclosureRef- Topic 220- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 11- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482790/220-10-45-11 Details Name: us-gaap\_OtherComprehensiveIncomeUnrealizedGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix Standards Codification- Section S99- Paragraph 3- Subparagraph (SX 210.6-09 (4) (b)) - Publisher FASB- URI https://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220-320- Name Accounting Standards Codification- Section S99- Paragraph 3-6- Subparagraph (SX 210.6-12-09-14 (6 Column E) (2)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483575-2147477271/946-220-320-599-3Reference-6Reference-36-2: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220-320- Name Accounting Standards Codification- Section S99- Paragraph 3-6- Subparagraph (SX 210.6-12-09-14 (7 Column E) (Footnote 4)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483575-2147477271/946-220-320-599-3Reference-6Reference-37-3: http://www.xbrl.org/2003/role/disclosureRef- Topic 505-946- SubTopic 40-320- Name Accounting Standards Codification- Section S99- Paragraph 1-6- Subparagraph (SX 210.3-12-04-14 (Column E) (Footnote 6) (b)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480008-2147477271/505-946-40-320-599-4Reference-6Reference-38-4: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 235-944- SubTopic 40-220- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.7-04 (4-08 (g) (1) (ii))) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480678-2147477250/235-944-40-220-599-1Reference-39-5: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 323-946- SubTopic 40-220- Name Accounting Standards Codification- Section 50-S99- Paragraph 3-1- Subparagraph (SX 210.6-07 (1) (c)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147481687-2147479134/323-946-40-220-50-S99-3Reference-40-1 Details Name: us-gaap\_OtherIncome http://www.Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 235-250- SubTopic 10- Name Accounting Standards Codification- Section S99-50- Paragraph 6-1- Subparagraph (SX 210.4-08 (g) (1) (iii)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480678-2147483443/235-250-10-599-50-1Reference-6Reference-2: http://www.xbrl.org/2003/role/disclosureRef- Topic 323-250- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9-3- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147481687-2147483443/323-250-10-50-3Reference-9Reference-3: http://www.xbrl.org/2003/role/disclosureRef- Topic 825-805- SubTopic 40-60- Name Accounting Standards Codification- Section 50-65- Paragraph 28-1- Subparagraph (4 g) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482907-2147476176/825-805-40-60-50-65-28Reference-1Reference-4: http://www.xbrl.org/2003/role/disclosureRef- Topic 250-740- SubTopic 40-323- Name Accounting Standards Codification- Section 50-65- Paragraph 1-2- Subparagraph (b g) (2-3) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483443-2147478666/250-740-323-65-2Reference-5: http://www.xbrl.org/2003/role/disclosureRef- Topic 235- SubTopic 10-50-1Reference-5: http://www.xbrl.org/2003/role/disclosureRef- Topic 815- SubTopic 40- Name Accounting Standards Codification- Section 65-S99- Paragraph 1- Subparagraph (4 SX 210.4-08 (g) (1) (ii)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480175-2147480678/815-235-40-10-65-S99-1Reference-6: http://www.xbrl.org/2003/role/disclosureRef- Topic 250-323- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8-3- Subparagraph (c) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483443-2147481687/250-323-10-50-8Reference-3Reference-7: http://www.xbrl.org/2003/role/disclosureRef- Topic 250-825- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9-28- Subparagraph (f) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483443-2147482907/825-10-50-28Reference-8: http://www.xbrl.org/2003/role/disclosureRef- Topic 250- SubTopic 10-50-9Reference-8: http://www.xbrl.org/2003/role/exampleRef- Topic 946- SubTopic 830- Name Accounting Standards Codification- Section 55-50- Paragraph 11-1- Subparagraph (b) (2) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480167-2147483443/946-250-830-10-55-50-11Reference-1Reference-9: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-815- SubTopic 205-40- Name Accounting Standards Codification- Section 45-65- Paragraph 3-1- Subparagraph (a f) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480767-2147480175/946-815-205-40-45-65-3Reference-1Reference-10: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-250- SubTopic 220-10- Name Accounting Standards Codification- Section 45-50- Paragraph 7-8- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483581-2147483443/250-10-50-8Reference-11: http://www.xbrl.org/2003/role/exampleRef- Topic 946-220-45-7Reference-11: http://www.xbrl.org/2003/role/disclosureRef- Topic 944- SubTopic 220-830- Name Accounting Standards Codification- Section S99-55- Paragraph 11-1- Subparagraph (SX 210.7-04 (16)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483586-2147479168/944-946-220-830-599-55-11Reference-11Reference-12: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-946- SubTopic 10-205- Name Accounting Standards Codification- Section 50-45- Paragraph 22-3- Subparagraph (a) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482810-2147478009/280-946-40-205-50-45-22Reference-3Reference-13: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220- Name Accounting Standards Codification- Section S99-45- Paragraph 7-1- Subparagraph (SX 210.6-07 (9)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483575-2147479105/946-220-599-45-7Reference-7Reference-14: http://www.xbrl.org/2003/role/disclosureRef- Topic 946-944- SubTopic 220- Name Accounting Standards Codification- Section S99- Paragraph 3-1- Subparagraph (SX 210.6-7-09-04 (16) (d)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147483575-2147477250/944-220-599-1Reference-15: http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 220-599-3Reference-15: http://www.xbrl.org/2003/role/disclosureRef- Topic 810- SubTopic 10- Name Accounting Standards Codification- Section 45-S99- Paragraph 19-1- Subparagraph (SX 210.6-07 (9)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147481231-2147479134/810-946-40-220-45-S99-19Reference-1Reference-16: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 946- SubTopic 220- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 3- Subparagraph (SX 210.6-09 (1) (d)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482765-2147479134/946-220-40-S99-50-6Reference-3Reference-17: http://www.xbrl.org/2003/role/disclosureRef- Topic 470-810- SubTopic 10- Name Accounting Standards Codification- Section S99-45- Paragraph 19-1A- Subparagraph (SX 210.13-01 (a) (4) (i)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097-2147481231/470-810-10-599-45-1AReference-19Reference-18: http://www.xbrl.org/2009/role/commonPracticeRef- Topic 470-220- SubTopic 10- Name Accounting Standards Codification- Section S99-50- Paragraph 6-1A- Subparagraph (SX 210.13-01 (a) (4) (ii)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097-2147482765/470-220-10-599-50-6Reference-6Reference-19: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210.13-01 (a) (4) (i iii) (A)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1AReference-20: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210.13-01 (a) (4) (i iv) (ii)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1AReference-21: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210.13-01 (a) (5-4) (iii) (A)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1AReference-22: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210.13-02-01 (a) (4) (i iv)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1BReference-1AReference-23: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B-1A- Subparagraph (SX 210.13-02-01 (a) (5-4) (iii) (A)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1BReference-24: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13-02 (a) (4) (i iii) (B)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1BReference-25: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13-02 (a) (4) (i-iii) (A)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1BReference-26: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210.13-02 (a) (5-4) (iii) (B)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147480097/470-10-S99-1BReference-27: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 30-1B- Subparagraph (b SX 210.13-02 (a) (4) (iv)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482810-2147480097/280-470-10-50-S99-30Reference-1BReference-28: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 32-1B- Subparagraph (f SX 210.13-02 (a) (5)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482810-2147480097/280-470-10-50-S99-32Reference-1BReference-29: http://www.xbrl.org/2003/role/exampleRef-disclosureRef- Topic 280-942- SubTopic 40-235- Name Accounting Standards Codification- Section 50-S99- Paragraph 31-1- Subparagraph (SX 210.9-05 (b) (2)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482810-2147477314/280-942-40-235-50-S99-31Reference-1Reference-30: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-205- SubTopic 40-20- Name Accounting Standards Codification- Section 50- Paragraph 7-32- Subparagraph (e)- Publisher FASB- URI https://asc.fasb.org/ /1943274/2147482810-2147483499/205-280-20-50-7Reference-31: http://www.xbrl.org/2003/role/exampleRef- Topic 810- SubTopic 10-50-32Reference-31: http://www.xbrl.org/2003/role/disclosureRef- Topic 942- SubTopic 235- Name Accounting Standards Codification- Section S99-55- Paragraph 4J-1- Subparagraph (SX 210.9-05 (b) (2)) - Publisher FASB- URI https://asc.fasb.org/ /1943274/2147479557-2147481175/942-810-235-10-599-55-1Reference-4JReference-32: http://www.xbrl.org/2003/role/disclosureRef-exampleRef- Topic 205-810- SubTopic 20-10- Name Accounting Standards Codification- Section 50-55- Paragraph 7

**4K** - Publisher FASB- URI <https://asc.fasb.org/1943274/2147483499-2147481175/205-810-20-10-50-55-7Reference-4KReference-33>; [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-45-Paragraph-41A-Subparagraph\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481175-2147482790-810-220-10-55-45-4KReference-1AReference-34](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-45-Paragraph-41A-Subparagraph(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481175-2147482790-810-220-10-55-45-4KReference-1AReference-34); [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-45-Paragraph-4K-1B-Subparagraph\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481175-2147482790/810-220-10-55-45-4KReference-1BReference-35](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-45-Paragraph-4K-1B-Subparagraph(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481175-2147482790/810-220-10-55-45-4KReference-1BReference-35); [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-21A-Subparagraph\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790-2147482740-220-230-10-45-1AReference-2Reference-36](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-21A-Subparagraph(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790-2147482740-220-230-10-45-1AReference-2Reference-36); [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-1B-1A-Subparagraph\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790-2147481203/220-810-10-45-50-1BReference-1AReference-37](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-1B-1A-Subparagraph(a)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790-2147481203/220-810-10-45-50-1BReference-1AReference-37); [http://www.xbrl.org/2003/role/disclosureRef-Topic-230-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-21A-Subparagraph\(c\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740-2147481203/230-810-10-45-50-2Reference-381A-Details-Name-us-gaap-ProfitLoss-Namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-credit-Period-Type-durationX-DefinitionAmount-of-realized-gain-loss-on-investment-ReferencesReference-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-230-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-21A-Subparagraph(c)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740-2147481203/230-810-10-45-50-2Reference-381A-Details-Name-us-gaap-ProfitLoss-Namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-credit-Period-Type-durationX-DefinitionAmount-of-realized-gain-loss-on-investment-ReferencesReference-1); [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-944-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1A-1-Subparagraph\(SX-210.7-04\(3\)\(a\)\(+\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203-2147477250-810-944-10-220-50-S99-1AReference-391-Details-Name-us-gaap-RealizedInvestmentGainsLosses-Namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-credit-Period-Type-durationX-DefinitionAmount-of-expense-for-research-and-development-Includes-but-is-not-limited-to-cost-for-computer-software-product-to-be-sold-leased-or-otherwise-marketed-and-writeoff-of-research-and-development-assets-acquired-in-transaction-other-than-business-combination-or-joint-venture-formation-or-both-Excludes-write-down-of-intangible-asset-acquired-in-business-combination-or-from-joint-venture-formation-or-both-used-in-research-and-development-activity-ReferencesReference-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-944-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1A-1-Subparagraph(SX-210.7-04(3)(a)(+)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203-2147477250-810-944-10-220-50-S99-1AReference-391-Details-Name-us-gaap-RealizedInvestmentGainsLosses-Namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-credit-Period-Type-durationX-DefinitionAmount-of-expense-for-research-and-development-Includes-but-is-not-limited-to-cost-for-computer-software-product-to-be-sold-leased-or-otherwise-marketed-and-writeoff-of-research-and-development-assets-acquired-in-transaction-other-than-business-combination-or-joint-venture-formation-or-both-Excludes-write-down-of-intangible-asset-acquired-in-business-combination-or-from-joint-venture-formation-or-both-used-in-research-and-development-activity-ReferencesReference-1); [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-48-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference-2](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-810-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-48-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference-2); <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147481004/280-946-10-505-50-32Reference-3Reference-25-32>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph\(SX-210.4-6-08-04\(19\)\(g\)\(+\)\(+\)\(+\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678-2147479617/235-946-10-210-S99-1Reference-8-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph(SX-210.4-6-08-04(19)(g)(+)(+)(+)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678-2147479617/235-946-10-210-S99-1Reference-8-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-946-SubTopic-10-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph\(e\)-SX-210.13-01\(1\)\(a\)\(4\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147481004/280-946-10-505-50-22Reference-3Reference-25-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-946-SubTopic-10-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph(e)-SX-210.13-01(1)(a)(4)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147481004/280-946-10-505-50-22Reference-3Reference-25-32); [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph\(SX-210.9-6-05-04\(19\)\(b\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477314-2147479617/942-946-235-210-S99-1Reference-26-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph(SX-210.9-6-05-04(19)(b)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477314-2147479617/942-946-235-210-S99-1Reference-26-33); <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-946-SubTopic-10-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-1943274/2147481203/810-10-50-1A-Details-Name-us-gaap-ProfitLoss-gaap-NoncontrollingInterestDecreaseFromDeconsolidation-Namespace-Prefix-us-gaap-Data-Type-xbrli:monetaryItemType-Balance-Type-credit-Debit-Period-Type-durationX-DefinitionAmount-of-realized-gain-loss-on-investment-increase-in-noncontrolling-interest-from-a-business-combination-ReferencesReference-1>; [http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Topic-805-SubTopic-20-Section-50-Paragraph-1-Subparagraph\(e\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479907/805-20-50-1Reference-2](http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Topic-805-SubTopic-20-Section-50-Paragraph-1-Subparagraph(e)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479907/805-20-50-1Reference-2); <http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-S99-Paragraph-1-Accounting-Standards-Codification-Section-50-Paragraph-9-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443-2147481004/250-946-10-505-50-9Reference-3Reference-3-32>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-946-SubTopic-60-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-1-Subparagraph\(g\)-SX-210.6-04\(19\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147476176-2147479617/805-946-60-210-65-S99-1Reference-4-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-946-SubTopic-60-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-1-Subparagraph(g)-SX-210.6-04(19)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147476176-2147479617/805-946-60-210-65-S99-1Reference-4-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-946-SubTopic-323-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-2-Subparagraph\(SX-210.7-4-04-08\(3-g\)\(a\)\(1\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586-2147480678-740-946-323-210-S99-2Reference-5-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-946-SubTopic-323-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-2-Subparagraph(SX-210.7-4-04-08(3-g)(a)(1)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586-2147480678-740-946-323-210-S99-2Reference-5-33); <http://www.xbrl.org/2003/role/disclosureRef-Topic-805-946-60-210-65-S99-1Reference-9-33>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-1-Subparagraph\(b\)-SX-210.6-04\(19\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443-2147479617/250-946-10-210-50-S99-1Reference-9-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-65-S99-Paragraph-1-Subparagraph(b)-SX-210.6-04(19)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443-2147479617/250-946-10-210-50-S99-1Reference-9-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1-Subparagraph\(SX-210.6-07-04\(9-19\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-16-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1-Subparagraph(SX-210.6-07-04(9-19)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-16-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph\(SX-210.6-07-04\(9-19\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-16-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph(SX-210.6-07-04(9-19)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-16-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph\(c\)-Costs-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147481004/946-220-505-S99-50-1Reference-9-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph(c)-Costs-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147481004/946-220-505-S99-50-1Reference-9-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph\(SX-210.6-07-04\(19\)\(2\)\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-9-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph(SX-210.6-07-04(19)(2)(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-9-33); [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph\(SX-210.6-07-04\(19\)\(2\)\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-9-33](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph(SX-210.6-07-04(19)(2)(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134-2147479617/946-220-210-S99-1Reference-9-33);

- 2147479617 / 606-946 - 40-210 - 50-S99 - 20Reference-1Reference-8-33: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-946-SubTopic-40-210> - Name Accounting Standards Codification- Section 50-S99 - Paragraph 20-Details Name: us-gaap-ResearchAndDevelopmentExpense

gaap-RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap Data Type: xbrli-dtr-types: textBlockItem Type: textBlockItem Type Balance Type: debit-na Period Type: durationX- DefinitionTabular disclosure of accounting policy revenue recognized from goods sold, services rendered, insurance premiums, or for other activities that constitute an earning process award under share-based payment arrangement. Includes, but is not limited to, investment methodology and assumption used in measuring cost interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-2-Subparagraph-\(f\)-\(i\)-\(1\)-Subparagraph-\(SX-210-4-08-\(g\)-\(1\)-\(iii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-2-Subparagraph-(f)-(i)-(1)-Subparagraph-(SX-210-4-08-(g)-(1)-(iii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678/2147480429/235-718-10-S99-50-1Reference-2Reference-2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-1-Subparagraph-\(e-f\)-\(2\)-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480097/323-718-10-50-3Reference-2Reference-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-1-Subparagraph-(e-f)-(2)-(i)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480097/323-718-10-50-3Reference-2Reference-3): [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-2-Subparagraph-\(f\)-\(2\)-\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907-2147480429/825-718-10-50-28Reference-2Reference-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-2-Subparagraph-(f)-(2)-(ii)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482907-2147480429/825-718-10-50-28Reference-2Reference-4): [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-2-Subparagraph-\(f\)-\(2\)-\(v\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147483621-2147480429/220-718-10-S99-50-2Reference-5](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-2-Subparagraph-(f)-(2)-(v)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147483621-2147480429/220-718-10-S99-50-2Reference-5): [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-\(SX-210-SAB-Topic-14-C-Q3-13-01-\(a\)-\(4\)-\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-(SX-210-SAB-Topic-14-C-Q3-13-01-(a)-(4)-(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/2147479830/470-718-10-S99-1AReference-1Reference-6>: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-\(SX-210-SAB-Topic-14-D.1-Q5-13-01-\(a\)-\(4\)-\(ii\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-(SX-210-SAB-Topic-14-D.1-Q5-13-01-(a)-(4)-(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/2147479830/470-718-10-S99-1AReference-1Reference-7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-\(SX-210-SAB-Topic-14-D.3-Q2-13-01-\(a\)-\(4\)-\(iii\)-\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-(SX-210-SAB-Topic-14-D.3-Q2-13-01-(a)-(4)-(iii)-(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/2147479830/470-718-10-S99-1AReference-1Reference-8>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-\(SX-210-SAB-Topic-14-D.2-Q6-13-01-\(a\)-\(4\)-\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-1-Subparagraph-(SX-210-SAB-Topic-14-D.2-Q6-13-01-(a)-(4)-(iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/2147479830/470-718-10-S99-1AReference-1Reference-9>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-718-10-S99-1AReference-10>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-2-Subparagraph-\(b\)-SX-210-13-02-\(a\)-\(4\)-\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-2-Subparagraph-(b)-SX-210-13-02-(a)-(4)-(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147480429/470-718-10-S99-50-1BReference-2Reference-11>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-2-Subparagraph-\(f\)-\(2\)-\(a\)-\(4\)-\(iii\)-\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-2-Subparagraph-(f)-(2)-(a)-(4)-(iii)-(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147480429/470-718-10-S99-50-1BReference-12-2-Details-Name-us-gaap-ShareBasedCompensationOptionAndIncentivePlansPolicy> Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItem Type Balance Type: na Period Type: durationX- DefinitionTabular disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. ReferencesReference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-599-50-Paragraph-9-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(B\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-599-50-Paragraph-9-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147482861/470-275-10-S99-50-1BReference-9Reference-13-2>: [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-599-50-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iv\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-599-50-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147482861/470-275-10-S99-50-1BReference-4Reference-14-3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-1-Subparagraph-\(SX-b\)-SubTopic-210-10-13-Topic-275-02-\(a\)-\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-50-Paragraph-1B-1-Subparagraph-(SX-b)-SubTopic-210-10-13-Topic-275-02-(a)-(5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147482861/470-275-10-S99-50-1BReference-15-4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-1-Subparagraph-\(a-c\)-SubTopic-10-Topic-275](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-1-Subparagraph-(a-c)-SubTopic-10-Topic-275) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482861/280-275-10-50-30Reference-1Reference-16-5>: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-42-11-SubTopic-10-Topic-275> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482861/280-275-10-50-42Reference-11Reference-17-6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-12-Subparagraph-\(b\)-SubTopic-10-Topic-275](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-12-Subparagraph-(b)-SubTopic-10-Topic-275) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482861/280-275-10-50-22Reference-12Reference-18-7>: [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-50-Paragraph-8-32-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482810-2147482861/280-275-10-50-stage-development-efforts-including-pre-clinical-research-at-Barer-The-decision-was-taken-to-reduce-spending-as-the-company-focuses-on-exploring-strategic-opportunities.\\*-During-Fiscal-2022-the-company-discontinued-further-material-investment-in-Leveo-In-August-2023-Leveo-was-dissolved.\\*-50%of-CS-Pharma-Holdings,LLC-is-owned-by-Pharma-Holdings,LLC.We-have-a-90%ownership-in-Pharma-Holdings,LLC-and-therefore-an-effective-45%interest-in-CS-Pharma-Holdings,LLC.The-company-along-with-CS-Pharma-Holdings,LLC-and-Pharma-Holdings,LLC-collectively-own-securities-representing-67.51%of-the-outstanding-capital-stock-of-Cornerstone-Pharmaceuticals-and-42%of-the-capital-stock-on-a-fully-diluted-basis-\(excluding-the-remainder-of-the-Warrant\).\\*-\\*-\\*In-May-Refer-to-Note-4-for-further-details.During-Fiscal-2024-2022-the-company-discontinued-further-material-investment-in-Leveo.On-February-9,2023-the-company-increased-its-ownership-interest-in-LipoMedix-Pharmaceuticals-Ltd-Day-Three-Labs,Inc.-from-79-an-additional-32Reference-11Reference-19](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-50-Paragraph-8-32-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482810-2147482861/280-275-10-50-stage-development-efforts-including-pre-clinical-research-at-Barer-The-decision-was-taken-to-reduce-spending-as-the-company-focuses-on-exploring-strategic-opportunities.*-During-Fiscal-2022-the-company-discontinued-further-material-investment-in-Leveo-In-August-2023-Leveo-was-dissolved.*-50%of-CS-Pharma-Holdings,LLC-is-owned-by-Pharma-Holdings,LLC.We-have-a-90%ownership-in-Pharma-Holdings,LLC-and-therefore-an-effective-45%interest-in-CS-Pharma-Holdings,LLC.The-company-along-with-CS-Pharma-Holdings,LLC-and-Pharma-Holdings,LLC-collectively-own-securities-representing-67.51%of-the-outstanding-capital-stock-of-Cornerstone-Pharmaceuticals-and-42%of-the-capital-stock-on-a-fully-diluted-basis-(excluding-the-remainder-of-the-Warrant).*-*-*In-May-Refer-to-Note-4-for-further-details.During-Fiscal-2024-2022-the-company-discontinued-further-material-investment-in-Leveo.On-February-9,2023-the-company-increased-its-ownership-interest-in-LipoMedix-Pharmaceuticals-Ltd-Day-Three-Labs,Inc.-from-79-an-additional-32Reference-11Reference-19) - ReferencesNo definition available. Details Name: us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership. ReferencesNo definition available. Details Name: us-gaap-ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock Namespace Prefix: us-gaap Data Type: dtr-types: textBlockItem Type Balance Type: na Period Type: durationSummary of Significant Accounting Policies (Tables) 12 Months Ended Jul. 31, 2024 Summary of Significant Accounting Policies [ Abstract ] Schedule of Estimated Useful Lives of Long-Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost less accumulated depreciation and amortization. The related depreciation and amortization are computed using the straight-line method over the estimated useful lives, which range as follows: Classification Years Building and improvements Tenant improvements 7- 15 Machinery and equipment 3- 5 Other (primarily office equipment, furniture and fixtures) X- DefinitionTabular disclosure of estimated useful lives of long lived assets. ReferencesNo definition available. Details Name: rfl-ScheduleOfEstimatedUsefulLivesOfLongLivedAssets Namespace Prefix: rfl Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap-AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationCornerstone Restructuring, Acquisition, and RP Finance Consolidation (Tables) 12 Months Ended Jul. 31, 2024 Cornerstone Restructuring, Acquisition, and RP Finance Consolidation [ Abstract ] Schedule of Fair Value Measurements and Disclosures The following table presents, in accordance with ASC 810, the sum of (i) the fair value of consideration paid, (ii) the fair value of noncontrolling interests, and (iii) the reported amount of previously held interests (amounts in thousands): Fair value of consideration paid Fair value of RFL Line of Credit \$ 37, 845 Fair value of 2023 Promissory Note 2, 663 Cash consideration 1, 500 (i) Total fair value of consideration paid 42, 008 (ii) Fair value of noncontrolling interests 27, 501 (iii) Reported value of previously held interests (1) — Sum of (i), (ii), and (iii) \$ 69, 509 (1) Rafael's interest in the Series D Preferred Stock of Cornerstone, that was converted into Cornerstone Common Stock in the Cornerstone Restructuring, represents a previously held interest in Cornerstone that is included at its reported amount, or \$ 0. (i) Fair value of consideration paid \$ — (ii) Fair value of noncontrolling interests 12, 667 (iii) Reported value of previously held interests (1) — Sum of (i), (ii), and (iii) \$ 12, 667 (1) Rafael ownership of 37. 5 % of the equity interests in RP Finance, accounted for as an equity method investment prior to the RP Finance Consolidation, represents a previously held interest in Cornerstone that is included at its reported amount, or \$ 0. Schedule of Assets and Liabilities Recognized The following table presents, in accordance with ASC 810, the net preliminary amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805 (amounts in thousands): Assets acquired and liabilities assumed Cash and cash equivalents \$ 2, 756 Prepaid expenses and other current assets 121 Property and equipment 19 Other assets 48 Acquired IPR & D 89, 861 Accounts payable (2, 006) Accrued expenses (1, 188) Series C Convertible Notes, short-term portion (614) Due to related parties (1, 289) Other current liabilities (28) Series C Convertible Notes, long-term portion (70) Creditor payable, noncurrent (2, 745) Amended RPF Line of Credit (15, 336) Other liabilities (20) Total \$ 69, 509 The following table presents, in accordance with ASC 810, the net amount of the VIE's identifiable assets and liabilities recognized and measured in accordance with ASC 805 (amounts in thousands): Assets acquired and liabilities assumed Investments- Cornerstone common stock \$ 4, 931 Due from Cornerstone- Amended RPF Line of Credit 15, 336 Total \$ 20, 267 Schedule of Pro Forma Results of Operations The pro forma results of operations are presented for informational purposes only and are not indicative of the results of operations that would have been achieved if the Cornerstone Restructuring, the Cornerstone Acquisition, and RP Finance Consolidation had taken place on the date noted above, or of results that may occur in the future. (in thousands, except for share and per share amounts) Twelve Months ended July 31, 2024 2023 Revenue \$ 637 \$ 279 Loss from operations (15, 803) (117, 234) Net loss from continuing operations attributable to common stockholders (6, 745) (42, 483) Net loss per share from continuing operations attributable to common stockholders (0. 28) (1. 83) Weighted average common shares outstanding 23, 745, 516 23, 263, 211 X- DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. ReferencesReference 1: [http://www.xbrl.org/2003-2009/role/commonPracticeRef-disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-40-2-Subparagraph-\(h\)-\(2\)-SubTopic-10-Topic-805](http://www.xbrl.org/2003-2009/role/commonPracticeRef-disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-40-2-Subparagraph-(h)-(2)-SubTopic-10-Topic-805) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147479328/280-805-10-50-40Reference-2Reference-20-2>: <http://www.xbrl.org/2003-2009/role/commonPracticeRef>



43.00 % Lipomedix Pharmaceuticals Ltd. [ Member ] Investment In Cornerstone [ Line Items ] Ownership percentage 95.00 % 95.00 % Financing principal amount (in Dollars) \$ 400,000 Interest rate 8.00 % Purchase of ordinary shares (in Shares) 15,975,000 15,975,000 15,975,000 Purchase price (in Dollars) \$ 3,000,000 Principal amount outstanding (in Dollars) \$ 400,000 Accrued interest (in Dollars) \$ 211,800 Cash payment (in Dollars) \$ 2,600,000 Noncontrolling interest percentage 16.00 % 16.00 % Issued and outstanding ordinary shares, percentage 95.00 % Lipomedix Pharmaceuticals Ltd. [ Member ] [ Warrant [ Member ] Investment In Cornerstone [ Line Items ] Price per share (in Dollars per share) \$ 0.1878 LipoMedix SPA [ Member ] Investment In Cornerstone [ Line Items ] Purchase of ordinary shares (in Shares) 70,000,000 Price per share (in Dollars per share) \$ 0.03 Purchase price (in Dollars) \$ 2,100,000 \$ 3,000,000 Investment owned percentage 5.00 % RPF Line of Credit [ Member ] Investment In Cornerstone [ Line Items ] Amount of revolving commitment to funds (in Dollars) \$ 50,000,000 \$ 50,000,000 Post- Reverse Stock Split [ Member ] Investment In Cornerstone [ Line Items ] Stock split (in Shares) 261,230 Line of Credit Agreement [ Member ] Investment In Cornerstone [ Line Items ] Loan from line of credit agreement (in Dollars) 25,000,000 \$ 25,000,000 Payment to fund RP finance line of credit (in Dollars) 21,900,000 Amount of revolving commitment to funds (in Dollars) \$ 50,000,000 Minimum [ Member ] Investment In Cornerstone [ Line Items ] Interest rate 5.01 % Minimum [ Member ] RPF Line of Credit [ Member ] Investment In Cornerstone [ Line Items ] Debt instrument amount (in Dollars) 21,900,000 21,900,000 Maximum [ Member ] Investment In Cornerstone [ Line Items ] Interest rate 5.19 % 767,342X-DefinitionThe-% Maximum [ Member ] RPF Line of Credit [ Member ] Investment In Cornerstone [ Line Items ] Debt instrument amount of net income ( loss in Dollars ) for Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_RentalThirdPartyMember Namespace Prefix: rf1-Data Type: na Balance Type: Period Type: X-Details Name: rf1-FullyDilutedCapitalStock us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_RentalRelatedPartyMember Namespace Prefix: rf1-Data Type: na dtr:percentItem Type-Balance Type: na-Period Type: durationX-X-ReferencesNo definition available-Details Name: rf1-IndirectInterestAssetsPercentage us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_OtherRelatedPartyMember Namespace Prefix: rf1-Data Type: na dtr:percentItem Type-Balance Type: na-Period Type: durationX-X-ReferencesNo definition available-Details Name: rf1-InvestmentInCornerstoneLineItems us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_InvestmentInCycloTherapeuticsIncMember Namespace Prefix: rf1-Data Type: na xbrli:stringItem Type-Balance Type: na-Period Type: durationX-X-ReferencesNo definition available-Details Name: rf1-IssuedAndOutstandingOrdinarySharesPercentage us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap\_HedgeFundsMember Namespace Prefix: rf1-Data Type: na dtr:percentItem Type-Balance Type: na-Period Type: durationX-X-DefinitionOwnership interest percentage-ReferencesNo definition available-Details Name: rf1-OwnershipInterestPercentage us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_DayThreeLabsIncMember Namespace Prefix: rf1-Data Type: na dtr:percentItem Type-Balance Type: na-Period Type: durationX-X-DefinitionOwnership interests-ReferencesNo definition available-Details Name: rf1-OwnershipInterests us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = rf1\_RPFinanceLLCMember Namespace Prefix: rf1-Data Type: na dtr:percentItem Type-Balance Type: na-Period Type: Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. ReferencesNo definition available to each-Details Name: rf1\_PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent Namespace Prefix: rf1-Data Type: dtr:percentItem Type-Balance Type: na-Period Type: durationX-DefinitionPercentage of issued and outstanding equity. ReferencesNo definition available. Details Name: rf1\_PercentageOfIssuedAndOutstandingEquity Namespace Prefix: rf1-Data Type: dtr:percentItem Type-Balance Type: na-Period Type: durationX-DefinitionPercentage of issued and outstanding share shares of common stock or common unit outstanding during the reporting-ReferencesNo definition available. Details Name: rf1\_PercentageOfIssuedAndOutstandingShare Namespace Prefix: rf1-Data Type: dtr:percentItem Type-Balance Type: na-Period Type: and to each Type: durationX-DefinitionPercentage of RP finance line of credit. ReferencesNo definition available. Details Name: rf1\_PercentageOfRPFfinanceLineOfCredit Namespace Prefix: rf1-Data Type: dtr:percentItem Type-Balance Type: na-Period Type: durationX-DefinitionPrincipal due accrued interest. ReferencesNo definition available. Details Name: rf1\_PrincipalDueAccruedInterest Namespace Prefix: rf1-Data Type: xbrli:monetaryItem Type-Balance Type: debit Period Type: durationX-DefinitionAmount of promissory note. ReferencesNo definition available. Details Name: rf1\_PromissoryNote Namespace Prefix: rf1-Data Type: xbrli:monetaryItem Type-Balance Type: debit Period Type: durationX-DefinitionThe percentage of promissory note interest rate. ReferencesNo definition available. Details Name: rf1\_PromissoryNoteInterestRate Namespace Prefix: rf1-Data Type: dtr:percentItem Type-Balance Type: na-Period Type: durationX-DefinitionAmount of receivable balance due. ReferencesNo definition available. Details Name: rf1\_ReceivableBalanceDue Namespace Prefix: rf1-Data Type: xbrli:monetaryItem Type-Balance Type: debit Period Type: durationX-DefinitionExercise price per share or per unit that would have been of warrants or rights outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period-ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147481112-250-505-10-50-3-Reference 2-3 Details Name: us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Namespace Prefix: us-gaap-Data Type: dtr:types:perShareItem Type-Balance Type: na-Period Type: instantX-DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-505-SubTopic 10-Name Accounting Standards Codification-Section 55-50-Paragraph 15-3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482635-2147481112/260-505-10-55-50-15-Reference 3-Details Name: us-gaap\_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type-Balance Type: na-Period Type: instantX-DefinitionFace (par) amount of debt instrument at time of issuance. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 815-835-SubTopic 40-30-Name Accounting Standards Codification-Section 65-55-Paragraph 8-1-Subparagraph (e)-(4)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480175-2147482949-815-835-40-30-65-55-8-Reference 8-Reference 4-2: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-470-SubTopic 40-20-Name Accounting Standards Codification-Section 65-50-Paragraph 1-B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480175-2147481139-815-40-470-65-20-50-1-Reference 1-Reference 5-3: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 250-470-SubTopic 40-20-Name Accounting Standards Codification-Section 50-55-Paragraph 69B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147481568/470-250-20-10-55-50-11-Reference 69B-Reference 6-4: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 250-470-SubTopic 40-20-Name Accounting Standards Codification-Section 50-55-Paragraph 69C-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147481568/470-250-20-10-55-50-11-Reference 69C-Reference 7-5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-835-SubTopic 40-30-Name Accounting Standards Codification-Section 50-Paragraph 1-7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147482900/250-835-40-30-50-7-Reference 1-Reference 8-6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-835-SubTopic 40-30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482689-2147482925/260-835-40-30-45-2-Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-323-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 2-Subparagraph (SX 210. 5-03 (9))-Subparagraph (d-a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481800-2147483621/320-220-10-50-S99-9-Reference 2-Reference 2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 10A-2-Subparagraph (e-SX 210. 5-03 (7)(c))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482790-2147483621/220-10-45-S99-10A-Reference 2-Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 11-Subparagraph (SX 210. 7-04 (3)(d)(1))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482790-2147477250/944-220-10-S99-11-Details Name: us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax us-gaap-DebtSecuritiesRealizedGainLoss Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type-Balance Type: credit Period Type: durationX-DefinitionThe consolidated profit percentage of ownership of common stock or loss equity participation in the investee accounted for under the equity method period, net of accounting income taxes, including the portion attributable to the noncontrolling interest. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-323-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-Subparagraph (a)(1)-Subparagraph (SX 210. 4-08 (g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480678-2147481687/235-323-10-S99-50-3-Reference 2-3 Details Name: us-gaap\_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap-Data Type: dtr:types:percentItem Type-Balance Type: na-Period Type: instantX-DefinitionRate of interest on investment. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 323-946-SubTopic 40-210-Name Accounting Standards Codification-Section 50-55-Paragraph 1-3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481687-2147477439/323-946-40-210-50-55-3-Reference 1-Reference 3-2: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 825-320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482907-2147481800/825-320-10-50-28-Reference 2-Reference 4-3: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 250-320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147481800/250-320-10-50-5-Reference 5-Reference 5-4: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-946-SubTopic 40-320-Name Accounting Standards Codification-Section 65-S99-Paragraph 1-2-Subparagraph (fSX 210. 12-12A (Column A) (Footnote 2))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480175-2147477271/815-946-40-320-65-S99-1-Reference 2-Reference 6-5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-946-SubTopic 40-320-Name Accounting Standards Codification-Section 50-S99-Paragraph 8-2-Subparagraph (SX 210. 12-12A (Column A) (Footnote 3))-

Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483443-2147477271/250-946-40-320-50-S99-8Reference-2Reference-7-6>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-9-1-Subparagraph-\(SX-210-12-12-Column-A\)-\(Footnote-2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-9-1-Subparagraph-(SX-210-12-12-Column-A)-(Footnote-2))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483443-2147477271/250-946-40-320-50-S99-9Reference-1Reference-8-7>; [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-946-SubTopic-830-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-1-6-Subparagraph-\(SX-210-12-14-Column-A\)-\(Footnote-2\)\)](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-946-SubTopic-830-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-1-6-Subparagraph-(SX-210-12-14-Column-A)-(Footnote-2))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480167-2147477271/946-830-320-55-S99-11Reference-6Reference-9-8>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-205-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-3-1-Subparagraph-\(a-SX-210-12-12-Column-A\)-\(Footnote-4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-205-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-3-1-Subparagraph-(a-SX-210-12-12-Column-A)-(Footnote-4))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480767-2147477271/946-205-320-45-S99-3Reference-1Reference-10-9>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-7-3-Subparagraph-\(SX-210-12-12B-Column-A\)-\(Footnote-3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-7-3-Subparagraph-(SX-210-12-12B-Column-A)-(Footnote-3))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483581-2147477271/946-220-320-45-S99-7Reference-3Reference-11-10>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-946-SubTopic-220-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-3-Subparagraph-\(SX-210-7-12-04-12B-16-Column-A\)-\(Footnote-4\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-946-SubTopic-220-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-3-Subparagraph-(SX-210-7-12-04-12B-16-Column-A)-(Footnote-4)(a))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483586-2147477271/944-946-220-320-S99-1Reference-3Reference-12-11>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-22-6-Subparagraph-\(SX-210-12-14-Column-A\)-\(Footnote-3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-22-6-Subparagraph-(SX-210-12-14-Column-A)-(Footnote-3))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147477271/280-946-40-320-50-S99-22Reference-13-6-Details-Name-us-gaap-InvestmentInterestRate-namespace-Prefix-us-gaap-Data-Type-dtr-types-percentItem-Type-Balance-Type-na-Period-Type-instantX-Definition-Maturity-Date-of-investment-in-YYYY-MM-DD-format-References-Reference-1>; [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-\(SX-210-6-07-\(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-946-SubTopic-220-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-(SX-210-6-07-(9))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147477439/946-220-210-S99-55-1Reference-14-2>; [http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic-946-320-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-3-5-Subparagraph-\(f-SX-210-6-09-\(1\)-\(d\)\)](http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic-946-320-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-3-5-Subparagraph-(f-SX-210-6-09-(1)-(d))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147481800/946-320-220-10-S99-50-3Reference-5Reference-15-3>; [http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic-810-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-49-2-Subparagraph-\(d\)\)](http://www.xbrl.org/2003/2009/role/disclosureRef-commonPracticeRef-Topic-810-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-49-2-Subparagraph-(d))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481800/810-320-10-45-50-19Reference-2Reference-16-4>; [http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-Topic-220-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-6-2-Subparagraph-\(SX-210-12-12A-Column-A\)-\(Footnote-2\)\)](http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-Topic-220-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-6-2-Subparagraph-(SX-210-12-12A-Column-A)-(Footnote-2))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482765-2147477271/220-946-40-320-50-S99-6Reference-2Reference-17-5>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-2-Subparagraph-\(SX-210-13-12-01-12A-\(a-Column-A\)-\(Footnote-3\)\(4\)-\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-2-Subparagraph-(SX-210-13-12-01-12A-(a-Column-A)-(Footnote-3)(4)-(i))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-40-320-S99-1Reference-1Reference-18-6>; [http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-\(SX-210-13-12-01-12-\(a-Column-A\)-\(Footnote-2\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-(SX-210-13-12-01-12-(a-Column-A)-(Footnote-2)(4)(ii))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-40-320-S99-1Reference-1Reference-19-7>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-\(SX-210-13-12-01-12-\(a-Column-A\)-\(Footnote-4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-(SX-210-13-12-01-12-(a-Column-A)-(Footnote-4)(iv))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-40-320-S99-1Reference-1Reference-20-9>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-3-Subparagraph-\(SX-210-13-12-01-12B-\(a-Column-A\)-\(5-Footnote-3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-3-Subparagraph-(SX-210-13-12-01-12B-(a-Column-A)-(5-Footnote-3))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-320-S99-3Reference-10-S99-1Reference-22-1>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-3-Subparagraph-\(SX-210-13-12-02-12B-Column-A\)-\(Footnote-4\)\(a\)-\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-3-Subparagraph-(SX-210-13-12-02-12B-Column-A)-(Footnote-4)(a)-(4)(i))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-40-320-S99-1BReference-3Reference-23-11>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-6-Subparagraph-\(SX-210-13-12-02-14-Column-A\)-\(4\)\(iii\)-\(A\)-\(Footnote-3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-6-Subparagraph-(SX-210-13-12-02-14-Column-A)-(4)(iii)-(A)-(Footnote-3))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477271/470-946-40-320-S99-1BReference-24-6-Details-Name-us-gaap-InvestmentMaturityDate-namespace-Prefix-us-gaap-Data-Type-xbrl:dateTimeType-Balance-Type-na-Period-Type-instantX-Definition-Amount-of-principal-of-investment-owned-References-Reference-1>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1B-6-Subparagraph-\(c-SX-210-13-02-\(a\)-\(4\)\(iii\)-\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1B-6-Subparagraph-(c-SX-210-13-02-(a)-(4)(iii)-(B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147478795/470-946-40-210-S99-50-1BReference-6Reference-25-2>; [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-1B-Subparagraph-(SX-210-13-02-(a)-(4)(iv))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147477439/470-946-40-210-S99-55-1BReference-1Reference-26-3>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1B-1-Subparagraph-\(SX-210-13-02-\(a\)-\(1\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1B-1-Subparagraph-(SX-210-13-02-(a)-(1)(5))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147478795/470-946-40-210-S99-50-1BReference-1Reference-27-4>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-30-1-Subparagraph-\(b-SX-210-12-12-Column-B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-30-1-Subparagraph-(b-SX-210-12-12-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147477271/280-946-40-320-50-S99-30Reference-1Reference-28-5>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-32-3-Subparagraph-\(f-SX-210-12-12B-Column-B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-32-3-Subparagraph-(f-SX-210-12-12B-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147477271/280-946-40-320-50-S99-32Reference-3Reference-29-6>; [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-31-6-Subparagraph-\(SX-210-12-14-Column-B\)\)](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-280-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-31-6-Subparagraph-(SX-210-12-14-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147477271/280-946-40-320-50-S99-31Reference-30-320-S99-6-Details-Name-us-gaap-InvestmentOwnedBalancePrincipalAmount-namespace-Prefix-us-gaap-Data-Type-xbrl:monetaryItem-Type-Balance-Type-debit-Period-Type-instantX-Definition-Number-of-shares-of-investment-owned-References-Reference-1>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-6-Subparagraph-\(c\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-6-Subparagraph-(c)-Publisher-FASB-URI) <https://asc.fasb.org/#1943274/2147482810-2147478795/280-946-40-210-50-32Reference-6Reference-31-2>; [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-\(SX-210-9-05-\(b\)-\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-942-946-SubTopic-235-210-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-(SX-210-9-05-(b)-(2))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479557-2147477439/942-946-235-210-S99-55-1Reference-32-3>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-205-946-SubTopic-20-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-1-Subparagraph-\(a\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-205-946-SubTopic-20-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-1-Subparagraph-(a)(1))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483499-2147478795/205-946-20-210-50-7Reference-1Reference-33-4>; [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-4-1-Subparagraph-\(SX-210-12-12-Column-B\)\)](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-4-1-Subparagraph-(SX-210-12-12-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481175-2147477271/810-946-40-320-55-S99-4Reference-1Reference-34-5>; [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-4K-3-Subparagraph-\(SX-210-12-12B-Column-B\)\)](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic-810-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-55-S99-Paragraph-4K-3-Subparagraph-(SX-210-12-12B-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481175-2147477271/810-946-40-320-55-S99-4Reference-3Reference-35-6>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1A-6-Subparagraph-\(a-SX-210-12-14-Column-B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-946-SubTopic-40-320-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1A-6-Subparagraph-(a-SX-210-12-14-Column-B))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482790-2147477271/220-946-40-320-45-S99-1AReference-36-6-Details-Name-us-gaap-InvestmentOwnedBalanceShares-namespace-Prefix-us-gaap-Data-Type-xbrl:sharesItem-Type-Balance-Type-na-Period-Type-instantX-Definition-Percentage-of-investment-owned-to-net-assets-References-Reference-1>; [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-220-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-45-55-Paragraph-1-1B-Subparagraph-\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-220-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-45-55-Paragraph-1-1B-Subparagraph-(a))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482790-2147477439/220-946-40-210-45-55-1BReference-1Reference-37-2>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-230-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-2-6-Subparagraph-\(a\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-230-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-2-6-Subparagraph-(a)(1))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482740-2147478795/230-946-40-210-45-50-2Reference-6Reference-38-3>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-6-Subparagraph-\(a\)-\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-6-Subparagraph-(a)-(2))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203-2147478795/810-946-40-210-50-1AReference-6Reference-39-4>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-1-Subparagraph-\(c\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-946-SubTopic-40-210-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-1-Subparagraph-(c)(1))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203-2147478795/810-946-Paragraph-3-Publisher-FASB-URI> <https://asc.fasb.org/#1943274/2147478795-2147481004/946-210-505-50-6Reference-3Reference-6-32>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-12-6-12-04-19-Column-C\)-\(Footnote-5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-12-6-12-04-19-Column-C)-(Footnote-5))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147477271/946-320-210-S99-1Reference-7-33>; <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-10>; [http://www.xbrl.org/2003/role/disclosureRef-50-Topic-946-1A-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-\(SX-210-12-14-Column-F\)-\(Footnote-7\)\)](http://www.xbrl.org/2003/role/disclosureRef-50-Topic-946-1A-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-(SX-210-12-14-Column-F)-(Footnote-7))); Publisher FASB- URI <https://asc.fasb.org/#1943274/2147477271/946-320-S99-6-Details-Name-us-gaap-ProfitLoss-gaap-InvestmentOwnedPercentOfNetAssets-namespace-Prefix-us-gaap-Data-Type-dtr-Publisher-FASB-types-URI> <https://asc.fasb.org/#1943274/2147480008/505-40-S99-1Reference-38-Definition-Fair-value-portion-of-investment-securities-including-but-not-limited-to-marketable-securities-derivative-financial-instruments-and-investments-accounted-for-under-the-equity-method-References-Reference-1>; [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-2E-1-Subparagraph-\(SX-210-4-08-\(g\)-\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-2E-1-Subparagraph-(SX-210-4-08-(g)-(1)(ii))); Publisher FASB- URI [https://asc.fasb.org/#19](https://asc.fasb.org/#1943274/2147480678-2147482106/235-820-10-S99-50-1Reference-2Reference-39-2)

www.xbrl.org / 2009 / role / commonPracticeRef- Topic 825-820 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 28-2 - Subparagraph (f-a) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147482907 2147482106 / 825-820 - 10- 50- 28Reference 41-2 Details Name: http://fasb.org / us-  
gaap\_ InvestmentsFairValueDisclosure Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: 210- Paragraph 3 - Publisher FASB- URI  
https://asc.fasb.org / #1943274 / 2147480566-2147481004 / 210-946 - 10-505- S99-50- 1Reference 3Reference 2-32 http:// fasb- www.xbrl. org / 2003 us- gaap- role /  
disclosureRef- ref/ legacyRef- Topic 942-946 - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9-6- 03-04 (16-19  
))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147478546-2147479617 / 942-946 - 210- S99- 1Reference 3-33 http:// www.xbrl. org / 2009-2003 / role /  
commonPracticeRef- disclosureRef- Topic 944-946 - SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- credit Period Type: monetaryItemType  
Balance Type- Paragraph 3- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147481004 / 946 - 505- DefinitionAmount of cash outflow to  
acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV- 50- 3Reference 32 NI), classified as investing activity.  
ReferencesReference 1: http:// www.xbrl. org / 2003 / role / disclosureRef- Topic 230-946 - SubTopic 40-210 - Name Accounting Standards Codification- Section 45- S99-  
Paragraph 1- Subparagraph (SX 210.6- 04 (19)) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147482740-2147479617 / 230-946 - 40-210 - 45- S99- 19Reference-  
1Reference 2-33 http:// www.xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting Standards Codification- Section 45- S99- Paragraph 1-  
SubTopic durationX- e)- Paragraph 3-3A- Section S99- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480244- 2147481004 / 480-946 - 40-505- S99-50-  
3AReference- 3Reference 3-32 http:// fasb- www.xbrl. org / 2003 us- gaap- role / disclosureRef- ref/ legacyRef- Topic 480-946 - SubTopic 40-210 - Name Accounting  
Standards Codification- Section S99- Paragraph 3A- 1 - Subparagraph (45-SX 210.6- 04 (19)) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480244-2147479617 /  
480-946 - 40-210 - S99- 3AReference 1Reference 4-33 http:// fasb- www.xbrl. org / 2003 us- gaap- role / disclosureRef- ref/ legacyRef- Topic 480-946 - SubTopic 40-210 -  
Name Accounting Standards Codification- Section S99- Paragraph DefinitionNumber of a) Paragraph 3 - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147478448  
2147481004 / 946- 505- 50- 2Reference 3Reference 5-32 http:// www.xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 220-210 - Name Accounting Standards  
Codification- Section S99- Paragraph 3-1 - Subparagraph (SX 210.6- 09-04 (19-4)(b))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147479134-2147479617 / 946-  
220-210 - S99- 3Reference 1Reference 6-33 http:// www.xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 40-210 - Name Accounting Standards Codification- Section  
S99- Paragraph shares issued during the period as a result of an employee a reverse stock split purchase plan. ReferencesReference 1: http:// fasb. org / us- gaap / role / ref /  
legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147481112 /  
505- 10- 50- 2Reference 2 Details Name: us- gaap\_ StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType  
Balance Type: na Period Type: durationX- DefinitionNumber of shares issued during the period as a result of a stock split. ReferencesReference 1: http:// fasb. org / us-  
gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 1-2 - SubTopic Subparagraph (SX 210- 10- 5-  
Topic 505 02 (28))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566-2147481112 / 505- 10- 50- 2Reference 2: http:// fasb. org / us- gaap / role / ref /  
legacyRef- Topic 210 -10- S99- 1Reference 3: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section  
S99- Paragraph 1- Subparagraph (SX 210. 3-5- 04-02 (28))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480008-2147480566 / 505-210 - 10- S99- 1Reference  
4-3: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-  
02 (29))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566 / 210 - 10- S99- 1Reference 4: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 505-  
SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3-04)- Publisher FASB- URI https://asc.fasb.org /  
1943274 / 2147480008 / 505 - 10- S99- 1 Details Name: us- gaap\_ StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-----  
gaap\_ StockIssuedDuringPeriodSharesStockSplits Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX Paragraph 3 (d)-  
- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147479886-2147481004 / 946 - 10-505- S99-50- 3Reference 14-32 http:// www.xbrl. org / 2003 / role / disclosureRef-  
Topic 946- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.6- 04 (19))- Publisher FASB- URI https://asc.fasb.org /  
#1943274 / 2147479170 - 2147479617 / 946- 210- S99- 1Reference 15-33 http:// www.xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 210- Name Accounting  
Standards Codification- Section S99- Paragraph - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not  
limited to, shares issued for services contributed by vendors and founders. ReferencesNo definition available. Details Name: us-  
gaap\_ StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX-  
DefinitionNumber of new stock issued during the period. ReferencesReference 1: http:// fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification-  
Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http:// www.fasb. xbrl-  
org / 2003- us- gaap / role / disclosureRef- ref / legacyRef- Topic 946-210 - SubTopic 505-10 - Name Accounting Standards Codification- Section 50-S99 - Paragraph 2-1 -  
Subparagraph (a- SX 210. 5- 02 (28)) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147481004-2147480566 / 946-210 - 505-10 - 50-S99 - 2Reference 1Reference  
3: http:// www.fasb. xbrl- org / 2003- us- gaap / role / disclosureRef- ref / legacyRef- Topic 946-210 - SubTopic 220-10 - Name Accounting Standards Codification- Section S99-  
Paragraph 3-1 - Subparagraph (SX 210. 6-5- 09-02 (29-4)(b))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147483575-2147480566 / 946-210 - 220-10 - S99-  
3Reference 1Reference 4: http:// www. xbrl. org / 2003 / role / disclosureRef- Topic 946- SubTopic 40-505 - Name Accounting Standards Codification- Section S99-50 -  
Paragraph 3-2 - Subparagraph (a SX 210- 6- 03 (i)(1))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147479886 -- 2147478448 / 946- 10-505- S99-50 -  
3Reference 2Reference 5: http:// fasb- www. xbrl. org / 2003 us- gaap- role / disclosureRef- ref/ legacyRef- Topic 210-946 - SubTopic 40-220 - Name Accounting Standards  
Codification- Section S99- Paragraph 1-3 - Subparagraph (SX 210. 5-6- 02-09 (28-4)(b))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566-2147479134 /  
210-946 - 40-220 - S99- 4Reference 3Reference 6: http:// fasb- www. xbrl. org / 2003 us- gaap- role / disclosureRef- ref/ legacyRef- Topic 505-946 - SubTopic 10- Name  
Accounting Standards Codification- Section S99- Paragraph 1-3 - Subparagraph (SX 210. 3-6- 04-03 (i) (1)) - Publisher FASB- URI https://asc.fasb.org / #1943274 /  
2147480008-2147479886 / 946- 10- S99- 3Reference 7: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 505 -10- S99- 1Reference 7: http:// fasb. org / us- gaap / role  
/ ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-3- 04-02 (29))- Publisher FASB- URI  
https://asc.fasb.org / #1943274 / 2147480566-2147480008 / 210-505 - 10- S99- 1 Details Name: us- gaap\_ StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-  
gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber of shares related of stock issued during the period as part of a  
transaction to acquire assets that do not qualify as a business combination. ReferencesNo definition available. Details Name: us-  
gaap\_ StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us- gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX-  
DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Award Awards forfeited during the period.  
ReferencesReference 1: http:// fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher  
FASB- URI https://asc.fasb.org / #1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 210-505 - SubTopic 10- Name  
Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-3- 04-02 (28))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566  
2147480008 / 210-505 - 10- S99- 4Reference 3-1 Details Name: us- gaap\_ StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us- gaap\_ Data  
Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber of share options (or share units) exercised during the current period.  
ReferencesReference 1: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 1-2  
- SubTopic Subparagraph (SX 210- 10- 3- 04) Topic 505 - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480008-2147481112 / 505- 10- S99-50 - 1Reference  
2Reference 4-2: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph  
(SX 210. 5- 02 (29-28))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566 / 210- fasb. org / #1943274 / 2147480008 / 505- 10- S99- 1Reference 38-3: http://  
www.fasb. xbrl- org / 2009- us- gaap / role / commonPracticeRef- ref / legacyRef- Topic 235-210 - SubTopic 10- Name Accounting Standards Codification- Section S99-  
Paragraph 1- Subparagraph (SX 210. 4-5- 08-02 (29- g)(i)(1))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480678-2147480566 / 235-210 - 10- S99-  
1Reference 39-4: http:// www.xbrl. org / 2009-2003 / role / commonPracticeRef- disclosureRef- Topic 323-718 - SubTopic 10- Name Accounting Standards Codification- Section  
50- Paragraph 3-2 - Subparagraph (c) (1) (iv) (02) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147481687-2147480429 / 323-718 - 10- 50- 3Reference 2Reference  
40-5: http:// www.fasb. xbrl- org / 2009- us- gaap / role / commonPracticeRef- ref / legacyRef- Topic 825-505 - SubTopic 10- Name Accounting Standards Codification- Section  
50-S99 - Paragraph 28-1 - Subparagraph (F SX 210.3- 04) - Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147482907-2147480008 / 505 - 10- S99- 1 Details Name: us-  
gaap\_ StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited- gaap\_ StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us- gaap\_ Data Type:  
xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber, after forfeiture, of shares..... credit Period Type: durationX- DefinitionAggregate change in  
value for stock issued during the period as..... credit Period Type: durationX- DefinitionValue of stock related to Restricted Stock Awards forfeited issued during the period.  
ReferencesReference 1: http:// fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher  
FASB- URI https://asc.fasb.org / #1943274 / 2147481112 / 505- 10- 50- 2Reference 2: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 210- SubTopic 10- Name  
Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566 / 210-  
10- S99- 1Reference 3: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 505-210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1-  
Subparagraph (SX 210. 3-5- 04-02 (29))- Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480008-2147480566 / 505-210 - 10- S99- 1Reference 4: http:// fasb. org  
/ us- gaap / role / ref / legacyRef- Topic 210-505 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-3- 04-02 (29))-  
Publisher FASB- URI https://asc.fasb.org / #1943274 / 2147480566-2147480008 / 210-505 - 10- S99- 1 Details Name: us-  
gaap\_ StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures----- gaap\_ StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-  
gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit-credit Period Type: durationX- DefinitionValue of, after forfeiture-- forfeited, of shares issued under share-  
based payment arrangement. Excludes employee stock ownership plan (ESOP). ReferencesReference 1: http:// fasb. org / us- gaap / role / ref / legacyRef- Topic 210-718 -  
SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 2- Subparagraph (c) (1 - Subparagraph (SX 210. 5- 02 (28))- Publisher FASB- URI https://

/asc.fasb.org/#1943274/2147480566-2147480429/210-718-10-S99-50-1-Reference-2 Details Name: us-gaap\_StockIssuedDuringPeriodValueShareBasedCompensationForfeited Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. ReferencesNo definition available. Details Name: us-gaap\_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. ReferencesReference 1: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-2-SubTopic Subparagraph (SX 210-10-3-04)-Topic 505-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480008-2147481112/505-10-S99-50-1-Reference-2Reference-3-2: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210, 5-02 (29-28))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480566/210-10-S99-1-Reference-4-3: http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147478448-2147481004/946-505-50-2Reference-3Reference-5-32: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-210-Name Accounting Standards Codification-Section S99-Paragraph 3-1-Subparagraph (SX 210.6-09 04 (19-4)(b))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479134-2147479617/946-220-210-S99-3Reference-1Reference-6-33: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 40-210-Name Accounting Standards Codification-Section S99-Paragraph 3-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d-c) (1) (iii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429/718-10-50-2 Details Name: us-gaap\_StockIssuedDuringPeriodValueShareBasedCompensation-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit na Period Type: durationX- instantX- DefinitionAmount DefinitionThe weighted-average price as of equity (deficit) attributable to parent-the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and noncontrolling interest-Excludes temporary equity currently exercisable under the stock option plan ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-718-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 24-2-Subparagraph (c) (1) (iii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483421-2147480429/250-718-10-45-50-24Reference-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-718-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 23-2-Subparagraph (b-c) (1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483421-2147480429/250-718-10-45-50-23Reference-3-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-718-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 5-2-Subparagraph (b-c) (1) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483421-2147480429/250-718-10-45-50-5Reference-4-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX- DefinitionGross number of share options (or share units) granted during the period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-718-SubTopic 10-Name Accounting Standards Codification-Section 65-50-Paragraph 5-2-Subparagraph (c) (2-1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479654-2147480429/326-718-10-65-50-5Reference-5-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: durationX- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 65-50-Paragraph 2-6-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-10-65-50-6Reference-6-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionNumber of options outstanding, including both vested and non-vested options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-718-SubTopic 20-10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (h-c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-10-65-50-6Reference-2Reference-7-2: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-718-SubTopic 20-10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (h-c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-10-65-50-6Reference-8-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli: sharesItem Type Balance Type: na Period Type: instantX- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-718-SubTopic 20-10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (h-c) (1) (iii)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-10-65-50-6Reference-2Reference-9-2: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-718-SubTopic 20-10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (h-c) (1) (iv)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-65-6Reference-10-50-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: instantX- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-718-SubTopic 20-10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (h-c) (3-1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480528-2147480429/815-718-20-10-65-50-6Reference-11-2 Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 848-718-SubTopic 10-Name Accounting Standards Codification-Section 65-50-Paragraph 2-Subparagraph (a-c) (3-1) (iii-iv) (03)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483550-2147480429/848-718-10-65-50-2Reference-12-2 Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 405-718-SubTopic 10-Name Accounting Standards Codification-Section 65-50-Paragraph 6-2-Subparagraph (c) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479343-2147480429/405-718-10-65-50-6Reference-13-2 Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr- types: perShareItem Type Balance Type: na Period Type: durationX- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 65-50-Paragraph 2-6-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479343-2147480429/405-718-10-65-50-6Reference-14-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmMnDtHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 944-718-SubTopic 40-10-Subparagraph (e) (1)-Name Accounting Standards Codification-Section 65-Paragraph 2-Section 50 Subparagraph (f) (1)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480016-2147480429/944-718-40-10-65-50-2Reference-15-2 Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap\_Data Type: xbrli: durationItem Type Balance Type: na Period Type: durationX- DefinitionWeighted average remaining contractual term of outstanding stock options, in 'PnYmMnDtHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 944-718-SubTopic 40-10-Subparagraph (e) (1)-Name Accounting Standards Codification-Section 65-Paragraph 2-Section 50 Subparagraph (f) (2)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480016-2147480429/944-718-40-10-65-50-2 Details Name: us-gaap\_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap\_Data Type: xbrli: durationItem Type Balance Type: na Period Type: durationX- Details Name: us-gaap\_RelatedPartyTransactionAxis =





commonPracticeRef- Topic 825- gaap\_ Data Type: xbrli:dateTimeType Balance Type: na Period Type: durationX- SubTopic 10- Name- Definition The amount of early contract termination fees included in liabilities subject to shares withheld for employee taxes (218) (75) Net cash (used in) provided by continuing operations (218) compromise. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic103-10-864> Net cash used in financing activities of discontinued operations - Name Accounting Standards Codification- Section 50- Paragraph 2- Subparagraph (b) (5,000) Net cash (used in) provided by financing activities (+5,218)- Publisher FASB- URI <https://asc.fasb.org/1943274/2147481404/852-103-10-864> Effect of exchange rate changes on cash and cash equivalents (146) (306) Net (decrease) increase in cash and cash equivalents (5,039) 13,683 Cash and cash equivalents, beginning of year 26,537 12,854 Cash and cash equivalents, end of year 21,498 26,537 Non-cash supplemental disclosure Acquisition of additional ownership- 50- 2 Details Name: us-gaap\_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- Definition The parent entity's interest in LipoMedix \$ 16 \$ 8 net assets of the subsidiary, expressed as a percentage. References No definition available. Details Name: us-gaap\_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: instantX- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section509-Paragraph1-Subparagraph\(SX210-5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section509-Paragraph1-Subparagraph(SX210-5-02(28)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-13) Details Name: us-gaap\_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap\_ Data Type: dtr- types: perShareItemType Balance Type: na Period Type: instantX- Definition The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate. References No definition available. Details Name: us-gaap\_ShortTermDebtPercentageBearingFixedInterestRate Namespace Prefix: us-gaap\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: instantX- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic830-SubTopic30-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481674/830-30-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic855-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483399/855-10-50-2> Details Name: us-gaap\_SubsequentEventLineItems Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Details Name: us-gaap\_StatementEquityComponentsAxis = us-gaap\_PREFERREDStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: dei\_LegalEntityAxis = rfl\_RefaelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubsequentEventTypeAxis = us-gaap\_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_DebtInstrumentAxis = rfl\_CycloConvertibleNoteIIIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: srt\_OwnershipAxis = rfl\_RefaelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_DebtInstrumentAxis = rfl\_CycloConvertibleNoteIVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_DebtInstrumentAxis = rfl\_CycloConvertibleNoteVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_ShortTermDebtTypeAxis = us-gaap\_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_StatementClassOfStockAxis = us-gaap\_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: